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Abstract 
 
Anterior gradient protein 2 (AGR2) is overexpressed in many cancers, in particular 
those of the breast, ovary, prostate and pancreas. This overexpression tends to correlate 
with a poor disease prognosis for patients, probably as a result of increased incidence of 
metastases, and indeed, AGR2 has been shown to play a role in cell adhesion in different 
cell lines. Whilst AGR2 is a member of the protein disulphide isomerase (PDI) family of 
endoplasmic reticulum (ER) chaperones, there are also multiple reports of the secretion of 
AGR2 by cultured cells and the protein is also found in the serum and urine of cancer 
patients. AGR2 is a dimer, and the dimerisation interface is characterised here. A short, 
flexible region of the protein is also described, that seems to be involved in the regulation 
of the adhesion activity of AGR2. Through the use of stable cell lines expressing wild type 
and several mutant AGR2 proteins, it is shown here that wild-type AGR2 expression is 
associated with changes in cell adhesion and anchorage-independent cell growth, that are 
lost upon inhibition of protein dimerisation, mutation of the putative active site or a change 
in the sub-cellular localisation of the AGR2. Furthermore, the secretion of AGR2 has been 
confirmed through the discovery of a glycosylated, extracellular form of the protein. The 
expression of AGR2 is shown to be associated with a number of changes to the secreted 
proteome, with effects on both pro-adhesive and anti-adhesive proteins that may 
contribute to the role of AGR2 in cell adhesion. Overall, through combined biochemical, cell 
biology and mass spectrometry approaches, potential mechanisms whereby AGR2 might 
contribute to cell adhesion and metastasis are explored and discussed. 
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Chapter 1 
 
 
 
Introduction 
 
 
 
1.1 Cancer metastasis 
 
 Metastatic spread of tumour cells is one of the final hallmarks of cancer described 
by Hanahan and Weinberg [1]. It represents a defining step in the oncogenic process that is 
responsible for the majority of patient deaths, sometimes accounting for 90 % of fatalities 
[2-4]. The metastatic cascade is a highly complex process, and it is this complexity that 
presents such a major challenge for the treatment of metastatic disease, and thus 
understanding the different mechanisms that underpin metastasis is of great importance to 
the advancement of disease treatment. 
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1.1.1 Events in the metastatic cascade 
 
 Normal cells must undergo a number of changes to become tumourigenic [1], and 
in the same way tumour cells must generally undergo several changes to become 
metastatic. Changes in cell adhesion play a key role in metastasis, as cells must release cell-
cell and cell-matrix adhesions in order to break free from the main tumour mass, 
transmigrate into blood or lymph vessels and then adhere to the vessel endothelium at 
secondary sites, in order to extravasate and establish new tumours [5]. However, to fully 
understand this process, the factors contributing to each step of this cascade must be 
considered. 
 
 
1.1.1.1 Loss of cell-cell adhesion 
 
 Cell-cell contacts are maintained by three classes of intercellular adhesion 
complexes: adherens junctions, desmosomes and tight junctions [6]. Adherens (Fig. 1.1) are 
made up of two families of proteins, cadherins and catenins [7]. The transmembrane 
cadherins (including E-, N-, P- and R-cadherins [8]) form the anchoring interactions of 
adherens between adjacent cells, and they interact in a homotypic and calcium-dependent 
fashion [9, 10]. The cytoplasmic catenin proteins (α-, β- and p120-catenin) provide a link 
between the cadherin molecules and the cytoskeleton and also perform a number of 
signalling roles. p120-catenin in particular, which binds to the membrane adjacent region of 
the cadherin cytoplasmic domain [11], is thought to stabilise the adherens junction, 
possibly through prevention of cadherin internalisation [11-13]. p120-catenin is also 
required to promote cadherin-based adhesion [14, 15], and is an important regulator of cell 
migration through regulation of Rac (Ras-related C3 botulinum toxin substrate) and Cdc42 
(cell division control homolog 42), members of the Rho GTPase family [16]. Binding of β-
catenin to both α-catenin and to cadherins is mediated by phosphorylation [17, 18], and 
this positional regulation is important given the function of non-adherens-bound β-catenin 
as a co-activator of the T cell factor/lymphoid enhancer factor (TCF/LEF) transcription factor 
in the Wnt pathway [19].  
α-catenin is classically thought of as the connection between β-catenin and the 
cadherin molecule, due to its ability to bind both β-catenin [20] and actin bundles [21]. 
However, its role is probably more complex, and it may be that binding-induced clustering 
of cadherins increases the local concentration of α-catenin, which is then able to dimerise 
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and inhibit lamellipodia formation, a crucial membrane structure involved in migration [22] 
(see Section 1.1.1.3). In this way α-catenin promotes a non-motile phenotype, required for 
the maintenance of epithelial linings.  
 Desmosomes (Fig. 1.1) are largely responsible for coupling intercellular adhesion 
molecules to the intracellular intermediate filament system, thus providing resistance to 
mechanical stresses [23, 24]. Like cadherins in adherens junctions, the desmosomal 
cadherins (desmocollins 1-3 and desmogleins 1-4) are transmembrane proteins, but they 
exist as desmocollin-desmoglein heterodimers. These heterodimers interact in largely 
homotypic fashion, in that the desmocollin molecule from one hereodimer interacts with 
the desmocolin molecule in the opposing heterodimer, with the same being true for the 
desmoglein molecules [25-27] (Fig. 1.1). Desmoplakin binds intermediate filaments and 
links them to desmosomal cadherins [23], and is essential for desmosome function, as 
demonstrated by the complete loss of skin integrity by its deletion [28]. Plakoglobin 
(sometimes called γ-catenin) and plakophilins 1-3 bind the desmosomal cadherins 
themselves and also desmoplakin, thus completing the connection between intermediate 
filaments and intercellular junctions [23]. Plakoglobin is also thought to play a role in 
crosstalk between desmosomes and adherens [29, 30], and can also influence the Wnt 
pathway in a similar manner to β-catenin [31]. 
 Tight junctions (Fig. 1.1) are important structures for maintaining cell polarity by 
forming a physical barrier that separates apical and basolateral membrane proteins and 
prevents them from mixing [32]. They are composed of the transmembrane occludin, 
claudin, tricellulin and junction adhesion molecule (JAM) proteins. The claudin molecules 
play an important role in the second function of tight junctions, that of controlling the 
passage of ions between adjacent cells [33]. In the cytoplasm, the zonula occludens (ZO) 
proteins 1-3 interact with the cytoplasmic tails of occludin [34-36], and act as scaffold and 
signalling proteins, as well as providing a link to the actin cytoskeleton [32, 34, 37]. These 
ZO proteins are also known to play roles in cell proliferation [38] and probably also 
migration [39]. 
 Downregulation of cell-cell adhesion molecules is a hallmark of cells undergoing 
epithelial-mesenchymal transition (EMT), the process whereby, in cancer, epithelial cells 
gain a more migratory and invasive phenotype that allows them to spread and metastasise 
(see Section 1.2). Loss of cadherins not only results in loss of anchoring adhesion between 
epithelial layers, but liberates β-catenin from the junction complex, which can then 
promote transcription of pro-EMT genes under the influence of Wnt signalling [40, 41]. A 
similar picture exists for desmosomes, where loss of intracellular desmosome components 
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such as desmoplakin and plakophilins leads to increase tumour cell invasion and metastasis 
[24, 42] by similarly promoting Wnt/β-catenin signalling [43]. Loss of occludin and claudin 
from tight junctions is also evident in metastatic cells [44-47], where loss of tight junction 
integrity leads to loss of cell polarity and may also promote proliferation, through loss of 
ZO-mediated sequestration of pro-proliferative transcription factors (reviewed in [48]). 
Thus, maintaining the integrity of cell-cell junctions plays an important role in preventing 
tumourigenesis. 
 
 
           
 
 
Figure 1.1. Epithelial intercellular junctions. The architecture of representative tight, 
adherens and desmosome junctions are shown. ZO: zonula occludens. JAM: junction 
adhesion molecule. Figure adapted from Knights et al., 2012 [6]. 
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1.1.1.2 Altered cell-matrix adhesion 
 
 Interactions between cells and their surrounding matrix are responsible for not only 
the spatial and structural arrangement of cells within tissues, but are also required for a 
plethora of cell processes, including proliferation, survival and differentiation [49-51]. The 
integrin family of cell surface receptors play an integral part in this process, mediating the 
attachment of cells to various extracellular matrix (ECM) ligands. Integrin molecules are 
heterodimeric complexes of an α and β subunit [52], of which there exists 18 α subunits 
and 8 β subunits that can combine to form 24 different integrin receptors (Fig. 1.2), that 
show different tissue distribution and different ligand specificities [53, 54]. This broad 
ligand binding has been attributed to the relatively short ligand recognition sites of 
integrins [55], the most widely studied of which is the RGD motif (consisting of Arg-Gly-Asp 
residues), which is found in a number of ECM components, namely fibronectin, vitronectin, 
fibrinogen and von Willebrand factor [56].  
 
 
 
Figure 1.2. Members of the vertebrate integrin family. The 24 possible combinations of α 
and β subunits are displayed, with different colours representing groups containing an 
identical subunit. Figure adapted from Bouvard et al., 2001 [57]. 
 
 
 Structurally, integrins contain large globular extracellular domains, coupled to a 
single-pass transmembrane region and a short cytoplasmic tail, usually of approximately 60 
residues [52, 55, 58]. Integrins can exist in two different states: a bent, inactive or low-
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affinity state, and in an upright, active or high affinity state [50, 55]. Switching from an 
inactive to active state is initiated by the binding of extracellular ligands (termed ‘outside-
in’ signalling) [55] or through binding of cytoplasmic adapter proteins such as talin (known 
as ‘inside-out’ signalling) [59-61]. The talin proteins (talin-1 and -2) play a major role in 
‘inside-out’ signalling, along with the related kindlin proteins (kindlin-1 to -3). Talin is a large 
cytoskeletal protein containing an N-terminal FERM (4.1 protein (F), ezrin (E), radixin (R) 
moesin (M)) domain linked to a C-terminal rod-like domain [62]. Within the FERM domain 
sits the F3 domain that mediates talin binding to the integrin β subunit cytoplasmic tail 
which is responsible for talin-mediated activation of integrins [63-65]. The mechanism of 
activation relates to an interaction between the talin F3 domain and the juxtamembrane 
region of the β subunit cytoplasmic tail upon talin binding, which causes a conformational 
change in the β subunit, causing it to extend away from the α subunit [66]. As association of 
the α and β subunits maintains the integrin in an inactive conformation [67], their talin-
induced disassociation leads to receptor activation. Binding of the F3 domain also disrupts a 
salt bridge between the α and β subunits, further promoting their disassociation [68]. 
 Several pathways can promote the talin-mediated activation of integrins. Non-
integrin-bound talin largely exists in the cytoplasm in an auto-inhibited form, whereby the 
crucial F3 domain is bound to a region in the C-terminal rod domain [69-71]. 
Phosphatidylinositol 4,5-bisphosphate (PIP2), most likely generated through PIP-kinase type 
1γ [72], can interrupt this inhibitory binding and promote recruitment of talin to the 
membrane and subsequent integrin activation through the F2 region in the FERM domain 
[68, 69]. The generation of PIP2 is also implicated in the Rap1A (repressor/activator protein 
1A) GTPase ‘inside-out’ pathway of integrin activation. Recruitment of Rap1A to the plasma 
membrane, probably through PIP2, in turn recruits Rap1-GTP-interacting adaptor molecule 
(RIAM) to membrane-bound Rap1A [73, 74]. RIAM contains an N-terminal talin-binding 
domain, which promotes talin recruitment to the membrane, leading to integrin activation 
[74, 75]. A third pathway of intracellular integrin activation relates to the focal adhesion 
kinase (FAK)-mediated recruitment of talin to the membrane [76]. This strays from the 
classical role of post-talin-recruited FAK (see Section 1.1.1.3), but is only an emerging 
concept, and as such little is known about the mechanism involved, except that this 
pathway may be regulated through p190RhoGEF (guanine nucleotide exchange factor), 
which has been shown to bind to FAK [77]. 
 The second class of proteins involved in ‘inside-out’ signalling, the kindlins, are not 
as well characterised as the talins, but are known to contain a similar FERM domain to talin 
[78], containing the F3 domain that mediates kindlin binding to the integrin β subunit tail 
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[79-81]. In vitro at least, a ternary complex is formed between kindlin, the talin head FERM 
domain and integrin β tail [82, 83], but kindlin binding to integrins does not seem to 
promote recruitment of talin, nor enhance talin-integrin binding [83, 84]. However, kindlins 
are required for the activation of β1 integrins at least, as their activation is impaired by 
kindlin knockdown [85-87]. Kindlins have therefore been suggested to act as talin co-
activators, influencing events that occur post-talin binding to integrins [84]. The nature of 
this effect is not clear, but may relate to further dissociation of the α and β transmembrane 
domains, through simultaneous kindlin binding to the integrin β subunit tail and membrane 
lipids [88-90]. Another proposed function of kindlins is displacement of integrin β subunit-
bound inhibitory proteins. Evidence for this stems from the overlapping binding sites on 
integrin β subunits for kindlins and the inhibitory proteins filamin and ICAP1 (integrin 
cytoplasmic domain–associated protein 1) [91, 92]. In this way, talins and kindlins act 
together in the activation of integrin receptors. 
 During the metastatic cascade, tumour cells tend to undergo a switching of integrin 
receptors, where receptors mediating adhesion of epithelial cells to the basement 
membrane are downregulated (e.g. α6β4 [93]) and β1 integrins tend to be upregulated, 
promoting the disruption of E-cadherin junctions and thus downregulating cell-cell contacts 
[94, 95]. Expression of fibronectin-binding integrins such as α5β1 in transformed cells 
promotes cell migration, as fibronectin also tends to be upregulated by these cells [96, 97]. 
Similarly, non-β1 integrins are also displayed by tumour cells, which can also promote 
fibronectin-dependent migration (e.g. αvβ6 [98]), but this switching of integrins can also 
promote changes in adhesion related to EMT. Using several cancer cell lines, including lung, 
liver and colon, both the aforementioned αvβ6 and also αvβ8 were shown to promote the 
release of active TGFβ (a major inducer of EMT (see Section 1.2)) from its latent 
extracellular form [99, 100]. TGFβ is secreted in an inactive form bound to both the latency-
associated peptide (LAP) and the latent-TGFβ-binding protein (LTBP) (reviewed in [101]). 
The LAP- TGFβ interaction is non-covalent, and TGFβ can be released through proteolytic 
degradation of LAP, or through integrin binding to the LAP, which is thought to cause a 
conformational change in the LAP, resulting in TGFβ release (reviewed in [101]). αvβ6 was 
shown to release TGFβ in a protease-independent manner [99], while the action of αvβ8 
was protease dependent [100], but both led to a local increase of active TGFβ. Thus integrin 
switching in tumour cells can perpetuate changes to cell adhesion.   
 Additionally, the role of integrins in oncogenesis can also involve their intracellular 
signalling functions. This is illustrated by integrin α6β4, which is often overexpressed in a 
number of cancers [102] and activation of which promotes cell proliferation [103]. Its 
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cytoplasmic domain also acts as a scaffold for hepatocyte growth factor (HGF)-mediated 
signalling, amplifying pro-invasive signals [104], and α6β4 integrin also similarly signals 
through Rac to promote invasion [105]. Integrin α6β4-mediated activation of NF-κB also 
promotes cell survival [106, 107].  
 Thus, changes to integrin receptors during tumourigenesis do not simply result in 
loss or gain of adhesion to a specific substrate, but additionally affect many other pathways 
that contribute to the overall metastatic process. Like changes in cell-cell adhesion, 
alterations to cell-matrix adhesions also promote EMT, thus coupling loss of cell adhesion at 
the primary tumour with increased migratory potential. 
 
 
1.1.1.3 Cell migration 
 
 The formation of focal adhesions (FAs), the structures through which cells generate 
traction forces to allow cell migration, progresses through defined stages [52] and is 
dependent on both integrin-mediated adhesions to the ECM and also the flow of actin into 
and out of cell membrane protrusions, namely lamellipodia [108]. These membrane 
projections are driven by polymerisation of branched actin filaments at the cytosolic face of 
the membrane [109], and this polymerisation of actin at the leading edge of lamellipodia is 
also coupled to a rearward, retrograde flow of actin filaments mediated by both the force 
exerted by actin on the cell membrane and myosin II [110-112]. Initial or nascent focal 
adhesions are formed within the lamellipodia [108, 113], where talin is then recruited to 
stabilise the interaction between the clustered integrins and the ECM [114]. Recruitment of 
talin also starts the FA maturation process, initially preventing the breakdown of the 
nascent FA by slowing the rate of retrograde actin flow, which otherwise causes the 
disassembly of a proportion of the nascent FAs [108]. This stabilisation is important given 
the dynamic nature of FA assembly and disassembly, where substrate stiffness and 
mechanical load on the individual FA contribute to their turnover [115-117]. 
 Clustered integrins can exert a small amount of traction force on the matrix and at 
the same time, the retrograde actin flow pulls on the integrin-bound talin, in turn pulling on 
β1 integrin subunit, which leads to unfolding of the extracellularly-bound fibronectin [118]. 
This results not only in the strengthening of the interaction between talin and actin [119], 
but the stretching of talin reveals binding sites for other focal adhesion proteins, including 
vinculin, FAK and paxilllin, which promote the maturation of the nascent FA [120-123]. In 
particular, vinculin enhances the binding of actin to FAs and promotes clustering of ECM-
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bound integrins [124, 125], and is also involved in the regulation of contractility [126]. FAK 
couples talin binding to cell cycle progression [127], but also promotes the eventual 
disassembly of the FA, which allows the cell to migrate [76, 127]. 
 During FA maturation, the contractile force provided by myosin II contributes to the 
maturation of the FA through stretching of the bound talin and influences on FAK signalling 
[121, 128, 129]. Myosin contraction also pulls clustered integrins inwards [130], which, 
along with other mechanical stresses, also serves to promote the maturation of the 
filamentous actin network into higher order structures known a stress fibres [131-133]. 
These stress fibres are composed of 10 to 30 actin filaments which are bundled together 
through crosslinking by α-actinin [134]. This generates small bundles of actins that are then 
joined end-to-end through myosin II [133]. Two broad types of stress fibre are formed: 
transverse fibres that tend to form to the rear of the leading edge  [135-137] and are at first 
not tethered to FAs [137], and dorsal and ventral stress fibres that are formed at FA sites 
through the actions of RhoA [138], the downstream effector ROCK (Rho-associated protein 
kinase) and the formin mDia1 (reviewed in [139]). The transverse and dorsal/ventral fibres 
eventually fuse and provide contractile forces [133, 140], but the mechanism involved in 
their assembly is largely unknown. 
 Further maturation of FAs is characterised by the gradual recruitment of increasing 
levels of zyxin [141] and also by its recruitment to stress fibres [142]. The size of the FA, 
which grows over time under the influence of contractile and mechanical stresses, at this 
point reaches its peak and they no longer provide great traction forces [141, 143]. The role 
of these mature FAs evolves into one of cell anchoring [144, 145], maturing further into 
fibrillar adhesion which are characterised by the presence of tensin, lack of vinculin and 
replacement of stress fibre interaction back to interactions with thinner actin filaments 
[146-149]. They also play a role in the organisation and modulation of extracellular 
fibronectin [149]. 
 Directional migration mediated by FAs necessitates the disassembly of FAs 
(particularly at the trailing edge of the cell), but the processes involved in disassembly are 
less well understood than those involved in assembly. The assembly and disassembly of FAs 
at the leading edge is largely regulated by the forces generated from polymerising and de-
polymerising actin [108, 150]. In terms of disassembly of mature FAs, one major regulatory 
mechanism involves their removal by endocytosis [151, 152], but microtubules are also 
implicated in their disassembly, by causing relaxation of the actin filaments around FAs, 
destabilising them and aiding in their endocytosis [152-154]. Src and FAK are important 
mediators of FA disassembly [146, 155]. They probably increase myosin II contraction 
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through activation of mitogen-activated protein kinase (MAPK), which in turn activates 
myosin light chain kinase (MLCK) [156], which is then able to phosphorylate myosin light 
chain and promote actomyosin contraction [157]. This contractility mediates the 
recruitment of endocytic machinery and the calpain-2 protease [158], which breaks down 
talin and FAK, severing the link between integrins and actin and promoting their turnover 
[159, 160]. Endocytosed integrins can be degraded but are more often recycled back to the 
leading edge (reviewed in [161]), where they can again bind extracellular ligands [162]. 
 
 
1.1.1.4 Angiogenesis, intra- and extravasation 
 
 Cell-cell and cell-matrix interactions regulate the tethering to, but also migration 
and invasion through, the ECM (as outlined above). In order to disseminate and metastasise 
however, tumours tend to engage the formation of new blood vessels (angiogenesis), 
through which they can then gain access to a host of secondary colonising sites. The 
initiation of angiogenesis is related to the dysregulated growth of the primary tumour, 
where tumours reaching a certain size become hypoxic [163]. This generates hypoxia 
inducible factors (HIFs), which in turn promote the production of members of the vascular 
endothelial growth factor (VEGF) family [164], the best characterised inducers of 
angiogenesis [165]. The release of VEGFs (VEGF-A, -B, -C, D, and –E) is also brought about 
by their proteolytic release from the ECM by MMP9 [166]. Their effects are mainly 
mediated on the vessel endothelium [167], promoting  proliferation, migration and invasion 
of endothelial cells ([168, 169]. Interestingly, autocrine production of VEGF also promotes 
EMT, linking the vascularisation of the tumour with the induction of a more migratory and 
metastatic cell type [170]. 
 A number of other secreted and membrane-bound ligands contribute to the 
induction of angiogenesis, including the fibroblast growth factor (FGF) family, the platelet-
derived growth factor (PDGF) family the angiopoietin family [171]. FGFs tend to promote 
endothelial cell proliferation and migration [172], whilst PDGF and the angiopoietins are 
important for the recruitment of pericytes and vascular smooth muscle cells, which 
promote vessel maturation [173-175]. The angiopoeitins are also involved in the 
recruitment of macrophages to the site of angiogenesis [176, 177], further promoting 
vessel development (see below). 
 Release of TGFβ is also involved in angiogenesis, although it appears that low levels 
promote angiogenesis, whereas high levels slow down the process and promote vessel 
Chapter 1  Introduction 
11 
 
maturation [178]. Similarly, the transmembrane Delta/Jagged and Notch pathways dampen 
down angiogenesis through modulation of VEGF activity and limit the levels of vessel 
branching [179]. The CXC chemokines can also be pro-angiogenic (e.g. CXCL1 and CXCL2) or 
anti-angiogenic (e.g. CXCL4), through the induction or repression of endothelial cell 
proliferation and chemotaxis, respectively (reviewed in [180]). 
 The release of VEGF and other growth factors and cytokines from tumour cells also 
allows the recruitment of hematopoietic cells, which support the formation of new vessels 
[181, 182]. These tumour-associated macrophages and neutrophils provide a ready-supply 
of pro-angiogenic factors such as VEGF and FGF and promote matrix degradation, thus 
favouring invasion of endothelial cells towards the tumour (reviewed in [183] and [184]). 
They also manipulate and downregulate the anti-tumour response. Cancer-associated 
fibroblasts are also recruited to sites of angiogenesis, where they provide not only pro-
angiogenic factors such as VEGF [185], but crucially remodel the ECM, without-which the 
vessel lumens fail to form [186]. 
  
 
 1.1.1.4.1 Intravasation 
 
 The vessels formed by tumour angiogenesis are very leaky, due to the defects in or 
absence of endothelial basement membrane, abnormal growth and shape of endothelial 
cells and increased space between cell junctions [187, 188]. These poorly-formed vessels 
favour the intravasation of migrating tumour cells into these vessels [189]. This is 
potentiated by the local release of factors such as TGFβ and VEGF, which further promote 
vessel permeability through breakdown of endothelial cell junctions, thus creating openings 
between endothelial cells [190-192]. 
 Intravasation is regulated by similar factors governing migration and ECM 
degradation, such as N-WASP [193], MMT4-MMP [194] and ADAM12 [195]. Both MMT4-
MMP and ADAM12 act to disrupt vessel integrity, with ADAM12 appearing to cleave 
vascular endothelial cadherin, thus weakening the lateral attachments between endothelial 
cells [194, 195]. Notch signalling also appears to be involved in the intravasation process, as 
suppression of Notch signalling prevents intravasation, at least in colon cancer [196]. 
Induction of endothelial cell apoptosis by tumour cells also contributes to enhanced 
vascular permeability [190]. 
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 1.1.1.4.2 Extravasation 
 
 Once within the vessel, tumour cells tend to associate with platelets and 
coagulation factors such as fibrin and thrombin, which serve to protect the cell from the 
shear stress of blood flow but also affect its arrest at secondary sites [197, 198]. These 
secondary sites tend to be in small capillaries and are thought to result from the size-
restriction imposed on the tumour cell by the size of the capillary [199-201]. This arrest 
allows adhesion interactions to take place between the tumour cell and capillary 
endothelium [190, 202]. These initial interactions are mediated by endothelial (E)-selectin 
binding of ligands expressed on the tumour cell, notably haematopoietic cell E-selectin/L-
selectin ligand (HCELL), P-selectin glycoprotein ligand 1 (PSGL1), mucin 1, CD24 and 
galectin-3-binding protein (LGALS3BP) [190, 202, 203]. N-cadherin may also be important in 
these initial interactions [202, 204]. 
 More stable interactions are subsequently formed between the tumour cell and 
endothelium, mainly mediated by CD44 [205, 206] and a number of integrins (reviewed in 
[207]). Endothelium-bound tumour cells are then able to extravasate from the vessel via 
the same mechanisms used to intravasate, but must overcome one final hurdle, that of the 
endothelial cell basement membrane [207]. Presumably this is achieved through the 
release of matrix-degrading proteins, although this has not been shown experimentally. 
 Opposing changes in cell adhesion thus seem to contribute to intra- and 
extravasation. On the one hand, cell must become less adherent in order to leave the 
primary tumour site, but must then be more adhesive in order to bind to the vessel 
endothelium or risk never exiting the bloodstream. However, these processes appear to be 
regulated by different classes of adhesion molecules; cadherins and integrins mediate the 
former, while the latter is regulated by glycoproteins and lectins. Thus, in the context of 
tumour dissemination, the favourable loss of cell-cell and cell-ECM adhesions need not 
impact on the requirement to form adhesion-based interactions with the vessel 
endothelium that allows colonisation of secondary sites. 
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1.2 Epithelial-mesenchymal transition  
 
 As hinted at above, many of the processes that favour metastasis, especially those 
relating to adhesion and migration, are linked with epithelial-mesenchymal transition, a 
characteristic feature of cancers arising from epithelial tissues where there is a loss of 
epithelial-like characteristics and the acquisition of mesenchymal-like properties [208-210]. 
These changes are mediated by a number of pathways and culminate, at least in the 
context of carcinogenesis, in the production of highly motile and invasive cells [208, 209]. 
EMT is not necessarily a pathological process however, and occurs in embryo and tissue 
development as well as in wound healing [211]. It is also becoming clear that EMT is a 
plastic process which can be reversible, with cells also able to undergo only partial EMT 
[210]. 
 
 
1.2.1 Induction of cellular changes in EMT 
 
 As mentioned in section 1.1.1.1, intercellular adhesion complexes are involved in 
maintaining epithelial cell polarity. Polarisation of the apical compartment is achieved 
through interactions of cell junctions with two complexes: the Crumbs complex (consisting 
of Crumbs protein, PALS1 (protein associated with Lin-7 1) and PATJ (PALS1-associated 
tight-junction protein) and partitioning-defective (PAR) complex (comprising PAR3, PAR6 
and atypical protein kinase C (aPKC)) [212]. Similarly, the basolateral compartment contains 
the Scribble complex (Scribble, Discs large (DLG) and lethal giant larvae (LGL)) [212]. When 
EMT is initiated, there is a downregulation of cell junction proteins which disrupts the 
interactions with the cell polarity complexes, ultimately leading to a loss of cell polarity 
[213, 214]. Thus the loss of cell-cell adhesions promotes loss of cell polarity, and the loss of 
E-cadherin in particular (which is cleaved and degraded [214]) results in release of β-catenin 
and p120 catenin, which are further involved in driving the EMT process through their 
effects on gene transcription [215, 216] (see below). The loss of cell polarity has knock-on 
effects on actin cytoskeleton dynamics, allowing increased migration through the 
generation of increased numbers of lamellipodia [209, 214, 217]. 
 The migratory behaviour of cells undergoing EMT is typically further modulated by 
the ‘cadherin-switch’, where the repression of E-cadherin is coupled with the expression of 
neural (N)-cadherin [214, 218]. As described in Section 1.1.1.1, cadherins regulate cell-cell 
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adhesion, and as N-cadherin is also expressed on mesenchymal cells, cell-cell interactions of 
cells undergoing EMT with the mesenchyme are promoted, favouring migration away from 
the epithelial lining [210]. Furthermore, these homotypic N-cadherin interactions are 
weaker than homotypic E-cadherin interactions, further favouring migration and invasion of 
the surrounding stroma [219]. Importantly, N-cadherin expression also induces expression 
of neural cell adhesion molecule (NCAM) [214, 220], through which focal adhesion 
assembly is promoted, thus further promoting cell migration [221]. The loss of E-cadherin is 
further potentiated by changes to the make-up of intermediate filaments, with the 
upregulation of vimentin at the expense of cytokeratins, which results in a loss of 
cytokeratin-mediated transport of E-cadherin to the membrane [213, 222]. Vimentin-
mediated interactions with motor proteins may also promote an increase in cell migration 
[223]. Also, as outlined in section 1.1.1.2, EMT also drives alterations to cell-ECM adhesion, 
promoting a switch from basement membrane-binding integrins such as α6β4 [93] to 
fibronectin-binding integrins such as α5β1 [96, 97], thus favouring detachment from the 
basement membrane and driving migration. 
 
 
1.2.2 Inducers of EMT 
 
1.2.2.1 TGFβ 
 
 Both TGFβ and bone morphogenic protein (BMP) ligands bind to and exert their 
actions through two TGF receptors, TGFRI and TGFRII [224, 225]. Binding of TGF ligands to 
TGFRII promotes its association with TGFRI, leading to the modulation of the activity of the 
SMAD (mothers against decapentaplegic) family of intracellular signalling molecules, which 
can be activating or inhibitory (reviewed in [226]). The major effects of TGFβ signalling are 
mediated by the SMAD-dependent upregulation of a number of transcription factors that 
regulate the expression of EMT genes, including Snail1 and 2 [227, 228], ZEB1 (Zinc-finger E-
box-binding 1) [229] and Twist1 [230] (see below). Some genes are upregulated by SMADs 
without the need for EMT transcription factors, including fibronectin and vimentin [231-
233]. 
 TGFβ also has SMAD-independent functions, signalling through phosphoinositide 3-
kinase (PI3K)/Akt, RhoA GTPase and MAPK pathways to promote EMT [234]. EMT is 
prevented by pharmacological inhibition of PI3K, suggesting that it plays an important role 
in relaying pro-EMT signals [235]. Similarly, inhibition of the extracellular signal-regulated 
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kinase (ERK) and p38 MAPK pathways inhibits the TGFβ-mediated EMT, and the c-Jun N-
terminal kinases (JNK) pathway is also thought to be involved [234, 236, 237]. The effects of 
these pathways on EMT seem to revolve around increasing Snail activity and promoting the 
expression of N-cadherin and MMPs, as well as the repression of E-cadherin, although their 
exact roles are not yet clear [210, 238-241]. 
 Another SMAD-independent mechanism of TGFβ-induced EMT involves RhoA, 
where effects are mediated in two opposing ways, related to the involvement of RhoA in 
both cell-cell junction and lamellipodia formation [242, 243]. In the initial stages of EMT, 
TGFβ promotes the SMURF1 (SMAD ubiquitination regulatory factor 1)-dependent 
ubiquitination and degradation of RhoA, promoting the breakdown of cell-cell junctions 
[244] whereas in the later stages of EMT, TGFβ signalling events promote RhoA activation 
and lamellipodia formation, thus promoting migration [245]. The mechanism involved in 
switching between RhoA degradation and RhoA activation is not clear, however.  
 It is interesting that TGFβ -SMAD signalling mediates non-pathological EMT during 
organ development [234, 246], and in normal cells it generally has growth inhibitory and 
pro-apoptotic effects, and can thus be considered a tumour-suppressive pathway [234, 
247]. Thus in tumourigenesis, it appears that crosstalk between the TGFβ pathway with 
other pathways such as MAPK, PI3K and RhoA (as outlined above), effectively suppress the 
growth-inhibitory functions of TGFβ [245, 247, 248], presumably by overriding the 
cytostatic TGFβ effects through their own overwhelming pro-proliferative and anti-
apoptotic signals, but also through mediating nuclear translocation of SMADs through 
phosphorylation [249]. In this way, EMT regulatory function of TGFβ signalling remains in 
the absence of its cytostatic effects, promoting tumour cell EMT [247, 248]. 
 
 
1.2.2.2 Growth factor receptors 
 
 In addition to the TGFβ-mediated activation of PI3K/Akt and MAPK pathways 
described above, the activation of these pathways by growth factor receptors can also 
induce EMT. Here, oncogenic activation of Raf and Ras seem to be important, promoting 
Snail1 and 2 expression and Rho activation [241, 250]. FGF1 can induce EMT in tumour cells 
through expression of Snail2, dissolution of desmosomes and expression of pro-migratory 
integrins and MMPs [251-253]. Similarly, PDGF promotes cell junction breakdown and E-
cadherin downregulation in tumour cells [254], whilst VEGF can also promote EMT through 
Snail and possibly also Twist [254, 255]. In turn, Snail also upregulates VEGF expression 
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[256]. Overall, involvement of FGFs, PDGF and VEGF in both EMT and angiogenesis provides 
a useful mechanism in the context of tumour development, where the induction a cell type 
with altered adhesion properties and a more migratory phenotype is coupled to a means of 
disseminating to secondary sites. 
 
 
1.2.2.3 Induction by developmental pathways 
 
 Developmental pathways can promote EMT in tumour cells, probably as a result of 
their involvement in physiological EMT mechanisms. The Wnt pathway, which is involved in 
embryo formation [257], induces EMT in tumour cells through β-catenin-mediated gene 
expression and also by increasing the stability of Snail1 [215, 258]. Likewise, the Delta-
like/Jagged-Notch pathway enhances Snail2 expression, which has been shown to 
contribute to lung cancer invasion [259, 260]. 
 
 
1.2.3 Transcriptional regulation of EMT 
 
 As alluded to above, inducers of EMT converge on the modulation of several key 
transcription factors that drive the cellular changes associated with EMT. These 
transcription factor families, namely of the Snail family (Snail1 and 2), ZEB family (ZEB1 and 
2) and the basic helix-loop-helix (bHLH) family (including Twist1 and 2), not only control 
each other’s expression but also co-operate with each other to promote the expression of 
EMT genes, whilst at the same time repressing epithelial gene transcription [261, 262]. It is 
these transcription factors that can directly change the adhesion properties of cells that are 
characteristic of EMT, repressing many intercellular adhesion molecules such as E-cadherin, 
occludin, claudin, desmoplakin and plakophilin, whilst at the same time promoting 
expression of N-cadherin and fibronectin, amongst others (reviewed in [210]). 
 
 
1.2.4 MicroRNA regulation of EMT  
 
 EMT is not only controlled at the protein level and the role of microRNAs in the 
control of EMT is becoming ever more apparent. Many of the major transcription factors 
described above are also regulated at the mRNA level through the actions of microRNAs, 
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including Snail 1 and 2, ZEB 1 and 2 and Twist, as is the expression of epithelial junction 
proteins such as E- and N-cadherin (reviewed in [263]). It is therefore through the balance 
of these microRNAs and the protein factors outlined above that progression or inhibition of 
EMT is controlled. 
 
 
1.2.5 Mesenchymal-epithelial transition (MET) 
 
 There is increasing evidence to suggest that metastatic cells that have undergone 
EMT to migrate and colonise secondary site subsequently undergo the reverse process of 
MET, in order to establish tumours at these secondary sites. This stems from several 
observations (reviewed in [264]), including that metastases tend to contain cells with 
epithelial-like phenotypes [265-267] and that in animal models, epithelial-type cells rather 
than EMT-type cells were better able to form metastases [268, 269]. The mechanism of 
induction of MET is not yet clear, but it has been suggested that it might occur due to the 
loss of pro-EMT signals at the metastatic site, thus reverting these cells back to their 
‘default’ epithelial phenotype [270, 271], or potentially through more pro-MET-type signals 
originating from the presumably non-transformed stroma at the secondary site, as 
evidenced by the apparent differentiation of prostate cancer cells cultured in the presence 
of normal hepatocytes [272]. An element of the ‘seed and soil’ hypothesis might also be 
involved here, where the secondary target site must provide a suitable microenvironment 
(i.e. soil) to support the induction of MET in the metastatic cell (i.e. the seed), to allow 
tumour growth and establishment of the secondary tumour [273, 274]. Regardless of the 
mechanism of induction, it appears that, in the opposite manner to EMT, the MET process 
is characterised by the re-acquisition of E-cadherin expression [275], and thus presumably 
more epithelial-like adhesion properties. The regulation of MET does appear to be similar 
to EMT however, in that it is associated with downregulation of Snail, ZEB and Twist 
proteins (reviewed in [264]), suggesting that the transcriptional activity, or loss thereof, of 
these transcription factors are important mediators of MET. 
 
 
1.2.6 EMT and anoikis 
 
 Anoikis is a form of apoptosis that occurs when cells detach and lose contacts with 
the ECM [276]. As EMT promotes migration of cells away from their tissue of origin and 
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hence causes disruption to the ECM-cell adhesion contacts, resistance to anoikis is 
necessarily linked to the EMT process, and is a required step in the metastatic cascade 
[277]. Like classical apoptosis, anoikis is activated through both intrinsic and extrinsic 
pathways that converge on the activation of caspases [278], but a caspase-independent 
pathway also exists (see below). 
 
 
1.2.6.1 Intrinsic pathway of anoikis 
 
 The intrinsic pathway is regulated by members of the Bcl-2 (B-cell lymphoma-2) 
family, which lie downstream of the PI3K/Akt and Ras pathways regulated by FAK and Src, 
including Mcl-1 (induced myeloid leukemia cell differentiation protein 1) and Bcl-XL, as well 
as caveolin-1 (Cav-1) and 14-3-3ζ (reviewed in [279]). Mcl-1 and Bcl-XL both block the 
release of cytochrome c from the mitochondrial membrane, promoting cell survival [280] 
and overexpression of both is associated with increased resistance to apoptosis and 
decreased patient survival [281, 282]. The overexpression of Cav-1 has been reported in 
lung cancer, where it probably promotes the activity of Mcl-1 by preventing its degradation 
[283]. On the other hand, 14-3-3ζ is thought to contribute to anoikis-resistance through 
blocking pro-apoptotic signal from Bad [284] and p53 [285]. The involvement of 14-3-3ζ in 
anoikis-resistance is particularly interesting, as it is associated with increased potential for 
metastasis [286], whilst also increasing the risk of tumour recurrence [287]. 
 
 
1.2.6.2 Extrinsic pathway of anoikis 
 
 The extrinsic apoptotic pathway of anoikis is activated by ligation of Fas ligand with 
death receptors on the cell surface [288]. Active Fas ligand can be bound to the ECM [289] 
and thus cells migrating through the matrix presumably risk activation of the extrinsic 
apoptotic pathway. Resistance to the extrinsic pathway is thought to be mediated by cFLIP 
(cellular FLICE (FADD (Fas-associated death domain)-like IL-1β-converting enzyme)-
inhibitory protein), whose overexpression is associated with increased metastasis and can 
also confer anoikis-resistance [290, 291]. It functions through competitive inhibition of 
death receptor-induced procaspase-8 activation, thus preventing the initiation of the 
caspase cascade and cell death [292]. 
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1.2.6.3 Caspase-independent pathway of anoikis 
 
 A third pathway of apoptosis is regulated by the actions of the mitochondrial 
protein Bit-1 (Bcl-2 inhibitor of transcription 1). Upon disengagement of integrin-ECM 
interactions, Bit-1 translocates to the cytoplasm and causes the relocalisation of TLE1 
(transducin-like enhancer of Split 1) from the nucleus to the cytoplasm and its subsequent 
proteasomal degradation [293, 294]. TLE1 is a repressor of endonuclease expression, and 
its export from the nucleus promotes endonuclease expression and subsequent cell death 
[295]. Reduction in cytoplasmic Bit-1 promotes tumour progression in breast cancer and 
appears to promote anoikis resistance in breast cancer cell lines [293, 296]. 
 It is unclear whether one of these three pathways of anoikis in particular is more 
important for preventing apoptosis of metastatic cells over any other, and further 
investigation will be required to determine whether they occur together or separately. 
Regardless of the mechanism involved, it is clear that, like many other regulatory processes, 
anoikis is an obstacle that must be overcome by tumour cells in order to metastasise. In 
addition to the pathways described above, oncogenic activation of intracellular signalling 
pathways such as PI3K, ERK and RhoA, also promote resistance to anoikis, by providing pro-
survival signals that can ‘override’ the pro-apoptotic signals from loss of cell adhesion [269]. 
In this way, the pro-EMT signals provided through these same signalling pathways (see 
Section 1.2.2.2) also promote the survival of these metastatic cells, as only anoikis-resistant 
cells will be able to colonise secondary sites [297]. In this way, the transformation and 
metastatic spread of tumour cells is linked by the crosstalk between core intracellular 
signalling pathways that have multiple and complementary outcomes on tumour cell fate, 
which eventually lead to the promotion of tumour cell dissemination.  
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1.3 Protein folding and secretion 
 
 The processes identified so far that contribute to metastasis often involve dynamic 
changes in protein abundance, and thus must necessarily involve regulation of the protein 
folding machinery, as well as the regulation of the secretory pathway in the context of 
extracellular and cell surface proteins such as TGFβ and integrins. As regulators of this 
protein homeostasis, it is evident that protein chaperones can be exploited in the 
metastatic process to increase the output of correctly folded proteins that promote various 
aspects of tumour progression. Indeed, protein chaperones have been directly linked to 
oncogenesis, where inhibition of heat shock protein 70 (HSP70) stimulates cancer cell 
apoptosis [298] and HSP90 expression is associated with neoplasia and poor prognosis of 
breast and gastric cancers [299]. It is also interesting that several HSP90 substrates include 
known oncogenes such as Abl, Src and Akt [300], and the chaperone AGR2 (anterior 
gradient protein 2) is also associated with metastasis [301-309]. Thus the control of protein 
folding is an important aspect of tumour biology. 
 
 
1.3.1 Protein disulphide isomerases and protein folding within the endoplasmic reticulum 
 
 Many proteins require the assistance of protein folding chaperones, in particular 
proteins destined for secretion or the cell surface, which also contain several modifications 
that are mediated by enzymes and chaperones within the ER and Golgi [310]. The 
assumption of correct disulphide bonds within these proteins is often the rate-limiting step 
in the folding process within the ER [311] and it is estimated that approximately 30 % of 
proteins travelling through the ER contain at least one disulphide bond [312]. Disulphide 
bonds are important structural determinants, as they limit the possible structural 
conformations of a given protein due to their covalent nature [313]. Formation of 
disulphide bonds in ER proteins is regulated by members of the protein disulphide 
isomerase (PDI) family of chaperones, which also catalyse their reduction and 
isomerisation. PDI itself is the archetypal member of the enzyme family, and was the first 
enzyme involved in protein folding to be discovered [314]. Structurally, the 20 PDI family 
members identified to date have a similar feature, in that they contain a thioredoxin-like 
fold, based on a βαβαβαββα secondary structure arrangement, but otherwise their size and 
domain structure varies quite considerably [315, 316]. In general, PDI proteins tend to 
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contain at least one catalytic domain or ‘a’ domain, and can contain one or more 
catalytically-inactive or ‘b’ domains [315] (Fig.1.3). These b domains tend to be involved in 
substrate binding or recruitment of co-factors and as such have only limited sequence and 
structural homology [312, 315]. 
 The PDI a domains house the active site, with the consensus sequence CxxC [312, 
315]. In general, the N-terminal Cys in this sequence forms mixed disulphides with the 
substrate protein, as its thiol group tends to become deprotonated at physiological pH, 
whilst the C-terminal Cys is required for subsequent release of the substrate [312, 317]. 
PDIs containing only a single Cys in the active site can also form mixed disulphides with 
target proteins, as exemplified by PDILT (protein disulphide isomerise-like protein of the 
testis) and ERp44 [318-320]. However, it appears that at least two CxxC-containing catalytic 
domains are required for efficient isomerisation reactions [321, 322]. Interestingly, PDIs 
need not be catalytically active towards thiol groups to be denoted as PDI family members, 
as demonstrated by two family members containing thioredoxin-like folds but no active site 
Cys residues, ERp27 and ERp29 [323, 324]. These proteins are obviously not redox-active 
and are therefore probably involved in a different type of chaperone activity than the CxxC 
and CxxS PDI proteins. Classification as a PDI therefore relates more to the presence of a 
structurally similar thioredoxin fold than a necessarily redox-active domain. 
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Figure 1.3. Overview of PDI family domain structures. a domains are shaded in 
purple and b domains in blue. a’ and b’ denotes their positions in the sequence. 
Yellow boxes represent linker regions, which probably increase the flexibility 
between a and b domains, and the green box denotes the ERdj5 DnaJ domain, a 
protein interaction domain. White boxes denote transmembrane regions. The 
hashed PDILT domain denotes its similarity to other a domains. Figure adapted from 
Kozlov et al., 2010 [315]. 
 
 
 
 
1.3.2 Intrinsically disordered regions in protein chaperones 
 
 Intrinsically disordered regions (IDRs) are flexible sections of proteins that have no 
defined 3-dimensional conformation, at least in the absence of interactions with other 
proteins [325, 326]. These IDRs tend to contain a high proportion of polar amino acids, 
whereas hydrophobic residues are underrepresented, thus favouring the solvent exposure 
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of these regions over their internalisation towards the protein hydrophobic core [327]. 
Importantly, IDRs of 30 residues in length or more are reported to be present in over a third 
of all eukaryotic proteins, pointing to the possible global importance of these regions [328]. 
 The functions of these IDRs are wide-ranging, including roles in signal transduction, 
regulation of subunit assembly, and transcription and translation [325, 329-331]. This 
functional flexibility stems from their structural flexibility, which provides a freedom of 
movement lacking in more structured regions of proteins, allowing increased sampling of 
the environment, which leads to increased numbers of interactions. These linear, unfolded 
regions are also more accessible to other molecules than tightly folded structured domains, 
providing larger interaction surfaces [332]. This trade off between increased chances of 
interactions at the expense of rigid interaction domains creates IDR-mediated interactions 
that are weak but specific, ideal for regulatory-based functions [332]. These interactions 
should allow rapid but specific activation and deactivation of interaction events, and are 
thought to be mediated by binding-coupled folding, where the unstructured region 
assumes a defined fold upon binding to a target protein [326, 333]. 
 The characteristics of IDRs are also particularly suited to the roles of protein 
chaperones. One study into the prevalence of IDRs in RNA and protein chaperones found 
that, in the dataset used, around 80 % of protein chaperones possessed an IDR of at least 
30 residues in length, and 50 % had an IDR of at least 40 residue in length [334]. In contrast 
to RNA chaperones however, longer IDRs of more than 40 residues in length seem to 
appear less frequently in protein chaperones, possibly reflecting the need for an overall 
more ordered structure that still remains pliable, that presumably must accommodate a 
bulkier protein substrate than the less bulky RNA [334, 335]. The prevalence of IDRs in 
chaperone molecules probably stems from the requirement to constantly probe the 
surrounding environment for the presence of misfolded proteins through the process of 
‘fly-casting’ [333] and also the need for chaperones to bind multiple substrate molecules, 
most likely in different folded states, where a highly structured region would not allow this 
range of conformational substrate interactions [334]. A further advantage of substrate 
binding through IDRs is that binding tends to prevent aggregation of substrate proteins due 
to the general polar nature of these regions that aid in protein solubilisation [333, 336]. 
  The importance of IDRs in chaperone activity is highlighted by the RNA chaperone 
α-crystallin, where mutations reducing the flexibility of its IDR reduce its chaperone activity, 
showing a functional link between IDRs and chaperone function [337]. Similarly, the 
importance of IDRs in the contribution to disease states was highlighted in a study of 
missense mutations in the UniProt database, where over 20 % of all mutations were found 
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within IDRs [338]. Interestingly, 20 % of these IDR mutations resulted in a shift towards a 
more ordered structure, providing evidence that it is the inherent flexibility of these regions 
that contribute significantly to IDR-containing protein function. 
 
 
1.3.3 ER-Golgi transport, protein glycosylation and secretion 
 
1.3.3.1 ER-Golgi transport 
 
 The transport of proteins destined for secretion or the cell membrane is mediated 
by the COPII (coat protein II) complex (reviewed in [339]). COPII-coated vesicles capture 
and deliver protein cargo to the cis-Golgi network, but a retrograde transport system from 
the Golgi back to the ER also exists for the retrieval of ER proteins that have ‘escaped’ to 
the Golgi [339, 340]. This retrograde transport is mediated by COPI-coated vesicles [339, 
340], but the cargo itself is recognised by the ERD2 (ER retention-defective 
complementation group 2) family of receptors in the cis-Golgi [341]. In humans this family 
is made up by ERD21, 22 and 23 [342], and these receptors recognise cargo for retrograde 
transport through binding to C-terminal HDEL motifs (and derivatives thereof) in relevant 
ER-luminal proteins and K(X)KXX and RXR motifs in transmembrane ER proteins [339, 342]. 
The ERD2 receptors appear to bind directly to the COPI coat to promote their transport 
back to the ER [341, 343], where release of the cargo protein from the ERD2 receptors 
appears to be mediated by the rise in pH in the ER [344]. 
 
 
1.3.3.2 N-linked glycosylation 
 
 N-linked glycosylation occurs co-translationally in the ER, where a 14-moiety core 
glycan is added to target Asn residues by the OST (oligosaccharyl-transferase) complex, 
after which trimming occurs by glucosidases and mannosidases (reviewed in [345]). 
Although these ‘high mannose’ N-glycans can continue unchanged along the secretory 
pathway, they are not often found in differentiated cell types, but are prevalent in stem 
cells [346, 347]. Instead, these glycan chains are usually edited as the protein travels 
through the Golgi network. The glycans are first trimmed by the actions of Golgi-
mannosidases (mannosidase IA, IB, IC and II), which generate structures containing either 5 
or 3 mannose residues, which in turn affect the later glycan processing steps [347, 348]. 
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The trimmed glycans then become substrates for glycosyltransferases (GTs), which catalyse 
the addition of N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), galactose, 
fucose and sialic acid residues, leading to the formation of complex, branched glycan chains 
[347, 349]. 
 GTs are located throughout the Golgi, from the cis- to trans-face [347, 350] and in 
general, the cis-compartment contains GTs involved in initiating O-glycosylation (see below) 
(as well as the N-glycan mannosidases), the medial-Golgi contains GTs for branching both 
N- and O-glycans, and in the trans-compartment and trans-Golgi network, GTs cap the 
glycan chains through the addition of terminal galactose, sialic acid or fucose residues [347, 
349, 351]. However, the story in reality is much more complex, as there are an estimated 
200 to 250 GTs residing in the Golgi and their localisations appear to overlap or change 
between cell types [352-354]. Thus the regulation of glycan maturation is still not totally 
clear, but probably involves recognition of specific structures for individual GTs, the 
sequestration of different GTs into different Golgi cisternae and sub-compartments, as well 
as complex COP-mediated intra-Golgi transport of GTs [349, 352, 355]. Another interesting 
regulatory mechanisms probably stems from gradual acidification of the Golgi from cis to 
trans [356], as Golgi pH has been shown to affect both the activity and distribution of Golgi 
GTs [357, 358]. 
 
 
1.3.3.3 O-linked glycosylation 
 
 Several types of O-glycosylation of Ser and Thr residues exist, including O-
fucosylation, O-galactosylation, O-glucosylation and O-mannosylation, but the majority of 
O-glycosylations is made up by mucin-type O-glycans [347, 359]. As the name suggest, this 
type of glycosylation is predominant in mucin proteins, where extensive glycosylation 
allows them to form mucus gels which protect epithelial linings (reviewed in [360]). Mucin-
type O-glycosylation is initiated by the transfer of a GalNAc residue onto Ser or Thr residues 
within the Golgi [359, 361], although studies have shown that the addition of GalNAc can 
be initiated in the ER during oncogenesis [362, 363]. An important feature of mucin-type O-
glycosylation is that there exists 15 or more GalNAc GTs that catalyse the initial transfer of 
the GalNAc residue, whereas other types of O-glycosylation use just one or two enzymes, 
and N-glycosylation uses the OST complex [345, 347, 359]. The purpose of so many GTs is 
not clear, though it might provide functional redundancy within the system, or could be the 
cause of, or result of, the lack of observed consensus sequence for O-glycosylation, such 
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that different GTs are required to recognise different substrates [347, 359, 364]. The 
addition of the GalNAc residues then allows the extension and branching of the glycan 
chain through the actions of other Golgi GTs as described above for N-glycosylation. 
 
 
1.3.3.4 Protein secretion 
 
 Secretory and plasma membrane proteins that have travelled through the Golgi 
eventually make their way to the trans-Golgi network (TGN), a tubular membrane network 
that acts as the major sorting point for proteins exiting the Golgi (reviewed in [365]). The 
TGN provides the vesicles required for transport to the plasma membrane, and loaded TGN 
vesicles are transported to the plasma membrane along microtubules, where they 
encounter the exocyst complex. This octameric complex is involved in several vesicle 
trafficking processes, but in the context of secretion it promotes the tethering of the vesicle 
to the plasma membrane and the subsequent release of the cargo (reviewed in [366]). 
Interestingly, the exocyst complex also appears to be involved in the regulation of 
membrane protrusions and cell migration, possibly through promoting the generation of 
branched actin networks [367-369] (see Section 1.1.1.3). Furthermore, the exocyst is found 
at E-cadherin-containing cell junctions in normal epithelia [370, 371] and is required for E-
cadherin delivery to the membrane in Drosophila [372]. However, the exocyst is 
redistributed to sites of membrane protrusions upon dissolution of cell-cell junctions in rat 
prostate cancer cells, where it is associated with adhesion complexes [373]. It was also 
shown to regulate the delivery of β1 integrins to the leading edge of migrating MDA-MB-
231 and HeLa cells [374]. The exocyst complex may play an important role in cell-cell 
adhesion, cell-ECM adhesion and the metastatic spread of tumours. 
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1.4 Anterior Gradient protein 2 
 
 First identified in a screen of oestrogen responsive genes in the MCF7A mammary 
adenocarcinoma cell line [375] and then shortly afterwards as a protein expressed in 
murine goblet cells in the intestinal tract [376], anterior gradient protein 2 (AGR2) is the 
human homologue of the Xenopus laevis XAG-2 (Xenopus anterior gradient 2) protein. XAG-
2 functions along with XAG-1 to regulate the formation of the mucus-secreting cement 
gland during Xenopus embryogenesis [377]. The human homologue of XAG-1 is 
ERp18/AGR1 [378], but apart from displaying PDI activity, its specific function is unknown 
[379, 380]. The AGR family is completed by AGR3 [381-383], which, in ovarian cancer, is 
associated with differentiation and also appears to mediate cisplatin resistance, but its 
function in normal tissue is largely unknown [384-386]. 
 
 
1.4.1 Regulation of AGR2 expression 
 
 The AGR2 gene is situated on chromosome 7p21.3 [387]. Two mRNA transcripts 
have been reported for AGR2, but the functional consequences of the transcript containing 
an additional 5’ exon are not known [384, 388]. Oestrogen was one of the first regulators of 
AGR2 gene expression identified, in the original discovery of AGR2 by Thompson and 
colleagues [375]. Here they found that AGR2 was expressed in the oestrogen receptor (OR)-
positive MCF7A mammary cell line but absent in the OR-negative mammary cell line MDA-
MB-231. Several studies have since shown an association of AGR2 expression with OR in 
breast cancer [309, 389, 390], and its expression has similarly been shown to be regulated 
by androgens in prostate cancer [309, 388, 390, 391]. 
 Other important regulators of AGR2 expression have also been identified in a 
variety of experimental systems, including the forkhead box transcription factors Foxa1, 
Foxa2, Foxp1 and Foxp4 [305, 384, 392-394], as well as hepatic nuclear factor 1 which 
belongs to the same transcription factor family [384]. The Foxa family is a key regulator of 
the development of organs arising from the endoderm which include the lung, prostate, 
pancreas and liver (reviewed in [395]), where knockout of Foxa2 is embryonically lethal 
[396] and Foxa1 knockout results in early neonatal death [397]. Foxp proteins appear to be 
involved in the regulation of heart, lung, gut and oesophageal development, where again, 
loss of Foxp1 or Foxp4 are both embryonically lethal [398-402]. The fact that AGR2 
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expression is found in the human foetal liver [403] and also promotes the development of 
the lung epithelium [392] also suggests that AGR2 plays a role in organ morphogenesis. It is 
also interesting that Foxp1 enhances oestrogen-driven gene transcription in MCF7A breast 
cancer cells [404], whilst, in a panel of breast cancer cell lines, Foxa1 was found to be 
required for OR binding to chromatin [405], thus further cementing AGR2 as a hormone 
responsive gene.  
Direct binding of the Sox10 (SRY (sex-determining region Y)-related HMG (high 
mobility box) box 10) transcription factor to the AGR2 promoter has been demonstrated 
during otic vessel formation in the zebrafish embryo, where Sox10 knockdown also reduced 
AGR2 expression [406]. Similarly, a binding site for Sox9 is predicted in the AGR2 promoter 
[407], but no experimental evidence exists of its regulation of AGR2 expression. 
Interestingly, AGR2 knockdown results in increased levels of Sox9 expression in the murine 
gut, suggesting that AGR2 is a repressor of Sox9 [408, 409]. Sox9 may be a stem cell marker 
[410], and thus, its repression by AGR2 suggests that AGR2 promotes differentiation of 
Sox9-positive cells in the murine gut [409]. 
Whilst the transcriptional regulators mentioned above suggest a role for AGR2 in 
tissue development, the demonstrated binding of the oncogenesis-associated zinc finger 
transcription factor ZNF217 to the AGR2 promoter in the metastatic lung cancer cell line 
Ntera2 [411] points to a role for AGR2 in cancer and metastasis (see below). In line with 
this, AGR2 expression is also regulated by TGFβ (itself implicated in oncogenesis and EMT, 
see section 1.2.2.1) through the SMAD4 transcription factor in pancreatic neoplasia [412]. 
 Aside from the specific transcriptional regulators noted above, expression of AGR2 
is also controlled by physiological stress. Serum-starvation in combination with hypoxia was 
found to induce AGR2 expression in vitro, and was mediated at least in part through the 
ERK1/2 pathway in the breast cancer cell line, MDA-MB-231 [413]. A further study indicated 
that this AGR2 induction was HIF1α-dependent, and that together these two proteins 
contributed to angiogenesis in glioblastoma [414]. AGR2 is also expressed in response to ER 
stress, where it protects cells from stress-induced cell death [408, 415-419]. This induction 
appears to be dependent on the ATF6 (activating transcription factor 6) and IRE (inositol-
requiring protein 1) elements of the unfolded protein response [417], the process activated 
to restore ER homeostasis (reviewed in [420]). This implies that AGR2 might function as an 
ER chaperone. 
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1.4.2 Normal functions of AGR2 
 
1.4.2.1 AGR2 and mucin expression 
 
 AGR2 (and indeed AGR3 and ERp18/AGR1) are members of the PDI family of ER 
chaperones, based on their structural homology to PDIs [378] (Fig. 1.3), and the recently 
solved structure of AGR2 demonstrated that the protein does indeed contain a thioredoxin-
like fold [421] (see Appendix 1), a defining feature of PDI family members [315]. However, 
AGR2 possesses the divergent CxxS active site motif [315]. 
 The major function of AGR2 was illustrated through a mouse knockout model, 
where loss of AGR2 led to loss of intestinal mucus production through the loss of mucin 2 
(MUC2) expression [408, 422]. This suggests that AGR2 contributes to the process of 
protecting the intestinal epithelial layer from insult, further demonstrated by the decrease 
in TFF3 (trefoil factor 3) levels in the intestinal tract of Agr2-/- mice [422], a secretory 
protein that plays a role in mucosal repair [423]. Furthermore, AGR2 was shown to form 
thiol-dependent interactions with MUC2 in vitro [422], but whether this reflects an active 
role for AGR2 in disulphide bond formation or just an association with free-thiol groups is 
not clear. It is clear however that AGR2 plays a role in the differentiation of intestinal goblet 
cells, and also in maintaining both the distribution and integrity of mucin secretory goblet 
and antimicrobial Paneth cells within the linings of the intestine and stomach [384, 408, 
409, 424-426]. 
  AGR2 was similarly shown to be involved in the production of two other gel 
forming mucins, MUC5B and MUC5AC [418, 427]. In an Agr2-/- mouse model of asthma, 
mice lacking AGR2 showed defects in the production of airway mucus in response to 
allergen treatment, with a concurrent increase in ER-trapped MUC5B and MUC5AC and the 
appearance of ER stress markers [418]. The authors also reported a physical association 
between immature mucins and AGR2, further supporting the notion that AGR2 acts as a 
chaperone for mucin proteins. 
 There is evidence that AGR2 is involved in the regulation of the expression of a 
further mucin, MUC1 [412]. MUC1 is a cell surface mucin that is not involved in gel 
formation, but is involved in maintaining cell polarity and cell-cell adhesions [428-431], and 
as such is often aberrantly expressed in cancer (reviewed in [432]). Likewise, there is also a 
positive correlation between AGR2 and the expression of another cell surface mucin, 
MUC4, in pancreatic adenocarcinoma, where the elevated levels of both proteins together 
were associated with lower grade tumours [433]. This suggests that MUC4 may be a 
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protective factor against cancer, but overexpression of MUC4 also induces metastasis [434, 
435], thus the exact role of MUC4 is probably context dependent [436]. 
 
 
1.4.2.2 Extracellular role of AGR2 
 
 AGR2 generally localises to the ER [417, 422, 437-439], although several studies 
have reported the secretion of AGR2 into cell culture medium [388, 426, 440], but whether 
this occurs merely as a consequence of cell lysis and subsequent release of abundant 
intracellular AGR2 has not been addressed. However, the abundance of AGR2 in mucus all 
along the murine gastrointestinal tract [426, 441, 442], as well as in human colonic mucus 
[426] probably suggests that AGR2 can be secreted in vivo. Others have also reported the 
association of AGR2 with the plasma membrane [302, 437, 443-445]. The consequences of 
these non-ER localisations of AGR2 are not clear, but several ER chaperone proteins, such 
as calreticulin, BiP and PDI, are also known to be secreted or membrane-bound [446-449], 
so this phenomenon is not AGR2-specific.  
 The newt homologue of AGR2 (nAG) is also secreted and nAG secretion is involved 
in limb regeneration via intercellular signalling through its surface receptor Prod1 [450, 
451]. Although there was initial promise of a similar mechanism occurring in mammalian 
cells when a yeast two-hybrid screen reported an interaction of AGR2 with C4.4a (a 
structural homologue of the most closely related human counterpart of Prod1, urokinase-
type plasminogen activator receptor (uPAR) [452, 453]) and the cell surface protein 
dystroglycan [389], there has been no further evidence that there exists a bona fide 
interaction between these molecules in vitro or in vivo in mammals. Nonetheless, there is 
some evidence for a role of secreted AGR2 in humans, as a mutant, highly secreted form of 
AGR2 expressed in A375 malignant melanoma cells upregulated the production of several 
proteins, notably dysferlin and WNK1 (with no lysine 1) [438]. These proteins promote 
membrane repair [454] and cell proliferation [455], respectively, and thus may support the 
notion of AGR2 contributing to intestinal epithelium homeostasis [384, 406, 408, 409, 425, 
426]. Furthermore, conditioned medium from AGR2-secreting pancreatic cancer cells was 
shown to promote their proliferation and invasion, which was lost upon AGR2 knockdown 
[440]. It is not clear however if these effects are directly caused by extracellular AGR2 or by 
the loss of secretion of as yet unidentified factors under the control of AGR2. 
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1.4.3 AGR2 in cancer 
 
 Several regulators and potential substrates for AGR2 highlighted so far are known 
to play a role in tumourigenesis, and AGR2 itself has been associated with the progression 
of a number of different cancer types, although hormone-dependent cancers such as breast 
and prostate cancers have been the most studied, given the regulation of AGR2 by 
oestrogens and androgens (see above). 
 
 
1.4.3.1 Hormone-dependent cancers 
 
 AGR2 seems to be particularly associated with the progression of breast cancer, 
possibly due to its role in breast tissue development, where it mediates proliferation of the 
mammary epithelium [456]. Multiple reports have identified its expression as a marker of 
disease stage and as a prognostic factor for patient survival in breast cancer, where 
increased expression of AGR2 is associated with reduced patient survival [309, 443, 457-
462]. Importantly, AGR2 is also implicated in the resistance of breast cancers to drug 
treatment. AGR2 was shown to mediate resistance to cisplatin [463], where tumour 
xenografts stably-expressing AGR2 were insensitive to cisplatin-mediated growth arrest, in 
contrast to isogenic xenografts not expressing AGR2. Tamoxifen treatment leads to 
upregulation of AGR2 expression, directly through an OR and Akt-dependent manner [459, 
460], but also in an OR-independent fashion through Foxa1 [393]. Thus, AGR2 expression is 
also predictive of Tamoxifen resistance [460]. On the other hand, treatment of patients 
with aromatase inhibitors such as letrozole and anastrozole downregulates the expression 
of AGR2 [464] (presumably through loss of oestrogen-mediated gene transcription) and in 
one patient cohort, those who responded the best to letrozole treatment corresponded to 
those patients that saw the largest suppression of AGR2 expression [459]. Therefore 
combination therapies including drugs affecting AGR2 expression might have a favourable 
outcome for breast cancer patients. 
 A similar role for AGR2 in the progression of prostate cancer is also apparent, with a 
number of studies again showing a correlation between AGR2 and the occurrence of 
prostate cancer, as well as decreased patient survival [388, 391, 444, 465-469]. 
Interestingly, studies in prostate cancer cells have revealed that knockdown of AGR2 can 
promote cellular senescence [470], but also that ErbB3 binding protein 1 (EBP1) acts as a 
negative regulator of AGR2 expression [305]. EBP1 is often downregulated in prostate 
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cancers [471, 472], and seems to inhibit AGR2 expression through inhibition of Foxa1 and 2. 
As downregulation of EBP1 is associated with resistance to hormone treatment [471] and is 
also presumably associated with upregulation of AGR2 expression [305], AGR2 could be a 
valid target for reducing hormone treatment resistance in prostate cancer, in a similar 
fashion to that seen in breast cancer. 
 The presence of AGR2 acts as a similar prognostic factor for other hormone-
dependent cancers. It is a marker of higher grade ovarian cancers, and can also be used to 
distinguish between serous and mucinous-type ovarian cancers [301, 473-476]. Pancreatic 
cancers are also sensitive to oestrogens [477], and the expression of AGR2 also appears to 
correlate with appearance of neoplastic or pre-neoplastic pancreatic cells [302, 412, 433, 
437, 440, 478-480]. 
 The prevalence of elevated AGR2 levels in these cancers (but also in some non-
hormone-dependent cancers, see below) may relate to its pro-proliferative and anti-
apoptotic effects. AGR2 mediates growth-regulatory effects in several cancer cell lines [301, 
393, 440, 459], where AGR2 knockdown results in decreased or inhibited growth. More 
strikingly, AGR2 knockdown also results in apoptosis of several cancer cell lines [415, 445, 
459, 470, 481] but in the context of breast cancers at least, this only appears to be true for 
OR-positive cell lines [482]. This suggests that some cancers may be dependent on AGR2 for 
survival. AGR2 appears to mediate these effects, at least in part, through upregulation of 
the cell cycle protein cyclin D1, as well as the pro-survival protein survivin [482], although 
how it influences the cellular abundance of these proteins is not clear. Additionally, AGR2 is 
also an inhibitor of p53 activity, preventing activation of pro-apoptotic protein transcription 
through inhibiting its phosphorylation [438, 445]. Again, whether these effects are 
mediated through direct interactions or are the result of influences on upstream regulators 
is unknown. 
 
 
1.4.3.2 Non-hormone dependent cancers 
 
 The occurrence of AGR2 expression in non-hormone dependent cancers is not as 
widely reported, presumably due to the strong effects of oestrogens and androgens on 
AGR2 expression. Nonetheless, AGR2 also appears to play a role in carcinogenesis in other 
tissues, generally those that contain a secretory epithelium. 
 AGR2 has been associated with the progression of oesophageal carcinomas, where 
it tends to be upregulated relative to normal tissue [394, 419, 445, 481, 483-485]. As 
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oesophageal carcinomas have been reported to display a characteristic inhibition of p53 
[486], AGR2 may promote disease progression through inhibition of p53 activation [445]. 
Similarly, there is a correlation between AGR2 expression and disease progression in lung 
cancers [303, 487-491]. 
 In cancers originating from the liver, the role of AGR2 appears to depend on the 
specific sub-type of carcinoma. As mentioned previously, AGR2 is expressed during liver 
and biliary tree morphogenesis [403] and seems to be maintained in normal liver [492], as 
well as in extrahepatic and some intrahepatic cholangiocarcinomas, where AGR2 expression 
correlates with mucus production [403]. AGR2 was similarly overexpressed in fibrolamellar 
carcinomas, but not in primary hepatocellular carcinomas (HCC), or at least only very rarely 
[403, 492]. However, high levels of AGR2 were found in metastatic HCC cells [304], 
suggesting that different selection pressures exist on AGR2 expression, depending on the 
cell type of origin. Furthermore, Yu and colleagues demonstrated that AGR2 directly 
interacted with elements of the MAPK and caspase pathways using co-immunoprecipitation 
experiments, and that this may contribute to the induction of metastasis in these cells 
[304]. However, the cellular expression levels of these potential interacting proteins were 
not investigated, so it is unclear if AGR2 affects the abundance of these proteins (in a 
similar way to mucins) or whether interaction with AGR2 results in some activation or 
inhibitory action. Any activity not based on protein abundance suggests an additional, 
chaperone-independent role for AGR2. Likewise, in colorectal carcinomas, where AGR2 
expression also correlates with mucus production and can distinguish between mucinous 
and non-mucinous carcinomas, elevated expression of AGR2 can predict both better and 
poorer patient outcome, based on the specific cancer sub-type [493-495]. However, it is 
possible that the increase in serum AGR2 mRNA in colorectal cancer patients identified by 
Valladares-Ayerbes and colleagues [496] could also reflect the expression of AGR2 in 
circulating tumour cells as reported previously [306], thus again implicating AGR2 in the 
metastatic process. 
 
 
 1.4.3.3 AGR2 downregulation in cancer 
 
 Whilst the majority of reports demonstrate AGR2 expression to be an indicator of 
poor patient outcome, a number of studies have also demonstrated a correlation between 
high levels of AGR2 expression and better disease prognosis. Two individual studies of 
breast cancer and prostate cancer showed that AGR2 expression correlated with improved 
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patient survival [497, 498]. However, this is not entirely unexpected, given the role of AGR2 
in differentiation of breast, intestinal and stomach tissues [409, 422, 424, 439, 456], where 
in the latter, loss of AGR2 leads to dedifferentiation and metaplasia [409, 439]. It is also 
important to note that the aforementioned studies on breast and prostate cancers did not 
stratify groups based on hormone receptor status.  The fact that hormone receptor positive 
cancers are generally more treatable than receptor-negative cancers [499], and that AGR2 
expression correlates with hormone receptor expression, may explain the apparent 
protective effect of AGR2. There are similar reports of AGR2-protective effects in ovarian 
cancer and colorectal cancer [493, 500], but this also positively correlates with cell 
differentiation in ovarian cancer [500] and probably also in colorectal cancer, given the role 
of AGR2 in the development and maintenance of the intestinal epithelium (see Section 
1.4.2.1). Also in biliary tract tumours, expression of AGR2 correlates with cell 
differentiation, such that AGR2 can be downregulated during progression of these tumours 
[501].It appears then that, in tissues where AGR2 is normally expressed and functions 
normally, AGR2 tends to be lost during tumourigenesis due to the loss of a differentiated 
cell phenotype, whereas in tissues where AGR2 is not normally, or only weakly expressed, 
AGR2 overexpression leads to pro tumourigenic effects, including increased proliferation 
and survival. 
 
 
1.4.4 AGR2 and metastasis 
 
 In addition to the association of AGR2 with different cancer types outlined above, a 
number of studies have demonstrated differential expression of AGR2 in primary and 
metastatic tumour cells [301-309]. This association of elevated AGR2 levels in metastatic 
cells, coupled with the reported secretion of AGR2 and its correlation with disease 
progression and patient survival, has led to the exploration of AGR2 as a potential 
prognostic and diagnostic biomarker. Several studies have explored urinary or serum AGR2 
levels in this role, with encouraging results for not only tumour-secreted AGR2 [465, 469, 
475, 476, 479, 480, 488, 502-504], but also for the detection of circulating tumour cells 
within patient serum, based on the presence of AGR2 mRNA [306]. 
 The mechanism whereby AGR2 might induce metastasis however, is not yet clear, 
although the EGFR ligand amphiregulin (AREG), which plays a crucial role in promoting 
mammary gland development [505], may play a role here. AGR2 induces expression of the 
AREG, through the Hippo pathway transcriptional co-activator YAP1 (yes-associated protein 
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1) [506], by inhibiting YAP1 phosphorylation, which otherwise sequesters it in the cytosol 
[507]. Whether a direct interaction occurs between AGR2 and YAP1 has not been 
determined. AREG is often overexpressed in a number of cancers (including breast, 
prostate, lung and colorectal cancers (reviewed in [508]), where it acts as a growth and 
survival factor by signalling through the EGF receptor and also by upregulating anti-
apoptotic Bcl-XL protein whilst downregulating the pro-apoptotic Bac and Bax proteins 
[508-511]. It also mediates resistance to anti-EGFR therapy, probably through drug-induced 
activation of AREG transcription and thus increased anti-apoptotic signalling [512-514]. 
Importantly, AREG has pro-EMT effects, decreasing cell-cell adhesion and increasing 
migration and invasion, through downregulation of E-cadherin and the upregulation of 
matrix-degrading enzymes including MMP2 and MMP9 (reviewed in [508]). Therefore, an 
AGR2-AREG axis may be important in promoting cancer cell dissemination. Additionally, the 
demonstration that the ECM-degrading proteases cathepsin B and D are upregulated by 
AGR2 in pancreatic cancer cells [437] could feasibly also contribute to the pro-metastatic 
ability of AGR2, by promoting breakdown of the surrounding matrix and thus facilitating 
invasion. 
 Metastases promoted by AGR2 therefore probably relate to increased cell 
migration and invasion of AGR2-expressing cells [301, 305, 307, 308, 415, 437, 481]. 
Furthermore, a direct link between AGR2 and metastasis has also been demonstrated in a 
rat model of breast cancer, where normally benign rat mammary cells were induced to 
form lung metastases through the expression of AGR2 [309].  In this model, the forced 
expression of AGR2 enhanced the rate of adhesion of these cells to the substratum, which 
as outlined in section 1.1.1.4.2, might be important for circulating tumour cell attachment 
to the endothelium at secondary metastatic sites. A further study in prostate cancer cells 
demonstrated a similar effect, where knockdown of AGR2 in PC3 cells resulted in a 
decreased rate of adhesion to the substratum [515]. Thus AGR2 is associated with changes 
in cell adhesion, a process which is not only important for tumourigenesis in the context of 
adhesion at secondary sites, but also due to the fact that changes in adhesion are 
implicated in multiple steps in the metastatic cascade, including cell-cell adhesion, cell-
matrix adhesion, cell migration and anchorage-independent cell growth. AGR2-regulated 
adhesion could thus be a critical central component of the metastatic cascade.  
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1.5 Project aims 
 
 Given its role in cancer progression, the overall aim of the present project is to 
investigate the mechanism involved in AGR2-promoted metastasis. More specifically, the 
aims of the project are: (1) To explore the biophysical properties of AGR2 protein along 
with its effects on cell adhesion, in order to uncover and identify regions of AGR2 protein 
that might contribute to its adhesion-related activities, which are associated with its 
induction of metastasis. (2) To study the extent and nature of secreted AGR2, and (3) To 
identify significant changes to the intracellular and secreted proteomes arising from the 
overexpression of AGR2, to shed light on possible downstream targets of AGR2 
overexpression, with the longer term goal of identifying targets for anti-AGR2 drug 
development.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
37 
 
 
 
 
Chapter 2 
 
 
 
Materials and Methods 
 
 
 
2.1 Reagents and Materials 
 
 All chemicals were obtained from Sigma or Fisher Scientific unless otherwise stated. 
All cell culture plastic ware was obtained from Corning unless otherwise stated. 
 
 
2.2 Cell Culture 
 
 All cell culture media and supplements were obtained from Gibco, unless otherwise 
stated. All cell lines were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 
4500 mg/mL glucose, non-essential amino acids (NEAA), 3.7 g/L sodium bicarbonate and 
phenol-red. All growth media were supplemented with 4 mM L-glutamine, 100 units/mL 
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penicillin and 100 µg/mL streptomycin. Where added, foetal bovine serum (FBS) was from 
Lonza. Cells were maintained at 37° C in a humidified atmosphere containing 10 % CO2. 
 
 
2.2.1 Cell lines 
 
 Description Culture Medium Supplements 
Rama 37 
Benign, DMBA (dimethylbenzanthracene)-
derived rat mammary adenoma [516] 
5 % (v/v) FBS, 10 ng/mL insulin, 
10 ng/mL hydrocortisone 
MCF7A Metastatic human mammary adenocarcinoma 10 % (v/v) FBS, 10 µg/mL insulin 
 
Table 2.1. Parental cell lines and growth media. 
 
 The Rama 37 cell line was employed for this study with a view to utilising the cell 
lines created below in a syngeneic rat model to investigate the metastatic effects of AGR2 
in an in vivo model, as performed previously using WT AGR2-expressing Rama 37 cells 
[309]. 
 
 
2.2.2 Stably-transfected cell lines 
 
 All stably-transfected cell lines were grown in Rama 37 medium as described Table 
2.1, with the addition of 1 mg/mL G418 disulphate (Melford) as a selection agent. 
 
 
AGR2 Sequence Covered 
(amino acid number) 
Mutations 
Rama 37 Empty Vector None None 
Rama 37 WT AGR2 Full length (1-175) None 
Rama 37 E60A AGR2 Full length (1-175) Glutamate to alanine at position 60 
Rama 37 C81S AGR2 Full length (1-175) Cysteine to serine at position 81 
Rama 37 ∆1-20 AGR2 (21-175) Deletion of N-terminal signal peptide 
Rama 37 ∆21-40 AGR2 (41-175) Deletion of N-terminal residues 21-40 
Rama 37 ΔKTEL AGR2 (1-171) Deletion of four C-terminal residues (KTEL) 
 
Table 2.2. Rama 37 stably-transfected cell lines. 
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2.2.3 Thawing and subculturing cells 
 
 Cells were rapidly thawed in a 37°C waterbath and plated in 10 mL Rama 37 
medium in 10 cm culture dishes. After 24 h, the medium was changed to fresh growth 
medium. 
 Cells were subcultured every 2-3 days upon reaching 70-80 % confluence. For 
cuboidal Rama 37 cell lines, the cell monolayer was washed twice with PBS and incubated 
in 1 mL Versene (0.02 % EDTA (Ethylenediaminetetraacetic acid) in PBS)for 10 min in a 37°C 
incubator. For elongated Rama 37 cell lines, cells were incubated for only 3 min. After 
removing the Versene, cells were then incubated in 1 mL Trypsin solution (0.05 % in 
Versene) for 3 min in a 37°C incubator or until all cells had detached. Cells were collected in 
Rama 37 medium and subcultured at a ratio of 1:3 to 1:8, as required. 
 For the subculturing of MCF7A cells, the cell monolayer was washed twice in PBS 
and incubated in 1 mL Trypsin solution for 2 min in a 37°C incubator until all cells had 
detached. Cells were then collected in MCF7A medium and subcultured at a ratio of 1:2 to 
1:3, as required. 
 
 
2.2.4 Freezing cells 
 
 Frozen cell stocks were made using cells grown to 90-100 % confluence. Cells were 
collected as described in Section 2.2.3, and then centrifuged at 1000 x g at room 
temperature. The cell pellet was then resuspended in 2 mL freezing medium (complete 
growth medium supplemented with 20 % (v/v) FBS and 7.5 % (v/v) DMSO) per 10 cm 
culture dish, and 1 mL cell suspension added to each cryovial (Star Labs). Cryovials were 
placed in a Cryo freezing container (Nalgene) overnight at -80° C to ensure a cooling rate of 
approximately -1°C/min and then transferred to long-term storage at -135° C. 
 
 
2.2.5 Creation of cell lines 
 
2.2.5.1 Isolation of elongated Rama 37 cells (R37E) 
 
 Rama 37 cells can undergo spontaneous transformation from a cuboidal to an 
elongated morphology [516]. Elongated cells attach much more weakly to the cell culture 
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vessel (see Chapter 4) and so to isolate this elongated subpopulation of Rama 37 cells, 
confluent cultures of cells in 10 cm cell culture dishes were treated with Versene for 10 min 
at 37°C and then gently agitated, causing the most weakly attached cells to detach from the 
plate surface. These cells were gently aspirated and placed in Rama 37 medium in 6-well 
cell culture plates. Upon reaching confluency, the cells were transferred to 10 cm dishes 
and allowed to reach confluency again. These dishes were then treated with Versene again 
for 5 min at 37°C and again gently agitated. Detached cells were collected into 6-well cell 
culture plates and expanded, as before. This process was repeated a third time, such that 
cells had been selected from three rounds of Versene treatment, and the cells detaching 
from this final Versene treatment were expanded and named Rama 37-elongated (R37E). 
 
 
2.2.5.2 Transfection and generation of stably-expressing cell lines 
 
 Cells were transfected using FuGENE6 transfection reagent (Promega). Twenty-four 
hours prior to transfection, Rama 37 cells were seeded at 0.3 x 106 cells/well in 6-well cell 
culture plates in order to reach 50-60 % confluence. On the day of transfection, cells were 
washed twice with PBS and the medium replaced with Opti-MEM reduced serum medium 
(Gibco).  DNA (either 2 µg PiggyBac plasmid DNA, 0.8 µg PiggyBac transposase plasmid DNA 
or both) was complexed in a 1:3 ratio with FuGENE6, and complexes were incubated with 
cells at 37°C for 6 h. At this point the medium containing the complexes was aspirated and 
replaced with fresh Rama 37 medium. 
 For the generation of stably-expressing cell lines, cells reaching 80-100 % 
confluency 24 h post-transfection were transferred from 6-well cell culture plates to two 10 
cm cell culture plates. Forty-eight hours post-transfection, medium was replaced with 
selection medium containing 1 mg/mL G418 (Melford), and fresh medium was added to 
cells every 2-3 days for 10-14 days until cells had grown sufficiently to allow freezing of cell 
stocks. For cells transfected with shRNA constructs, the same procedure was followed 
except that selection was performed in Rama 37 medium supplemented with 250 µg/mL 
Hygromycin B. 
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2.2.6 Analysis of cell morphology using ImageJ 
 
 For measuring the morphological characteristics of cells, images were taken of 
cultured cells using a DC5000 CMEX microscope camera (Euromex). Images were opened in 
ImageJ [517], converted to 8-bit images and then set in black-and-white by entering the 
‘Threshold’ menu and selecting the default settings. Cell morphology was measured using 
the ‘Analyze particles’ function with the inclusion of ‘shape descriptors’. Cells were 
considered if they fell within the 100-5000 pixel2 size range and cells residing on the edges 
of the image were not considered in the analysis. Morphology was measured by the aspect 
ratio (AR) value, which measures the longest axis divided by the shortest axis. AR values 
were measured for all cells fitting the size criteria and the mean of these AR values used as 
the shape ratio (SR) for each cell line. A representative analysis is shown in Fig. 2.1. 
 
 
           
 
 
 
 
 
 
 
Figure 2.1. Analysis of cell morphology using ImageJ. Images of cultured cells (A) 
were converted to Threshold images (B) to delineate individual cells. Cells fitting the 
criteria outlined in the main text were then measured across the shortest and 
longest axes (C) to give an aspect ratio value.  
A B 
C 
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2.3 Cell-based assays 
 
2.3.1 Adhesion rate assay 
 
 Cells were grown to 70-80 % confluence and collected by Versene and trypsin 
treatment in Rama 37 medium. Cells were counted with a Z1 Coulter® particle counter 
(Beckman Coulter) and resuspended to 2 x 105 cells/mL. 1 mL of this cell suspension was 
then plated into each well of a 24-well plate and left in a 37°C incubator for the time 
indicated in the figure legends. After the allocated time, medium was aspirated from wells 
and adhering cells were washed twice with 1 mL PBS. Adhering cells were detached by 
adding 250 µl Versene for 10 min in a 37°C incubator, followed by the addition of 250 µl 
0.05 % (v/v) trypsin/Versene for 5 min in a 37°C incubator, without aspirating off the 
Versene  solution. Cells were then collected by the addition of 500 µL medium, leading to a 
cell suspension of 1 mL that was subsequently counted using a Z1 Coulter® particle counter 
(Beckman Coulter). The number of adhering cells was calculated as a percentage of the 2 x 
105 cells that were added to each well.  
 
 
2.3.2 Adhesion rate assay on protein-coated plates 
 
 For protein coating experiments, 500 µL of 2 µM purified protein in PBS buffer (pH 
7.4) was coated onto each well of a 24-well plate the day before the adhesion experiment. 
Plates were placed in a 37°C incubator uncovered overnight, until all liquid had evaporated. 
Prior to use, wells were washed with 1 mL PBS and allowed to dry again, before the 
addition of cells. The assay was then performed in the manner described above. 
 For peptide coating experiments, 100 µl of 2 µM peptide and 7.5 nM AGR2 protein 
were coated onto 96-well non-cell culture treated plates in 50 µl carbonate buffer (50 mM 
carbonate, 150 mM NaCl, pH 10.6) in the same manner described above. Wells were then 
washed once with 100 µL PBS and allowed to dry at room temperature. Cells were grown to 
70-80 % confluence and collected by Versene and trypsin treatment in Rama 37 medium. 
Cell were counted with a Z1 Coulter® particle counter (Beckman Coulter) and resuspended 
to 3 x 105 cells/mL. 100 µl of this cell suspension was then plated into each well of the 
peptide- or protein-coated 96-well plate and left in a 37°C incubator for 1 h. Medium was 
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aspirated from wells and adhering cells were washed twice with 100 µL PBS and quantified 
using crystal violet staining. 
 For staining, cell were fixed in 100 % ethanol for 10 min at room temperature and 
then incubated with 0.05 % (w/v) crystal violet in 20 % (v/v) methanol/distilled water 
(dH2O) for 10 min at room temperature. Following 5 washes of dH2O, cell-bound crystal 
violet was released through incubation with 100 µL/well of 10 % (v/v) acetic acid for 5 min 
at room temperature, with moderate agitation. Staining intensity was measured at 570 nm 
using a Spectramax plus384 (Molecular Devices) plate reader, and the staining of treated 
cells was expressed as a percentage of staining in control (non-protein coated) wells. Each 
condition was plated in duplicate. 
 
 
2.3.3 Cell detachment assays 
 
2.3.3.1 Short term trypsin resistance assay 
 
 The assay was performed in the same manner as the rate of adhesion assay 
(Section 2.3.1), up to and including the two washes of PBS after the allocated incubation 
time, but two sets of wells in separate plates were used: one control plate to measure the 
number of adhering cells in the allocated time, and one treatment plate to measure the 
adhesion strength of these cells. At this point, the control plate was quantified in exactly 
the same manner as the rate assay (Section 2.3.1). For the treatment plate, cells were 
incubated with 250 µL 0.0125 % (v/v) trypsin/Versene in a 37°C incubator for 5 min. The 
solution was aspirated and cells were gently washed with 1 mL PBS, and the remaining 
adhering cells were counted using a Z1 Coulter® particle counter (Beckman Coulter) as 
described in Section 2.3.1. The number of adhering cells was expressed as the number of 
cells still adhering to the treatment plate as a percentage of those adhering to the control 
plate. The process is illustrated in Fig. 2.2. 
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2.3.3.2 Monolayer trypsin resistance assay 
 
 Cells were plated into two sets of 24-well plates and left overnight to reach 70-80 % 
confluence by the next day, with one plate acting as the control and the other the 
treatment plate. The next day, cells in the control plate were collected and counted as 
described above. For the treatment plate, cells were incubated with 250 µL 0.0125 % (v/v) 
trypsin/Versene in a 37°C incubator for 5 min. The solution was aspirated and cells were 
gently washed with 1 mL PBS, and the remaining adhering cells were released and counted 
using a Z1 Coulter® particle counter (Beckman Coulter) as described in Section 2.3.1. The 
number of adhering cells was expressed as the number of cells still adhering to the 
treatment plate after treatment with 0.0125 % (v/v) trypsin, as a percentage of those 
adhering to the control plate. The process is illustrated in Fig. 2.3. 
 
 
 
 
  
 
  
  
  
  
 
 
 
      
  
 
 
 
      
 
      
Figure 2.2. Short term trypsin resistance assay. Cells are plated (A) and allowed to 
adhere to the plate surface for the indicated time (B). Bound cells are then treated 
with low strength trypsin for 5 min (C), and detached cells are washed away with PBS 
(D). Remaining, trypsin-resistant cells (E) are then counted using an automated cell 
counter. Red shapes represent trypsin molecules. 
A B 
E 
D C 
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2.3.3.3 Centrifugation assay 
 
 Assays were performed as described in [518, 519]. Cells were grown to 70-80 % 
confluence and then collected using Versene and trypsin as described above. Cells were 
resuspended to 3 x 105 cells/mL in normal medium, and 100 µL/well of this cell suspension 
were plated into 2 plates. Both sets of plates were then centrifuged at 10 x g for 5 min in a 
swing out plate rotor to sediment all cells and ensure they were in contact with the 
substratum. Plates were then left at room temperature for 5 min, before gently adding 240 
µL medium to all wells. Plates were sealed with sticky-back 96-well plate covers, avoiding 
the formation of air bubbles within wells. The treatment plate was then placed upside 
down and centrifuged at 800 x g for 10 min at room temperature. During this time, the 
control plate was kept the correct way up at room temperature without centrifugation. 
Following centrifugation, medium was aspirated from both sets of plates, and attached cells 
were quantified using crystal violet staining, as described in Section 2.3.2. The assay is 
illustrated in Fig 2.4. 
 
 
 
 
 
 
    
 
      
 
 
    
 
          
 
 
 
        
Figure 2.3. Monolayer trypsin resistance assay. Cells are plated and allowed to reach 
70-80 % confluence overnight (A) and then treated with low strength trypsin for 5 
min (B). Detached cells are washed away with PBS (C) and the remaining, trypsin-
resistant cells (D) are then released and counted using an automated cell counter. 
Red shapes represent trypsin molecules. 
A B 
D C 
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Figure 2.4. Centrifugation cell detachment assay. Cells are plated into 96-well plates 
(A) and centrifuged at 10 x g for 5 min to ensure all cells are in contact with the 
substratum (B). Plates are sealed and centrifuged upside down for 10 min at 800 x g 
(C) and cells that remained attached (D) are quantified using crystal violet staining. 
Arrows indicate the direction of centrifugal force 
 
 
2.3.3.4 Migration assay 
 
 Cells were grown to 70-80 % confluence, washed twice with PBS and incubated 
with serum-free medium for 2 h in a 37°C incubator. Cells were then collected in fully 
supplemented medium containing only 1 % FBS, resuspended to 1 x 105 cells/mL and then 
100 µL (1 x104 cells) were added to the upper chamber of a Transwell insert, with 8.0 µm 
pore size. Inserts were placed into 24-well plates containing 600 µL fully supplemented 
medium containing 5 % (v/v) FBS, and cells were allowed to migrate for 16 h in a 37°C 
incubator. Cells were subsequently stained using a Reastain Quick Diff kit (Reagena) and 
 
  
  
  
 
  
  
  
   
  
  
 
  
A B 
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counted using a microscope. All cells were counted from each membrane and each 
condition was plated in duplicate. 
 
 
2.3.3.5 Anchorage-independent growth assay 
 
 50 µl of semi-solid agar base layers consisting 0.5 % agar (w/v) in normal growth 
medium were plated into 96-well plates by diluting 2.5 % (w/v) autoclaved Ultrapure CM 
agarose (Affymetrix)/dH2O 1:4 into 1.2 x concentrated normal growth medium. 1.2 x 
medium was made by adding all supplements for Rama 37 medium or G418 medium (as 
described in Section 2.2.1) required to make 50 mL medium to only 40 mL DMEM. Plates 
were covered and placed at 4°C for 5 min to ensure agar solidification. During this time, 1.5 
% (w/v) MacroSieve Clone CM low melting temperature agarose (Flowgen Biosciences) was 
prepared by microwaving in dH2O and subsequently kept in a 40°C waterbath until needed. 
 For the top, cell-containing layer, cells were grown to 70-80 % confluence, collected 
and resuspended to 2.5 x 104 cells/mL in 1.2 x normal medium. This cell suspension was 
then mixed in a 1:4 ratio with warm 1.5 % (w/v) agarose and 50 µL (1 x 103 cells) were 
gently pipetted onto the agar base layer. Plates were then incubated at 4°C for 10 minutes 
to ensure agarose solidification, and this cell layer was then overlaid with 50 µL normal 
medium. Cells were kept in a 37°C, 10 % (v/v) CO2 incubator for four weeks, and medium 
was changed once a week by gently pipetting off the top medium layer and gently adding 
new medium using a multi-channel pipette. After four weeks, colonies were imaged using a 
DC5000 CMEX microscope camera (Euromex) and subsequently quantified using CellTiter 
Glo 2.0 cell viability reagent (Promega), as described by the manufacturer. Using a TriStar 
LB 941 multimode microplate reader (Berthold Technologies), 50 µl of CellTiter Glo 2.0 
reagent was dispensed into each well, still containing the 50 µl medium overlay. Samples 
were gently agitated for 2 min and then left to incubate at room temperature for 10 min. 
The signal in relative light units (RLU) was collected for 2 seconds. RLU is proportional to the 
number of viable cells, and the value from test samples was normalised to the RLU signal 
obtained from control WT AGR2 clone 2 cells to allow comparison across experiments. Cells 
were plated in quadruplicate, onto clear (Corning) and opaque (Berthold Technologies) 96-
well cell culture plates for imaging and quantification by luminometry, respectively. 
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2.4 Immunocytochemistry 
 
2.4.1 Preparation of paraformaldehyde 
 
 4 % (w/v) paraformaldehyde (PFA) was made by adding 4 grams PFA powder to 
approximately 90 mL of sterile PBS. The solution was heated and several drops of 
concentrated NaOH were added until the PFA had completely dissolved. The pH was then 
adjusted back to pH 7.4 and the solution was sterile filtered through a 0.22 µm filter before 
being aliquotted and frozen at -20°C. Frozen aliquots were kept for a maximum of 4 weeks. 
  
 
2.4.2 Cell fixing and staining 
 
 One day before imaging, CultureSlides (Beckman Coulter) were coated with 
approximately 2.5 µg bovine fibronectin in PBS per cm2 by evaporation at room 
temperature for 3-4 h. Slides were then washed once in PBS and left to air dry. Cells were 
collected and 3 x 104 cells were plated per well and left to grow overnight. 
 The next day, cells were washed once with PBS and then fixed in 4 % (w/v) PFA for 
10 min at room temperature. Cells were then washed twice in PBS before incubation for 20 
min with 50 mM NH4Cl at room temperature to block any remaining reactive aldehyde 
groups. For permeabilisation, cells were treated with 0.5 % (v/v) Triton X-100 in PBS for 10 
min at room temperature and were then blocked with 2 % (w/v) BSA, 3 % (w/v) skimmed 
milk powder in 0.5 % (v/v) Triton X-100/PBS for 1 h at room temperature. The blocking 
solution was aspirated off and cells were stained with a 100 µL solution of the antibodies 
shown in Table 2.3 in blocking buffer, overnight at 4°C. For co-staining experiments, both 
antibodies were incubated with cells at the same time. 
 The next day, antibody solutions were aspirated off and cells were washed 4 times 
with 0.5 % (v/v) Triton X-100/PBS before the addition of 100 µL secondary antibody 
solution (see Table 2.3) in blocking buffer for 30 min at room temperature. Cells were 
washed 4 times in 0.5 % (v/v) Triton X-100/PBS before incubation with 0.1 µg/ml DAPI for 
10 min at room temperature, and subsequently washed twice more in PBS. CultureSlides 
were then soaked in 100 % methanol for 10 min to separate the glass slide from the plastic 
wells, and coverslips were mounted using Hydromount mounting medium (National 
Diagnostics) and allowed to air dry for at least 15 min at room temperature. Slides were 
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subsequently imaged using an EVOS® FL microscope imaging system (Life Technologies), 
equipped with DAPI, GFP and RFP light cubes.  
 For experiments involving non-permeabilised cells, all steps described above using 
0.5 % (v/v) Triton X-100/PBS were replaced with PBS only, except for the permeabilisation 
step which was omitted. 
 
Primary Antibodies 
Antibody Host Species Company Product Code Dilution Used 
AGR2 Mouse Abcam ab56703 1:200 
AGR2 Rabbit Proteintech Group 12275-1-AP 1:200 
CD44 Mouse Thermo Scientific MS-668-P0 1:20 
Giantin Rabbit Abcam ab24586 1:500 
MEK1 Rabbit Abcam ab32091 1:200 
Paxillin Rabbit Abcam ab32048 1:500 
PDI Rabbit Abcam ab3672 1:100 
     
Secondary Antibodies 
Antibody Company Product Code Dilution Used 
AlexaFluor488 Goat anti-mouse IgG Life Technologies A-11029 1:500 
AlexaFluor488 Goat anti-rabbit IgG Life Technologies A-11034 1:500 
AlexaFluor568 Goat anti-rabbit IgG Life Technologies A-11036 1:500 
 
Table 2.3. Antibodies used for immunocytochemistry. 
 
 
2.4.3 Cell surface staining 
 
 Staining of cell surface proteins was based on the method of Zhuang et al., 2008 
[520]. Slides were prepared and cells plated and allowed to grow overnight as described in 
Section 2.4.2. All subsequent steps were performed on ice with ice-cold reagents. Cells 
were incubated with primary antibodies (Table 2.3) for 1 h in staining medium consisting of 
DMEM supplemented with 10 % (v/v) FBS, 100 units/mL penicillin and 100 µg/mL 
streptomycin, 4 mM L-glutamine, 10 mM HEPES and 15 mM sodium azide. Inclusion of 
azide helps prevent internalisation of surface antigens [521]. Following this incubation, the 
staining solution was aspirated and cells were gently washed 3 times with a wash solution 
consisting of PBS supplemented with 1 mg/mL glucose, 10 mM HEPES and 15 mM sodium 
azide. Cells were then incubated with the relevant secondary antibodies (Table 2.3) for 30 
min in staining medium, before gently washing 3 times in wash solution. Cells were then 
fixed on ice with 4 % (w/v) PFA at room temperature, before being washed twice with PBS. 
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Slides were then stained with DAPI at room temperature and mounted and imaged as 
described above.  
 
 
2.5 Bacterial transformation and growth 
 
2.5.1 Preparation of agar plates  
 
LB agar 
1 % (w/v) tryptone 
0.5 % (w/v) yeast extract 
1 % (w/v) NaCl 
1.5 % (w/v) agar 
 
 Stock solutions of 100 mg/mL ampicillin (Sigma) and 30 mg/mL kanamycin 
(Calbiochem) in dH2O were filter sterilised through a 0.22 µm filter and stored at -20°C. 
Autoclaved LB-agar (Merck) was melted in a microwave oven and allowed to cool to 
approximately 50°C and ampicillin or kanamycin was added to a final concentration of 100 
µg/mL or 30 µg/mL, respectively. Agar was then quickly dispensed into 10 cm Petri dishes 
(Sterilin) and allowed to set at room temperature for at least 15 min. Unused plates were 
sealed and kept at 4°C no longer than 4 weeks. 
 
 
2.5.2 Transformation 
 
SOC medium 
  
2 % vegetable peptone 
  
0.5 % yeast extract 
 
LB broth 
10 mM NaCl 
 
1 % (w/v) tryptone 
2.5 mM KCl 
 
0.5 % (w/v) yeast extract 
10 mM MgCl2 
 
1 % (w/v) NaCl 
10 mM MgSO4 
  
20 mM glucose 
  
 
 50 µL of One-shot ® Top10 chemically competent E .coli cells (Invitrogen) or 50 µL 
of One-shot ® BL21 star ™ chemically competent E. coli cells (Invitrogen) were used for the 
expression of plasmid DNA and recombinant proteins, respectively. Cells were thawed on 
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ice and incubated with DNA on ice for 30 min before being heat shocked at 42°C for 30 
seconds. Cells were then placed back on ice for 5 min before the addition of 250 µL SOC 
medium (New England Biolabs) and agitation at 220 rpm for 1 h at 37°C. 100 µL of 
transformation mixture was then plated onto LB-agar plates and left overnight in a 
humidified incubator at 37°C. 
 Starter cultures were prepared by inoculating 5 mL or 100 mL LB broth (Merck) with 
a single colony picked from transformed agar plates and agitating at 220 rpm overnight in a 
37°C incubator. The volume of LB broth in the culture vessels did not exceed 25 % of the 
total vessel volume, in order to allow adequate aeration of the culture. 
 
 
2.5.3 Glycerol stocks 
 
 800 µL of overnight bacterial culture was mixed with 200 µL sterile glycerol by 
gentle pipetting, and tubes were immediately frozen at – 80°C. 
 
 
2.6 Cloning, PCR and DNA amplification 
  
2.6.1 Expression vectors 
 
 A previously-constructed pBK-CMV vector containing AGR2 (pBK-CMV-AGR2, kindly 
provided by Dr Dong Barraclough, Institute of Ageing and Chronic Disease, University of 
Liverpool) was used as a template for subcloning WT and mutant AGR2 into the PiggyBac 
expression vector (System Biosciences, see Appendix 2), as described in Section 2.6.3. For 
recombinant protein expression in E. coli, two previously constructed expression vectors 
were used: an IMPACT-TWIN1 vector (Intein Mediated Purification with an Affinity Chitin-
binding Tag-Two Intein, New England Biolabs) expressing residues 21-175 of AGR2 (AGR221-
175) with a cleavable N-terminal chitin-binding tag (kindly provided by Dr Dong Barraclough, 
Institute of Ageing and Chronic Disease, University of Liverpool), and a Champion™ pET151 
Directional TOPO® vector (Life Technologies) expressing residues 41-175 of AGR2 (AGR2 41-
175) with a cleavable N-terminal polyhistidine tag (Patel, 2013, see Appendix 1).  
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2.6.2 Primer design 
 
 Primers were designed using the Invitrogen OligoPerfect ™ Designer [736]. Melting 
temperature was set at 60°C (range: 57-63°C) and GC content at 50 % (range: 20-80 %). 
After generation, primers were manually edited by addition or deletion of bases within the 
sequence so that the final base at the 3’ end was either guanine or cytosine, to aid 
anchoring of the primer to the template strand. A 5’ XbaI restriction site was added to 
forward primers where required and a 5’ EcoRI site added to the reverse primer, where 
required (Table 2.4). Where restriction sites were added, further guanine and/or cytosine 
nucleosides were added to the 5’ end of the restriction site to aid better digestion of the 
sequence, as described by New England Biolabs [737]. Primers were then synthesised by 
Integrated DNA Technologies (IDT). 
 
Primer Sequence 
Tm 
(°C) 
WT AGR2 
Forward 
GCTCTAGAATGGAGAAAATTCCAGTGTCAGC 60.4 
WT AGR2 
Reverse 
CCGGAATTCTTACAATTCAGTCTTCAGCAACTG 60.7 
E60A AGR2 
Forward 
CTGGACTCAGACATATGAAGAAGCTCTATATAAATCCAAGAC 60.8 
E60A AGR2 
Reverse 
GTCTTGGATTTATATAGAGCTTCTTCATATGTCTGAGTCCAG 60.8 
Y63A AGR2 
Forward 
ACTCAGACATATGAAGAAGCTCTAGCTAAATCCAAGACAAGCAACAAACC 65.4 
Y63A AGR2 
Forward 
GGTTTGTTGCTTGTCTTGGATTTAGCTAGAGCTTCTTCATATGTCTGAGT 65.4 
K64A AGR2 
Forward 
GACATATGAAGAAGCTCTATATAAATCCAAGACAAGCAACAAACCC 62.6 
K64A AGR2 
Reverse 
GGGTTTGTTGCTTGTCTTGGATTTATATAGAGCTTCTTCATATGTC 62.6 
∆1-20 AGR2 
Forward 
GCTCTAGAATGAGAGATACCACAGTCAAACCTGG 61.9 
∆21-40 AGR2 
Forward 
(incl. signal 
sequence) 
GCTCTAGAATGGAGAAAATTCCAGTGTCAGCATCTTGCTCCTTGTGGCCCTCTC
CTACACTCTGGCCCCCCAGACCCTCTCCAGAGG 
73.0 
∆KTEL AGR2 
Reverse 
CCGGAATTCTTAGAGAGCTTTCTTCATGTTGTCAAGC 62.6 
 
Table 2.4. Primers used for AGR2 subcloning and mutagenesis. Restriction sites (if present) 
are underlined. 
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2.6.3 Sub-cloning of AGR2 
 
 The open reading frame (ORF) containing only the AGR2 coding sequence was 
amplified from the pBK-CMV-AGR2 into the PiggyBac transposon vector (catalogue no. 
PB533A-2, see Appendix 2) using the primers detailed in Table 2.4, and using REDTaq® 
ReadyMix™ PCR reaction mix (Sigma) with the method described by the manufacturer, but 
using the following cycling parameters: 
 
PCR reaction mix 
Template 10 ng 
Forward primer 125 ng 
Reverse primer 125 ng 
REDTaq ReadyMix 12.5 µL 
PCR water to 25 µL 
 
PCR cycling parameters 
 
Step Temp. (°C)  
Time 
(seconds)  
Initial denaturation 95 120 
 
Denaturation 95 30 
 
Annealing 60 30        30 cycles 
Elongation 72 30 
 
Final elongation 72 420 
 
 
 After amplification, the reaction mix was run on a 0.7 % (w/v) agarose gel (see 
Section 2.7) to separate the amplified insert from parental plasmid DNA. The insert was 
excised and purified using a QuiaQuick Gel Extraction kit (Qiagen), as described by the 
manufacturer. 1 µg each of the PiggyBac vector and insert were then digested with XbaI 
and EcoRI HF enzymes (New England Biolabs) for 1 h at 37°C, as described by the 
manufacturer. Enzymes were then heat inactivated for 20 min at 65°C and the digested 
DNA was purified using a QiaQuick PCR Cleanup kit (Qiagen). 0.025 pmol of digested vector 
was mixed with 0.075 pmol digested insert and ligated overnight at room temperature 
using T4 DNA ligase (New England Biolabs), as described by the manufacturer. The ligase 
was inactivated by incubation at 65°C for 10 min and One-shot ® Top10 chemically 
competent E.coli cells were then transformed with 5 µL of ligation mixture as described in 
Section 2.5.2. 
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2.6.4 Mutagenesis 
 
 Due to the size of the PiggyBac expression vector (approximately 7,400 bp with 
AGR2 insert), point mutations were introduced into the pBK-CMV-AGR2 expression vector 
and pET151 expression vector by site-directed mutagenesis using the QuickChange 
Lightning kit (Agilent), and mutated inserts were then subcloned into the PiggyBac vector as 
described above. The following reaction conditions were used for site-directed 
mutagenesis:  
 
PCR reaction mix 
Template 10 ng 
Forward primer 125 ng 
Reverse primer 125 ng 
REDTaq ReadyMix 12.5 µL 
10 x reaction buffer 5 µL 
dNTP mix 1 µL 
QuickSolution 1.5 µL 
QuickChange Lightning enzyme 1 µL 
PCR water to 50 µL 
 
Site-directed mutagenesis cycling parameters 
 
Step Temp. (°C)  
Time 
(min.)  
Initial denaturation 95 2 
 
Denaturation 95 1 
 
Annealing 55 1       18 cycles 
Elongation 68 14 
 
Final elongation 68 14 
 
 
 Methylated, parental DNA was removed with treatment with Dpn1 enzyme for 1 h 
at 37°C, and 2 µL Dpn1-digested plasmid DNA was transformed into XL10-Gold 
ultracompetent E.coli cells in the same way as described for One-shot ® Top10 chemically 
competent cells in Section 2.5.2. 
 For the ∆1-20 AGR2 and ∆KTEL AGR2 truncation mutations, AGR2 was amplified 
from the pBK-CMV-AGR2 vector using the appropriate primers detailed in Table 2.4. For the 
∆21-40 AGR2 truncation, a forward primer containing the AGR2 signal sequence (Table 2.4) 
was used to amplify the 41-175 region of AGR2 from the pET151 expression vector. In this 
way, the signal sequence was joined directly to residue 41, effectively deleting the 21-40 
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region. All truncation mutations were amplified using REDTaq ® ReadyMix ™ PCR reaction 
mix and were subsequently purified, digested and ligated as described in Section 2.6.3.  
 The presence of DNA inserts was checked by submitting purified DNA (see Section 
2.6.5) to restriction digest with XbaI and EcoRI as described in Section 2.6.3. Appropriate 
base changes were confirmed by DNA sequencing of purified DNA (Beckman Coulter 
Genomics). 
 
 
2.6.5 DNA purification 
 
 For use in cloning, mutagenesis and sequencing reactions, transformed cells were 
grown as 5 mL cultures as described in Section 2.5.2. Cultures were then centrifuged at 
3,500 rpm in a Sigma 4K15 refrigerated centrifuge for 10 min at 4°C to pellet the bacteria, 
and plasmid DNA was isolated using a QIAprep® spin mini kit (Qiagen), using the protocol 
described by the manufacturer. Purified DNA was stored at -20°C. 
 For use in transfection of mammalian cells, transformed cells were picked from a 
single colony on an agar plate and grown in 100 mL LB broth for 20 h in a 37°C incubator 
with agitation at 220 rpm. Cells were then pelleted by centrifugation at 3,500 rpm as above 
and plasmid DNA purified using a Plasmid Midi Prep kit (Qiagen), using the protocol 
described by the manufacturer. Purified DNA was stored at -20°C. 
 DNA concentration was measured by absorbance at 260 nm using a NanoDrop 
1000 spectrophotometer (Thermo Scientific) and DNA purity was monitored by the ratio of 
absorbance at 260 nm to 280 nm. 
 
 
2.6.6 Agarose gel electrophoresis 
 
TAE buffer (50 x) 
2 M Tris-HCl, pH 8.0 
1 M glacial acetic acid 
50 mM EDTA 
 
 Agarose gels were prepared by adding the required amount of agarose (Bioline) 
into 1 x TAE buffer, diluted from a concentrated stock with dH2O. Agarose was dissolved by 
heating in a microwave oven, and when cooled to approximately 50°C, Midori Green 
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nucleic acid dye (Nippon Genetics) was added at a final dilution of 1:20,000 and the 
solution was poured into a horizontal casting tray. After solidification, gels were submerged 
in 1 x TAE buffer in a horizontal electrophoresis tank (Geneflow). Samples diluted 1:5 with 6 
x DNA loading buffer (New England Biolabs) were loaded, along with 5 µL of a 100 bp DNA 
ladder (New England Biolabs) or 1 kbp ladder (Fermentas) and gels were run until the 
desired separation was achieved at 100 V at room temperature. Bands were visualised 
using a UV transilluminator and gels were imaged using a Bio-Rad Gel Doc EQ system. 
 
 
2.7 Recombinant protein purification 
  
2.7.1 Recombinant protein expression and cell lysis 
  
 One-shot ® BL21 star ™ chemically competent E. coli cells were transformed and 
100 mL starter cultures were prepared as described in Section 2.5.2. These cultures were 
diluted into 500 mL LB broth so as to reach a starting optical density (O.D.) at 600 nm of 
0.1. Cultures were then placed in a 37°C incubator with agitation at 220 rpm for 
approximately 2 h, until reaching an O.D. 600 nm of between 0.6 and 0.8. At this point, 1 M 
isopropyl β-D-1-thiogalactopyranoside (IPTG), previously made up in dH2O, sterile filtered 
through a 0.22 µm filter and frozen at -20°C, was added at a final concentration of 1 mM 
and cultures were grown for 16-20 h in an 18°C incubator with agitation at 180 rpm. 
 Cultures were subsequently centrifuged at 4,500 rpm in a Fiberlite™ F9-4 x 1000y 
rotor for 20 min at 4°C, and pelleted bacteria were resuspended in a minimal volume of the 
appropriate lysis buffer on ice (see below). Resuspended cell pellets were frozen at -80°C 
for future use or lysed using a Soniprep 150 plus sonicator (MSE), set at the highest 
amplitude. Lysis was performed on ice and was achieved by 10 successive cycles of 30 s. 
sonication followed by 60 s. rest. Lysates were subsequently centrifuged at 15,000 rpm in a 
Sorvall SS-34 Rotor (Thermo Scientific) for 30 min at 4°C to pellet cell debris. Supernatants 
were then filtered through a 0.22 µm filter on ice and protein was purified using the 
appropriate method described below. 
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2.7.2 Purification of AGR2 21-175 from IMPACT-TWIN1 vector 
 
IMPACT-TWIN1 vector lysis 
buffer  
Chitin column 
elution/cleavage buffer 
20 mM HEPES, pH 8.0 
 
20 mM HEPES, pH 6.5 
500 mM NaCl 
 
500 mM NaCl 
1 mM EDTA 
 
1 mM EDTA 
   
Chitin column stripping 
buffer  
Chitin column regeneration 
buffer 
300 mM NaOH 
 
300 mM NaOH 
1 % (w/v) SDS 
  
 
 All steps were performed under gravity flow and all buffers were made with 
ultrapure water. All buffers (including ultrapure water) were filtered and degassed through 
a 0.22 µm bottle top filter using a vacuum pump prior to use. Chitin resin slurry (New 
England Biolabs) was poured into an empty PD-10 column (GE Life Sciences) to form a 6 mL 
bead bed. Beads were washed with 10 column volumes (CV) ultrapure water and 
equilibrated with 10 CV lysis buffer, as described by the manufacturer. Filtered protein 
expression supernatant (see above) was passed through the column 3 times at room 
temperature, each time collecting the flowthrough on ice before re-applying it to the 
column. The column was then extensively washed with 20 CV of lysis buffer before being 
flushed with 3 CV of elution buffer. The column was left in elution buffer overnight at room 
temperature to allow the cleavage reaction to take place (Fig. 2.5). 
 After overnight incubation, cleaved protein was eluted with 2 CV elution buffer and 
1 ml elution fractions were collected. Protein concentration was measured using a 
NanoDrop 1000, reading absorbance at 280 nm. This value was corrected using the 
theoretical extinction co-efficient at 1 g/L (1.203) predicted from the Expasy ProtParam 
server [738]. The five most concentrated elution fractions were combined, filtered through 
a 0.22 µm filter and subjected to gel filtration (see below). 
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Figure 2.5. Mechanism of pH-induced cleavage of Intein-tag. By acidifying the pH on the 
chitin column, the C-terminal Asn residue in the Intein-tag undergoes cyclisation of its side-
chain, resulting in cleavage of the peptide bond between the tag and target protein. 
Reproduced from NEB.com [737]. 
 
 
2.7.2.1 Regeneration of chitin beads 
 
 Chitin-binding tags and uncleaved protein were stripped from the column by 
passing 3 CV stripping buffer through the column at room temperature. The column was 
then washed with 3 CV regeneration buffer, soaked for 30 min in this buffer and then 
washed with another 7 CV regeneration buffer. The column was washed with 20 CV 
ultrapure water and then 5 CV 20 % (v/v) ethanol, before storing the column at 4°C. 
Columns were regenerated after each separate purification and any one column was 
regenerated no more than five times. 
 
2.7.3 Purification of AGR2 41-175 from pET151 vector 
 
pET151 vector lysis buffer 
 
HisTrap FF elution buffer 
20 mM Tris-HCl, pH 7.5 
 
20 mM Tris-HCl, pH 7.5 
500 mM NaCl 
 
500 mM NaCl 
20 mM imidazole 
 
500 mM imidazole 
 
HisTrap FF stripping buffer 
20 mM Tris-HCl, pH 7.5 
500 mM NaCl 
50 mM EDTA 
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 All steps were performed using an ÄKTA purifier FPLC system unless otherwise 
stated and all buffers were made with ultrapure water. All buffers (including ultrapure 
water) were filtered and degassed through a 0.22 µm bottle top filter using a vacuum pump 
prior to use.  
 5 mL HisTrap FF columns (GE Life Sciences) were charged with nickel by passing 2 
CV 100 mM NiSO4 through the column and excess NiSO4 was removed with 4 CV washes 
ultrapure water. Filtered protein expression supernatant (see Section 2.7.1) was manually 
loaded onto the column at room temperature using a syringe. Flowthrough was collected 
on ice and passed through the column a second time. The column was then connected to 
the ÄKTA purifier and washed with 5 CV pET151 vector lysis buffer. Elution buffer was 
added on a gradient up to 100 % (v/v) over 10 CV and His-tagged eluted protein was 
collected using an automated fraction collector. Removal of all column-bound protein was 
achieved by passing through 5 CV elution buffer. 
 Protein concentration was measured using a NanoDrop 1000, reading absorbance 
at 280 nm. This value was corrected using the theoretical extinction co-efficient at 1 g/L 
(1.325) predicted from the Expasy ProtParam server [738]. The five most concentrated 
elution fractions were combined and the histidine tag was cleaved by incubation with 
recombinant TEV (tobacco etch virus) protease (kindly provided by Prof. Lu-Yun Lian, 
Institute of Integrative Biology, University of Liverpool) and 1 mM dithiothreitol (DTT). 
Imidazole is inhibitory to TEV activity [522], therefore the cleavage reaction was performed 
with simultaneous dialysis. 5 mL purified protein with TEV protease was first dialysed 
against 1 L gel filtration buffer (see below) for 4 h at room temperature and then dialysed 
again against fresh gel filtration buffer overnight at 4°C. Protein was then dialysed against 1 
L fresh gel filtration buffer for a third time for 4 h at room temperature the next day. The 
extent of histidine tag cleavage was then assessed by running 5 µL of the cleavage reaction 
on an SDS-PAGE gel and staining with Coomassie brilliant blue. If cleavage was insufficient, 
the reaction was allowed to proceed for a further 1-4 h at room temperature. 
 The histidine tag and residual uncleaved protein was removed from the sample by 
manually passing it once through a 5 mL HisTrap FF column at room temperature using a 
syringe. Flowthrough containing cleaved protein was collected on ice and protein 
concentration measured as described above. Suitable fractions were concentrated using 
Amicon® Ultra-15 centrifugal spin cartridges (Millipore), by centrifuging at 4,500 rpm at 4°C 
in a Sigma 4K15 refrigerated centrifuge until the volume was reduced to 5 mL or less. This 
concentrated protein was then subjected to gel filtration (see below). 
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2.7.3.1 Column regeneration 
 
 Following each purification, columns were washed with 4 CV ultrapure water and 
the NiSO4 was stripped from the column by manually passing through 4 CV stripping buffer. 
Columns were washed with 4 CV ultrapure water and 4 CV 20 % (v/v) ethanol was passed 
through, before storage at 4°C. Before the next use, columns were first washed with 4 CV 
ultrapure water before charging with NiSO4. 
 
 
2.7.4 Gel filtration 
 
Gel filtration buffer 
20 mM sodium phosphate, 
pH 6.5 
150 mM NaCl 
 
 All buffers were made with ultrapure water and all buffers (including ultrapure 
water) were filtered and degassed through a 0.22 µm bottle top filter using a vacuum pump 
prior to use. 
 A Superdex 75 26/60 column (GE Life Sciences) was equilibrated overnight at room 
temperature with gel filtration buffer, using an ÄKTA purifier. Up to 5 mL of purified protein 
was then manually loaded onto the system using a syringe and the system was run at room 
temperature. Protein was collected using an automated fraction collector and the 
concentration of protein in these fractions was measured as described in Section 2.7.2. 
Purity of the collected fractions was assessed by running 5 µL of each fraction on an SDS-
PAGE gels and staining with Coomassie brilliant blue (see Section 2.8). Samples were 
concentrated using Amicon® Ultra-15 centrifugal spin cartridges (Millipore), by centrifuging 
at 4,500 rpm at 4°C in a Sigma 4K15 refrigerated centrifuge if required. The gel filtration 
column was washed with 1.5 CV ultrapure water and then 1.5 CV 20 % ethanol and stored 
at room temperature. 
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2.7.4 Size-exclusion chromatography – multi-angle laser-light scattering (SEC-MALLS) 
  
 Protein samples were prepared as described above, without a gel filtration step. 
Except where noted, all samples were buffer-exchanged into 20 mM NaPO4, 150 mM NaCl 
using a PD-10 desalting column (GE Life Sciences). Columns were washed with 25 mL 
ultrapure water under gravity flow and equilibrated with 25 mL buffer. 2.5 mL purified 
protein was added and eluted with 3.5 mL equilibration buffer, all of which was collected 
and the protein concentration measured using a NanoDrop 1000. Columns were washed 
with 25 mL ultrapure water and then 25 mL 20 % (v/v) ethanol, and stored at room 
temperature. Except where noted, samples were provided at a concentration of 1 mg/mL. 
 Samples for SEC-MALLS were sent to the University of Manchester for analysis, 
where they were loaded onto a Superdex 75 10/300 GL column and analysed using EOS 18-
angle laser photometer (Wyatt Technology), an rEX refractive index detector (Optilab) and 
a UV-2077 Plus UV/Vis spectrophotometer (Jasco). Simultaneous measurement of 
hydrodynamic radius was achieved through a coupled quasi elastic light-scattering 
detector. Molar mass measurements were performed using both Astra 5.3.2.16 software 
(Wyatt Technology) and the “three detector method”. 
 
 
2.8 SDS-PAGE 
 
2.8.1 Cell lysis 
 
RIPA lysis buffer 
50 mM Tris-HCl, pH 6.8 
150 mM NaCl 
2 mM EDTA 
1 % (v/v) Tergitol® (NP-40, nonyl phenoxypolyethoxylethanol-40) 
0.5 % (w/v) sodium deoxycholate 
0.1 % (w/v) SDS 
Protease inhibitor cocktail 
 
 RIPA buffer was prepared in dH2O and kept at 4°C for up to 4 weeks. Protease 
inhibitor cocktail (cOmplete EDTA-free, Roche) was prepared in dH2O, aliquotted and frozen 
at -20°C. Protease inhibitor cocktail was added to lysis buffer immediately prior to use. 
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 Cells were grown to 70-80 % confluence, placed on ice and washed twice with ice-
cold PBS. Cells were scraped into RIPA buffer and placed on an end-over-end mixer for 30 
min at 4°C. Lysates were then centrifuged at 12,000 x g for 20 min at 4°C in an Eppendorf 
5415R refrigerated centrifuge. Supernatants were collected, transferred to fresh tubes on 
ice and frozen at -80°C. 
 
 
2.8.2 Protein concentration quantification 
 
 The protein concentrations of cell lysates prepared using RIPA buffer were 
measured using a BCA protein assay kit (Pierce Biotechnology). A standard curve was 
produced using a BSA standard (Pierce) diluted in lysis buffer, as described by the 
manufacturer. Protein samples were dilute 1 in 5 also using lysis buffer. 10 µL BSA protein 
standard or protein sample was pipetted in triplicate into a 96-well plate. 200 µL BCA 
reagent was then added using a multi-channel pipette, briefly mixed using a plate shaker 
and then covered and incubated at 37°C for 30 min. After this time, the plate was left for 5 
min at room temperature before reading the absorbance at 562 nm using a Spectramax 
plus384 (Molecular Devices) plate reader. The concentration of the protein samples was 
determined from their mean absorbance values, using a linear standard curve produced 
from the mean absorbance values of the BSA protein standards. 
 For samples from conditioned medium (CM) collected in DMEM medium, protein 
concentration was also measured using the BCA method. For CM collected in Opti-MEM 
medium (see Section 2.12.1), protein concentration was measured by Bradford assay due 
to an interfering substance within the medium. As with the BCA assay, a standard curve was 
produced using a BSA standard (Pierce) diluted in Opti-MEM medium. 5 µL BSA protein 
standard or undiluted CM samples were pipetted in triplicate into a 96-well plate. 200 µL 
Bradford reagent was then added using a multi-channel pipette, briefly mixed using a plate 
shaker and incubated at room temperature for 10 min. Absorbance was read at 595 nm and 
the concentration of the protein samples was determined from their mean absorbance 
values, using the linear region of the standard curve produced from the mean absorbance 
values of the BSA protein standards. 
 For recombinant protein, protein concentration was determined using a NanoDrop 
1000 as described previously. 
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2.8.3 Preparation and running of polyacrylamide gels 
 
Stacking gel 
 
Resolving gel 
250 mM Tris-HCl, pH 6.8 
 
750 mM Tris-HCl, pH 8.9 
0.1 % (v/v) SDS 
 
0.1 % (v/v) SDS 
4 % or 5 % acrylamide* (37.5:1 
acrylamide:bis-acrylamide)  
8 %, 10 % or 15 % acrylamide* (37.5:1 
acrylamide:bis-acrylamide) 
0.06 % (w/v) ammonium 
persulfate (APS)#  
0.06 % (w/v) ammonium persulfate 
(APS)# 
0.015 % (v/v) TEMED 
 
0.015 % (v/v) TEMED 
 
* final percentage of acrylamide used as required. 
# 10 % (w/v) solution made up in dH2O and kept at 4°C for up to 4 weeks. 
 
SDS-PAGE running buffer 
50 mM Tris 
192 mM glycine 
0.1 % (w/v) SDS 
pH 8.3 
 
3 x SDS-PAGE loading buffer$ 
 
3 x SDS-PAGE loading buffer for 
conditioned medium samples$ 
187.5 mM Tris-HCl, pH 6.8 
 
187.5 mM Tris-HCl, pH 6.8 
6 % (v/v) SDS 
 
1 % (v/v) SDS 
30 % (v/v) glycerol 
 
30 % (v/v) glycerol 
300 mM  DTT 
 
300 mM DTT 
0.625 % (v/v) bromophenol blue 
 
0.625 % (v/v) bromophenol blue 
 
$Aliquotted and frozen at -20°C. 
 
 Acrylamide gels were poured into 1 mm-thick glass plates in a vertical casting 
apparatus (Bio Rad). Resolving gels were overlaid with 200 µL butanol to flatten the gel 
surface and prevent drying out of the gel, and left to polymerise at room temperature for 
45 min. Butanol was washed away using dH2O and stacking gel was poured over the set 
resolving gel. 10- or 15-well combs were immediately inserted into the stacking gel and gels 
were left to polymerise for 15 min at room temperature. Residual unpolymerised 
acrylamide was removed from the wells using dH2O, and gels were then placed in a vertical 
gel electrophoresis tank (Bio Rad) and submerged in 1 x SDS running buffer. 
 All protein samples were made up to the same volume with dH2O before the 
addition of 3 x SDS loading buffer in a 1:2 ratio. Precipitated protein from CM samples 
Chapter 2  Materials and Methods 
 
64 
 
already contain 2 % (w/v) SDS (see Section 2.12.2), so a modified loading buffer containing 
a lower percentage SDS was added to these samples so that the final concentration of SDS 
remained at 2 % (w/v). All samples were mixed by vortex and were then heated in a 98°C 
heating block for 5 min before being briefly centrifuged at 5,000 rpm in an Eppendorf 
5415D centrifuge prior to loading on the gel. Gels were run at 220 V for 45-60 min at room 
temperature, until the bromophenol blue dye front reached the bottom of the gel. 
 
 
2.8.4 Coomassie brilliant blue staining 
 
Coomassie brilliant blue stain 
 
Destain 
0.1 % (w/v) Coomassie brilliant blue 
 
20 % (v/v) methanol 
50 % (v/v) methanol 
 
10 % (v/v) glacial acetic acid 
7 % (v/v) glacial acetic acid 
  
 
 
 Electrophoresed gels were removed from their glass plates and rinsed twice in 
reverse osmosis (RO) water. Gels were then submerged in Coomassie brilliant blue stain for 
at least 30 min at room temperature on an oscillating platform. Gels were then rinsed 
several times in RO water to remove all excess stain and then submerged in destain buffer 
until protein bands became visible and background staining was suitably reduced. Destain 
buffer removed and fresh buffer was added as required. Gels were scanned using an 
ImageScanner III gel scanner (GE Life Sciences). 
 
 
2.8.5 Western blotting 
 
Western blot transfer buffer* 
 
TBST-T 
120 mM Tris 
 
20 mM Tris-HCl, pH 7.5 
192 mM glycine 
 
150 mM NaCl 
20 % (v/v) methanol 
 
0.1 % (v/v) Tween20 
        * Made fresh. 
 For the analysis of mammalian cell lysates, 10 µg of protein were loaded per well. 
For CM samples, either 20 µL of sample were loaded per well for qualitative experiments or 
samples were equally loaded based on the maximum amount of protein that could be 
loaded for the least concentrated sample in the experiment, e.g. if the least concentrated 
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sample had a concentration of 0.1 µg/mL, 20 µL of this sample was loaded on the gel, along 
with 2 µg/well of all other samples. 
 After SDS-PAGE, proteins were transferred onto Immobilon-P PVDF membrane 
(Millipore) via wet transfer. Gels were removed from their casting plates and rinsed twice in 
RO water before being submerged in freshly prepared transfer buffer for 15 min at room 
temperature. During this time, PVDF membrane was activated by submersion in 100 % 
methanol for 30 s. at room temperature, before being submerged in transfer buffer, along 
with sponges and filter paper. The transfer apparatus was assembled, whilst maintaining 
the whole apparatus submerged in transfer buffer to prevent the generation of air bubbles. 
The apparatus was then placed in a vertical electrophoresis tank and filled with transfer 
buffer and a -80°C freezer pack. The tank was placed in an ice tray and electroblotting was 
performed at 100 V for 90 min. 
 After transfer, membranes were rinsed twice with RO water and stained with ATX 
Ponceau S stain (Fluka) to check the efficiency of transfer. Membranes were then briefly 
washed in TBS-Tween 20 (TBS-T) to remove the stain. Membranes were then blocked for 1 
h at room temperature in blocking buffer (5 % (w/v) skimmed-milk powder (Marvel) in TBS-
T), on an oscillating platform. Membranes were then placed in 50 mL tubes and incubated 
with primary antibody (Table 2.5) in blocking buffer overnight at 4°C on a rolling mixer. 
 The following day, membranes were washed 3 x 10 min in TBS-T at room 
temperature. They were then placed in 50 mL tubes and incubated with secondary 
antibody (Table 2.5) in blocking buffer for 1 h at room temperature on a rolling mixer. 
Membranes were then washed a further 3 x 10 min in TBS-T. Excess liquid was removed 
and membranes were incubated with 1 mL Amersham™ ECL™ substrate (GE Life Sciences) 
per membrane, as described by the manufacturer. Excess reagent was removed and 
membranes were exposed to Super RX X-ray film (Kodak) for 1-60 min and then manually 
developed, in a dark room. If signal was weak or non-existent after 60 min exposure, 
membranes were briefly rinsed in TBS-T and incubated with 1 mL Amersham™ ECL Select™ 
substrate (GE Life Sciences) for 5 min at room temperature, before being re-exposed to X-
ray film. 
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Primary Antibodies 
Antibody Host Species Company Product Code 
Dilution 
Used 
AGR2 Mouse Millipore MABC48 1:5,000 
LDHA Rabbit Cell Signaling Technology 2012 1:2,000 
β-actin Mouse Sigma A5316 1:20,000 
     
Secondary  Antibodies 
Antibody Company Product Code 
Dilution 
Used 
HRP-conjugated Rabbit anti-mouse IgG Dako PO260 1:5,000 
HRP-conjugated Swine anti-rabbit IgG Dako PO217 1:5,000 
 
Table 2.5. Antibodies used for Western blotting. 
 
 
2.8.6 Densitometry 
 
 Developed X-ray film was scanned using a flatbed scanner (Ricoh). Densitometry 
was performed on developed blots or scanned SDS-PAGE gels using ImageStudio Lite 
software (LI-COR Biosciences). 
 
 
2.9 Immunoprecipitation (IP) 
 
IP wash buffer 
 
2 x SDS-PAGE loading buffer 
10 mM Tris-HCl, pH 7.5 
 
125 mM Tris-HCl, pH 6.8 
150 mM NaCl 
 
4 % (w/v) SDS 
2 mM EDTA 
 
30 % (v/v) glycerol 
1 %  (v/v) Triton X-100 
 
200 mM DTT 
  
0.415 % (w/v) bromophenol blue 
 
 Cell were lysed in RIPA buffer as described in Section 2.8.1. 100 µL Protein A/G 
bead slurry (Pierce) was centrifuged for 15 s. at 10,000 rpm in an Eppendorf 5415D 
centrifuge, the buffer removed and the beads washed 3 times with 1 mL PBS, with 
centrifugation for 15 s. at 10,000 rpm in between washes. 200 µL cleared lysate was added 
to the washed beads and incubated for 1 h on an end-over-end mixer at 4°C to remove 
proteins that bind non-specifically to the Protein A/G beads. The sample was then 
centrifuged for 5 min at 10,000 rpm at 4°C in a Eppendorf 5415R refrigerated centrifuge. 
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The supernatant was placed into a fresh tube on ice, 5 µL AGR2 antibody (Millipore) was 
added and the tube placed on an end-over-end mixer overnight at 4°C. 
 The next day, 30 µL Protein A/G bead slurry was washed 3 times in PBS as above 
and the lysate/antibody mix was incubated with bead slurry for 4 h at 4°C on an end over 
end mixer. Beads were centrifuged for 5 min at 10,000 rpm in an Eppendorf 5415R 
refrigerated centrifuge at 4°C and the supernatant removed. Beads were then washed 3 
times with 1 mL IP wash buffer, with mixing by brief vortexing and centrifugation for 5 min 
at 10,000 rpm at 4°C in between washes. After the final wash and centrifugation, 30 µL 2 x 
SDS loading buffer was added to the beads and heated for 5 min in a 98°C heat block. 
Samples were centrifuged for 5 min at 10,000 rpm in an Eppendorf 5415D centrifuge and 
the supernatant was loaded onto an SDS-PAGE gel and analysed by Western blotting as 
described in Section 2.8. 
 
 
2.10 Direct ELISA assay 
 
ELISA wash buffer 
50 mM NaPO4, pH 7.2 
150 mM NaCl 
0.05 % (v/v) Tween20 
 
 AGR2 protein and peptide were coated onto 96-well non-tissue culture-treated 
plates in the same way as described in Section 2.3.2. After coating, plates were washed 
once with 100 µL PBS and then incubated with 200 µL Superblock blocking buffer (Thermo 
Scientific) for 2 h at room temperature. Blocking buffer was removed and wells were 
incubated with 100 µL AGR2 antibody (Millipore, Table above) diluted 1 in 5000 in 
Superblock T20 blocking buffer (Thermo Scientific) at 4°C overnight. 
 The next day, wells were washed 6 times with 100 µL wash buffer and then 
incubated with 100 µL HRP-conjugated Rabbit anti-mouse IgG (Dako) diluted 1 in 10,000 in 
Superblock T20 blocking buffer for 2 h at room temperature. Wells were then washed a 
further 6 times in 100 µL wash buffer. Bound antibody was detected by the addition of 80 
µL 1-Step Ultra TMB-ELISA substrate (Thermo Scientific) and colour was allowed to develop 
for up to 30 min at room temperature. The reaction was quenched by the addition of 80 µL 
2 M sulphuric acid and plates were read at 450 nm in a Spectramax plus384 plate reader 
(Molecular Devices). 
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2.11 Biochemical assays for PDI activity 
 
2.11.1 Insulin turbidity assay 
 
 The assay was based on the method described by Holmgren, 1979 [523]. In a 96-
well clear plate, reagents were added to a final concentration of 50 mM NaPO4 (pH 7.0), 
2mM EDTA, 1 mg/mL insulin from bovine pancreas (Sigma) and either 0.5 µM recombinant 
thioredoxin from E. coli (Sigma) or 5 µM recombinant AGR2 (prepared as described in 
Section 2.7) in a final reaction volume of 200 µL. The reaction was started by the addition of 
DTT to a final concentration of 1 mM and the absorbance at 650 nm was measured every 5 
min for 90 min in a Spectramax plus384 plate reader (Molecular Devices) set at 25°C. A 
control reaction without thioredoxin or AGR2 was also included. Reactions were carried out 
in duplicate. 
 
 
2.11.2 Glutaredoxin assay 
 
 The assay was based on the method described by Holmgren, 1979 [524]. In a 96-
well clear plate, reagents were added to a final concentration of 100 mM Tris-HCl (pH 8.0), 
2 mM EDTA, 1 mM GSH, 0.4 mM NADPH, 100 µg/mL BSA and 6 µg/mL recombinant human 
glutathione reductase from E.coli (Sigma) in a final reaction volume of 200 µL. The substrate 
2-hydroxyethyl disulphide (HED) was then added to a final concentration of 0.7 mM and 
after a 2-min incubation at room temperature, recombinant human glutaredoxin-1 from 
E.coli (Sigma) or recombinant AGR2 (prepared as described in Section 2.7) was added to a 
final concentration of 5 µM. The absorbance at 340 nm was then measured every 2 min for 
120 min in a Spectramax plus384 plate reader (Molecular Devices) set to 25°C. A control 
reaction without glutaredoxin or AGR2 was also included. Reactions were carried out in 
duplicate. 
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2.12 Collection and analysis of cell secretomes 
 
2.12.1 Collection of condition medium (CM) 
 
 Cells were grown to 30-40 % confluence in normal medium and then washed 5 
times in PBS supplemented with 0.9 mM CaCl2 and 0.5 mM MgCl2 to remove serum 
proteins whist limiting the amount of cell detachment. Cells were then incubated for 24 h in 
a 37°C, 10 % (v/v) CO2 incubator in 7 mL Opti-MEM medium without phenol-red, 
supplemented with final concentrations of 25 mM glucose, 3.7 g/mL sodium bicarbonate, 
1.8 mM CaCl2, 4 % (w/v) NEAA, 100 units/mL penicillin, 100 µg/mL streptomycin and 10 
ng/mL hydrocortisone, so that this serum-free medium was as close to the formulation of 
normal Rama 37 medium as possible. 
 After 24 h, CM was collected on ice, cells washed with 1 mL ice-cold supplemented 
Opti-MEM medium and the combined CM and wash were centrifuged at 1000 x g for 5 min 
at 4°C in a Sigma 4K15 refrigerated centrifuge to pellet any large cellular debris. 
Supernatants were then centrifuged at 100,000 x g for 1 h at 4°C in a in a Sorvall Combi Plus 
ultracentrifuge (DuPont Instruments). Supernatants were removed and stored at -80°C for 
future use or directly subjected to trichloroacetic acid (TCA) precipitation. 
 
2.12.2 TCA precipitation 
    
Solubilisation buffer 
50 mM Tris-HCl, pH 8.0 
2 % (w/v) SDS 
 
 100 % (w/v) TCA solution was prepared by adding 227 mL ultrapure water to 500 g 
TCA powder. The powder was dissolved by gentle swirling at room temperature and the 
solution was subsequently stored at 4°C. 
 On ice, N-lauroylsarcosine (N-LS) solution was added to CM samples to a final 
concentration of 0.1 %* (w/v), vortexed and then TCA was added to a final concentration of 
7.5 %* (w/v). Samples were briefly mixed by vortexing and incubated at -20° for 2 h. After 
this time, samples were thawed at room temperature and 1.5 mL fractions were 
sequentially centrifuged at 10,000 x g for 10 min at 4°C in an Eppendorf 5415R refrigerated 
centrifuge in the same tube, until the whole sample had been processed. The pellet 
containing precipitated proteins was then washed twice with 1 mL ice-cold acetone, with 
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mixing by vortexing and centrifugation at 10,000 x g for 10 min at 4°C. After the second 
wash, the acetone was removed and excess acetone was allowed to evaporate for 5-10 min 
at room temperature in a fume hood. Pellets were incubated with 10 µL (or 1 volume) 200 
mM NaOH on ice for 5 min to aid protein solubilisation [525]. 90 µL (or 9 volumes) 1.1 x 
solubilisation buffer was added and the samples were subjected to two cycles of mixing by 
vortexing and a 10 min incubation in a sonicating waterbath at room temperature. The 
samples were then heated for 5 min in a 98°C heat block before a final 10 min incubation in 
a sonicating waterbath at room temperature. Samples were then centrifuged for 1 min at 
13,000 rpm in an Eppendorf 5415D centrifuge to pellet any remaining insoluble material 
and the supernatant frozen at -80°C. Supernatants were analysed by Western blot as 
described in Section 2.8 . 
 
* Concentrations are indicated for the final concentration of both reagents, after the 
addition of both of these reagents. 
 
 
2.12.3 Periodic acid-Schiff (PAS) staining 
 
 CM from eight 10 cm cell culture plates collected from cells in supplemented Opti-
MEM medium as described above and combined, but instead of TCA precipitation, CM was 
concentrated down to approximately 1 mL using Amicon® Ultra-15 centrifugal spin 
cartridges (Millipore) by centrifuging at 4,500 rpm at 4°C in a Sigma 4K15 refrigerated 
centrifuge. Samples were concentrated in this manner rather than by TCA precipitation as 
precipitated protein could not be efficiently immunoprecipitated. The concentrated sample 
was subjected to immunoprecipitation (IP) as described in Section 2.9, except that 10 µL 
AGR2 antibody was added and the next day the sample was incubated with 100 µL Protein 
A/G bead slurry. After IP, the beads were incubated with 30 µL 2x SDS sample buffer, 
heated for 5 min in a 98°C heat block and run on an SDS-PAGE gel as described in Section 
2.8.  
 All PAS staining steps were performed at room temperature. Following SDS-PAGE, 
gels were fixed in 50 % (v/v) methanol for 30 min and then washed for 3 x 5 min in 3 % (v/v) 
acetic acid. Gels were then incubated with 1 % (w/v) freshly prepared sodium periodate 
(Sigma) in 3 % (v/v) acetic acid for 30 min in the dark and then washed 3 more times with 3 
% (v/v) acetic acid for 5 min each, prior to the addition of Schiff’s Fuchsin-sulphite reagent 
(Sigma) for 15 min. Gels were then washed a final time in 3 % (v/v) acetic acid for 5 min and 
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then washed several times in RO water. Gels were scanned using an ImageScanner III gel 
scanner (GE Life Sciences) and were then counter-stained with Coomassie brilliant blue as 
described in Section 2.8.4, before being scanned again. 
 
 
2.12.4 Enzymatic deglycosylation of proteins 
 
  For deglycosylation of secreted proteins, CM from eight 10 cm cell culture plates 
collected from cells in supplemented Opti-MEM medium were combined and concentrated 
down to approximately 0.5 mL using Amicon® Ultra-15 centrifugal spin cartridges 
(Millipore) as described above. For deglycosylation of intracellular proteins, cells were 
grown to 70-80 % confluence and lysed using RIPA buffer as described in Section 2.8.1. Two 
10 cm plates were lysed into 200 µL buffer. 
 Deglycosylation was performed using a Protein Deglycosylation Mix (New England 
Biolabs) using the method described by the manufacturer. For CM samples, 9 µL 
concentrated CM was added to 1 µL denaturing buffer, whereas 5 µl cell lysate was added 
to 1 µL denaturing buffer and made up to 10 µL with dH2O. Both types of sample were 
subsequently treated in the same manner. Samples were heated in a heat block at 98°C for 
10 min, chilled on ice and then briefly centrifuged. Reaction buffer (50 mM NaCl, 20 mM 
Tris-HCl (pH 7.5) and 0.1 mM EDTA) and NP-40 were added to a final concentration of 1 x  
and 1 % (v/v), respectively, before the addition of 2.5 µL deglycosylation enzyme cocktail in 
a final reaction volume of 25 µl. Samples were then incubated in a 37°C waterbath for 4 h. 
After incubation, samples were briefly centrifuged before the addition of 3 x SDS loading 
buffer and samples were then subjected to analysis by Western blot as described in Section 
2.8. 
 
 
2.12.4.1 PNGase F treatment of proteins 
 
 Samples were resuspended in reaction buffer consisting of a final concentration of 
50 mM NaPO4 (pH 7.5), 40 mM DTT and 0.1 % (w/v) SDS, and heated at 98°C for 5 min. 
After brief centrifugation, NP-40 was added to a final concentration of 0.75 % (v/v), before 
the addition of PNGase F (Peptide-N-Glycosidase F, Europa Bioproducts) to a final 
concentration of[312, 377, 383, 457, 458, 526-535] 50 mU/mL. Samples were incubated 
overnight at room temperature. Deglycosylation of α-acid glycoprotein (α-AG) was used as 
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a positive control for these experiments. Note that concentrations denote final 
concentrations, after the addition of all reagents. PNGase F enzyme and recombinant α-AG 
protein were kindly provided by Dr Mark Wilkinson (Institute of Integrative Biology, 
University of Liverpool). 
 
 
2.12.5 λphosphatase treatment of proteins 
 
 Samples were resuspended in NEBuffer for protein metalloproteinases (PMP, New 
England Biolabs) consisting of a final concentration of 50 mM HEPES (pH 7.5), 10 mM NaCl, 
2 mM DTT and 0.01 % (v/v) Brij 35 detergent. MnCl2 was added at a final concentration of 1 
mM. Recombinant λphosphatase was then added to a final concentration of 10 µg/mL and 
samples were incubated at 30°C for 30 min. Dephosphorylation of recombinant Mps1 
(monopolar spindle 1) was used as a positive control for these experiments. Recombinant 
λphosphatase and recombinant Mps1 were kindly provided by Dr Patrick Eyers (Institute of 
Integrative Biology, University of Liverpool).  
 
 
2.13 LC-MS analysis 
 
2.13.1 Analysis of conditioned medium 
 
 CM was collected and processed as described in Section 2.12.1 from quadruplicate 
plates and samples were sent for analysis by the Centre of Proteome Research, Institute of 
Integrative Biology at the University of Liverpool. Protein concentration was determined by 
Bradford assay as described in Section 2.8.2. Equal amounts of protein were prepared in a 1 
mL reaction volume and captured onto 10 µL Strataclean beads (Agilent Technologies) by 
vortexing for 1 min. The process was repeated to capture proteins from 2 mL sample onto 
20 µl beads. Beads were pelleted by brief centrifugation and then washed in 1 mL 25 mM 
NH4HCO3 before being resuspended in fresh 25 mM NH4HCO3. Samples were subsequently 
incubated with a final concentration of 0.05 % (v/v) RapiGest SF™ (Waters) in 25 mM 
NH4HCO3 for 10 min at 80°C, before the addition of 60 mM DTT for 10 min at 60°C and then 
178 mM idoacetamide for 30 min at room temperature in the dark. Gold mass 
spectrometry grade trypsin (Promega, 1 µg) was then added and samples were incubated 
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at 37°C for 45 min and then centrifuged for 30 min at 17,000 x g at room temperature. 10 
µL of supernatant was then transferred to a Total Recovery Vial (Waters) and placed in an 
instrument auto sampler. 1 µL of sample was injected onto a trap column (Acclaim® 
PepMap 100, Dionex/Thermo Scientific) in buffer containing 0.1 % (v/v) trifluoroacetic acid 
(TFA) and 2 % (v/v) acetonitrile at a flow rate of 5 mL/min.  After 3 min, the trap column 
was set in-line with an Easy-Spray PepMap® RSLC analytical column (Dionex/Thermo 
Scientific), and peptides were separated over a linear gradient up to 40 % (v/v) acetonitrile 
in 0.1 % (v/v) formic acid, at a flow rate of 300 nL/min, using an UltiMate® 3000 Nano HPLC 
system (Dionex/Thermo Scientific). MS/MS analysis of eluted peptides was then performed 
on a Q Exactive™ Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Scientific).  
 Progenesis LC-MS label-free quantification software (Nonlinear Dynamics) was used 
for protein quantification. Data were normalised using an in-built algorithm that considers 
all peptide features and compares them to a chosen reference sample. The software 
assumes that most of the peptide abundances will not change between samples and 
calculates a global scaling factor, based on the mean scaling factor for each feature and 
iterating the process to remove any influencing outlying values. The top 5 MS/MS spectra 
for each peptide were then searched using the Mascot search engine and database (Matrix 
Science), and using a 1 % false discovery rate. The peptide score threshold for this false 
discovery rate was then used as a cut-off score for peptides within Progenesis. 
 For CM experiments, samples could not be normalised to protein concentration 
due to the presence of non-cell derived culture medium proteins at a concentration of 15 
µg/mL, which masked the concentration of cell-derived proteins. Therefore, for 
normalisation of these samples, protein was captured onto Strataclean beads and digested 
as described above. The digests were then analysed using a 1 h elution gradient LC-MS 
method to obtain an approximate normalisation value from Progenesis. Using this value, 
normalised amounts of sample were then loaded and analysed over a 2 h elution gradient 
method, and differences in protein abundance identified using Progenesis. Subcellular 
distribution of proteins, pathway analysis and construction of regulatory/interaction 
networks was performed using Ingenuity Pathway Analysis software (Qiagen). 
 
 
2.13.2 Analysis of whole cell lysates 
 
 Cells were grown for two passages in DMEM without phenol-red, supplemented 
with 5 % (v/v) FBS, 4 % (v/v) NEAA, 4 mM L-glutamine, 10 ng/mL insulin, 10 ng/mL 
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hydrocortisone, 100 units/mL penicillin and 100 µg/mL streptomycin. Upon reaching 70-80 
% confluence, cells from five 10 cm cell culture plates were washed 3 times with PBS and 
detached by treatment with an enzyme-free dissociation buffer (Enzyme-free cell 
dissociation solution (PBS-based), Millipore) for 30-45 min in a 37°C, 10 % (v/v) CO2 
incubator. Cells were collected in PBS, combined and centrifuged for 5 min at 1000 x g at 
room temperature to remove the dissociation reagent. Cells were washed once more in 
PBS, centrifuged for 5 min as before and resuspended in 10 mL PBS. 100 µL of this cell 
suspension was counted using a Z1 Coulter® particle counter (Beckman Coulter) and 1 x 107 
cells were transferred to a fresh tube. These cells were pelleted by centrifugation for 5 min 
as before, the supernatant removed and the cell pellets were snap-frozen in liquid nitrogen 
and stored at -80°C until needed. Cells were collected in this manner in quadruplicate. 
 Samples were sent for analysis by the Protein Function Group, Institute of 
Integrative Biology, at the University of Liverpool. Cell pellets were thawed, resuspended in 
25 mM NH4HCO3 and lysed by sonication. DNA was removed by digestion with 25 units 
benzonase nuclease (Novagen). Protein concentration was then determined by Bradford 
assay and 100 µg of protein was digested and analysed as described for CM samples, with 
500 ng being injected onto the trap column, as above. Whole cell samples were directly 
separated over a 2 h gradient as they had already been normalised to protein 
concentration. 
 
 
2.14 Statistics 
 
 Statistical analyses were performed using the SPSS software package, version 20 
(IBM).  
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Chapter 3 
 
 
 
Characterisation of Recombinant AGR2 
and AGR2-expressing Stable Cell Lines 
 
 
 
3.1 Introduction 
 
 AGR2 is a member of the protein disulphide isomerase (PDI) family of endoplasmic 
reticulum (ER) chaperones, based on its sequence homology to the PDI ERp18 and its 
housing of a divergent PDI active site motif with the sequence CxxS, which normally sits 
within a thioredoxin fold [378]. Several other structural features within the AGR2 sequence 
have been identified and are outlined in Fig. 3.1A. The protein contains an N-terminal signal 
peptide that promotes its translocation into the ER [536], where it is mostly resident [417, 
422, 437-439]. At the C-terminus, there is an ER-retention sequence (KTEL) that mediates 
retrograde transport from the Golgi to the ER, further maintaining the protein within the ER 
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[342]. More recently, the solving of the structure of AGR2 by nuclear magnetic resonance 
(NMR) revealed that the protein does indeed contain a thioredoxin fold [421], where the 
active site motif lies at the N-terminus of α-helix 2 (Fig. 3.1A and B), as in other family 
members [315]. Importantly, the structure revealed that AGR2 exists in monomer-dimer 
equilibrium [421], with AGR2 dimerisation subsequently also shown in other reports [416, 
438]. The determination of the AGR2 dimer structure also revealed the nature of the 
dimerisation interface, with the complex being assembled with anti-parallel facing subunits 
that interact along α-helix-1 (Fig. 3.1B and C), and also suggested the involvement of charge 
interactions between a glutamate and lysine residue in dimerisation [421]. 
Homodimerisation plays a role in the regulation and function of the PDI ERp29, an unusual 
PDI that contains a thioredoxin fold but no active site cysteines [315]. Like AGR2, ERp29 is 
also thought to dimerise through charge-based interactions, with hydrogen bonding 
probably occurring between the aspartate side-chain on one subunit with a glycine residue 
on the opposing subunit, such that mutation of the aspartate residue alone was enough to 
prevent dimerisation [537]. As this dimerisation was of crucial importance to ERp29 
chaperone function [537], a similar dimerisation-dependent mechanism may regulate AGR2 
function, and thus it will be important to decipher the forces governing its dimerisation.  
 Through the afore-mentioned structural studies of AGR2, an unstructured, highly 
flexible region of the protein was also identified, initially within the residues immediately 
following the cleavable signal peptide (and thus termed the ’21-40’ region [421]), but later 
predicted to extend up to and including Thr57 (Fig. 3.1A). Whilst 3-dimensional structures 
can be attributed to these intrinsically disordered regions [326], it is noteworthy that the 
published structure for AGR2 does not contain the flexible 21-40 region. There are 
difficulties in assigning a structure to such disordered regions in the context of a protein in 
dynamic equilibrium, which relate to the necessity of labelling core hydrophobic residues 
for NMR.  Thus signals from the charged N-terminal flexible region of AGR2 were not 
obtained [421, 538].  
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Figure 3.1. AGR2 can form a homodimer. (A) Positions of notable regions within the 
AGR2 primary structure, relative to secondary structure elements (adapted from Patel et 
al., 2013 [421]). Note that the signal peptide comprising residues 1-20 is not shown and 
the binding site for Reptin refers to the minimum sequence requirement for the 
reported binding of AGR2 to the histone acetyltransferase component Reptin [539]. (B) 
Solution structure of AGR2 derived by NMR (reproduced from Patel et al., 2013 [421]). 
Note that the small β-sheet 4 is obscured by α-helix 2.  
A 
B 
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 To date, biochemical assays have failed to detect PDI activity for recombinant AGR2 
(i.e. in assays of disulphide bond reduction or isomerisation, or assays of thiol oxidation), 
although recombinant AGR2 does promote cell attachment when coated on a plastic 
substratum [309]. Similarly, AGR2-expressing cells showed an enhanced rate of cell 
adhesion compared to non-expressing cells [309, 515], and further studies have shown that 
AGR2 can promote migration and invasion in vitro [301, 414, 415, 440, 481], indicating that 
AGR2 expression has functional consequences related to adhesion and migration. 
 
 
3.1.1 Chapter objectives 
 
 The aims of this chapter are to explore the factors affecting the extent of AGR2 
dimerisation and thus the mechanism whereby AGR2 is able to form a dimer. In light of the 
difficulties of assaying recombinant AGR2 activity, the aim of this chapter is also to 
generate and characterise a panel of cell lines stably expressing structural mutant AGR2 
proteins, with a view to determining their contributions to AGR2 biological activity.  
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3.2 Results 
 
3.2.1 Characterisation of recombinant AGR2 
 
3.2.1.1 Identification of residues involved in AGR2 dimerisation 
 
 AGR2 can form a homodimer in solution, as revealed by both NMR and size-
exclusion chromatography-multiple angle laser light scattering (SEC-MALLS, [421]). 
Furthermore, paramagnetic relaxation experiments and residual dipolar coupling (RDC)-
assisted modelling of symmetry [538] suggested that AGR2 subunits most likely dimerise 
along α-helix 1 of both subunits [421] (see Appendix 1). An electrostatic interaction 
between Glu60 and Lys64 in this α-helix 1 on opposing subunits was also predicted to be 
responsible for maintaining protein dimerisation. The presence of a tyrosine (Tyr63) on 
each chain within the proposed dimerisation interface also raised the possibility that 
hydrophobic interactions between these two tyrosine rings may further contribute to the 
extent of AGR2 dimerisation (Fig. 3.2). 
 
 
 
Figure 3.2. Proposed interface of the AGR2 dimer. The residues thought to be involved 
in protein dimerisation along α-helix 1 are labelled, with asterisks (*) marking residues 
from a second subunit. Reproduced from Patel et al., 2013 [421]. 
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 The relative contributions of the above-mentioned residues to the dimerisation of 
AGR2 were tested on recombinant protein using mutagenesis and SEC-MALLS (Fig. 3.3). 
Furthermore, as one study has reported that AGR2 dimerises through Cys81 in the putative 
active site [416], the oligomerisation status of AGR241-175 with a mutation of this cysteine to 
a serine (C81S AGR241-175) was also analysed (Fig. 3.3E). As noted previously, residues 21-40 
of AGR2 form part of an intrinsically disordered region of the protein. Regions with such a 
flexibility are a challenge for NMR structural determination [540] and, given the already 
challenging nature of determining the structure of a homodimer [538], a truncated form of 
AGR2 was used for structural and subunit studies. This truncated protein, AGR241-175, lacks 
both the signal peptide and 21-40 flexible region.  
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Figure 3.3. Determination of residues involved in AGR2 dimerisation. Recombinant 
AGR2 proteins were purified and subjected to SEC-MALLS analysis. The 
oligomerisation of wild-type (WT) AGR241-175 was compared to (A) E60A AGR241-175, 
(B) Y63A AGR241-175, (C) K64A AGR241-175, (D) all three interface mutations and (E) 
C81S AGR241-175. The refractive indices of the measured proteins are represented by 
solid lines, whilst the corresponding molecular masses of the protein species across 
these peaks are shown by dashed lines. Experiments were performed at 150 mM 
NaCl. 
WT AGR241-175         E60A AGR241-175         Y63A AGR241-175         K64A AGR241-175         C81S AGR241-175 
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 The elution profile of WT AGR241-175 yielded an asymmetrical peak, consistent with 
a sample of heterogeneous molecular mass. Indeed, molecular mass across the major 
isolated peak (dashed blue line, Fig. 3.3A) was not uniform, with a mean mass of 26.0 kDa. 
Together, these data imply that recombinant AGR2 exists in a monomer-dimer equilibrium, 
rather than as a pure dimer. The mean molecular mass of 26.0 kDa does suggest that the 
dimer is favoured, given that it is closer to the expected mass of 32.2 kDa for a dimer than 
16.1 kDa for a monomer of AGR241-175 [738]. 
 Strikingly, mutation of the Glu60 residue to Ala (E60A) resulted in complete 
ablation of dimerisation potential (Fig. 3.3A). The protein here gave a symmetrical elution 
profile (indicative of uniform molecular mass) with a corresponding mean molecular mass 
of 16.4 kDa across the peak, the expected mass for a monomeric AGR241-175 protein. On the 
other hand, mutation of the Tyr63 residue to Ala (Y63A) produced an asymmetrical peak 
similar to that of WT AGR241-175 (Fig. 3.3B), but with an average molecular mass of 18.9 kDa. 
This suggests that this mutant protein is still in monomer-dimer equilibrium, but that the 
monomer is more favoured than for WT protein, given that the average molecular mass of 
the sample was very close to that of monomeric AGR241-175. These changes in equilibrium 
and average molecular mass for Y63A AGR241-175 would indicate that Tyr63 also contributes 
to AGR2 dimerisation. 
 Surprisingly, mutation of the Lys64 residue (the predicted residue involved in salt 
bridge formation with Glu60) to Ala did not completely disrupt dimerisation in the same 
way as the E60A mutation (Fig. 3.3A and C). The elution profile of K64A AGR241-175 was more 
reminiscent of Y63A AGR241-175, with a very similar average molecular mass of 18.7 kDa. This 
points to the protein being largely monomeric, with a limited ability to dimerise. AGR2 
possessing the C81S mutation behaved in almost exactly the same manner as WT AGR241-175 
(Fig. 3.3E), with a very similar elution profile and mean molecular mass (26.2 kDa and 25.4 
kDa, respectively), indicating that Cys81 does not play a role in AGR241-175 dimerisation. 
Taken together, these data support the proposed model of AGR2 dimerisation, by 
demonstrating the importance of the three residues E60, Y63 and K64 in α-helix 1 to dimer 
formation, and that dimerisation is not mediated through Cys81, as reported  by others  
[416]. 
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3.2.1.2 Full length AGR221-175 dimerises in the same way as truncated AGR241-175 
 
 Within the cell, AGR2 is synthesised with an N-terminal signal peptide that is 
cleaved upon translocation into the ER [309, 541]. This mature form of the protein, devoid 
of signal peptide, is denoted as AGR221-175. In order to determine whether the natural form 
of AGR2 (AGR221-175) exhibits the same dimerisation properties as those observed with 
AGR241-175, recombinant WT AGR221-175 and E60A AGR221-175 were purified and subjected to 
SEC-MALLS analysis.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 WT AGR221-175 displayed a very similar elution profile to that of WT AGR241-175, also 
showing an asymmetrical peak with a non-uniform molecular mass, again suggestive of 
monomer-dimer equilibrium (Fig. 3.4). The mean molecular mass across the peak was 30.9 
kDa, again closer to the 35.6 kDa theoretical mass of a dimer than 17.8 kDa, the theoretical 
mass of a monomer. It is interesting that the mean molecular masses for AGR221-175 and 
AGR241-175 were 80.7 % and 86.8 %, respectively, of the theoretical masses for dimers of 
their respective species. This might suggest that both proteins dimerise to approximately 
the same extent, with AGR221-175 possibly producing a slightly more favoured dimer.  
 Mutating the Glu60 residue of AGR221-175 (E60A AGR221-175, Fig. 3.4) had the same 
effect as with the truncated AGR241-175 protein, in that there was a uniform molecular mass 
across the peak (17.2 kDa) which matched the expected mass for an AGR221-175 monomer 
Figure 3.4. AGR221-175 exists in monomer dimer equilibrium, mediated by Glu60. 
Wild-type (WT) AGR2 (AGR221-175) and (A) AGR2 bearing a Glu to Ala mutation at 
position 60 (E60A AGR221-175) were purified and subjected to subunit analysis using 
SEC-MALLS. The refractive indices of the measured proteins are represented by solid 
lines, whilst the corresponding molecular masses of the protein species across these 
peaks are shown by dashed lines. Experiments were performed at 150 mM NaCl. 
 
AGR221-175          E60A AGR221-175 
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(17.8 kDa). This is consistent with the observation made with AGR241-175 protein [421], and 
suggests that AGR221-175 and AGR241-175 behave in essentially the same manner, with 
dimerisation occurring through the α-helix 1 interface (amino acids Glu60 to Lys64). 
 
 
3.2.1.3 Protein concentration contributes to the extent of AGR2 dimerisation 
 
 Protein concentration can be a factor in determining both the extent of 
dimerisation in proteins exhibiting monomer-dimer equilibria and also in their biological 
activity [542, 543]. This might be particularly relevant in the context of tumourigenesis, 
where abnormal overexpression of proteins such as AGR2 would increase the local 
concentration of protein and potentially affect its oligomerisation state. To this end, 
AGR221-175 was purified and analysed by SEC-MALLS at three different protein 
concentrations (Fig. 3.5). 
 
 
 
 
 
 
 There was a small effect of protein concentration on AGR2 oligomerisation, with 
protein at 0.5, 1.0 and 2.0 mg/mL all displaying a very similar elution profile. There was a 
small upward shift in mean molecular mass across the peaks with increasing protein 
concentration, rising from 29.9 kDa at 0.5 mg/mL, to 31.0 kDa at 1.0 mg/mL and then 
further to 31.8 kDa at 2.0 mg/mL. These data provide some evidence that an increase in 
local concentration of AGR2 could favour dimer formation to some extent in the cell, but 
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Figure 3.5. Protein concentration 
affects monomer-dimer 
equilibrium of AGR2. 
Recombinant wild-type AGR221-
175 was purified and analysed at 
three different concentrations by 
SEC-MALLS. The refractive 
indices of the measured proteins 
are represented by solid lines, 
whilst the corresponding 
molecular masses of the protein 
species across these peaks are 
shown by dashed lines. 
Experiments were performed at 
150 mM NaCl. 
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without information on physiological concentrations of AGR2, it is difficult to say whether 
this has any functional significance in vivo.  
 
 
3.2.1.4 The flexible 21-40 region stabilises the AGR2 dimer 
 
 To further explore the type of forces driving dimerisation of AGR2, the potential of 
higher salt concentration to disrupt the dimer was tested, given that the complex is held 
together through predominantly ionic interactions. 
 
 
   
 
 
 
 
 
 
 
 
 Interestingly, there was no difference in mean molecular mass of AGR221-175 in 150 
mM or 300 mM NaCl (Fig. 3.6A), with values of 30.9 kDa for 150 mM NaCl and 31.0 kDa for 
300 mM NaCl. However, the presence of 600 mM NaCl did reduce the mean molecular 
mass to 29.5 kDa, indicating a small change in monomer-dimer equilibrium at this high salt 
concentration. 
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Figure 3.6. The AGR241-175 dimer is more susceptible to dissociation from high salt 
concentration than AGR221-175 dimer. (A) Wild-type (WT) full length AGR2 (AGR221-
175) and (B) WT truncated AGR2 (AGR241-175) were purified and the concentration of 
NaCl adjusted as shown. The proteins were then subjected to SEC-MALLS analysis. 
The refractive indices of the measured proteins are represented by solid lines, whilst 
the corresponding molecular masses of the protein species across these peaks are 
shown by dashed lines.  
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600 mM NaCl 
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 In contrast, AGR241-175  in only 300 mM NaCl (Fig. 3.6B), exhibited  a much greater 
shift in mean molecular mass than was observed even at 600 mM NaCl for AGR221-175, 
reducing the mean molecular mass from 27.2 kDa to 22.6 kDa. Such a large shift in 
molecular mass supports the notion of the complex forming through ionic interactions, but 
the dramatic difference in resistance to salt concentration observed between AGR221-175 
and AGR241-175 suggests that the presence of the flexible region stabilises the AGR2 dimer, 
possibly through protecting the dimer interface from solvent attack. However, while these 
experiments were performed in buffer containing non-physiological concentrations of NaCl, 
intracellular KCl is present at a concentration of around 140 mM [544], and so the 
relevance of these results to in vivo AGR2 protein may depend on whether K+ ions have a 
different effect than Na+ ions on AGR2 dimerisation. With this in mind however, even at 
150 mM NaCl, there was little difference in the monomer-dimer equilibria of AGR221-175 and 
AGR241-175 (see Section 3.2.1.2), and so in vivo, the 21-40 region probably does not play a 
significant role in AGR2 dimerisation. Whether these experiments are evidence of a 
protective effect of the 21-40 region on the dimer interface could be an interesting avenue 
of investigation. 
 
 
3.2.1.5 AGR2 does not function in biochemical assays of PDI function 
 
 Having established the consequences of mutations in the dimer interface on the 
dimerisation of AGR2, the functional consequences of these mutations were next 
investigated through the use of biochemical assays. PDI proteins catalyse the 
reduction, formation and isomerisation of disulphide bonds (DSBs) in substrate proteins 
within the ER [311]. Measuring this activity in in vitro biochemical assays facilitates the 
assessment of changes to enzyme activity as a result of any protein modifications. 
Therefore, the PDI activity of AGR2 was explored, with a view to pinpointing the functional 
consequences of the loss of protein dimerisation and loss of the flexible 21-40 region. 
 The insulin turbidity assay is a measure of dithiol reductase activity, i.e. the ability 
to catalyse the reduction of DSBs. When the interchain DSB between insulin α- and β-chains 
is reduced, the β-chain precipitates and this can be measured at 650 nm (reviewed in 
[311]). AGR2 was unable to catalyse this DSB reduction at a measurable rate, as it showed 
no difference in reaction rate compared to the control reaction without enzyme (Fig. 3.7A). 
Thioredoxin, a cellular reductase [545], exhibited similar activity to that reported before 
[524] in control reactions carried out at the same time (Fig 3.7A). 
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 AGR2 also showed no isomerase activity as measured by scrambled RNAse assays 
(Pryank Patel, personal communication). Here, an active PDI should promote the correct re-
folding of RNAse with mispaired disulphides, producing an active form of RNAse [546]. This 
lack of isomerase activity is perhaps not unexpected given that isomerase activity generally 
requires two CxxC-containing catalytic domains [321, 322]. 
 Some proteins containing the single-cysteine CxxS active site motif are able to 
function as glutaredoxins [547, 548], contributing to cellular redox reactions through 
catalysing the reduction of DSBs between glutathione and protein thiol groups (reviewed in 
[548]). However, AGR2 did not display any glutaredoxin activity, showing no difference in 
reaction rate compared to the negative control reaction (Fig. 3.7B).  
 
 
 
 
 
 
 
 
 
 
 This lack of PDI-like enzyme activity may indicate that AGR2 does not in fact 
function as a PDI. This creates a problem for studying the functional consequences of 
changes to AGR2 oligomerisation and other potentially important domains, given the lack 
of suitable assays to assess their activity. AGR2 does, however, promote cell adhesion [309, 
421, 515], and so in the absence of a biochemical  assay for AGR2 activity, cell-based 
biological assays are the major tool for determining the effects of sequence- and structure-
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Figure 3.7. AGR2 is inactive in biochemical assays of PDI activity. (A) Insulin turbidity 
assay. The reduction of the interchain disulphide bond between insulin α- and β-
subunits by DTT was measured in the absence (blue) and presence of thioredoxin 
(red) or WT AGR2 21-175 (green). Precipitation of the β-chain as a result of DSB 
reduction was measured at 650 nm.  (B) Glutaredoxin assay. The reduction of DSBs 
within the HED substrate was monitored by the consumption of NADPH, measured at 
340 nm. Both panels show representative outputs from experiments performed 
using duplicate wells.  
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based alterations to AGR2 on its activity. In this context, the generation and 
characterisation of AGR2-expressing cell lines are an important means of relating AGR2 
structure and activity. Therefore, cell lines stably-expressing WT AGR2 and AGR2 mutant 
proteins were created, with a view to testing their adhesion properties as a measure of 
AGR2 activity. 
 
 
3.2.2 Characterising AGR2-expressing stable cell lines 
 
3.2.2.1 Creating cell lines to study AGR2 function in vitro 
 
 AGR2 contains several protein domains that might be relevant to its function, 
including its putative cysteine-containing thioredoxin domain (C81) and its C-terminal ER-
retention sequence (KTEL), that controls not only its localisation but also plays a role in 
anchorage-independent cell growth [445, 481, 482]. In addition to these domains, the 
structural work described in Section 3.2.1 demonstrates that protein dimerisation (crucially 
mediated through Glu60) and also the intrinsically disordered, flexible 21-40 region may 
also play important roles in AGR2 function. Therefore, rat mammary cells (Rama 37) stably 
expressing wild-type (WT) and mutant forms of AGR2 were created to investigate AGR2 
structure/function relationships (Table 3.1). In addition to the mutants described above, a 
further mutant protein devoid of signal peptide was also created, in order to block entry of 
AGR2 into the ER and investigate whether any or all of its functions are dependent on 
residency within the ER. 
 
Mutant Domain mutated Expected effect on protein 
E60A AGR2 Dimerisation interface Monomeric 
C81S AGR2 Putative thioredoxin domain Potentially catalytically inactive 
∆1-20 AGR2 Signal sequence Prevention of entry into the ER 
∆21-40 AGR2 Flexible region Deletion of flexible region 
∆KTEL AGR2  ER-retention sequence Enhanced secretion 
 
Table 3.1. AGR2 mutant proteins stably expressed by Rama 37 cell lines. 
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3.2.2.2 Transposase-based plasmid integration 
 
 Rama 37 cell lines stably expressing both WT and mutant AGR2 protein under the 
control of a cytomegalovirus (CMV) promoter had previously been constructed [309], but 
these cells appeared to lose expression of these proteins upon subculturing. The reasons 
for this are not clear, but may be related to the propensity of CMV promoters to become 
silenced during long term culture [549-552]. Therefore, new stably-expressing cell lines 
were created, using a more robust and efficient transposase-based system, under the 
control of the robust EF1α promoter, which appears to be much less frequently silenced 
[551]. 
 The PiggyBac transposon vector system has several key features that promote 
efficient mammalian cell transfection. In addition to the EF1α promoter mentioned above, 
the main attraction of the system is that, through the co-transfection of a transposase-
expressing plasmid with the vector expressing the gene of interest (GOI), the entire GOI 
expression cassette is inserted into the host genome at specific AT-rich sites, through a “cut 
and paste” mechanism [553]. These AT-rich regions are not well characterised in higher 
eukaryotes, but in prokaryotes and yeast, they tend to be found at origins of DNA 
replication, where the weaker A-T interactions relative to G-C interactions facilitate DNA 
strand separation (reviewed in [554]). For the most part, these sites are therefore 
presumably located outside of coding regions, and thus insertion of a GOI into these 
regions of DNA should limit the likelihood of inducing unwanted mutagenesis into the host 
genome through disruption of existing gene architecture.  
 The transposase-catalysed insertion of the GOI into the host genome permits not 
only a higher transfection efficiency (Fig. 3.8) but, due to core insulator sites flanking the 
expression cassette (Appendix 2), the integrity of the cassette is conserved and should not 
be broken during genome integration. A final important feature of the system is the use of 
an internal ribosome entry site (IRES) that allows the expression of an antibiotic resistance 
gene (here, neomycin) on the same mRNA as the GOI, at its 3’ end. Thus, only cells 
expressing the GOI will be resistant to the selection agent, ensuring that the population of 
cells demonstrating antibiotic resistance do also express the GOI. Using this system, stable 
cell lines were produced rapidly and reliably (Fig. 3.8A). 
 The benefits of working with the PiggyBac transposase system are outlined in Fig. 
3.8. There was a greater transfection efficiency when co-transfecting the GOI vector with 
the transposase plasmid, rather than using the GOI vector alone, represented by the 
relative increase in AGR2 expression 24 h after transfection (Fig. 3.8A). Expression was 
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monitored over the active period of the transposase (72 h), but appears to be lost during 
this period, most likely due to the effects of the growth of non-transfected cells ‘diluting’ 
the apparent amount of AGR2 protein. 
 It is interesting that after selection in G418, the stable cell line created using 
transposase co-transfection seemed to produce more AGR2 protein than the cell line 
created without transposase (Fig. 3.8A), probably reflecting the more efficient process of 
using the transposase, but also the fact that without the enzyme, chromosomal integration 
will be more random, and so chromosomal insertion points may affect cellular components 
involved in gene expression and protein synthesis, such that protein production is less 
efficient. It is also important to note that transposase co-transfection allowed the much 
more rapid production of a stably-expressing cell line, with the vector-only cell line 
requiring an extra 7-10 days growth to reach the same confluence as transposase co-
transfected cells. This again most likely stems from the increased transfection efficiency of 
the transposase system, producing a higher percentage of transfected cells so that more 
survive under selection and confluency is reached much more quickly. 
 Another interesting feature of the transposase system is highlighted in Fig. 3.8B. 
The amount of vector DNA transfected into Rama 37 cells was varied from the 2 µg 
recommended by the manufacturer to 12 µg. Regardless of the amount of DNA transfected, 
all stable cell lines showed the same steady-state levels of protein, possibly reflecting the 
saturation of AT-rich insertion sites available within the host genome. This meant that low 
amount of DNA could be used, requiring less transfection reagent, leading to lower 
amounts of cell death, with the ultimate outcome of further speeding up the generation of 
stable cell lines. 
 A potential pitfall in the generation of stable cell lines is the loss of protein 
expression over time, as mentioned above. Therefore, the expression of AGR2 from a 
PiggyBac-created cell line was monitored over a ten week period (Fig. 3.8C). These cells 
grow rapidly and were subcultured every two days, and whole cell lysates were collected 
after the indicated number of passages. Expression of AGR2 protein was maintained at a 
similar level throughout the time-course, with possibly a slight reduction in expression after 
35 passages. This continued expression of AGR2 over a relatively long culture period 
alleviated any concerns that expression of the protein might be repressed in the long term, 
and highlights the robustness of the EF1α promoter. Together, these data demonstrate the 
PiggyBac system to be an effective tool for both transient and stable transfection of cells. 
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Figure 3.8. The PiggyBac transposon system is a robust system for the generation of 
stable cell lines. (A) Rama 37 cells were transiently transfected with either 
transposase plasmid only, AGR2-containing PiggyBac vector only or co-transfected 
with both. Cells were harvested and probed for AGR2 expression at the indicated 
timepoints. Cells were then subjected to G418 selection to establish stable cell lines, 
and probed for AGR2 expression. Transposase-only transfected cells do not survive 
selection, as expected. (B) Rama 37 cells were co-transfected with the indicated 
amount of AGR2-containing PiggyBac plasmid and transposase plasmid. After G418 
selection, cells were harvested and probed for AGR2 expression. (C) Rama 37 cells 
stably expressing AGR2 were cultured for 10 weeks (35 passages) and harvested and 
probed for AGR2 at the indicated passages. 
A 
B 
C 
Chapter 3  Results 
92 
 
3.2.2.3 Generation of mutant AGR2-expressing cell lines 
 
 Having established the PiggyBac system as a suitable tool for the generation of 
stable cell lines, other cell lines expressing the mutant AGR2 proteins outlined in Table 3.1 
were created (Fig. 3.9). Surprisingly, given the consistent efficiency of transfection (Fig. 
3.8B), mutant proteins displayed a wide range of expression levels, with only the ∆21-40 
AGR2 mutation being expressed at a comparable level to WT protein (Fig. 3.9A). These 
differences in steady-state protein levels therefore likely reflect differences in protein 
stability or turnover within the cell, rather than differences in transfection efficiency. 
 In order to be effective tools for examining the effects of mutations on protein 
activity, these cells lines must express similar levels of proteins to discount any effects 
mediated by protein concentration. Therefore, multiple clonal cell lines were created from 
each pooled mutant cell line, to isolate cell lines expressing similar protein levels across all 
six cell lines. The three clonal cell lines expressing the highest amount of protein for each 
mutation were identified (Fig. 3.9B and C). 
 As seen with the pooled cell lines, overall steady state levels of mutant proteins 
were largely lower in clonal mutant cell lines than for clonal WT cell lines, possibly as a 
result of decreased protein or mRNA stability. Nevertheless, clonal cell lines expressing 
similar amounts of protein were found, providing tools for subsequent experiments. The 
two major exceptions to this were ∆1-20 AGR2 clones and ∆KTEL AGR2 clones, where 
steady state levels were substantially lower (Fig. 3.9C). Given that ∆KTEL AGR2 lacks an ER-
retention sequence, the protein would be expected to be secreted to a greater degree than 
WT protein and this could explain the apparent low intracellular steady state levels in these 
cells. Indeed, when the levels of secreted AGR2 were measured by Western blot for WT 
clone 2 and ∆KTEL clone 8, there was no detectable secreted WT AGR2 but ∆KTEL AGR2 was 
highly secreted (Fig. 3.10).  
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Figure 3.9. Generation of AGR2-expressing stable cell lines. (A) Equal numbers of 
Rama 37 cells were transfected with equal amount of PiggyBac vector containing the 
indicated AGR2 mutation and subjected to selection for 10-14 days. Cells were 
harvested and probed for AGR2 by Western blot. (B and C) From the cells in (A), 
clonal cell lines were created using a limiting dilution technique, where the pooled 
cell lines are subjected to serial dilutions, until one cell per well is obtained. After 
expansion, the clonal cells were harvested and probed for AGR2 by Western blot. The 
three highest expressing clonal cell lines for each mutant and WT AGR2 are shown, 
with expression in WT pool cells for comparison. (C) AGR2 expression levels in ∆1-20 
AGR2 and ∆KTEL AGR2 clones. WT pool expression is shown from a different part of 
the same blot. 
A 
B 
C 
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 The low expression of ∆1-20 AGR2 is not as easy to explain. The protein is 
essentially the same as WT protein (it is in fact fully mature WT AGR2) except that it does 
not gain access into the ER. Assuming that there is no difference in the extent of gene 
expression between these two proteins, it may be that AGR2 itself requires one or more ER 
chaperones to help it fold correctly and so lack of entry into the ER limits its correct folding, 
possibly resulting in lower levels of AGR2 protein as incorrectly folded protein will 
presumably be degraded. Alternatively, its apparently low expression may be related to its 
sub-cellular localisation, as outlined below. 
 
 
 
 
 
 
Figure 3.10. ∆KTEL AGR2 is highly secreted compared to WT AGR2. Whole cell 
lysates from WT and ∆KTEL AGR2 cells grown in normal medium were collected and 
probed for AGR2. For measuring secreted AGR2, conditioned medium (CM) was 
collected from cells of approximately equal confluency, in Opti-MEM-based serum-
free medium. As CM loading could not be normalised to protein concentration due to 
the high concentration of transferrin in the Opti-MEM medium (15 µg/mL) which 
masks the concentration of cell-derived proteins, only equal volumes of CM were 
loaded. However, samples were collected in duplicate to limit the effects of any 
differences in protein concentration on any observed differences. Equal amounts of 
cell lysate, measured by BCA assay, were loaded and intracellular actin levels were 
used as a loading control for these samples 
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3.2.2.4 Sub-cellular localisation of WT and mutant AGR2 
 
 In order to further characterise the stable cell lines expressing AGR2 and attempt to 
explain the differences in steady state levels between the various mutants, the sub-cellular 
localisations of the proteins were investigated using fluorescence microscopy. AGR2 is an 
ER-resident protein [417, 422, 437-439], but has also been reported to be secreted [388, 
426, 440].  Therefore, to examine whether mutations to AGR2 might affect its sub-cellular 
localisation, but also to confirm that ∆1-20 AGR2 and ∆KTEL AGR2 do not enter the ER or 
are secreted, respectively (Table 3.1), cells were co-stained with AGR2 and one of three 
sub-cellular markers: PDI for the ER [555], giantin for the Golgi [556] and MEK1 for the 
cytoplasm [557]. Secreted proteins must generally travel through the Golgi towards the cell 
exterior (see Section 1.3.3.1), and thus co-localisation of AGR2 with a Golgi marker was 
used as an indicator of proteins potentially destined for secretion. However, it should be 
noted that non-secreted, ER proteins can be briefly resident in the Golgi before retrograde 
transport back into the ER [342].  
In cells expressing WT AGR2 and the E60A, C81S and ∆21-40 AGR2 mutations, the 
protein localised largely to the ER, as demonstrated by co-localisation with PDI (Fig. 3.11A-C 
and E). There was no evidence of Golgi-located protein nor cytoplasmic protein, consistent 
with AGR2 being an ER-resident protein. Interestingly, some cells did appear to show some 
nuclear staining, but in the absence of a suitable nuclear protein marker this cannot be 
confirmed. However, it is interesting that in ∆1-20 AGR2 cells, AGR2 localised not only to 
the cytoplasm as expected (as evidenced by co-localisation with MEK1) but also showed 
strong nuclear staining (Fig. 3.11D). To ensure that this nuclear staining was not artefactual, 
empty vector (EV)-transfected cells were also stained for AGR2. These cells express no 
detectable amounts of AGR2 by Western blot (Fig. 3.9A) and whilst they showed no nuclear 
AGR2 staining, they did display a very weak staining for AGR2 in the nucleoli (Fig. 3.11H). 
However, given the lack of predicted nucleolar localisation sequence (NoLS) for AGR2 
(Appendix 3), this nucleolar staining is most likely a staining artefact. Therefore, it appears 
that ∆1-20 AGR2 does indeed localise to the nucleus, and, along with the predicted weak 
NLS for AGR2 (Appendix 4), these data may support the observed weak nuclear localisation 
of WT AGR2, indicating that it can enter the nucleus as previously reported [467]. 
  In ∆KTEL cells, the low abundance of intracellular protein meant that it was difficult 
to determine whether there was co-localisation between AGR2 and PDI (Fig. 3.11F). Despite 
this, ∆KTEL cells were the only cell type where co-localisation of AGR2 with the Golgi 
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marker, giantin was observed, consistent with the loss of the ER-retention sequence leading 
to onward transport to the Golgi and increased protein secretion.  
 Overall, these imaging data show these cell lines to be suitable tools for exploring 
the functional consequences of AGR2 mutation, as only the mutation designed to alter 
protein localisation (∆1-20 AGR2 and ∆KTEL AGR2) actually did so, with other mutations 
localising to the same sub-cellular compartment as WT protein. 
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3.3 Discussion 
 
3.3.1 Molecular characterisation of AGR2 dimer formation 
 
 It has been demonstrated here that AGR2 exists in a monomer-dimer equilibrium 
(also see Appendix 1), a fact that has been subsequently supported by the work of others 
[416, 558]. Dimerisation is also observed in other PDIs and oxidoreductases, notably PDI 
itself [559, 560], ER oxidoreductin 1α (Ero1α) [561] and Ero1β [562]. Interestingly, ERp29, 
along with the Legionella pneumophila disulphide bond A2 (DsBA2) protein, require 
dimerisation for activity [537, 563]. Dimerisation of AGR2 could therefore also be important 
for its activity, given that AGR2 is also a member of the PDI family [378]. 
 The AGR2 dimer complex was predicted to be held together by salt bridges 
between Glu60 and Lys64 residues on opposing subunits, but only mutation of the Glu60 
totally inhibited dimer formation. However, the shift towards a monomer species seen with 
Tyr63 mutation points to an important role for Tyr63 in AGR2 dimerisation. The aromatic 
ring interactions measured between the phenol side chains of the Tyr63 residues (Appendix 
5) could provide some stabilisation to the structure [564], but another implication of the 
presence of these aromatic rings is the possibility of electrostatic interactions between 
these electron-dense π-orbitals, and the positively-charged side chain of Lys64. These 
cation-π interactions are found in a number of protein structures [565] and can often be 
found at homodimer interfaces [566]. Importantly, these interactions have been calculated 
to provide greater stabilisation than salt bridge interactions [567]. However, using the 
CaPTURE server for measurement of cation-π interactions [565], these lysine-tyrosine 
interactions do occur, but are not predicted to be energetically significant in AGR2 
(Appendix 6) nor were these interactions detected for AGR241-175 using the Protein 
Interaction Calculator (PIC) server (Appendix 5).  
 Tyrosine residues have also been shown to contribute to the stabilisation of protein 
molecules through hydrogen bonding from their hydroxide groups, for example, intrachain 
hydrogen bonding between tyrosine and glutamate residues stabilise RNase Sa from 
Streptomyces aureofaciens [568]. The close proximity of two tyrosine and two glutamate 
residues in the dimer interface raised the possibility that inter-chain hydrogen bonding 
could occur between these residues. However, while such intra-chain Tyr-Glu hydrogen 
bonds exist in the AGR2 structure (Appendix 7), there were no measured inter-chain 
hydrogen bonds between tyrosine and glutamate residues (Appendix 5 and 7).  However, 
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the AGR2 dimer structure was determined using a labelling scheme involving heavy-isotope 
labelling of leucine, isoleucine and valine residues. As a result, the exact positions of amino 
acid side-chains on residues other than these three could not be determined [421] 
(Appendix 1). Therefore, as tyrosine side-chains exhibit high degrees of flexibility and can 
exist in a number of conformations [569], the uncertainty about the orientation of the side-
chain within the dimer interface means that the presence of these inter-chain hydrogen 
bonds cannot be totally discounted, as the measurements by the PIC and HBPLUS servers 
(Appendix 5 and 7) were based on the orientations shown in the NMR structure in Fig. 3.2. 
It would be interesting therefore to test the oligomerisation state of AGR2 with a tyrosine 
to phenylalanine mutation at Tyr63, both in the presence and absence of Lys64. This should 
shed some light on whether hydrogen bonding and/or π-stacking interactions contribute to 
dimer formation. Overall, considering these factors and the oligomerisation data presented 
above, the complete loss of dimerisation after Glu60 mutation can probably be attributed 
to the loss of both salt bridge formation with Lys64 and also loss of any potential hydrogen 
bonding with Tyr63. The presence of aromatic ring stacking interactions between Tyr63 
residues probably also contributes to dimerisation, although these forces alone are not 
sufficient to hold the complex together. The incomplete loss of dimerisation with the loss of 
Lys64 may provide some support for the existence of hydrogen bonding between Tyr63 and 
Glu60, as these relatively weaker interactions could allow limited dimerisation, but this will 
require further investigation as outlined above.  
 
 
3.3.2 Contributions to AGR2 dimer formation 
 
 In addition to the actual interactions involved in promoting AGR2 dimerisation at 
the homodimer interface, other factors influencing the extent of dimerisation were also 
explored. Higher concentrations of AGR2 protein promote increased dimerisation of the 
protein in vitro, as demonstrated here and by others [558]. Gray and colleagues [558] in 
fact demonstrated a greater effect of AGR2 concentration on dimer formation using 5-2500 
µg/mL AGR2 concentrations than seen here in the 500-2000 µg/mL concentration range. 
The functional significance of these observations however is not yet clear, as they were 
observed at non-intracellular concentrations of NaCl and the local intracellular 
concentration of AGR2 is unknown. The contribution of the 21-40 flexible region to AGR2 
dimer formation must also be considered. Whilst the dimerisation potential of AGR221-175 
and AGR241-175 appeared to be relatively similar, the much higher susceptibility of AGR241-175 
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to dimer dissociation at high salt concentration points to a possible contribution of the 
flexible region in dimer stabilisation, but as mentioned in Section 3.2.1.4, the relevance of 
the contribution of the flexible region at physiological salt concentration is unclear. The 21-
40 region has been implicated in dimer stability [558], but the authors found that deletion 
of residues 1-45 of AGR2 led to a more stable dimer, as evidenced by higher rates of 
spontaneous dimer formation seen on SDS-PAGE gels. 
 It is difficult to correlate these opposing findings, and whilst it seems unusual that a 
dimer held together through electrostatic interactions would remain virtually intact during 
denaturing SDS-PAGE [558], a low amount of these SDS-resistant dimers have been 
observed during recombinant protein production for the present study, and there does 
appear to be a higher percentage of these dimers in AGR2 41-175 (Appendix 8). Conversely, 
recombinant E60A AGR221-175 did not seem to produce these dimers, suggesting that they 
do occur through electrostatic interactions. SDS-resistant dimers have been previously 
observed in other proteins, with the authors suggesting that this might result from 
unfavourable SDS interactions with negatively charged regions of the protein [570]. The 
region surrounding Glu60 contains a relatively high proportion of negatively charged and 
hydrophobic residues (Fig. 3.1A), which would not interact favourably with negatively-
charged SDS and thus a small percentage of dimers might remain bound through 
electrostatic interactions of the dimerisation interface. However, the relatively high amount 
of positive charge within the 1-40 and 1-45 regions should provide favourable interactions 
with the negatively charged SDS, thus helping to ‘rip open’ the dimer in the majority of 
species. Deletion of this region would result in a loss of this dimer-disrupting interaction, 
increasing the percentage of dimers able to complex through the Glu60 region. Therefore, 
analysis by SDS-PAGE may not be the optimal method for investigating such a dynamic 
process and could possibly help dimer formation through electrostatic exclusion. Further 
experimentation will be required to account for these differences. 
 It is important to highlight that any role in dimerisation played by the 21-40 region 
appears to be in the context of high, non-physiological Na+ concentration, although this 
concentration was similar to physiological KCl concentration [544]. While the data 
presented here support the notion that AGR2 dimerises through electrostatic interactions, 
the effects of high salt concentration demonstrate not only that these interactions appear 
to be fairly robust, but also that the presence of the 21-40 region stabilises the AGR221-175 
dimer relative to the AGR241-175 dimer. Whether this has any physiological significance is not 
clear. A second point to address is the report from Ryu and colleagues [416] of AGR2 
dimerising through its single cysteine. This observation was based on crosslinking in 
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cultured cells using a membrane-permeable crosslinker, where mutation of Cys81 led to a 
loss of crosslinked AGR2 homodimers. It has been demonstrated here however that in the 
presence of only recombinant AGR2, dimerisation is not affected by mutation of Cys81 (see 
also Appendix 1). The authors also reported the requirement of AGR2 Cys81 for interaction 
with glucose-related protein 78 kDa (GRP78), but it is not clear whether these interactions 
occur via free thiol-groups in GRP78 as previously reported [571], or whether it is the 
reported thiol-dependent dimerisation of AGR2 that is required for this interaction. With 
this in mind, it seems unlikely that AGR2 would dimerise through the same residue required 
to interact with one of its substrates MUC2 [422], unless this acts as another form of AGR2 
regulation. It may be that, rather than allowing dimerisation, Cys81 allows similar thiol-
dependent AGR2-GRP78 interactions, thereby bringing two AGR2 molecules together long 
enough to be crosslinked. This might also suggest that in vivo, AGR2 may exist primarily as a 
monomer. A possible alternative is that the apparent dimer observed in the experiments 
described by Ryu and colleagues [416] is a crosslinked heterodimer of AGR2 with a similar 
sized protein. 
 Overall, there is conflicting evidence on the dimerisation of AGR2, but it appears 
that in isolation, AGR2 dimerises through a disulphide-independent mechanism [421, 558]. 
The dimerisation of AGR2 within the cell may require further investigation, perhaps through 
the use of fluorescence resonance energy transfer (FRET) in living cells as carried out 
previously [572] to demonstrate association (or lack of association) of mixed WT, E60A and 
C81S proteins. 
 
 
3.3.3 Biochemical activity of AGR2 
 
 Having explored the factors influencing AGR2 dimerisation, the effects of this 
dimerisation on the function of AGR2 were tested through the use of biochemical assays. 
However, AGR2 did not appear to function in any biochemical assays for PDI-related 
activity, showing no activity in reductase, isomerase and glutaredoxin assays. This brings 
into question the enzymatic activity of the protein. It is possible that AGR2 might act as just 
an oxidase, but this seems somewhat unlikely given that PDIs with a single Cys to Ser 
mutation in the active site become trapped in disulphide bonded intermediates [317]. 
While the cysteine from the second AGR2 subunit might provide the necessary reducing 
power to break the AGR2-substrate interaction [317], its position on the opposite side of 
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the molecule as indicated in the three-dimensional structure of AGR2 (Fig. 3.1) makes this 
geometrically hard to achieve. 
 A clue to the activity of AGR2 might come from ERp44, another PDI family member 
containing a CxxS active site [320]. Like AGR2, ERp44 is upregulated in response to ER 
stress, indicating an involvement in protein folding [320]. Interestingly, rather than 
functioning as a PDI, ERp44 appears to contribute to protein folding through interactions 
with free thiol groups on substrate proteins and the oxidoreductase Ero1α [320, 573]. This 
stems from the initial observation that an exposed thiol in the tail of immunoglobulin (Ig) µ 
chain mediates retention of the chain in the ER [574], and it was later determined that this 
retention was dependent on reversible DSB formation with ERp44 [573]. The ERp44-
mediated retention of Ero1 in the ER then points to a mechanism whereby ERp44 links 
unpaired thiols with an oxidoreductase, thereby aiding the correct folding of the substrate 
proteins. 
 It is possible therefore that AGR2 may function in a similar manner. MUC2 is a thiol-
dependent substrate of AGR2 [422], and its large size and high number of DSBs presumably 
requires extended interactions with PDIs and chaperones to fold correctly. Therefore 
binding of free thiol groups by AGR2 may both prevent the secretion of an incorrectly 
folded MUC2 and other substrates by retaining them within the ER, and could also act as a 
‘signpost’ to other PDIs, directing them to sites of unpaired cysteines. The fact that the 
Cys81 residues of AGR2 are located on opposite sides of the dimer suggest that it could 
hold adjacent unpaired thiols on substrate proteins in close proximity for oxidation by PDIs, 
or alternatively use one of these Cys81 thiols to bind a PDI and target its activity to a 
particular free thiol. This idea is supported to some extent by the reported Cys81-
dependent interaction of AGR2 with GRP78 [416] as discussed above, although it is not 
clear if these two proteins directly interact through thiol-dependent interactions.  
 
 
3.3.4 AGR2-expressing cell lines as a tool for exploring protein domains involved in 
protein function 
 
 The lack of AGR2 activity in biochemical assays, as discussed above, requires the 
use of a different assay to measure the effects of dimerisation and other protein domains 
on AGR2 function. AGR2 has been shown to be involved in mediating cell adhesion [309, 
515] and so stable cell lines expressing various mutant forms of AGR2 were created and 
characterised here with a view to later use in adhesion-based assays. However, it is crucial 
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that mutations did not affect sub-cellular distribution of the protein (unless intentionally 
done so) to avoid any potential effects caused by protein localisation rather than the 
desired mutation itself. 
 WT and mutant AGR2 protein localised largely to their expected cellular 
compartments, with the majority of protein localising to the ER and ∆KTEL protein localising 
to the Golgi, consistent with its high levels of secretion. Unexpectedly, ∆1-20 AGR2, which is 
expected to localise to the cytoplasm as a result of losing its ER entry sequence, was 
abundantly found within the nucleus. This was also observed, but to a much lesser extent, 
with WT AGR2. The reasons for this nuclear accumulation are not clear, but it is interesting 
that two putative but overlapping nuclear localisation sequences (NLS) at the C-terminus of 
AGR2 are predicted (Fig. 3.12), that are also predicted to localise the protein to both the 
nucleus and cytoplasm (Appendix 4). These NLS’s are dependent on importin for nuclear 
localisation [575], which acts as a receptor for NLS-containing proteins and promotes their 
interaction with the nuclear pore complex, thus facilitating their transport across the 
nuclear membrane (reviewed in [576]). 
 
MEKIPVSAFLLLVALSYTLARDTTVKPGAKKDTKDSRPKLPQTLSRGWGDQLIWTQTYEE 
ALYKSKTSNKPLMIIHHLDECPHSQALKKVFAENKEIQKLAEQFVLLNLVYETTDKHLSP 
DGQYVPRIMFVDPSLTVRADITGRYSNRLYAYEPADTALLLDNMKKALKLLKTEL 
 
Figure 3.12. Prediction of AGR2 nuclear localisation sequences (NLS) by cNLS 
Mapper server [575]. The two predicted sequences overlap, thus one is highlighted 
in red and the other underlined. 
 
 
 Whether this sequence is active in promoting nuclear import of AGR2 is not clear, 
but it is interesting that Pohler and colleagues [445] noted that C-terminal truncation of 
AGR2, which included most of the putative NLS, led to a switch from promoting 
oesophageal cancer cell survival to reducing it, relative to non-AGR2 expressing cells. 
Whether this equates with a loss of AGR2 nuclear accumulation would be interesting to 
determine. Additionally, AGR2 is reported to interact with Reptin, a member of the NuA4 
histone acetyltransferase complex [539]. Reptin is found both in the nucleus and cytoplasm, 
although its role in the cytoplasm is not clear (reviewed in [577]). This interaction with 
Reptin may provide evidence of nuclear AGR2, or at least non-ER AGR2, although the 
subcellular localisation of this AGR2-Reptin interaction was not determined. Further 
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investigation of the AGR2-Reptin interaction could provide crucial evidence as to whether 
AGR2 can indeed enter the nucleus.  
 This nuclear accumulation of AGR2 offers some new insights into the possible 
roles of AGR2 within the cell, but overall the cell lines created in this chapter offer suitable 
tools for the study of the effects AGR2 mutations on its function. Apart from ∆1-20 AGR2, 
all mutations localised to their expected compartments and as ∆1-20 AGR2 was utilised to 
examine the dependence of AGR2 residency within the ER on its function, it still remains a 
viable tool to achieve this aim. Overall, these cell lines should provide an adequate tool for 
investigating AGR2 function in a cellular context. 
 
 
3.4 Conclusions 
 
 In this chapter, the dimerisation of AGR2 has been explored in detail and the 
residues involved in this process have been determined, although the exact way that AGR2 
dimerises requires a little more investigation. The demonstration that AGR2 does not 
appear to display any PDI activity raises the possibility of an enzyme-independent function 
of the protein that might involve sequestration of free thiol groups. Determining the exact 
mechanisms of AGR2 dimerisation may be crucially important in the design of any potential 
inhibitors of AGR2, should the inhibition of dimerisation prove an effective manner to 
inhibit AGR2 activity. In a similar vein, investigating any enzyme activity of AGR2 has similar 
prospects for the design of anti-AGR2 therapeutics. In line with this, the creation of a panel 
of mutant-AGR2-expressing cell lines in this chapter provides tools for the exploration of 
the contributions of these structural features to AGR2 activity, in the absence of other 
suitable, biochemical-based assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 111 
 
 
 
 
Chapter 4 
 
 
 
The Role of AGR2 in Cell Adhesion 
 
 
 
4.1 Introduction 
 
 Expression of AGR2 has been linked to reduced patient survival in a several cancers 
[309, 433, 443, 457, 458, 467, 474]. A number of studies have also linked AGR2 to cell 
migration and invasion, both through actions of endogenous protein [301, 415, 440, 481] 
and also through the stimulatory actions of extracellular recombinant protein [414], 
demonstrating that AGR2 can increase the migratory and invasive potential of cells in vitro. 
The elevated levels of AGR2 observed in metastatic cells of differing origin further implicate 
AGR2 in the metastatic process [302-304, 306, 469], with the strongest evidence for an 
association of AGR2 with metastasis coming from the ability of AGR2 to confer a metastatic 
phenotype on an otherwise benign cell line in a rat model [309].  
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 Cell metastasis and cell adhesion are inexorably linked, due to metastatic cells 
requiring reduced cell-cell adhesion and cell-matrix interaction in the primary tumour, as 
well as enhanced adhesion of circulating tumour cells to the vasculature at sites of 
secondary colonisation (reviewed in [578]). Accordingly, AGR2-expressing rat mammary 
tumour cells show a high rate of cell adhesion to a substratum [309], which was later 
confirmed to be an AGR2-dependent effect in cultured prostate cancer cells, through 
targeted knockdown of AGR2 [515]. Similarly, when coated onto a plastic substratum, 
extracellular AGR2 is able to promote adhesion of rat mammary cells, suggesting that AGR2 
could also have an extracellular role in cell adhesion [309], as there are also several reports 
of its secretion by cells in culture [388, 426, 440].  
 In addition to these effects on cell adhesion, AGR2 has also been demonstrated to 
play a role in anchorage-independent cell growth, an important characteristic that 
metastasising tumour cells must acquire in order to avoid cell death induced by loss of 
contact with the extracellular matrix (anoikis), that occurs upon migration away from the 
primary tumour site [279]. AGR2 was shown to confer resistance to anoikis in oesophageal, 
lung and breast cancer cell lines [445, 481, 482], as well as mouse NIH3T3 cells [481], as 
knockdown of AGR2 resulted in loss of anchorage-independent growth [445, 481, 482], 
whereas forced expression of AGR2 resulted in gain of anchorage-independent cell growth 
[445, 481]. Furthermore, the anti-apoptotic protein survivin has been implicated in 
mediating AGR2-driven anoikis resistance in breast cancer cells, as it is upregulated by 
AGR2 [482] and inhibits caspase-3 [579], a major effector of anoikis [580]. Additionally, 
resistance to anoikis in AGR2-expressing oesophageal cancer cells is driven by inhibition of 
p53 activity through blocking an activating phosphorylation event at Ser15 [445]. Thus 
AGR2 is implicated in two adhesion-based roles that can favour tumour progression.  
 
 
4.1.4 Chapter objectives 
 
 Using the AGR2-expressing cell lines described in the previous chapter, the aim of 
the current chapter is to determine the contribution of several sequence and structural 
features of AGR2 to its effect on cell adhesion and anchorage-independent cell growth. As 
extracellular recombinant AGR2 is also known to affect the adhesion of Rama 37 cells, the 
aim here is also to investigate whether extracellular and intracellular AGR2 affect cell 
adhesion in different ways. 
Chapter 4  Results 
113 
 
4.2 Results  
 
4.2.1 Effects of extracellular AGR2 on rate of cell attachment 
 
 Previous studies have shown that AGR2 promotes cell adhesion when coated onto 
cell culture plates [309]. In the present experiments, recombinant WT AGR2 (AGR221-175) 
coated onto cell culture plates increased the percentage of applied Rama 37 cells attaching 
to these plates in 60 min from 18.6 % in uncoated wells to 45.0 % in coated wells (Fig. 4.1), 
values that were similar to those obtained previously [309], but achieved over a 60 min 
rather than a 30 minute time period. In contrast, coating with an equimolar amount of BSA 
resulted in a significant reduction in the percentage of cells adhering compared to uncoated 
controls (2.9 % vs. 18.6% of cells adhering, p < 0.001, Student’s t-test). A similar effect of 
BSA has been reported previously using Chinese hamster ovary (CHO) cells [581]. 
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Figure 4.1. Extracellular AGR2 promotes cell adhesion. A 2 µM solution of each of 
the indicated proteins was coated onto plastic cell culture multiwell dishes overnight. 
Rama 37 cells were then allowed to adhere to the coated wells for 60 min and the 
number of bound cells was determined using an automated cell counter. The number 
of adhering cells is expressed as a percentage of the total number of cells added to 
each well at the start of the experiment. The means from duplicate wells from 3 
independent experiments are shown, ±SE. The numbers in subscript denote the 
amino acids present in the relevant proteins, while prefixes denote point mutations 
present in these proteins (see main text for description). BSA: bovine serum albumin. 
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Given that AGR2 can be a dimer and is a member of the PDI family, the importance 
of dimerisation or the putative CxxS active site to AGR2-promoted cell adhesion was 
investigated, using monomeric AGR2 protein (E60A AGR221-175) and active site-null AGR2 
protein (C81S AGR221-175, see Chapter 3), respectively. There was no significant difference in 
adhesion rate compared to WT protein with either C81S AGR221-175 (p = 0.593, Student’s t-
test) or with E60A AGR221-175 (p = 0.772). By contrast, coating the wells with AGR2 lacking 
the flexible 21-40 amino acid region (see Chapter 3), either in dimeric form (AGR241-175) or 
monomeric form (E60A AGR241-175), led to a significant decrease in adhesion rate compared 
to AGR221-175-coated wells (p < 0.001 in both cases). While this decrease alone could result 
from AGR241-175 and E60A AGR241-175 proteins not adhering to the wells, the fact that coating 
with these two proteins also led to a significant decrease in adhesion relative to uncoated 
wells (p = 0.001 and p = 0.021, respectively) suggests that they must be indeed be present 
to actively reduce adhesion relative to uncoated wells. Therefore, these results suggest that 
amino acids 21-40, present in AGR221-175, but not in AGR241-175, may be important in AGR2-
enhanced cell adhesion on a plastic substratum. As further evidence of the importance of 
these residues, coating wells with WT AGR3 protein (AGR324-166), which is closely related to 
AGR2 in sequence, but naturally lacks the region corresponding to AGR2 residues 21-40 
[378], not only failed to enhance adhesion but also decreased adhesion relative to 
uncoated wells (p = 0.05) as observed with AGR241-175. 
 The flexible AGR2 21-40 region contains seven positively charged amino acids (two 
arginine and five lysine residues) and only three negatively charged residues (three 
aspartate residues). This raises the possibility that the increase in cell adhesion observed 
with AGR2 could be the result of a non-specific interaction simply caused by the presence 
of increased positive charge, in a manner akin to coating with poly-lysine [582]. However, 
experiments where wells were coated with solutions of equal concentration of 21-40 
peptide or an unrelated peptide showed no difference in adhesion between uncoated and 
peptide-coated wells, suggesting that the overall positive charge of the flexible region is not 
responsible for the increased adhesion seen with AGR221-175- coated wells (Appendix 9). 
 To ensure that the observed effects on adhesion from peptide coating were not 
due to inefficient peptide coating of the wells, indirect ELISA assays were performed on 
AGR2- and peptide-coated wells to determine the amount of peptide attached to the wells 
after coating, using an antibody raised against an epitope in this 21-40 region, which thus 
recognises both AGR221-175 protein and 21-40 peptide [475]. These assays indicated that it 
was not possible to coat the 21-40 peptide at as high a level as that achieved with 2 µM 
AGR221-175 protein solution, although this conclusion assumes that the antibody binds 
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equally well to AGR2 protein and to the 21-40 peptide. Further calibration experiments 
indicated that, on average, a 7.5 nM solution of AGR221-175 protein needed to be coated 
onto wells in order to achieve the same ELISA signal intensity as a 2 µM peptide solution 
coating (Appendix 10). Thus, wells coated with a 7.5 nM AGR221-175 protein solution or 2 µM 
21-40 peptide solution were then subjected to an adhesion assay as above, with slight 
modifications due to the low numbers of adhering cells observed, as a consequence of 
coating very low amounts of AGR2 protein (see Materials and Methods for full description). 
 
         
 
 
 
 
 
 
 
 
Coating with just 7.5 nM AGR221-175 solution had no effect on cell adhesion 
compared to uncoated wells (p = 0.448), but a corresponding equal amount of 21-40 
peptide attached to the plate resulted in a significant decrease in cell adhesion (61 % 
reduction in relative number of adhering cells, as indicate by crystal violet staining; p = 
0.001, Fig. 4.2). Together, these data provide evidence that the 21-40 peptide alone is not 
able to support cell adhesion, but rather that the adhesion-promoting activity of AGR2 
protein requires the presence of both the globular part of the protein (residues 41-175) and 
the flexible region composed of residues 21-40. 
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Figure 4.2. Amino acids 21-40 of AGR2 alone are not sufficient to promote cell 
adhesion. In order to reach equal levels of coating  (as determined by indirect ELISA 
assay), a 2 µM solution of 21-40 peptide and 7.5 nM solution of AGR221-40 protein in 
coating buffer were coated onto non-cell culture plates overnight. Rama 37 cells 
were then allowed to adhere to the plates for 60 min and the number of adhering 
cells was quantified using crystal violet staining, measured by optical density at 570 
nm. The intensity of cell staining for coated plates is expressed relative to intensity of 
cell staining in uncoated wells. The means from triplicate wells from 3 independent 
experiments are shown, ±SE. 
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4.2.2 Effects of intracellular AGR2 on cell attachment 
 
 The effects of AGR2 expression on the adhesion of rat mammary (Rama 37) cells 
were investigated, to further explore the AGR2-mediated changes to cell behaviour that 
might contribute to the metastatic potential of  AGR2-transfected Rama 37 cells [309]. 
 
 
 
 
 
 Cell attachment assays performed on uncoated cell culture plates using both 
pooled and clonal WT-AGR2-expressing and empty vector (EV) control cells are shown in 
Fig. 4.3. There was a reduction in the number of WT AGR2 pool cells attaching compared to 
EV pool cells, but this was not statistically significant (p = 0.131, Student’s t-test). Three 
separate EV clone cells showed levels of attachment that were not significantly different 
from each other (smallest p value = 0.445) or EV pool cells (smallest p value = 0.465), but 
there was a significant difference between EV clones and WT AGR2 clones 2 and 5 (highest 
p value = 0.016), but not between EV clones and WT AGR2 clone 13 (smallest p value = 
0.167). Clonal WT AGR2 cells not only attached more rapidly than EV clonal cells, but also 
exhibited resistance to trypsin once attached to the substratum, as demonstrated 
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Figure 4.3. Clonal AGR2-expressing cells exhibit a greater rate of cell attachment 
than control cells. Wild type (WT) AGR2-expressing and empty vector (EV) control 
cells were allowed to adhere for 30 min to cell culture plates and the number of 
bound cells was determined using an automated cell counter. The number of 
adhering cells is expressed as a percentage of the number of cells added to each well. 
The means from duplicate wells from 3 independent experiments are shown, ±SE. 
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qualitatively by increased trypsin incubation times required to detach these cells for 
counting. AGR2-dependent trypsin resistance was also observed during experiments with 
coated protein in Section 4.2.1, when being collected for counting. In order to better 
understand this process and to determine whether resistance to trypsin is a feature of 
AGR2-expressing cells and separate from the rate of cell attachment, cell lines were 
subjected to quantitative cell detachment assays: cells adhering more strongly to the plate 
will not be dislodged by trypsinisation to the same extent as loosely adhering cells (see 
Materials and Methods for full description). Preliminary experiments to determine the 
optimal concentration of trypsin in this assay are shown in Appendix 11. 
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 Clonal cells expressing WT AGR2 were significantly more resistant to removal by 
trypsin than EV clonal or pooled cells (largest p value = 0.014, Student’s t-test), with the 
greatest difference observed between EV clone 2 and WT AGR2 clone 2 (p < 0.001). There 
was no significant difference in the proportion of trypsin-resistant cells between WT AGR2 
and EV pool cells (p = 0.946), with EV clonal cells demonstrating an average strength of 
adhesion that was not significantly different from that of pooled cells (smallest p value = 
0.095, Fig. 4.4A). WT AGR2 clone 13, which expresses the lowest amount of AGR2 protein 
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Figure 4.4. Clonal AGR2-expressing cells are more resistant to trypsin than control 
cells. (A) Wild type (WT) AGR2-expressing and empty vector (EV) control cells were 
allowed to adhere for 30 min to cell culture plates. Attached cells were then treated 
with 0.0125 % (v/v) trypsin for 5 min and the remaining attached cells were counted 
with an automated cell counter after removal with 0.05 % (v/v) trypsin. The 
percentage of cells resistant to 0.0125 % (v/v) trypsin treatment represents the 
proportion of applied cells attaching in 30 min that remained adherent after 0.0125 
% (v/v) trypsin treatment. The means from duplicate wells from 3 independent 
experiments are shown, ±SE. (B) Western blot of AGR2 expression levels from the 
three clonal AGR2 cell lines used. 
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of the three clones tested in the trypsin-based assay (Fig. 4.4B), showed a lower resistance 
to trypsin than either clones 2 or 5, although this was just outside statistical significance (p 
= 0.052 and p = 0.164, respectively). WT AGR2 clone 13 cells were still significantly more 
resistant to trypsin than EV clone cells, however (largest p value = 0.006). These results 
suggest that increased expression of AGR2 correlates broadly with increased resistance to 
trypsin (Fig. 4.5), and a statistically significant correlation was indeed observed between 
these two cell properties (Spearman’s σ = 0.880, p = 0.021). 
 
 
 
Figure 4.5. Resistance to trypsin detachment correlates with AGR2 expression. The 
percentage of trypsin-resistant clonal WT AGR2 and clonal EV cells shown in Fig. 4.4A 
were plotted against the steady-state levels of AGR2 in these cells, as previously 
determined in Chapter 3.  
 
 
 In order to check that the above results were not due to the nature of the assay 
used, the two cell lines showing the greatest difference in trypsin resistance (EV clone 2 and 
WT AGR2 clone 2) were subjected to an alternative, centrifugation-based assay which 
measures the strength of cell adhesion based on the resistance of cells to detachment from 
a substratum by a direct perpendicular force [518, 519]. Here, a similar pattern was 
observed to that seen in the trypsin-resistance assay, with an approximate 2-fold increase 
in the proportion of WT AGR2 clone 2 cells remaining attached relative to EV clone 2 cells 
(Appendix 12). Although the difference was not as marked as with the trypsin-resistance 
assay, the results of this second assay confirm the enhanced strength of attachment of 
AGR2-expressing cells.  
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4.2.3 The effects of AGR2 on cell attachment change over time 
 
 The enhanced strength of adhesion of WT AGR2 clonal cells shown in section 4.2.2 
did not match an observation that during routine subculture of cells, WT AGR2 clonal cells 
detached much more readily than EV clonal cells. To investigate this further, the 
sensitivities of EV clone 2 and WT AGR2 clone 2 cells to trypsin were compared over a 6 h 
time course (Fig. 4.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 As expected, WT AGR2 clone 2 cells were very resistant to trypsin within the first 30 
to 60 min, with 75 % of cells remaining attached at 60 min. Conversely, EV clone 2 cells 
were not very resistant to trypsin during these early time points, with only 20 % of cells 
remaining attached at 60 min. EV clone 2 cells gradually became more resistant to trypsin 
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Figure 4.6. Time course of strength of adhesion. Wild type (WT) AGR2-expressing 
and empty vector (EV) control cells were allowed to adhere to cell culture plates for 
the indicated times. Cells were then treated with a 0.0125 % (v/v) trypsin for 5 min 
and the remaining adhering cells were counted with an automated cell counter. The 
percentage of cells resistant to 0.0125 % (v/v) trypsin treatment represents the 
proportion of applied cells, which had attached by the indicated time points, that 
remained adherent after 0.0125 % (v/v) trypsin treatment. A control plate, seeded 
simultaneously with the treatment plate but not treated with low strength trypsin, 
was used to determine the number of cells present in wells at each time point, to 
control for any effects of cell division over the timeframe of the experiment. Note 
that means from duplicate wells from a single experiment only are shown and so 
error bars show SD only. 
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over the next 300 min, with significantly more cells remaining attached by 180 min (p = 
0.019, Student’s t-test) and continuing at this level until the end of the assay. Conversely, 
there was a gradual fall in the resistance to trypsin of WT AGR2 clone 2 cells over the 60 
min to 360 min time points, falling from 75 % at 60 min to 45 % at 360 min, although this 
was just outside statistical significance (p = 0.075), but this may relate to the small sample 
size. 
 Over this 6 h period, cells begin to divide and spread over the surface of the cell 
culture well, suggesting that adhesion strength might change more dramatically if cells are 
allowed to form a monolayer. Therefore, cells were grown overnight to 70-80 % confluence 
and subjected to the same cell detachment assay (Fig. 4.7). 
 
 
Figure 4.7. Clonal WT AGR2 cells are less resistant to trypsin than control cells when 
allowed to form a monolayer. Wild type (WT) AGR2-expressing and empty vector 
(EV) control cells were grown overnight to 70-80 % confluence and then trypsinised 
in 0.0125 % (v/v) trypsin for 5 min. The remaining adhering cells were counted with 
an automated cell counter. The number of trypsin-resistant cells is expressed as a 
percentage of the total number of cells in each well. The means from duplicate wells 
from 3 independent experiments are shown, ±SE. 
 
 
 As predicted, WT AGR2 clonal cells were significantly less resistant to trypsin than 
EV clonal cells once these cells had formed monolayers (largest p value = 0.003, Student’s t-
test), exemplified by the fact that 56 % of EV clone 2 cells remained adherent compared to 
just 1 % of WT AGR2 clone 2 cells. Notably, WT AGR2 clone 13 cells, which express lower 
levels of AGR2 than clone 2 or 5 cells, were also significantly less resistant to trypsin than 
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the three EV cloned cell lines (largest p value = 0.01) and were not statistically significantly 
different from clones 2 and 5  (p = 0.362 and p = 0.552, respectively). This might suggest 
that the effects of AGR2 on adhesion of monolayer cells can occur at lower AGR2 levels 
than the effects observed on single cells (Fig. 4.4). 
A possible explanantion for the strong difference in adhesion between EV and WT 
AGR2-expressing cells is that, at least in the context of WT AGR2 clone 2 and EV clone 2 
cells, clonal WT AGR2-expressing cells produce much lower levels of the ECM protein 
fibronectin than EV clones (Fig. 4.8). As such, EV clone cells will have more matrix to adhere 
to, thus making them more resistant to trypsinisation. EV clones and WT AGR2 clones have 
a markedly different morphology (see Section 4.2.4 below) whereas EV and WT AGR2 
pooled cells have a very similar morphology, and as the latter two cell lines showed no 
difference in the level of fibronectin production (Fig. 4.8), it may be that changes in 
fibronectin production (and hence resistance to trypsin) are related to cell morphology. 
Overall, these experiments indicate that clonal WT AGR2 cells initially attach more 
rapidly and in a more trypsin-resistant manner than their AGR2-negative counterparts, but 
this trypsin resistance reduces over time until they become more easily detached once a 
monolayer is formed. 
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Figure 4.8. Comparison of secreted fibronectin from empty vector and WT AGR2-
transfected cell lines. (A) Cells were grown to 70-80 % confluence, washed in PBS 
supplemented with CaCl2 and MgCl2 (see Materials and Methods) and incubated in 
serum- and phenol red-free Rama 37 medium for 4 h (cells incubated for longer begin 
to die). Protein was precipitated by TCA and resuspended in an equal volume 
solubilisation buffer. Protein concentration was measured by BCA assay and equal 
amounts of protein were loaded in each well. Samples were subjected to SDS-PAGE 
and stained with Coomassie brilliant blue. The indicated high molecular weight band 
was confirmed as fibronectin through peptide mass fingerprinting. (B) Fibronectin 
abundance was measured by densitometry and the mean relative abundance of 
fibronectin from 2 replicate experiments is shown, ±SD. There was no significant 
difference in fibronectin between pool cells (p = 0.739, Student’s t test) or clonal cells 
(p = 0.133), although there was a noticeable difference in fibronectin secretion 
between clonal cell lines. 
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4.2.4 AGR2 expression correlates with an elongated cell morphology 
 
 As a cell line of epithelial origin, Rama 37 cells have a cuboidal morphology that is 
maintained after transfection with empty vector and clonal selection (Fig. 4.9A). However, 
some WT AGR2 clonal cells exhibit a more elongated morphology that is seemingly related 
to their level of AGR2 expression (Fig. 4.9B and C). This difference in morphology might 
explain both the striking differences in adhesion observed between EV and AGR2 clonal cell 
lines, and also the relationship between resistance to trypsin and the level of AGR2 
expression observed in Fig. 4.4. 
 To quantify this morphological change, eight clonal cell lines from a randomly- 
picked panel were selected, all with differing levels of AGR2 expression, and analysed using 
ImageJ (see Materials and Methods). The degree of cell elongation (shape ratio, SR) was 
expressed as the ratio between the length of the longest and shortest cross sections of 
each cell in the x/y plane: the greater this value, the more elongated the morphology. This 
value was plotted against the level of AGR2 protein, measured by Western blot. 
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Figure 4.9 (continued overleaf). AGR2 expression correlates with cell morphology. 
Images representing different cell morphologies: (A) empty vector clone 2, cuboidal; 
(B) WT AGR2 clone 13, slightly elongated; and (C) WT AGR2 clone 5, very elongated. 
(D) Western blot of AGR2 expression levels across eight clonal cell lines. Actin was 
used as a loading control. 
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 It is clear from the cell images that there is a change in morphology associated with 
AGR2-expressing cells (Fig. 4.9A-C). This difference in shape ratio was statistically significant 
between EV clone 2 and both WT clone 5 and 13 cells (p < 0.001 in both cases, Student’s t-
test), as well as between EV clone 2 and WT clone 2 (p < 0.001). There was no significant 
difference between WT clone 2 and 5 (p = 0.652), although these were both significantly 
different to WT clone 13 (p < 0.001 in both cases). This association of AGR2 expression with 
SR is further illustrated by the positive linear correlation observed between these two 
factors in Fig. 4.9E (Spearman’s σ = 0.633, p = 0.037).  
 
 
4.2.5 Cell morphology contributes to cell adhesion properties 
 
 In order to find out whether cell shape ratio was related to the observed changes in 
cell adhesion, a subpopulation of elongated cells was presently isolated from cuboidal 
Rama 37 cells and expanded (see Materials and Methods). These AGR2-negative cells 
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Figure 4.9 (cont.). AGR2 expression correlates with cell morphology. (E) Scatterplot of 
relative AGR2 expression and their relevant morphologies, expressed as a shape ratio 
(see main text), in eight WT AGR2-expressing clonal cell lines and three non-AGR2 
expressing (EV) clonal cell lines. AGR2 levels were normalised to actin levels for each 
clone, and then this normalised AGR2 expression was used to plot expression relative to 
WT AGR2 clone 2. At least 200 cells were analysed for each clone and the average SR 
value from these is plotted.  
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(Appendix 13), termed Rama 37-elongated (R37E), were tested in adhesion assays as above, 
offering a comparison between elongated, AGR2-positive cells (WT AGR2 clone 2) and 
elongated, AGR2-negative cells (R37E).  
 
 
                      
 
Figure 4.10. Comparison of adhesion properties of elongated AGR2-positive and –
negative cells. (A and B) Wild type (WT) AGR2-expressing cells and R37E cells were 
allowed to attach for 30 min (A) or allowed to form a monolayer overnight (B) and 
then trypsinised in a 0.0125 % (v/v) trypsin for 5 min. The remaining adherent cells 
were counted with an automated cell counter. The percentage of cells resistant to 
low strength trypsin treatment represents the proportion of cells attaching at the 
indicated time points that remained adherent after dilute trypsin treatment. The 
means from duplicate wells from 3 independent experiments are shown, ±SE. Images 
and SR values of (C) WT AGR2 clone 2 cells and (D) R37E cells. SR values were 
calculated for at least 200 cells for each cell type, and the average SR value is shown. 
SR: shape ratio. Scale bar: 100 µm 
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 The sensitivities of R37E and WT AGR2 clone 2 cells to 0.0125 % (v/v) trypsin were 
virtually identical. In the short term (Fig. 4.10A), WT AGR2 clone 2 and R37E cells were both 
more resistant to 0.0125 % (v/v) trypsin than EV clone 2 cells on average, although this 
difference was just outside statistical significance (p = 0.086 and 0.051, respectively, 
Student’s t-test). There was no significant difference to resistance of 0.0125 % (v/v) trypsin 
between WT AGR2 clone 2 and R37E cells, however (p = 0.972). Similarly, when grown to 
70-80 % confluence and subjected to the detachment assay (Fig. 4.10B), WT AGR2 clone 2 
and R37E cells were both highly significantly less resistant to 0.0125 % (v/v) trypsin than EV 
clone 2 cells (p = 0.008 and 0.009, respectively), but not significantly different from each 
other (p = 0.643). These data confirm the relationship between adhesive behaviour and cell 
morphology, given the similarity in morphologies and SR values of the two cell lines (Fig. 
4.10C and D). Together, these data point to an AGR2-associated change in cell morphology 
as being a major contributing factor determining cell adhesion properties in these cells.  
 
 
4.2.6 Effects of AGR2 mutations on cell morphology and adhesion 
 
 The establishment of several stable cell lines expressing mutant forms of AGR2 (see 
Chapter 3) were used as a tool to investigate the contribution of key regions of AGR2 
protein to AGR2-induced in cell adhesion. The effects of mutating the thioredoxin domain 
(C81S AGR2), preventing dimerisation (E60A AGR2), inhibiting ER entry (∆1-20 AGR2), 
deleting the flexible region (∆21-40 AGR2) and promoting AGR2 secretion (∆KTEL AGR2) 
were explored. As protein expression levels in mutant AGR2 pooled cell lines were largely 
lower than those observed in WT AGR2-expressing cells (see Chapter 3), only mutant clonal 
cell lines were assayed as they displayed a wider range of expression levels.  
 The resistance to trypsin of three separate clonal cell lines was assayed for each 
mutation, 30 min after plating (Fig. 4.11). Due to the large number of cells involved in these 
assays, cells were divided into three groups and three replicate experiments were 
performed for one group before passing on to the next. EV clone 2 and WT clone 2 cells 
were included in each set of assays as controls for the attachment behaviour of cuboidal 
and elongated cells, respectively. However, whilst the data between triplicate experiments 
were reproducible (as judged by the relatively tight standard error bars), there was marked 
variation in the behaviour of EV clone and WT clone 2 cells between sets of experiments 
(i.e. experiments A, B and C in Fig. 4.11). This was particularly true of EV clone 2 cells, where 
the percentage of cells resistant to trypsin varied from below 10 % in Fig. 4.11A to around 
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25 % in Fig. 4.11B and C. WT clone 2 cells behaved more consistently, with the proportion 
of trypsin-resistant cells varying from only 55 % to 45 %.  Thus, the data from these 
individual experiments are shown separately. 
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Figure 4.11. Initial 
attachment properties 
of mutant-AGR2- 
expressing clonal cell 
lines. The indicated cells 
were allowed to adhere 
for 30 min to cell culture 
plates. Cells were then 
trypsinised in 0.0125 % 
(v/v) trypsin for 5 min 
and the remaining 
adhering cells were 
counted with an 
automated cell counter. 
The percentage of 
adhering cells represents 
the proportion of cells 
adhering after 30 min 
that remained adhering 
after weak trypsin 
treatment. (A) E60A 
AGR2 and C81S AGR2 
clones. (B) ∆1-20 AGR2. 
(C) ∆21-40 AGR2 and 
∆KTEL AGR2 clones. The 
means from duplicate 
wells from 3 
independent 
experiments are shown, 
±SE. 
C 
Chapter 4  Results 
131 
 
 Despite this variability in control cells, the data showed that mutant cell lines 
behaved on the whole in a more similar way to EV clone 2 cells than WT clone 2 cells. 
However, these cell lines express a range of steady-state AGR2 protein levels (Chapter 3), 
and so to separate out any potential effects caused by differences in AGR2 levels within 
these cells, cell lines with similar steady-state AGR2 levels were considered for further 
analysis (Fig. 4.12A and B). In order to compare cell lines across different experiments, the 
number of trypsin-resistant cells were normalised to the levels observed with WT clone 2 
cells in each set of experiments. This was reasoned to provide the most appropriate 
normalisation factor, given the high variability of EV clone 2 cells, and allowed WT AGR2 
clone 13 cells to be directly compared to cells expressing mutant AGR2 proteins, due to 
similar levels of AGR2 protein expression. 
 Considering the trypsin sensitivity of these cell lines in the context of similar AGR2 
levels (Fig. 4.12C), both E60A AGR2 clone 18 and C81S AGR2 clone 10 cells showed 
significantly lower attachment compared to WT AGR2 clone 13 (p = 0.006 and p = 0.037, 
respectively, Student’s t-test). Conversely, attachment levels of ∆1-20, and ∆KTEL AGR2 
cells were not significantly different from WT AGR2 clone 13 cells (p = 0.827, and 0.140, 
respectively), whilst ∆21-40 exhibited a borderline significant reduction, p = 0.061). 
Comparison with EV clone 2 attachment levels is difficult, given the differences in 
attachment levels between experiments. Due to this fact, these data must be interpreted 
with some caution, but point to dimerisation and the thiol group of Cys81 as being 
important in mediating this resistance to trypsin, at least during these initial stages of cell 
attachment. 
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Figure 4.12. Initial attachment behaviour of mutant-AGR2-expressing clonal cell 
lines with similar steady-state protein levels. (A) Western blot showing AGR2 
protein levels in the most comparable clonal cell line of each listed mutation. Actin 
was used as a loading control (B) Longer exposure showing expression levels of the 
two weakest expressing cell lines. Note the difference in size of ∆21-40 AGR2 and 
∆KTEL AGR2. For quantitation of protein abundance, see Appendix 14. (C) The 
indicated cells were allowed to adhere for 30 min to cell culture plates. Cells were 
then trypsinised in 0.0125 % (v/v) trypsin for 5 min and the remaining adhering cells 
were counted with an automated cell counter. The proportion of trypsin-resistant 
cells is expressed relative to the number of trypsin-resistant WT clone 2 cells in each 
experiment shown in Fig. 4.10. The means from duplicate wells from 3 independent 
experiments are shown, ±SE. 
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 To further explore the effects of AGR2 mutations on trypsin sensitivity, mutant cell 
lines were also assayed for their resistance to trypsin once allowed to form a monolayer 
(Fig. 4.13A-C). The attachment levels of EV clone 2 and WT clone 2 cells in this assay were 
much more consistent than seen in the short term assay above. To filter out any effects of 
differences in steady-state AGR2 levels, the trypsin sensitivity of cells with similar steady-
state AGR2 levels were compared (Fig. 4.13D). The data here were normalised to the 
attachment levels of EV clone 2 cells as they were slightly more consistent across 
experiments than WT clone 2 attachment levels, although normalising to WT clone 2 gave a 
near identical relative attachment pattern (Appendix 15). 
 Comparing these cell lines, only ∆21-40 AGR2 clone was not significantly different 
to WT AGR2 clone 13 (p = 0.095, Student’s t-test). Comparisons of mutants with EV clone 2 
must be done in the context of each individual set of experiments, given that EV clone 2 
was used as a normalisation factor to allow comparison to WT AGR2 clone 13. In this way, 
only ∆21-40 AGR2 clone 4 and ∆KTEL AGR2 clone 8 were significantly different to EV clone 2 
(p = 0.006 and 0.004, respectively). 
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Figure 4.13 (continued 
overleaf). Monolayer 
attachment properties 
of mutant-AGR2- 
expressing clonal cell 
lines. The indicated cells 
were grown overnight to 
70-80 % confluence and 
then trypsinised in 
0.0125 % (v/v) trypsin for 
5 min. The remaining 
adhering cells were 
counted with an 
automated cell counter. 
The number of trypsin-
resistant cells is 
expressed as a 
percentage of the total 
number of cells in each 
well. (A) C81S AGR2 and 
E60A AGR2 clones. (B) 
∆1-20 AGR2. (C) ∆21-40 
AGR2 and ∆KTEL AGR2 
clones. The means from 
duplicate wells from 3 
independent 
experiments are shown, 
±SE. 
A 
B 
C 
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 Given the association of elongated morphology with trypsin sensitivity (Fig. 4.10), 
the correlation between morphology (measured by shape ratio, SR) and the relative trypsin 
sensitivity of all clonal cell lines was investigated (Fig. 4.14). There was a statistically 
significant correlation between SR and relative trypsin sensitivity in both the initial 
attachment (Spearman’s σ = 0.478, p = 0.028) and cell monolayer assays (Spearman’s σ = -
0.631, p = 0.002). This correlation was not conserved when considering only the cell lines 
with similar state-steady protein levels in the initial attachment assay (Spearman’s σ = 
0.486, p = 0.329) but the correlation was even more pronounced for this sub-set of cells in 
the monolayer assay (Spearman’s σ = -0.943, p = 0.005). These correlations suggest that the 
main factor affecting the resistance to trypsin for all of these cells in the monolayer 
adhesion assay is their morphology, but not in the cell suspension assay. Therefore, the use 
of changes in shape ratio were explored as a means of determining the effects of mutation 
on AGR2 function in the monolayer assay. 
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Figure 4.13 (cont.). Monolayer attachment properties of mutant-AGR2- expressing 
clonal cell lines. (D) The number of trypsin-resistant cells is expressed as a 
percentage of the total number of cells in each well. The proportion of trypsin-
resistant cells is expressed relative to the number of trypsin-resistant EV clone 2 cells 
in each of (A), (B) and (C). The means from duplicate wells from 3 independent 
experiments are shown, ±SE. 
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Figure 4.14. Correlation 
between cell morphology and 
attachment behaviour for 
AGR2-expressing clonal cells 
lines. Correlation was 
measured between (A) all 
AGR2-expressing clonal cell 
lines and initial attachment, 
(B) clonal cell lines of similar 
steady-state protein levels 
(shown in Fig. 4.12) and initial 
attachment, (C) all AGR2-
expressing clonal cell lines and 
monolayer attachment, (D) 
clonal cell lines of similar 
steady-state protein levels 
(shown in Fig. 4.13D) and 
monolayer attachment. Cell 
morphology was measured by 
shape ratio (SR, see Materials 
and Methods) for at least 150 
cells for each cell line and the 
mean SR value was plotted 
against the mean relative 
resistance to trypsin as 
measured in Fig. 4.11 for A 
and B, and as in Fig. 4.13D for 
C and D.  
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 The SR values from the three EV clones used in these experiments were combined, 
to avoid any bias given the slight variation in their SR values (Appendix 16). WT AGR2 clone 
13 SR was significantly higher than the combined SR of the three EV clones, but only Δ21-40 
AGR2 clone 4 had an SR value that was also significantly higher than EV clones (Table 4.1). 
Conversely, C81S AGR2 clone 10 and ∆1-20 AGR2 clone 6 had significantly lower SR values 
than EV clones, probably highlighting the importance of the thiol group and ER residence in 
particular in the function of AGR2, respectively. All mutant clones had an SR value that was 
significantly lower than WT AGR2 clone 13. 
 
Cell line 
Mean 
SR 
Statistical difference 
compared to EV clones 
(p value) 
Statistical difference 
compared to WT clone 13 
(p value) 
EV clones 1.85 - < 0.001 
WT AGR2 clone 13 2.09 < 0.001 - 
E60A AGR2 clone 18 1.78 0.506 < 0.001 
C81S AGR2 clone 10 1.58 < 0.001 < 0.001 
Δ1-20 AGR2 clone 6 1.68 0.001 < 0.001 
Δ21-40 AGR2 clone 4 1.99 0.029 0.021 
ΔKTEL AGR2 clone 8 1.85 0.698 < 0.001 
 
Table 4.1. Statistical analysis of differences in shape ratio (SR) values across 
mutant-AGR2-expressing clonal cell lines with similar steady-state protein levels. 
The SR values of at least 200 cells for each cell line were measured and the mean SR 
values are shown. The mean SR value across all three EV clones was used (see text). 
See Appendix 17 for representative cell morphology images and corresponding SR 
values. 
 
 
 Overall, these results suggest that dimerisation, the Cys81 thiol group, and protein 
localisation are important for AGR2-associated changes to cell morphology, as perturbation 
of any of these features resulted in a complete loss of the elongated cell type associated 
with WT AGR2 expression. The 21-40 region on the other hand is less important, given that 
its SR ratio was significantly different to both EV clones and WT13, possibly pointing to a 
less efficient AGR2-driven process. It is important to note however that it has not been 
expressly demonstrated that AGR2 is the cause of cell elongation. Several attempts were 
made to knockdown AGR2 expression in WT AGR2 clonal cells to address this notion, all of 
which were ultimately unsuccessful (Appendix 18). 
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4.2.7 Mutation of AGR2 completely ablates anchorage-independent cell growth 
 
 Aside from changes to the adhesion properties of tumour cells, anchorage-
independent growth is a necessary requirement for metastasis, and in vitro assays of 
anchorage-independent growth give clues to the metastatic potential of cells in vivo 
(reviewed in [583]). AGR2 is known to play a role in this process, as knockdown of AGR2 
severely reduced anchorage-independent growth of oesophageal cancer SEG-1 cells [481], 
as well as several breast cancer cell lines [482]. Expression of AGR2 also induces anchorage-
independent growth in NIH3T3 and lung cancer H1299 cells [445, 481]. 
 To this end, the ability of Rama 37 cells expressing WT and mutant AGR2 were 
assayed for anchorage-independent growth by the use of a soft agar assay. Only the three 
WT AGR2-expressing cell lines exhibited anchorage-independent cell growth, with all EV 
and AGR2 mutant clonal cell lines unable to grow in the soft agar (Fig. 4.15). The growth of 
R37E cells was also monitored as a control for elongated cell morphology. Representative 
images and quantitation of colony formation for cell lines expressing similar steady-state 
levels of AGR2 are shown in Fig. 4.16, along with EV clone 2 and R37E. Importantly, R37E 
cells were also able to form colonies, and there were on average approximately 2.5 times 
more viable, colony-forming R37E cells than WT AGR2 clone 13 cells (Fig. 4.16I), suggesting 
that these cells grow more efficiently in soft agar than AGR2-expressing cells with a similar 
morphology. Overall, these data further highlight the importance of cell morphology in 
bestowing pro-metastatic characteristics on Rama 37 cells, with only the most elongated 
cell types used here able to grow in soft agar, including those expressing AGR2. Whether 
continued expression of AGR2 creates some sort of survival disadvantage (as hinted at by 
the apparently more efficient growth of AGR2-negative, but elongated, R37E cells) will 
require further investigation. 
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Figure 4.15. Anchorage-independent growth assay of highest expressing clonal cell 
lines. The indicated cells were plated into 0.3 % agarose and left to form colonies for 
4 weeks. After that time, the number of viable cells was measured using 
bioluminescence (see Materials and Methods). Cells were plated in triplicate and the 
means of the luminescence relative to WT AGR2 clone 2 from three independent 
experiments are shown, ±SE. (A) Empty vector, WT AGR2, E60A AGR2 and C81S AGR2 
clones. (B) ∆1-20 AGR2, ∆21-40 AGR2 and ∆KTEL AGR2 clones. Insets: relative cell 
numbers for non-WT AGR2 cells using smaller scale. 
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Figure 4.16. Anchorage-independent growth of Rama 37 cells. The indicated cells 
were plated into 0.3 % agarose and left to form colonies for 4 weeks. Representative 
images of colony formation in wells containing (A) EV clone 2, (B) WT AGR2 clone 13, 
(C) E60A AGR2 clone 18, (D) C81S AGR2 clone 10, (E) Δ1-20 AGR2 clone 6, (F) Δ21-40 
AGR2  clone 4, (G) ΔKTEL AGR2 clone 8 and (H) R37E. The number of viable cells was 
quantified (I) using bioluminescence (see Materials and Methods). Cells were plated 
in triplicate and the means of the luminescence relative to WT AGR2 clone 2 from 
three independent experiments are shown, ±SE. Scale bar: 100 µm. 
 
After that time, the number of viable cells was quantified using bioluminescence (see 
Materials and Methods). Cells were plated in triplicate and the means of the 
luminescence relative to WT AGR2 clone 2 from three independent experiments are 
shown, ±SE.  
A) Whole experiment. (B) Non-WT AGR2 expressing cells only. Note the change of 
scale. 
I 
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4.2.8 Clonal WT AGR2-expressing cells are highly migratory 
 
 Having established that clonal AGR2-expressing cells display differences in adhesion 
and anchorage-independent growth relative to EV clonal cells, the migratory capacity of 
these cells were compared. Over a 16 h period, WT clone 2 cells migrated to a much greater 
extent than EV clone 2 cells, with an average of 140 times more WT AGR2 clone 2 cells 
migrating across the Transwell insert than EV clone 2 cells (Fig. 4.17). These data highlight 
that clonal WT AGR2-expressing cells possess several characteristics that are advantageous 
in the context of cancer metastasis, notably changes to cell adhesion, increased migration 
potential and anchorage-independent cell growth. 
 
           
 
Figure 4.17. Clonal WT AGR2 cells are highly migratory in the Boyden Chamber 
assay. (A) Cells were plated into the top of Transwell inserts in 1 % FBS medium and 
allowed to migrate for 16 h towards the lower compartment containing 5 % FBS. 
Cells were then fixed and stained, and all cells from each membrane were counted 
under a microscope. Data shown is from duplicate wells from a single experiment, 
±SD. Representative fields of view from Transwell membranes for (B) EV clone 2 cells 
and (C) WT AGR2 clone 2 cells following 16 h migration assay. Data collected in 
collaboration with Kathryn McCall, Institute of Integrative Biology, University of 
Liverpool. 
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4.3 Discussion 
 
4.3.1 AGR2-cell morphology correlation 
 
 It has been demonstrated here that there exists a positive correlation between WT 
AGR2 expression and elongated cell morphology, and AGR2 has indeed been previously 
linked to elongated morphology in prostate cancer PC3 cells [515]. If AGR2 were the cause 
of this morphology change, and that this would presumably be through induction of an 
EMT-type transformation, this could provide an explanation for the association of AGR2 
with metastasis [301, 305, 307, 309, 440, 481]. The fact that the elongated phenotype is 
only observed in clonal but not pooled WT AGR2 cells may be the result of some as yet 
unidentified positive feedback mechanism. The EGFR ligand amphiregulin (AREG) might 
play a role here, given its upregulation by AGR2 and its promotion of metastasis and 
invasion through an autocrine loop [506, 584, 585]. It may be that, in the context of a 
heterogeneous population of cells, signals from other, more cuboidal cells (with lower 
AGR2 expression) act to balance out pro-EMT signals such as amphiregulin, maintaining the 
majority of the population in a more cuboidal morphology. When a clonal population is 
created from a highly expressing cell, there may be a loss of this ‘off’ switch, pushing the 
cell towards a permanent elongated morphology. 
 An alternate explanation for the differences between pooled and clonal cells 
relates to the MET process. There is evidence to suggest that metastatic cells must revert 
back to epithelial–type cells in order to allow outgrowth of a secondary tumour, stemming 
from observations that secondary metastases from a number of adenocarcinomas 
(including breast, ovarian and prostate) seem to be made up of cells that are more 
differentiated than their tumour of origin (reviewed in [264]).  The reasons for this MET 
change are not clear, but suggest that there is some disadvantage to the mesenchymal 
phenotype in terms of maintaining a population of cells, rather than individual metastatic 
cells. It is interesting that the clonal WT AGR2 cells in the present experiments grow at a 
slower rate than pooled cells in culture (personal observation) and clonal and pooled AGR2-
expressing cells yield tumours that are slower growing in vivo than EV-transfected controls 
[309], hinting at a growth disadvantage for these cells in mixed populations. It may be then 
that, due to this growth disadvantage, elongated WT AGR2 cells, although present at a low 
level within the pooled population (personal observation), are unable to establish 
themselves as the dominant cell type within this pooled WT AGR2 population. Therefore, 
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since much of the adhesion behaviour of these AGR2-expressing cells can be explained by 
morphology, the cuboidal morphology of the majority of the WT AGR2 pooled cells may 
mask any change induced by AGR2. Indeed, WT AGR2 pool 2 cells and EV pool cells show no 
difference in overall morphology, with SR values of 1.88 and 1.89, respectively. It is 
probably for these reasons that no differences in adhesion are observed between WT AGR2 
and EV pool cells. 
 In line with this, and in order to better understand the role of AGR2 with regard to 
cell morphology, several attempts were made to knockdown AGR2 expression in both 
pooled and clonal cells to see whether their morphology would revert someway back 
towards cuboidal, as would be expected through an AGR2-dependent MET event. 
Unfortunately, despite the use of two different transposase vectors designed to remove the 
gene cassette containing AGR2 that was originally transfected into the cells, and the use of 
four shRNA plasmids individually, no knockdown could be achieved (Appendix 18).
 The reason for this failure is not clear, but the lack of activity from the transposase 
could be attributed to loss of enzyme recognition sites during plasmid integration, or some 
epigenetic change following transfection that now occludes the integration site. The shRNA 
plasmids used in knockdown experiments all target regions within the coding sequence of 
human AGR2 (Appendix 20), and so should not be affected by the fact that human AGR2 
has been introduced into rat cells. This could be tested using a cell line expressing 
endogenous AGR2, e.g. MCF7A, to ensure these are indeed functional shRNA sequences. A 
more likely explanation for the lack of knockdown by shRNA plasmids relates to the 
different promoters driving expression of AGR2 and AGR2-shRNA. In the transfection 
experiments above, the AGR2 gene is transcribed from a highly active EF1α promoter and 
so the rate of AGR2 mRNA transcription and the abundance of AGR2 mRNA transcript may 
be too high to be efficiently knocked down by the relatively weaker U1 promoter-driven 
shRNA [551]. Therefore, one possible way to achieve substantial knockdown of AGR2 may 
be to subclone the shRNA sequences into a different vector, under the control of a stronger 
RNA polymerase III promoter such as CMV [586, 587], rather than the U1 RNA polymerase II 
promoter used here. 
  
 
4.3.2 Adhesion properties of AGR2-expressing cells 
 
 To assess the effects of AGR2 on cell adhesion, a trypsin-resistance assay was used 
in the experiments presented here as a measure of the strength of cell attachment. Whilst 
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the assay does not directly measure forces required to overcome the strength of cell 
adhesion in the same way as the centrifugation assay, its use in other studies [588, 589] and 
the similar overall results seen between the trypsin and centrifugation assay here support 
its use as a proxy for strength of cell adhesion. Furthermore, in the context of Rama 37 cells 
at least, the centrifugation assay is only useful over short time periods (up to approximately 
30 min after plating cells), at which point, cells could no longer be detached by 
centrifugation (personal observation). The trypsin resistance assay therefore permits the 
study of cell adhesion where stronger adhesive forces are involved, such as those of cells in 
monolayers. Using this assay, AGR2 expression was shown to initially enhance cell 
attachment immediately after plating of cells. In this short timeframe, the initial stages of 
cell adhesion are thought to be mediated through electrostatic interactions between the 
cell surface and substratum, mainly through the negatively-charged glycosaminglycan 
(GAG) hyaluronan (HA) [590, 591]. The presence of HA in the pericellular matrix is required 
for this early interaction, solely mediating the adhesion of chondrocytes up to 10 min after 
plating, but HA also promotes the formation of FAs in the longer term, leading to an overall 
more rapid HA-mediated anchoring of the cell [592]. After these initial adhesion events, HA 
is sequestered from the cell-substratum interface, and focal adhesions (FAs) then become 
the major determinant of adhesion strength [592]. Given the reduction in the number of 
FAs in clonal WT AGR2 cells (Appendix 21), these would be expected to adhere less strongly 
than EV cells after the initial HA-mediated adhesion phase, which was indeed the case. Thus 
while the time scale of progression from HA- to FA-mediated adhesion might be longer than 
observed for chondrocytes [592], the overall pattern observed here for Rama 37 cells is 
very similar. It is noteworthy that chondrocytes contain a thick pericellular coat with 
probably multiple layers of HA [591], and thus may adhere more rapidly than Rama 37 cells, 
providing a possible explanation for the difference in time scale for the switch between HA- 
to FA-mediated adhesion.  
 It will be interesting to determine whether HA does play a major role in the 
adhesion of clonal WT AGR2 cells, as metastatic cells have been shown to produce high 
levels of HA and that this HA mediates the adhesion of these cells to the endothelium, in a 
similar manner to immune cell recruitment [593-595]. Whilst the ultimate arrest of 
circulating tumour cells in a particular vessel may be due to the size restriction of the 
vessels that these cells arrive at [199-201], it is clear that increased cellular adhesion is a 
favourable characteristic for promoting this metastatic process, as chemical inhibition of HA 
synthesis or blocking HA activity through the use of a synthetic peptide reduced the 
metastatic potential of melanoma and osteosarcoma cells [596, 597]. Thus, AGR2-
Chapter 4  Discussion 
145 
 
associated increases in the adhesion of single cells or clumps of cells may partially explain 
its pro-metastatic activity, by promoting adhesion of these cells at secondary sites.  
 The fact that the strength of attachment of clonal WT AGR2 cells reverses over time 
is probably also related to the switch from HA- to FA-mediated adhesion. Additionally, 
whist EV clone 2 cells (and indeed other cuboidal Rama 37 cell lines) secrete a large amount 
of fibronectin, WT AGR2 clone 2 cells produce comparatively much lower amounts (Fig. 
4.8). As such, this fibronectin-rich ECM deposited by EV cells will provide increased 
attachment for these cells over time [598, 599], compared to WT AGR2 clone 2 cells, where 
there will be little such ECM deposition. This could contribute to the switch from strong 
adhesion to weak adhesion over time for WT AGR2 cells, and vice versa for EV cells, as 
adhesion switches from HA- to FA- and ECM-mediated. 
 
 
4.3.3 Roles of extracellular and intracellular AGR2 in cell adhesion 
 
 AGR2 is an ER-resident protein (Chapter 3) but can also be secreted by some cells 
[301, 388, 426, 440], and so the effects on adhesion of both intracellular and extracellular 
AGR2 were tested in this chapter. A previous study showed that extracellular AGR2 coated 
onto cell culture plates increased the rate of cell adhesion [309], as demonstrated here. 
However, it should be noted that AGR2 has an overall positive charge of + 4, which may 
contribute to cell attachment through electrostatic interactions as described above. 
Furthermore, the inhibition of adhesion caused by BSA could be explained by its high 
overall negative charge (- 10), causing unfavourable interactions between itself and the 
negatively-charged cell surface [591]. AGR241-175 and AGR324-166 have an overall neutral 
charge, which may account for the reduction in adhesion compared to uncoated wells as a 
result of masking favourable electrostatic interactions with the plate surface. The absence 
of a negative charge could account for the lack of total adhesion inhibition as seen with 
BSA. However, the salt concentration in culture medium can negate the effects of 
electrostatic interaction between cells and coated surfaces [600], and the fact that BSA 
inhibits binding, and fibronectin increases binding despite both bearing a negative charge 
[581] indicates that charge is not the only factor in determining cell attachment to protein-
coated surfaces. Furthermore, the fact that coating with 21-40 peptide (which is positively 
charged) inhibited cell attachment further suggests that charge is not the only factor that 
influences cell adhesion in these experiments. 
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 Further evidence for a role of extracellular AGR2 stems from studies of newt 
anterior gradient protein (nAG), a member of the anterior gradient family [601]. nAG is 
important for limb regeneration in the salamander, where it functions through the GPI-
anchored surface receptor, Prod1 [450, 451]. Importantly, Prod1 is also implicated in 
mediating cell adhesion [451] and although Prod1 appears to be restricted to salamanders, 
the most closely related mammalian proteins are urokinase-type plasminogen activator 
receptor (uPAR) and CD59 [452, 602]. Both of these surface proteins are involved cell 
adhesion: uPAR mediates adhesion through interactions with integrins and vitronectin, and 
adhesion is enhanced when uPAR is also bound by uPA [603-605], whereas T-cell binding to 
CHO cells is mediated by CHO-expressed CD59 [606, 607]. Furthermore, AGR2 is reported 
to bind to C4.4a [389], a structural homologue of uPAR [453] as well as dystroglycan, a 
transmembrane glycoprotein linking the cytoskeleton to the ECM (reviewed in [608]). With 
this in mind, it is possible that AGR2 acts through one of these surface receptors to affect 
cell adhesion. In this context, it appears that the flexible region of the protein (comprising 
residues 21-40) is the key feature required to promote adhesion, though this must be in the 
presence of the rest of the protein as the 21-40 peptide alone did not promote adhesion. 
Such flexible regions are known to mediate protein-protein interactions (reviewed in [326]), 
and so it is possible that the 21-40 region might mediate receptor binding. However, the 
inhibition of adhesion observed with the 21-40 peptide suggests that this region alone is 
not sufficient to promote adhesion, pointing to the requirement of both the 21-40 region 
and the globular part of the protein (residues 41-175) in this function. It is interesting to 
note that deletion of part of this globular domain of AGR2 (the C-terminal α-helix and loop 
region) inhibits its ability to promote anchorage-independent growth [445], providing 
evidence that the AGR2 globular domain is at least involved in anchorage-independent 
growth.  The extracellular role of AGR2 in adhesion, while probably requiring the combined 
actions of the flexible and globular regions of the protein, appears to be independent of 
both the Cys81 thiol group and AGR2 dimerisation, given the lack of changes to cell 
adhesion between these mutant and WT AGR2 protein-coated wells (Fig. 4.1). Further 
experimentation will be required to determine whether the entire globular domain is 
required for AGR2 to promote adhesion.  
 The effect of intracellular AGR2 on cell adhesion depends upon the nature of the 
cells. In cell monolayers, the effect of AGR2 can be largely defined by its effects on cell 
morphology, as there exists a clear correlation between cell morphology and cell 
attachment, as previously reported [609, 610]. These effects on attachment were generally 
reciprocal, such that cells that were strongly adherent upon initial plating were 
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subsequently weakly adherent upon forming a monolayer, and vice versa. In the context of 
WT AGR2 clonal cells, this weak attachment upon monolayer formation may be explained 
by a reduction in the number of focal adhesions anchoring these cells to the substratum (as 
described above). This weakened attachment is presumably related to their more migratory 
phenotype relative to cuboidal EV clone 2 cells (Fig. 4.17), where the deposition of FAs for 
gripping the substratum to allow cellular movement must be balanced by opposing events 
that allow the cell to leave its previous location [611]. Therefore, migrating cells require a 
higher rate of FA turnover, such that fewer FAs will be present at any given time compared 
to a non-migratory cell (reviewed in [612]). Furthermore, this high turnover rate 
presumably stops or severely reduces the formation of the more anchoring fibrillar 
adhesions [144, 145], further weakening the cell-substratum interaction. 
 In all WT and mutant AGR2 cell lines, attachment behaviour was correlated with 
cell morphology, regardless of the particular mutation involved (Fig. 4.13). This provides 
clues as to how intracellular AGR2 might affect cell morphology, and in turn cell adhesion. 
The variability in the attachment levels in short term assay makes it hard to draw any firm 
conclusions about the involvement of mutations in AGR2 function, but the far more 
consistent attachment behaviour of cells in monolayers offers a better readout of the 
effects of these mutations. Interestingly, while the 21-40 region appears to be important 
for the activity of extracellular AGR2, ∆21-40 AGR2 clone 4 cells were the only mutant 
AGR2-expressing cells to maintain a SR value that was significantly different from EV clone 
cells, although it was also significantly different from WT clone 13 cells. Coupled with a level 
of cell attachment in between the levels of WT AGR2 clone 13 and EV clone 2 cells, this 
suggests that the loss of the flexible region may reduce the activity of AGR2 and indeed, 
deletions of flexible regions can affect the efficiency of protein interactions, at least in the 
context of enzyme-substrate interactions [613]. Therefore, while not critical to AGR2 
function, the loss of the flexible region may make AGR2 less efficient and thus less able to 
induce the strong morphological change observed with WT protein. 
 In both sets of attachment assays, E60A AGR2 clone 18 and C81S AGR2 clone 10 
cells displayed attachment behaviour that was no different to EV clone 2 cells, and also 
displayed an SR value that was more cuboidal than EV clone cells. This points to 
dimerisation and the Cys81 thiol group playing a particularly important role in mediating 
the morphological changes induce by AGR2. It is important to note that at least one PDI 
family member (ERp29) similarly requires dimerisation to function in its role as a chaperone 
[537], and, whereas the evidence in Chapter 3 points to a lack of PDI activity for AGR2, the 
thiol-dependent chaperone activity of ERp44 provides a mechanism whereby AGR2 might 
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also promote the production of protein involved in morphology regulation (discussed in 
Chapter 3). Importantly, AGR2 is known to affect the production of several mucins, 
including MUC1 [412], MUC2 [408, 422], MUC5AC and MUC5B [418, 427], and forms thiol-
mediated interactions with at least one of these proteins, MUC2 [301]. These mucins are 
large molecular weight glycoproteins which maintain cell polarisation, both enhance and 
decrease cell adhesion, and provide a protective epithelial surface lining (reviewed in 
[614]). Critically, MUC1, which is a marker of poor prognosis in several cancers [615-617] 
has been shown to induce EMT in pancreatic and breast cancer cells [618, 619], providing a 
direct mechanism whereby AGR2 might induce EMT. It will be interesting to examine the 
expression of MUC1 in WT AGR2-expressing clones and the role it may play in bringing 
about morphological changes in these cells. 
 The attachment behaviour of ∆KTEL AGR2 clone 8 cells provides an interesting link 
between intracellular and extracellular AGR2 activities. Whilst ∆KTEL AGR2 clone 8 cells 
have an SR value that is no different to EV clone cells, the differences in adhesion between 
these cells may point to the involvement of other factors that govern AGR2-induced 
changes to cell attachment, rather than morphology alone.  The high levels of secreted 
AGR2 in these cells (see Chapter 3) raises the possibility that secreted AGR2 plays a role in 
the adhesion of these cells, especially given the increase in adhesion seen when AGR2 is 
coated onto the substratum (Section 4.2.1). Indeed, reports have shown that the secretion 
of other ER chaperones such as calreticulin and GRP78 can support tumourigenesis, 
affecting pro-survival pathways and ECM modulation [448, 449, 620, 621]. Similarly, 
secretion of the cytoplasmic chaperone Hsp90 promotes cell motility and metastasis 
through activation of EMT [622]. Therefore, AGR2 may affect adhesion in two ways: 
intracellular protein affects the production of morphology-related proteins, whilst secreted 
AGR2 could presumably affect adhesion via signalling through cell surface receptors. 
 
 
4.4 Conclusions 
 
 In this chapter, intracellular production of AGR2 has been found to enhance the 
adhesion of newly attached cells but to reduce the adhesion of monolayers of cells.  A 
correlation between AGR2 expression and an elongated cell morphology has been 
described which might form the basis of the effect of AGR2 on cell adhesion, as these 
changes in cell morphology appear to be a major contributor to the altered attachment and 
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anchorage-independent growth properties of these cells. This chapter opens up the 
possibility of understanding the proteins and pathways that are affected by AGR2 to bring 
about these changes. 
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Chapter 5 
 
 
 
Proteome analysis of AGR2-expressing 
cells 
 
 
 
5.1 Introduction 
 
 The expression of AGR2 has been reported in a number of different cancers and is 
associated with metastasis [309] and decreased patient survival (see Section 1.4.2.2.1), but 
yet its mechanism of action in cancer remains largely undefined. The protein belongs to the 
protein disulphide isomerase (PDI) family of chaperones based on its sequence homology to 
other PDI proteins, but contains a divergent single-cysteine active site [378]. This divergent 
motif does not appear to be catalytically active in terms of PDI activity, but does 
permit thiol-dependent interactions between the luminal PDI ERp44 and target substrates 
[320, 573]. Therefore, as PDIs and chaperones 
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generally promote the folding of client proteins [310], AGR2 may function by increasing the 
output of correctly folded proteins from the endoplasmic reticulum (ER), in either a general 
or substrate-specific manner. 
 Accordingly, AGR2 is known to be directly required for the secretion of the gel-
forming mucin MUC2 in the gut [408, 422], with which it forms thiol-dependent 
interactions, supporting the notion that AGR2 can function as a protein chaperone.   AGR2 
is further implicated in the expression of two other gel forming mucins (MUC5AC and 
MUC5B), where it is reported to interact with immature mucin chains [418, 427]. The 
nature of these interactions has not been defined, but is likely to be also thiol-dependent, 
as AGR2 was shown to be associated only with immature mucin [418], where there are 
presumably a number of unpaired disulphides and thus free-thiols will be present. 
Additionally, immature MUC5AC co-immunoprecipitated with AGR2 [418], suggesting the 
presence of a reasonably stable interaction between the two. Similarly, the cell surface 
mucin, MUC1, has been shown also to co-immunoprecipitate with AGR2, and both proteins 
co-localise by immunofluorescence, seemingly in the ER in neoplastic pancreatic cells [412]. 
AGR2 is also associated with the expression of the surface mucin MUC4, but direct 
regulation by, or interaction with, AGR2 was not determined [433]. Both of these cell 
surface mucins are associated with cancer progression, where differences in expression 
levels or glycosylation patterns are observed, and thus these proteins may be useful 
biomarkers for monitoring disease progression [432, 623]. Additionally, AGR2 has been 
shown to upregulate the levels of the lysosomal proteases, cathepsins B and D in pancreatic 
cancer cells [437], which also led to an increase in their secretion and an increase in the 
invasive capability of these cells in vitro. Since a direct interaction with AGR2 could not be 
determined, the authors suggested that this may relate to the probable rapid and transient 
interaction between these proteins and AGR2. Such transient interactions may also be a 
reason why it has been possible to trap AGR2-mucin complexes, as these proteins contain 
numerous disulphide bonds and thus presumably either undergo extended interactions 
with AGR2 or are associated with multiple AGR2 molecules. 
 The abundances of intracellular proteins are also influenced by AGR2, with a recent 
proteomics screen identifying several differentially regulated proteins of the p53 pathway 
in AGR2-expressing cells compared to non-AGR2-expressing cells [438]. A previous report 
also demonstrated that AGR2 inhibits p53 phosphorylation and activation in response to UV 
damage [445]. Whether AGR2 interacts directly with elements of these intracellular 
pathways has not been determined, but it is interesting that AGR2 can also be secreted 
[166, 301, 388, 440], and thus could presumably influence these signalling pathways 
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through binding to cell surface receptors. AGR2 has indeed been reported to interact with 
the cell surface C4.4a and dystroglycan proteins in a yeast two-hybrid screen, but these 
interactions have yet to be validated in mammalian cells [389]. Thus, AGR2 appears to be 
able to both directly and indirectly regulate the abundances of proteins both inside and 
outside the cell. Whether the intracellular actions of AGR2 related solely to influences on 
the p53 pathway however, is not clear. Similarly, whilst AGR2 affects the secretion of 
several proteins, it is not known if these are AGR2-specific substrates or whether they 
reflect a more general upregulation of protein output. Therefore, given the largely 
unknown extent of AGR2 function, investigating AGR2-dependent global changes to the 
intracellular and extracellular proteomes may provide a better idea of processes and 
individual proteins regulated by AGR2, and in this way may help elucidate its role in cell 
adhesion and metastasis.  
 
 
5.1.1 Chapter objectives 
 
 The aims of this chapter are to employ a mass spectrometry-based approach to 
identify proteins whose abundances might be influenced by the expression of AGR2 in 
Rama 37 cells, and which might themselves influence the adhesive/metastatic properties of 
the cells.   
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5.2 Results 
 
5.2.1 AGR2-induced changes to the intracellular proteome 
  
 The Rama 37 cell line is a model system for highlighting AGR2-mediated effects on 
adhesion and metastasis [309] (Chapter 4), and thus a four-replicate mass spectrometric 
proteomic screen of differentially regulated proteins was performed on WT AGR2 positive 
and negative (EV) Rama 37 pool cells in order to investigate possible protein changes 
associated with the presence of AGR2. 2566 quantifiable proteins were detected in the 
comparative mass spectrometric screen between WT AGR2 and EV pool cells. Of these, only 
5 proteins, identified by two or more unique peptides, showed a greater than two-fold 
difference in expression between the two cell pools (Table 5.1).  
 
 
Upregulated in AGR2-positive cells 
Uniprot 
Accession 
Description 
Fold 
change 
up 
Anova 
(p) 
Unique 
peptides 
D3ZIA7 Anterior gradient 2 (AGR2) 7.58 <0.01 3 
Q4QRB8 Argininosuccinate lyase (ASL) 4.80 <0.01 2 
 
 
Downregulated in AGR2-positive cells 
Uniprot 
Accession 
Description 
Fold 
change 
down 
Anova 
(p) 
Unique 
peptides 
Q642B0 Glypican 4 (GPC4) 2.65 <0.01 3 
P62966 Cellular retinoic acid-binding protein 1 (CRABP1) 2.07 <0.01 3 
Q6P6Q2 Keratin, type II cytoskeletal 5 (KRT5) 2.02 <0.01 9 
 
Table 5.1. Effects of AGR2 expression on the intracellular proteome of pooled transfected 
Rama 37 cells.  
 
 
 AGR2 was identified as the protein with the highest fold-increase in AGR2-
transfected cells, indicating that the present methodology can indeed detect the increased 
levels of AGR2 previously observed in these cells (Chapter 3). Other than AGR2 however, 
only argininosuccinate lyase (ASL), a component of the arginine metabolism pathway, was 
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upregulated in WT AGR2 cells. Cancers including melanomas, hepatocellular carcinomas 
and glioblastomas can display a growth dependence on arginine, and ASL is indeed 
upregulated in some of these cancers (reviewed in [624]), and therefore upregulation may 
provide a survival advantage for AGR2-expressing cells. 
 There were moderate decreases in only three proteins associated with AGR2 
expression (Table 5.1): glypican-4, cellular retinoic acid-binding protein 1 (CRAPBP1) and 
cytokeratin 5. CRABP1 is involved in the binding and transport of retinoic acid (RA), a 
promoter of cell growth and differentiation [625]. Decreasing the levels of CRABP1 might 
decrease the availability of RA, in a similar manner to CRABP2 [626] and thus possibly 
promote de-differentiation or reduced growth of the cells, which may be important for the 
generation of cancer stem cells (reviewed in [627]). Glypican-4 is a GPI-anchored heparan 
sulphate proteoglycan (HSPG) that enhances insulin signalling through interaction with the 
insulin receptor [628], and is also a positive regulator of the Wnt/planar cell polarity (PCP) 
pathway, a pathway involved in promoting cell migration (reviewed in [629]). A reduction in 
glypican-4 may seem counter-intuitive given the increase in metastases observed in AGR2-
overexpressing cells [309], but overexpression of glypican-4 has also been shown to prevent 
migration [630]. The authors suggest that, as with other Wnt-regulating HSPGs such as 
Knypek [631], glypican-4 may regulate the availability of Wnt ligands in the extracellular 
space, and thus by decreasing levels of glypican-4, the levels of available Wnt molecules are 
increased. This could therefore result in an increase in signalling through the Wnt/PCP 
pathway, which leads to re-organisation of actin filaments and promotes migration [629]. 
Overall, although these changes in levels of intracellular proteins were minimal, they hint at 
AGR2 affecting pathways involved in cell migration, differentiation and survival, all aspects 
which could favour the development of metastases.  However, these changes will need to 
be validated and any causative link with changes in the levels of these proteins with an 
effect on metastasis will also have to be demonstrated.  
 As mentioned above, AGR2 has been shown to affect the secretion of several 
secreted proteins [408, 412, 418, 422, 427, 437] and so, given the limited effects on 
intracellular protein abundance observed in AGR2-expressing cells, the effects of AGR2 
expression on secreted proteins was next explored. 
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5.2.2 AGR2-induced changes to the secreted proteome 
 
5.2.2.1 Developing a methodology for the collection and analysis of cell secretomes 
 
 Studying the secreted proteome (or ‘secretome’) from cultured cells presents 
several challenges. These relate to the contamination of the pool of secreted proteins by 
intracellular proteins released from dead or dying cells, the low concentration of secreted 
protein within the culture medium and the masking of these proteins by serum proteins 
(e.g. BSA) used in most cell culture media [632]. Thus, experiments were carried out to 
establish methodologies that address these potential problems. 
 To avoid the effects of a large amount of contaminating serum proteins in both LC-
MS and gel electrophoresis analyses of the secretomes, cells were incubated in serum-free 
Rama 37 medium, and the resulting conditioned medium (CM) was collected for analysis by 
LC-MS (see Materials and Methods). A total of 802 proteins were identified in the 
comparative CMs of WT AGR2 pool and EV pool cells (including differentially and non-
differentially expressed proteins), and these proteins were subjected to further analysis 
using the Ingenuity Pathway Analysis (IPA) software package (Qiagen). Of the proteins 
identified, 627 (78.2 %) could be mapped to the IPA database, and information on the 
recorded subcellular localisation of these proteins could be collected for 527 (90.1 % 
mapped proteins, 71.1 % total proteins) of these (Fig. 5.1). 
 
 
 
 
 
300, 52% 
101, 18% 
81, 14% 
73, 13% 
15, 3% 
Cytoplasm 
Extracellular space 
Plasma membrane 
Nucleus 
Other 
Figure 5.1.  Distribution of proteins between intracellular and extracellular 
compartments from conditioned medium of WT AGR2 pool and EV pool cells 
incubated in serum-free DMEM medium. CM proteins were analysed by LC-MS and 
their cellular distribution determined using Ingenuity Pathway Analysis. Note that 
this encompasses all proteins identified in the CM of both cell types, not just 
differentially expressed proteins. 
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 Only 101 (18 %) of the identified proteins were listed as belonging to the 
extracellular space, with 81 (14 %) proteins labelled as membrane proteins. Given that one 
proteomic study identified 18 of 22 transmembrane proteins from human mammary 
epithelial cells as having an extracellular shed form [633], at least some of the membrane 
proteins identified in the WT AGR2 pool and EV pool secretomes could also be shed-
domains of membrane proteins. However, 373 (65 %) of the secretome proteins were of 
intracellular origin (cytoplasmic or nuclear), suggesting that there was substantial 
contamination of the secretome by intracellular proteins, presumably released from dead 
and dying cells. 
 Several studies investigating secreted proteins have used Opti-MEM serum-free 
medium (Gibco) for the collection of these proteins [634-638]. Opti-MEM is a chemically-
defined, low protein concentration medium containing growth factors to support growth in 
the absence of FBS. To try and minimise the contamination of the secretome by 
intracellular proteins observed with serum-free DMEM medium, EV and WT AGR2 pool cells 
were incubated in Opti-MEM medium and the CM again analysed by LC-MS and IPA (Fig. 
5.2). 
 
 
 
 
 
 
 A similar number of proteins were identified in the CM of Opti-MEM-incubated 
cells (783 proteins), and both the identity of these proteins and the overall distribution of 
proteins between cellular compartments was largely the same as from DMEM-incubated 
296, 51% 
117, 20% 
103, 17% 
58, 
10% 
10, 2% 
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Extracellular Space 
Plasma membrane 
Nucleus 
Other 
Figure 5.2. Distribution of proteins between intracellular and extracellular 
compartments from conditioned medium of WT AGR2 pool and EV pool cells 
incubated in serum-free Opti-MEM medium. CM proteins were analysed by LC-MS 
and their cellular distribution determined using Ingenuity Pathway Analysis. Note 
that this encompasses all proteins identified in the CM of both cell types, not just 
differentially expressed proteins. 
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cells. However, the overall concentrations of these proteins in the CMs, based on peptide 
abundances calculated by Progenesis software (see Materials and Methods), differed 
between DMEM- and Opti-MEM-incubated cells. This suggests that simply examining all the 
proteins identified in CMs may not be an appropriate method for determining the 
suitability of the CM collection method, and that the relative abundances of these proteins 
should be taken into account. This necessitates the use of a normalisation factor to 
compare protein abundances across different cell lines and CM collection methods. 
Therefore, one bona fide secreted protein, fibronectin [639, 640], was identified in both 
experiments shown in Fig. 5.1 and 5.2 that showed no significant difference in expression 
between EV or WT AGR2 cells, and could potentially be used as a normalisation factor for  
the levels of secreted proteins between WT AGR2 and EV pool cells. In addition, pilot data 
suggested that there was indeed no difference in the amount of fibronectin secreted from 
WT AGR2 and EV pool cells, as CM from both cell types analysed by SDS-PAGE showed 
comparable levels of fibronectin (Fig. 4.8). Similarly, there was no significant difference in 
intracellular levels of fibronectin between these cells (fold change: 1.12, p = 0.078, ANOVA). 
This suggests that the secreted levels of fibronectin could be used as a normalisation factor 
for the secretomes of WT AGR2 and EV pool cells. 
 With this in mind, the levels of proteins identified in CM collected from DMEM- and 
Opti-MEM-based serum-free media by LC-MS were normalised to the level of fibronectin in 
the CMs. The mean level of fibronectin across the four replicate samples for each cell type 
in each serum-free medium was used as a normalisation factor for the mean levels of each 
protein identified in the CM of each cell type. This yielded a fibronectin-normalised 
abundance value that was used to compare the abundances of CM proteins across cell 
types and incubation media. To determine the most appropriate collection method, the 
cellular localisation of the most abundant proteins in both collection media was assessed. 
The most abundant proteins were determined as those present at a level greater than 0.5 
times that of fibronectin, retaining 168 proteins from DMEM-incubated cells and 15 from 
Opti-MEM incubated cells. In essence, the value itself of the cutoff point is not important, 
as long as it selects for the most abundant proteins; choosing a lower cutoff will simply 
increase the proportion of proteins included in the analysis that are released as a 
consequence of cell lysis, which should be present at a lower concentration than true 
secreted proteins.  
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 Considering only the most abundant proteins, the proportion of proteins denoted 
as belonging to the extracellular space increased in DMEM-incubated cells rose from 18 % 
of all CM-derived proteins (Fig. 5.1) to 30 % of the most abundant proteins (Fig. 5.3A). 
However, 50 % of the most abundant proteins were still classified as cytoplasmic. In the CM 
from Opti-MEM-incubated WT AGR2 and EV pool cells, only 15 proteins out of all identified 
proteins from both cell types (i.e. including differentially and non-differentially expressed 
73, 43% 
50, 30% 
29, 17% 
11, 7% 
5, 3% 
Cytoplasm 
Extracellular space 
Plasma membrane 
Nucleus 
Other 
13, 87% 
2, 13% 
0, 0% 
Extracellular space 
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Figure 5.3. Comparison of distribution between intracellular and extracellular 
compartments of the most abundant proteins from conditioned medium of DMEM- 
and Opti-MEM-incubated WT AGR2 and EV pool cells. CM proteins were analysed by 
LC-MS and their cellular distribution determined using Ingenuity Pathway Analysis. 
Protein abundance was normalised to fibronectin, and the cellular localisation for 
most abundant proteins (present at a level ≥ 0.5 times the abundance of fibronectin) 
were determined using Ingenuity Pathway Analysis. (A) DMEM-incubated cells and 
(B) Opti-MEM-incubated cells. 
A 
B 
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proteins) were found at levels ≥ 0.5 times that of fibronectin (Fig. 5.3B). Of these, only 2 (13 
%) were not classified as belonging to the extracellular space. Of these two cytoplasmic 
proteins, one (nucleobindin-1) is resident in the Golgi and the other (SRPRB) is an ER 
protein. Given the previously observed secretion of other ER proteins [448, 449, 620, 621], 
these could potentially also be secreted proteins, but overall, this shows that the majority 
of the most abundant proteins in the CM from Opti-MEM medium are indeed extracellular 
proteins. These observed differences in the proportion of extracellular and intracellular 
proteins with these two serum-free media indicate that Opti-MEM is the more suitable 
method for minimising contamination from intracellular proteins. While CM from these 
Opti-MEM-incubated cells contained many fewer proteins expressed at ≥ 0.5 times the 
level of fibronectin, this is not surprising given the generally low abundance of secreted 
proteins [632]. An independent validation of the method can also be seen in the levels of 
the cytoplasmic protein lactate dehydrogenase A (LDHA) relative to fibronectin in the 
extracellular space. Extracellular LDHA is routinely used as a measure of cell lysis [641, 642], 
and the average levels of LDHA relative to fibronectin in the CM from both EV and WT AGR2 
cells were 0.12 for cells incubated in Opti-MEM and 8.44 for cells incubated in DMEM, a 70-
fold difference in the relative amount of extracellular LDHA between these methods. This 
indicates a much higher level of cell lysis in DMEM-incubated cells and reinforces the 
suitability of Opti-MEM as the optimal medium for collecting CM. 
 
 
5.2.2.2 Effects of AGR2 expression on secreted proteins 
 
 Using the LC-MS dataset collected from cells using the Opti-MEM protocol, the 
changes to secreted proteins associated with AGR2 expression were explored. A total of 
758 quantifiable proteins were identified from the comparative secretomes of WT AGR2 
positive and AGR2-negative (EV) pooled cells. The abundances of the identified proteins 
were normalised to the levels of fibronectin in each replicate, and the list reduced to 
proteins that were significantly differentially expressed (p < 0.05, Student’s t-test) and 
identified by 2 or more unique peptides, yielding a list of 30 proteins differentially 
expressed between the CM of WT AGR2 and EV pool cells (Table 5.2). 63 % of identified 
proteins were classed as extracellular by IPA and 30 % as plasma membrane proteins. Only 
four of the differentially regulated proteins were upregulated in the AGR2-expressing cells 
(including AGR2 itself), whilst the remainder were downregulated in these cells, relative to 
the EV controls. The identification of AGR2 in CM suggests that the protein is indeed 
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secreted, although it was present at a relatively low concentration relative to fibronectin 
(0.002 times the concentration of fibronectin). However, as AGR2 was found to localise 
mostly to the ER (Chapter 3), this is not unexpected and suggests that only a relatively low 
amount of AGR2 is secreted. Pathway analysis revealed that the top functions that the 
differentially regulated proteins (both up- and down-regulated) are involved in were 
cellular movement and cellular development, in keeping with the roles of AGR2 in cell 
differentiation and metastasis. In particular, there was downregulation of several adhesion 
molecules (cadherin 1, 2 and 11, as well as LGALS3BP), although to what extent levels of 
membrane proteins in the CM reflect the actual membrane levels is not clear. There was 
down-regulation of basement membrane proteins (LAMA4, LAMB2, fibulin and LOXL3), 
coupled with an increase in the matrix-degrading protease ADAMTS1. It is also interesting 
that there were changes to several cytokines (CXCL1, CXCL2 and granulin). Overall, in the 
pool cells tested here, the presence of AGR2, rather surprisingly for a potential chaperone, 
does not appear to be associated with an increase in the level of many proteins, other than 
the secretion of two CXCL cytokines, which is potentially important for the recruitment of 
hematopoietic cells that are known to support tumour growth and invasion [184, 643]. 
However, AGR2 might be associated with the downregulation of adhesion molecules.  
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 Table 5.2 (continued overleaf). Effects of AGR2 expression on the secretome of Rama 37 cells. 
 
Upregulated in AGR2-expressing cells 
Uniprot 
Accession 
Description 
Fold change 
up 
t-test (p) 
Unique 
peptides 
D3ZIA7 Anterior gradient 2 (AGR2) 22.48 <0.01 2 
P30348 C-X-C motif chemokine 2 (CXCL2) 4.25 0.02 2 
G3V6C6 Chemokine (C-X-C motif) ligand 1 (CXCL1) 3.64 0.03 2 
Q9WUQ1 A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS1) 3.49 <0.01 10 
 
 
Downregulated in AGR2-expressing cells 
UniProt 
Accession 
Description 
Fold change 
down 
t-test (p) 
Unique 
peptides 
D4ACD7 Follistatin-related protein 5 (FSTL5) 34.55 0.01 19 
F1LR45 Sushi repeat-containing protein 2 (SRPX2) 5.51 0.02 4 
F1MAP4 Multiple EGF-domains 10 (MEGF10) 4.52 0.048 7 
D3ZP82 Lysyl oxidase-like 3 (LOXL3) 4.40 <0.01 10 
F1MAH6 Cadherin-11 (CDH11) 4.25 <0.01 4 
P63090 Pleiotrophin (PTN) 4.18 0.02 5 
F1MAG8 Semaphorin 3D (SEMA3D) 3.70 <0.01 3 
H9KVF9 Proprotein convertase subtilisin/kexin type 5 (PCSK5) 3.69 <0.01 2 
Q642B0 Glypican 4 (GPC4) 3.45 <0.01 10 
D3ZEU2 Laminin subunit alpha-4 (LAMA4) 3.21 <0.01 4 
Q62894 Extracellular matrix protein 1 (ECM1) 3.09 <0.01 15 
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G3V803 Cadherin-2 (CDH2) 2.92 <0.01 10 
O70513 Galectin-3-binding protein (LGALS3BP) 2.74 <0.01 5 
Q9R0C5 N-acetylgalactosaminyltransferase 7 (GALNT7) 2.66 0.01 4 
Q6P9Z6 Tumor-associated calcium signal transducer 2 (TACSTD2) 2.61 <0.01 2 
Q4V8N0 Lipocalin 7 (TINAGL1) 2.59 <0.01 8 
G3V8V1 Granulin (GRN) 2.49 <0.01 10 
F1LRR7 Suppressor of tumorigenicity 14 (ST14) 2.33 0.01 13 
P15800 Laminin subunit beta-2 (LAMB2) 2.14 <0.01 31 
Q9R0T4 Cadherin-1 (CDH1) 2.13 <0.01 2 
P29524 Plasminogen activator inhibitor 2 type A (SERPIN B2) 2.13 0.04 5 
G3V6X1 Fibulin 2 (FBLN2) 2.12 0.01 22 
P55053 Fatty acid-binding protein, epidermal (FABP5) 2.02 0.01 2 
Q641Z6 EH domain-containing protein 1 (EHD1) 2.01 <0.01 2 
G3V6B1 Transforming growth factor beta-2 (TGFB2) 2.01 <0.01 2 
Q8R3Z7 EH-domain containing 4 (EHD4) 2.00 <0.01 4 
 
  Table 5.2 (cont.). Effects of AGR2 expression on the secretome of Rama 37 cells. 
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5.2.3 AGR2-induced changes to secreted proteins in clonal cell lines 
 
 As shown in Chapter 4, clonal cell lines expressing AGR2 exhibit altered cell 
adhesion properties compared to clonal AGR2-negative EV cell lines. The differences in 
secreted proteins between WT AGR2 clone 2 and EV clone 2 cells were therefore explored 
using LC-MS to investigate any changes that might explain these differences in cell 
behaviour (Table 5.3).   
 While the experiments involving the CM from WT AGR2 and EV pool cells in section 
5.2.2.2 could be normalised to fibronectin due to its equal expression between cell lines, 
the same was not true for WT AGR2 clone 2 cells and EV clone 2 cells, where EV clone 2 
cells secreted substantially more fibronectin that WT AGR2 clone 2 cells (Fig. 4.8). Thus, CM 
protein levels could not be normalised to fibronectin for these cell lines. Furthermore, due 
to the presence of significant amounts of transferrin in Opti-MEM medium, CM samples 
could not be normalised to protein concentration due to masking of actual secreted protein 
concentration by transferrin, although this is only a problem for clonal cell CM due to the 
lack of possible fibronectin normalisation. Similarly, normalising samples based on cell 
number, as reported in other studies [644, 645], were found to be poorly reproducible 
(Appendix 24). Therefore, normalisation for clonal CM samples in LC-MS experiments was 
achieved using the normalisation algorithm within the Progenesis software, which 
considers all peptides present within the sample to calculate a normalisation value (see 
Materials and Methods). However, WT AGR2 clone 2 cells have an average relative area 79 
% that of EV clone 2 cells (as measured by ImageJ), and because cultures were placed into 
serum-free medium for CM collection upon reaching 30-40 % confluence (see Materials and 
Methods), WT AGR2 clone 2 cells at this confluence will contain more cells than 30-40 % 
confluent EV clone 2 cells. Therefore, there could be a disproportionate abundance of 
secreted proteins in CM from the WT AGR2 clone 2 cells. However, to overcome this 
potential problem, the threshold for a meaningful difference in a secreted protein between 
the two cell lines was increased from 2-fold to a more conservative 3-fold change in protein 
abundance. Using this cut-off, there are still many differences in upregulated proteins 
observed between EV clone 2 and WT AGR2 clone 2 cells (Table 5.3).  
 Many differentially expressed proteins were identified in the comparative CMs of 
WT AGR2 and EV clonal cells. However, it is important to note that the observed decreases 
in histones H1.2, H2B, H3 and H4 in the CM of WT AGR2 clone 2 cells (Table 5.3), coupled 
with the fact that a number of the AGR2-downregulated proteins also belong to the 60S 
ribosomal family of cytoplasmic proteins, may suggest that some of these differences only 
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arise from a difference in the extent of cell lysis between EV clone 2 and WT AGR2 clone 2 
cells under serum-free conditions. The increased levels of extracellular LDHA found in the 
CM of EV clone 2 cells (3.82-fold increase relative to WT AGR2 clone 2, Table 5.3) also 
support this notion, and also suggests that WT AGR2 clone 2 cells are more resistant to cell 
lysis. However, without knowing the relative intracellular expression of LDHA between WT 
and EV cells (or indeed between any proteins identified in these secretomes), it is difficult 
to set a cutoff value for meaningful downregulation of proteins in the CM of these cell lines. 
Therefore, only actual extracellular proteins were considered in further analyses, as their 
presence in CM collected from Opti-MEM-incubated cells appears to represent actual 
secreted proteins, as described above. 
 It is interesting that the difference in the abundance of secreted AGR2 was lower 
between clonal cells than that observed with pooled cells (9.4 fold and 29.9 fold, 
respectively), despite very similar steady-state intracellular AGR2 levels between pooled 
and clonal WT AGR2 cells (see Chapter 3). This may indicate a general decrease in the 
secretory potential of elongated cells compared to cuboidal cells. Nevertheless, many more 
proteins were differentially secreted between clonal cells than were observed with pooled 
cells, probably reflecting the fundamental changes to cell morphology in WT AGR2 clonal 
cells. Of note, there was increased secretion of several proteases including ADAMTS2, 
ADAMTS8 and MMP19, but there was also a reduction in several other proteases, 
ADAMTS7, MMP3 and PRSS22 (Table 5.3). There was an upregulation of multiple collagen 
molecules, namely those of the collagen VI family but also members of the collagen I, II and 
VII families. At the same time, there was downregulation of several basement membrane 
proteins including agrin and laminins (LAMC2, LAMA3, LAMB3 and LAMA5), but also 
upregulation of LAMA4. There was downregulation of several members of the serpin family 
of protease inhibitors (serpin B2 (plasminogen activator inhibitor 2), B5 and B7), and also 
the SPINT1 protease inhibitor. However, there was also upregulation of serpin 1 
(plasminogen activator inhibitor 1) and serpin F1. 
 The axon guidance protein draxin [646] showed the largest increase in expression, 
with an increase of 770-fold in WT AGR2 clone 2 cells, suggesting that AGR2 may be 
involved in draxin secretion. Axon guidance proteins can act as both oncogenes and tumour 
suppressors, with both positive and negative effects on apoptosis, proliferation and 
adhesion (reviewed in [647]). The strong effect of AGR2 expression on axon guidance 
proteins, namely draxin, SLIT2 and members of the semaphorin family (SEMA3C, SEMA3D 
and SEMA3E) might suggest not only that AGR2 might regulate the secretion of these 
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proteins, but that regulating this class of molecules plays a role in AGR2-associated 
tumourigenesis. 
 The RT1-AW2 Class I histocompatibility antigen showed the greatest decrease in 
expression in WT AGR2 clone 2 cells, displaying a 200-fold reduction (Table 5.3). RT1-AW2 is 
thought to be involved in presenting antigens through the MHC class 1 pathway, based on 
its similarity to other RT1 proteins [648] but as a transmembrane protein, it is not clear 
whether the decrease in RT1-AW2 in the CM of WT AGR2 clone 2 cells necessarily reflects a 
change in protein expression or a decrease in a potential soluble form of the protein, as has 
been observed with at least one other histocompatibility-related transmembrane protein, 
MICA (major histocompatibility complex (MHC) class I–related chain A) [649]. The 
implications of reduced RT1-AW2 are unknown but could feasibly help to reduce 
unfavourable recognition of metastatic cells by immune cells. 
 Overall, these changes to the secretome of WT AGR2 clone 2 cells point to a cell 
type with altered adhesion and migration, a reduction in basement membrane proteins and 
an increase in abundance and activity of several extracellular proteases. These cells also 
appear to deposit more collagen molecules and may also undergo changes to bypass 
immune surveillance mechanisms. Together, the influences on these proteins provide 
information about how AGR2 might induce changes to cell adhesion metastasis, although 
further experimentation will be required to determine to what extent these changes in the 
secretome are directly caused by AGR2 and which are the result of a change in cell 
morphology, and how much they contribute to AGR2-associated tumourigenesis. Like 
differences in intracellular proteins, these changes will also have to be validated and direct 
links between differentially expressed proteins and influences on cell adhesion and 
metastasis will have to be explored. 
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 Table 5.3. Effects of AGR2 expression on the secretome of clonal Rama 37 cells 
Upregulated in AGR2-expressing cells 
UniProt 
Accession 
Description 
Fold change 
up 
Anova (p) 
Unique 
peptides 
D3ZDG4 Draxin 770.52 <0.01 3 
D3ZTE7 A disintegrin and metalloproteinase with thrombospondin motifs 2 (ADAMTS2) 151.30 <0.01 3 
P24594 Insulin-like growth factor-binding protein 5 (IGFBP5) 120.36 <0.01 12 
F1M7X3 Cadherin-13 (CDH13) 91.20 <0.01 3 
O08628 Procollagen C-endopeptidase enhancer 1 (PCOLCE) 84.62 <0.01 16 
D3ZUL3 Collagen alpha-1 (VI) chain (COL6A1) 79.86 <0.01 23 
F1LNH3 Collagen alpha-2 (VI) chain (COL6A2) 56.29 <0.01 18 
F1LS40 Collagen alpha-2 (I) chain (COL1A2) 47.73 <0.01 47 
D4AAT1 A disintegrin and metalloproteinase with thrombospondin motifs 8 (ADAMTS8) 39.91 <0.01 11 
P47853 Biglycan (BGN) 32.60 <0.01 12 
Q9ERB4 Versican core protein (VCAN) 30.68 <0.01 15 
Q01129 Decorin (DCN) 29.62 <0.01 4 
D3ZQM5 Fibrillin-1 (FBN1) 28.12 <0.01 30 
D3ZYI8 Secreted protein acidic and rich in cysteine (SPARC) 25.00 <0.01 10 
P02454 Collagen alpha-1 (I) chain (COL1A1) 24.88 <0.01 17 
F1LSW0 Serpin F1 24.09 <0.01 12 
D3ZE24 EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2) 23.60 <0.01 14 
P13941 Collagen alpha-1 (III) chain (COL3A1) 22.55 <0.01 15 
P12843 Insulin-like growth factor-binding protein 2 (IGFBP2) 19.64 <0.01 6 
Q8CHN8 Mannan-binding lectin serine protease 1 (MASP1) 16.84 <0.01 9 
Q06880 Neuroblastoma suppressor of tumorigenicity 1 (NBL1) 16.32 <0.01 2 
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B5DFC9 Nidogen-2 (NID2) 14.79 <0.01 23 
Q6IRK9 Carboxypeptidase Q (CPQ) 14.42 <0.01 3 
P15087 Carboxypeptidase E (CPE) 14.17 <0.01 6 
D3ZE04 Collagen alpha-1 (VII) chain (COL7A1) 13.63 <0.01 16 
G3V7F3 WNT1 inducible signaling pathway protein 2 (WISP2) 12.66 <0.01 2 
D4A115 Collagen alpha-3 (VI) chain (COL6A3) 12.58 <0.01 9 
Q9R0K8 Stanniocalcin-2 (STC2) 11.67 <0.01 2 
C0M4B0 Matrix metalloproteinase 19 (MMP19) 11.14 <0.01 6 
D3ZAE6 Vasorin (VASN) 10.08 <0.01 7 
Q63772 Growth arrest-specific protein 6 (GAS6) 10.03 <0.01 12 
D3ZIA7 Anterior gradient 2 (AGR2) 9.40 <0.01 1 
O70513 Galectin-3-binding protein (LGALS3BP) 9.30 <0.01 5 
P20961 Plasminogen activator inhibitor 1 (SERPINE1) 9.19 <0.01 22 
P03994 Hyaluronan and proteoglycan link protein 1 (HAPLN1) 9.11 <0.01 5 
Q6P7A4 Prosaposin (PSAP) 8.85 <0.01 2 
D4A9N1 HIPP-like protein-1 (HHIPL1) 7.66 <0.01 4 
G3V6K1 Transcobalamin 2 (TCN2) 7.46 <0.01 3 
F1LQC3 Collagen alpha-1 (XII) chain (COL12A1) 6.91 <0.01 41 
P17491 Inhibin beta B (INHBB) 6.85 <0.01 3 
P53813 Vitamin K-dependent protein S (PROS1) 6.63 <0.01 3 
G3V928 Prolow-density lipoprotein receptor-related protein 1 (LRP1) 6.44 <0.01 5 
G3V7Y9 Alpha-mannosidase 2 (MAN2A1) 6.07 <0.01 3 
F1LTJ5 Basement membrane-specific heparan sulfate proteoglycan core protein (HSPG2) 5.95 <0.01 15 
D3ZEU2 Laminin subunit alpha-4 (LAMA4) 5.83 <0.01 35 
D3ZPA9 Lysosomal protective protein (CTSA) 5.70 <0.01 4 
P43145 Adrenomedullin (ADM) 5.66 <0.01 4 
F1M6X4 Uncharacterized protein  5.65 <0.01 2 
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Q5RJL6 Meteorin-like protein (METRNL) 5.19 <0.01 5 
G3V9N9 Mannosidase 1, alpha (MAN1A1) 5.12 <0.01 2 
F1LTE5 Neural cell adhesion molecule 1 (NCAM1) 4.88 <0.01 13 
D3ZHA1 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase (B3GNT1) 4.57 <0.01 6 
P13852 Major prion protein (PRNP) 4.22 <0.01 3 
Q01460 Di-N-acetylchitobiase(CTBS) 4.12 <0.01 3 
Q63691 Monocyte differentiation antigen CD14 (CD14) 3.79 <0.01 3 
F1LML8 N-acetylglucosamine-1-phosphotransferase subunit gamma (GNPTG) 3.58 <0.01 3 
F1LWQ3 Follistatin-related protein 1 (FSTL1) 3.39 <0.01 16 
P01346 Insulin-like growth factor II (IGF2) 3.39 <0.01 2 
D4A2G6 Thrombospondin 2 (THBS2) 3.20 <0.01 10 
Q6AYE5 Out at first protein homolog (OAF) 3.01 <0.01 4 
F1M879 Platelet-derived growth factor subunit A (PDGFA) 2.82 <0.01 5 
G3V6B1 Transforming growth factor beta-2 (TGFB2) 2.74 <0.01 4 
P35053 Glypican-1 (GPC1) 2.69 <0.01 9 
F1M7L7 Latent-transforming growth factor beta-binding protein 2 (LTBP2) 2.65 <0.01 25 
P30121 Metalloproteinase inhibitor 2 (TIMP2) 2.64 <0.01 12 
P07154 Cathepsin L1 (CTSL1) 2.58 <0.01 12 
Q5RJR9 Serine (Or cysteine) proteinase inhibitor, clade H, member 1 (SERPINH1) 2.55 <0.01 5 
G3V6X1 Fibulin 2 (FBLN2) 2.53 <0.01 27 
F1LRG5 Galectin-1 (LGALS1) 2.52 <0.01 8 
F1MAG8 Semaphorin 3D (SEMA3D) 2.50 <0.01 14 
G3V901 Exostosin-1 (EXT1) 2.45 <0.01 3 
F1MA79 Slit homolog 2 (SLIT2) 2.43 0.01 4 
D3Z8H1 Thrombospondin-3 (THBS3) 2.41 <0.01 2 
G3V8L3 Lamin A (LMNA) 2.39 <0.01 15 
E9PTT2 Exostosin-2 (EXT2) 2.34 <0.01 7 
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P31000 Vimentin (VIM) 2.28 0.01 21 
P85972 Vinculin (VCL) 2.26 <0.01 11 
F1LN51 Tetraspanin-7 (TSPAN7) 2.24 <0.01 2 
F1LMA7 C-type mannose receptor 2 (MRC2) 2.24 <0.01 17 
P63090 Pleiotrophin (PTN) 2.17 0.02 5 
F1M766 Uncharacterized protein 2.16 <0.01 2 
G3V6S3 Calumenin (CALU) 2.11 <0.01 4 
Q9JI92 Syntenin-1 (SDCBP) 2.07 0.02 2 
F1M9B2 Insulin-like growth factor-binding protein 7 (IGFBP7) 2.06 <0.01 15 
F1M335 Peroxidasin (PXDN) 2.04 <0.01 28 
D3ZP79 Amyloid beta A4 protein C99 (APP) 2.01 <0.01 17 
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 Table 5.3 (cont). Effects of AGR2 expression on the secretome of clonal Rama37 cells 
Downregulated in AGR2-expressing cells 
UniProt 
Accession 
Description 
Fold 
change 
down 
Anova 
(p) 
Unique 
peptides 
P15978 Class I histocompatibility antigen, Non-RT1.A alpha-1 chain (RT1-AW2) 202.32 <0.01 2 
D3ZAX4 Tumor necrosis factor receptor superfamily member 27 (EDA2R) 59.94 <0.01 2 
D4AAE4 Protease, serine, 22 (PRSS22) 36.87 <0.01 14 
Q9WU74 Lipolysis-stimulated lipoprotein receptor (LSR) 34.48 <0.01 9 
Q4V8Q2 Kunitz-type protease inhibitor 1 (SPINT1) 32.87 <0.01 3 
P21674 Follistatin (FST) 32.53 <0.01 17 
P15865 Histone H1.2 (HIST1H1C) 30.39 <0.01 2 
F1M199 Agrin (AGRN) 28.97 <0.01 20 
D4A9V5 Lysyl oxidase-like 4 (LOXL4) 28.48 <0.01 5 
B0BMY8 Histone H3 (H3F3B) 26.46 <0.01 3 
G3V6C1 Serpin B5 24.28 <0.01 3 
O55162 Ly6/PLAUR domain-containing protein 3 (LYPD3) 22.16 <0.01 2 
D4A499 Phospholipase A2 inhibitor and Ly6/PLAUR domain-containing protein (PINLYP) 19.17 <0.01 3 
F1LNW5 Beta-nerve growth factor (NGF) 17.08 <0.01 6 
F1LRH4 Laminin subunit gamma-2 (LAMC2) 16.39 <0.01 28 
P08721 Osteopontin (SPP1) 16.38 <0.01 16 
P97523 Hepatocyte growth factor receptor (MET) 16.18 <0.01 5 
F1LQP8 Cadherin-6 (CDH6) 15.06 <0.01 3 
P62804 Histone H4 (HIST1H4B) 13.06 <0.01 4 
F1LS18 Histone H2B (HIST1H2BL) 13.02 <0.01 4 
G3V8P4 Receptor-type tyrosine-protein phosphatase F (PTPRF) 12.37 <0.01 2 
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F8WFK8 Cadherin-related family member 1 (CDHR1) 10.51 <0.01 14 
D3ZN05 Laminin subunit alpha-3 (LAMA3)  10.34 <0.01 39 
Q6P3V9 60S ribosomal protein L4 (RPL4) 9.48 <0.01 3 
G3V667 Integrin, alpha 6 (ITGA6) 9.45 <0.01 2 
D3ZI60 Protein RGD1561984 9.41 <0.01 2 
D3Z8E2 Semaphorin 3E (SEMA3E) 9.25 <0.01 9 
F1MAN8 Laminin subunit alpha-5 (LAMA5) 9.15 <0.01 53 
F1LQI2 Roundabout homolog 1 (ROBO1) 8.99 <0.01 2 
Q6PDV7 60S ribosomal protein L10 (RPL10) 8.75 <0.01 3 
D4A8R6 Cytosolic acyl coenzyme A thioester hydrolase (ACOT7) 8.61 <0.01 4 
Q6P686 Osteoclast-stimulating factor 1 (OSTF1) 7.82 <0.01 2 
G3V6B5 Serpin B7 7.40 <0.01 17 
F1LQ82 E3 ubiquitin-protein ligase (NEDD4) 7.35 <0.01 2 
G3V9W9 Protocadherin Fat 1 (FAT1) 7.34 <0.01 56 
Q3KR76 Plasminogen activator, urokinase (PLAU) 7.13 <0.01 13 
D3ZJR7 Desmocollin-2 (DSC2) 7.07 <0.01 9 
G3V7I9 Furin 6.89 <0.01 2 
F1LPL4 Receptor-type tyrosine-protein phosphatase kappa (PTPRK) 6.53 <0.01 9 
Q4V8H5 Aspartyl aminopeptidase (DNPEP) 6.44 <0.01 4 
Q5BJ93 Enolase 1, alpha (ENO1) 6.18 <0.01 15 
F1LPI5 Laminin subunit beta-3 (LAMB3) 6.07 <0.01 22 
Q9WVH8 Fibulin-5 (FBLN5) 6.06 <0.01 5 
P07150 Annexin A1 (ANXA1) 6.04 <0.01 8 
Q642A6 von Willebrand factor A domain-containing protein 1 (VWA1) 5.62 <0.01 3 
F1LS07 C-X-C motif chemokine 12 (CXCL12) 5.59 <0.01 2 
P29524 Plasminogen activator inhibitor 2 type A (SERPINB2) 5.56 <0.01 3 
P84100 60S ribosomal protein L19 (RPL19) 5.51 <0.01 2 
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F1LSD3 Integrin beta (ITGB4) 5.47 <0.01 8 
Q5RKH2 Galactokinase 1 (GALK1) 5.25 <0.01 2 
D3ZVF0 Calpain-3 (NCL) 5.25 <0.01 5 
F8WG74 Peptidyl-prolyl cis-trans isomerase FKBP4, N-terminally processed (FKBP4) 5.22 <0.01 2 
D3ZRM9 60S ribosomal protein L13 (RPL13) 5.04 <0.01 3 
P83732 60S ribosomal protein L24 (RPL24) 5.03 <0.01 3 
P62832 60S ribosomal protein L23 (RPL23) 4.92 <0.01 2 
F1LML0 Asparagine--tRNA ligase, cytoplasmic (NARS) 4.79 <0.01 2 
Q7M0E3 Destrin (DSTN) 4.79 <0.01 7 
F1LRR7 Suppressor of tumorigenicity 14 protein (ST14) 4.74 <0.01 13 
D3ZCG9 Integrin alpha 3 variant A (ITGA3) 4.68 <0.01 9 
Q5XIF6 Tubulin alpha-4A chain (TUBA4A) 4.68 <0.01 3 
D3ZYS7 Ras GTPase-activating protein-binding protein 1 (G3BP1) 4.66 <0.01 2 
G3V826 Transketolase (TKT) 4.63 <0.01 17 
B0K031 60S ribosomal protein L7 (RPL7) 4.52 <0.01 3 
P85968 6-phosphogluconate dehydrogenase, decarboxylating (PGD) 4.38 <0.01 4 
G3V786 Aldose reductase-related protein 2 (AKR1B3) 4.33 <0.01 4 
P49134 Integrin beta-1 (ITGB1) 4.27 <0.01 9 
G3V6A4 Heterogeneous nuclear ribonucleoprotein D (HNRPD) 4.16 0.01 2 
P03957 Stromelysin-1 (MMP3) 4.04 <0.01 10 
F1LV50 Collagen and calcium-binding EGF domain-containing protein 1 (CCBE1) 3.87 <0.01 3 
F1M6X1 Vascular endothelial growth factor A (VEGFA) 3.84 <0.01 3 
B5DEN4 L-lactate dehydrogenase (LDHA) 3.82 <0.01 10 
D3ZRR8 Semaphorin 3C (SEMA3C) 3.81 <0.01 10 
Q9WUQ1 A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) 3.81 <0.01 3 
P05369 Farnesyl pyrophosphate synthase (FDPS) 3.80 <0.01 7 
P05065 Fructose-bisphosphate aldolase A (ALDOA) 3.72 <0.01 19 
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Q63083 Nucleobindin-1 (NUCB1) 3.71 <0.01 34 
F1LSW7 60S ribosomal protein L14 RPL14) 3.65 <0.01 3 
B2RYX0 Nascent polypeptide-associated complex subunit alpha, muscle-specific form (NACA) 3.59 0.01 3 
F1LM41 Major vault protein (MVP) 3.57 0.02 2 
P34058 Heat shock protein HSP 90-beta (HSP90AB1) 3.56 <0.01 11 
Q6P502 T-complex protein 1 subunit gamma (CCT3) 3.55 <0.01 3 
P48500 Triosephosphate isomerase (TPI1) 3.52 <0.01 8 
Q66HL2 Cortactin (CTTN) 3.52 <0.01 3 
P04797 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 3.52 0.01 6 
Q8VHC1 Cystatin E/M (CST6) 3.49 <0.01 9 
D3ZH86 Uncharacterized protein 3.43 <0.01 2 
P16617 Phosphoglycerate kinase 1 (PGK1) 3.43 <0.01 12 
D4AC23 T-complex protein 1 subunit eta (CCT7) 3.43 0.02 2 
Q4FZY0 EF-hand domain-containing protein D2 (EFHD2) 3.42 <0.01 4 
D4AA31 Lysosomal Pro-X carboxypeptidase (PRCP) 3.37 <0.01 5 
Q6AYD3 Proliferation-associated 2G4 (PA2G4) 3.34 <0.01 3 
Q9ERA7 Mesothelin (MSLN) 3.31 <0.01 10 
D3ZTR7 N-acetyllactosaminide alpha-1,3-galactosyltransferase (GGTA1) 3.28 <0.01 2 
P97603 Neogenin (NEO1) 3.27 <0.01 7 
F1LST1 Fibronectin (FN1) 3.26 <0.01 4 
Q6P6V0 Glucose-6-phosphate isomerase (GPI) 3.26 <0.01 2 
Q9R1E9 Connective tissue growth factor (CTGF) 3.25 <0.01 21 
Q6AXS5 Plasminogen activator inhibitor 1 RNA-binding protein (SERBP1) 3.23 0.01 2 
F1LRD5 Isocitrate dehydrogenase [NADP] (IDH1) 3.23 <0.01 2 
P08699 Galectin-3 (LGALS3) 3.23 <0.01 2 
P62634 Cellular nucleic acid-binding protein (CNBP) 3.22 <0.01 2 
P05197 Elongation factor 2 (EEF2) 3.21 <0.01 15 
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P13084 Nucleophosmin (NPM1) 3.18 <0.01 3 
P21531 60S ribosomal protein L3 (RPL3) 3.17 <0.01 2 
Q9EPH8 Polyadenylate-binding protein 1 (PABPC1) 3.10 <0.01 4 
F1M390 Ezrin (EZR) 3.09 <0.01 14 
P63039 60 kDa heat shock protein, mitochondrial (HSPD1) 3.09 <0.01 6 
F1M798 Bone morphogenetic protein 1 (BMP1) 3.07 <0.01 20 
F1LWC2 Uncharacterized protein 3.06 <0.01 4 
F1LQS3 60S ribosomal protein L6 (RPL6) 3.06 <0.01 6 
Q3MHS9 Chaperonin containing Tcp1, subunit 6A (Zeta 1) (CCT6A) 3.06 0.01 3 
F1LYX9 Desmoglein-2 (DSG2) 3.05 <0.01 4 
Q6P3V8 Eukaryotic translation initiation factor 4A1 (EIF4A1) 3.04 0.01 3 
D3ZS68 Poly(rC)-binding protein 1 (PCBP1) 3.03 0.01 2 
Q1EHB3 A disintegrin and metalloproteinase with thrombospondin motifs 7 (ADAMTS7) 3.03 <0.01 14 
G3V7C6 Tubulin beta-4B chain (TUBB2C) 3.00 <0.01 2 
P28480 T-complex protein 1 subunit alpha (TCP1) 2.98 0.01 4 
Q68FR6 Elongation factor 1-gamma (EEF1G) 2.95 <0.01 4 
P19945 60S acidic ribosomal protein P0 (RPLP0) 2.95 0.01 2 
P12001 60S ribosomal protein L18 (RPL18) 2.92 <0.01 5 
D3ZC88 Elongation factor 1-alpha (EF1A) 2.89 0.01 7 
P11030 Acyl-CoA-binding protein (DBI) 2.87 <0.01 2 
Q99MZ8 LIM and SH3 domain protein 1 (LASP1) 2.85 <0.01 3 
Q6AYQ9 Peptidyl-prolyl cis-trans isomerase (PPIC) 2.82 <0.01 3 
B2GV92 Prostaglandin E synthase 3 (PTGES3) 2.81 0.03 2 
D3ZEI0 Protein LOC690096 2.79 <0.01 3 
F1MAC8 Pyruvate kinase (PKM2) 2.75 <0.01 2 
F1LQS4 ATP-citrate synthase (ACLY) 2.73 0.03 3 
Q9R0C5 N-acetylgalactosaminyltransferase 7 (GALNT7) 2.68 <0.01 4 
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G3V8R1 Nucleobindin 2 (NUCB2) 2.66 <0.01 8 
P11980 Pyruvate kinase isozymes M1/M2 (PKM2) 2.63 0.01 5 
P51635 Alcohol dehydrogenase [NADP(+)] (AKR1A1) 2.61 0.02 2 
D4AE41 RNA binding motif protein, X-linked-like-1 (RBMXL1) 2.60 0.02 2 
D4ACJ7 Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) 2.59 0.01 4 
E9PTS0 Heterogeneous nuclear ribonucleoprotein A/B (HNRNPAB) 2.58 <0.01 4 
F2Z3S4 60S ribosomal protein L11 (RPL11) 2.57 0.01 2 
Q794E4 Heterogeneous nuclear ribonucleoprotein F (HNRNPF) 2.57 0.01 2 
P82995 Heat shock protein HSP 90-alpha (HSP90AA1) 2.52 <0.01 7 
D3ZTK5 60S ribosomal protein L27 (RPL27) 2.51 <0.01 2 
Q6TUG0 DnaJ homolog subfamily B member 11 (DNAJB11) 2.51 <0.01 3 
Q9JLZ1 Glutaredoxin-3 (GLRX3) 2.50 0.03 3 
P25113 Phosphoglycerate mutase 1 (PGAM1) 2.50 0.01 5 
P26772 10 kDa heat shock protein, mitochondrial (HSPE1) 2.49 <0.01 3 
F1LM73 Netrin receptor UNC5C (UNC5C) 2.45 <0.01 3 
Q3T1J1 Eukaryotic translation initiation factor 5A-1 (EIF5A) 2.44 0.05 2 
F1LT35 Protein RGD1564606 2.41 <0.01 3 
Q4G097 Cyclic AMP-dependent transcription factor ATF-6 beta (ATF6B) 2.37 <0.01 3 
D4ABT3 Protein CDV3 homolog (CDV3) 2.36 <0.01 3 
F1LRX5 Spectrin beta chain, non-erythrocytic 1 (SPTBN1) 2.34 0.04 2 
F1LSS8 Neuropilin-2 (NRP2) 2.28 <0.01 16 
F1MAP4 Multiple epidermal growth factor-like domains protein 10 (MEGF10) 2.28 0.02 3 
D3ZC07 Serine/threonine-protein kinase N3 (PKN3) 2.25 <0.01 2 
D3ZD13 Filamin-B (FLNB) 2.25 0.02 3 
Q63610 Tropomyosin alpha-3 chain (TPM3) 2.23 <0.01 2 
P07943 Aldose reductase (AKR1B1) 2.23 0.02 3 
P69897 Tubulin beta-5 chain (TUBB5) 2.22 0.03 3 
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G3V836 Clusterin (CLU) 2.21 <0.01 11 
Q7TPB1 T-complex protein 1 subunit delta (CCT4) 2.21 <0.01 2 
F1LRV4 Heat shock 70 kDa protein 4 (HSPA4) 2.21 0.02 8 
P63245 Guanine nucleotide-binding protein subunit beta-2-like 1 (GNB2L1) 2.21 0.02 5 
P63018 Heat shock cognate 71 kDa protein (HSPA8) 2.21 <0.01 11 
F1LP72 Elongation factor 1-delta (EEF1D) 2.20 0.04 5 
D3ZPJ7 Clathrin light chain A (CLTA) 2.20 <0.01 2 
O35814 Stress-induced-phosphoprotein 1 (STIP1) 2.20 0.01 12 
A7VJC2 Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) 2.18 <0.01 6 
D3ZW98 Thioredoxin-like protein 1 (TXNL1) 2.17 0.01 3 
P62859 40S ribosomal protein S28 (RPS28) 2.12 <0.01 3 
P07151 Beta-2-microglobulin (B2M) 2.11 <0.01 4 
Q642B0 Glypican 4 (GPC4) 2.04 <0.01 12 
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5.2.4 Molecular characterisation of secreted AGR2 
 
 AGR2 was identified in the CM of WT AGR2-expressing cells in the experiments 
outlined above, and a number of studies have also reported secretion of AGR2 [301, 388, 
426, 440]. Potential evidence that secretion of AGR2 may be of functional importance has 
been demonstrated in part through a proteomic screen using a ∆KTEL AGR2 mutant, which 
is highly secreted [438]. Here it was found that ∆KTEL AGR2 appears to have pro-
proliferative effects as well as potentially promoting protein synthesis and secretion, but 
whether this has any relevance to WT AGR2 is uncertain. In addition, one study found that 
AGR2-containing CM from AGR2-expressing pancreatic cancer cells could promote 
proliferation of non-expressing cells, a feature that was lost upon AGR2 silencing [440]. 
However, whether this relates directly to extracellular AGR2 is also not clear. The question 
still remains however, of whether appearance of AGR2 in the extracellular space is an active 
process or simply the result of accumulation of intracellular AGR2 from dead and dying 
cells.  To address this question, a stable Rama 37 cell line expressing the same mutant 
∆KTEL AGR2  mentioned above (∆KTEL clone 8), previously  created for the present studies 
to explore the effects of AGR2 localisation on its function (Chapter 3), was used to explore 
the characteristics of secreted ∆KTEL AGR2. 
 
 
5.2.4.1 Secreted AGR2 has a higher molecular mass than intracellular AGR2 
 
 In Chapter 3, stable cell lines expressing a highly secreted form of AGR2 (∆KTEL 
AGR2) were constructed in order to investigate the effects of AGR2 secretion on its 
function. Very little intracellular ∆KTEL AGR2 protein could be detected in these cells, so to 
examine whether this was a result of increased secretion of the ∆KTEL mutant of AGR2, the 
level of intracellular and secreted AGR2 was compared between WT AGR2 clone 2 cells and 
∆KTEL AGR2 clone 8 cells (Fig. 3.9). Interestingly, when directly comparing secreted and 
intracellular AGR2, the secreted protein band was 2-3 kDa larger than the intracellular 
protein band (Fig. 5.4). This small increase in mass suggests that secreted ∆KTEL AGR2 
undergoes some post-translational modification (PTM). 
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5.2.4.2 Higher molecular weight AGR2 is also secreted under non-serum starved 
conditions 
 
 For reasons outlined in section 5.2.2.1, the detection of proteins of interest in 
conditioned medium requires incubation of cells in serum-free medium. To ensure that the 
shift in AGR2 mass observed in secreted protein was not a consequence of incubation of 
cells in serum-free medium, AGR2 was immunoprecipitated from the CM of WT AGR2 clone 
2 cells and ∆KTEL clone 8 cells collected in normal, fully supplemented growth medium 
(Fig.5.5). 
 
 
 
 
 
Figure 5.4. Extracellular AGR2 has an apparent higher molecular mass than 
intracellular AGR2. Whole cell lysate from WT AGR2 clone 2 cells and CM from ∆KTEL 
AGR2 clone 8 cells were collected and probed for the presence of AGR2 by Western 
blot.  
Figure 5.5. Higher molecular weight AGR2 is not necessarily induced by serum-
starvation. Conditioned medium was collected from WT AGR2 clone 2 cells and 
∆KTEL clone 8 cells in fully supplemented growth medium. Secreted AGR2 was 
immunoprecipitated and compared to higher molecular weight secreted AGR2 from 
CM of ∆KTEL clone 8 cells in serum-free medium.  
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 Extracellular AGR2 immunoprecipitated from ∆KTEL clone 8 CM had the same mass 
as AGR2 seen in concentrated ∆KTEL 8 CM collected in serum-free medium, indicating that 
the increase in mass of AGR2 was not caused by the use of serum-free medium. There was 
no detectable extracellular AGR2 immunoprecipitated from WT AGR2 clone 2 cells, but this 
may be the result of relatively low levels of secreted AGR2 from these cells (Table 5.3). The 
abundance of extracellular/secreted AGR2 from ∆KTEL clone 8 cells makes this cell line an 
ideal tool for investigating the nature of the modification to AGR2. 
 
 
5.2.4.3 Determination of post translational modifications in secreted AGR2 
 
 The small increase in molecular mass observed with the secreted ∆KTEL AGR2 
mutant suggested that it had undergone some post-translational modification (PTM). A 
bioinformatics-based study of all proteins within the Swiss-prot database found that the 
two most commonly predicted PTMs (based on prediction by similarity in the Swiss-prot 
database) were N-linked glycosylation (O-glycosylation being the 8th most common) 
followed by phosphorylation. For experimentally validated PTMs, phosphorylation was the 
most common, followed by acetylation and then N-linked glycosylation, with O-linked 
glycosylation the seventh most common [650]. It is well known that most secreted proteins 
are glycosylated [651], and phosphorylation of secreted proteins, which can be mediated 
through secreted kinases [652] is known to occur [653, 654]. Acetylation of secreted 
proteins is relatively rare [655], therefore, it was reasoned that the most likely cause of the 
shift in mass of secreted AGR2 was either glycosylation or phosphorylation. 
 Using several PTM prediction tools, the likelihood of these PTMs in AGR2 was 
assessed. As expected, there were no acetylation sites predicted for AGR2 [656], but 
several potential phosphorylation sites were identified, along with several O-linked (but not 
N-linked) glycosylation sites (Appendix 25 and 26). This prediction data pointed to the shift 
in mass most likely being caused by a phosphorylation or O-linked glycosylation event. 
 To test this hypothesis, CM from ∆KTEL clone 8 cells was collected and treated with 
λ-phosphatase (λPPase) to remove any phosphate groups attached to secreted AGR2 (Fig. 
5.6). In order to ensure that λPPase was active in the concentrated CM, the samples were 
spiked with the multi-phosphorylated protein Mps1 (monopolar spindle 1) and a decrease 
in its mass monitored as an indication of active λPPase. 
 
Chapter 5  Results 
180 
 
 
 
 
 
 
 
 
 
 
 
 
 Treatment with λPPase had no effect on the molecular mass of the secreted AGR2 
band. There was a decrease of approximately 10 kDa in the molecular mass of the 
exogenously added Mps1 protein with λPPase treatment, consistent with previous reports 
of the change in Mps1 molecular mass following dephosphorylation [657]. This suggests 
that λPPase enzyme was active in the concentrated CM and suggests that the shift in mass 
for secreted AGR2 is not caused by phosphorylation.  
 The possibility of AGR2 glycosylation was subsequently investigated, initially 
through the use of periodic acid-Schiff (PAS) staining. Intracellular and secreted AGR2 was 
immunoprecipitated from WT AGR2 pool cell lysate and concentrated KTEL clone 8 CM, 
respectively. The immunoprecipitated proteins were then run on an SDS-PAGE gel and 
subject to PAS staining (Fig. 5.7). Recombinant AGR2 from E. coli and culture medium 
containing large amounts of the glycosylated protein transferrin were used as negative and 
positive controls, respectively. 
Figure 5.6.  Secreted AGR2 is not phosphorylated. Conditioned medium (CM) from 
∆KTEL AGR2 clone 8 cells (containing secreted AGR2) was concentrated by centrifugal 
filter and treated with λ-phosphatase (λPPase) to dephosphorylate any 
phosphorylated proteins. To ensure the concentrated CM did not inhibit λPPase 
activity, the phoshoprotein Mps1 (molecular weight: 97 kDa unphnosphorylated) was 
added to CM to monitor λPPase activity. A weak lower molecular weight Mps1 band 
can be observed in the λPPase-positive lane, indicating that the enzyme remains 
active in concentrated CM. A Western blot was performed on the same samples but 
loaded in different wells to the Coomassie-stained wells, and for this reason the 
Western blot lanes and gel lanes do not completely align. 
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 Strong Schiff staining was seen for transferrin from CM (Fig. 5.7A), as well as for the 
IgG heavy chain in both immunoprecipitated lanes (approx. 50 kDa) resulting from their 
glycosylation. Secreted AGR2 but not intracellular AGR2 was stained in the PAS reaction, 
suggesting that secreted AGR2 is indeed glycosylated, although it is possible that the lower 
amount of intracellular AGR2 present in the gel (Fig. 5.7B) may fall below the detection limit 
of the Schiff stain. Also, the small amount of Schiff-positive recombinant AGR2 is surprising, 
but recent reports indicate that E. coli-derived proteins can be O-glycosylated [658], and 
thus the weak staining here may represent some glycosylation of recombinant AGR2.  
 To provide stronger evidence for the glycosylation of secreted AGR2, lysate from 
WT AGR2 pool cells and concentrated ∆KTEL clone 8 CM were subjected to enzymatic 
deglycosylation using a commercially available kit (New England Biolabs). Intracellular AGR2 
was unaffected by treatment with the deglycosylation mix, but secreted AGR2 was shifted 
back down to the mass of intracellular protein, confirming that the protein is glycosylated 
(Fig. 5.8A). However, as the deglycosylation mix contains glycosidases for both N- and O-
Figure 5.7.  Secreted AGR2 contains glycan chains. Intracellular and secreted AGR2 
were immunoprecipitated from WT AGR2 pool cell lysate and ∆KTEL clone 8 
conditioned medium (CM), respectively. Proteins were then run on an SDS-PAGE gel 
and (A) stained for the presence of glycoproteins using the periodic acid-Schiff stain 
method (see Materials and Methods) or (B) counterstained with Coomassie stain to 
show all proteins. 
B A 
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linked glycans, this data only provided evidence for the presence of glycosylation, rather 
than N- or O-linked glycosylation specifically.  
To try to determine whether the AGR2 was N- or O-glycosylated (or indeed both), 
secreted AGR2 was treated with PNGase F, an N-glycan-specific endoglycosidase that 
cleaves off the entire N-linked glycan at the Asp-GlcNAc linkage [659]. Once again, to 
ensure the concentrated ∆KTEL clone 8 CM did not interfere with PNGase F activity, its 
ability to remove N-glycans from spiked α-acid glycoprotein (α-AG) was tested (Fig. 5.8B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8.  Secreted AGR2 contains O-linked but not N-linked glycan chains. (A) 
Intracellular AGR2 from WT AGR2 pool cell lysate and secreted AGR2 from 
conditioned medium (CM) from ∆KTEL AGR2 clone 8 cells were subjected to 
enzymatic deglycosylation using a commercial kit containing PNGase F, O-
glycosidase, neuraminidase, β1-4 galactosidase and β-N-acetylglucosaminidase. The 
activities of the enzymes appeared to be unaffected by either lysis buffer or 
concentrated CM as the deglycosylation of fetuin in these buffers was unaffected 
(Appendix 27). (B) CM from ∆KTEL AGR2 clone 8 cells was subjected to PNGase F 
treatment. To ensure concentrated CM did not inhibit PNGase F, the N-glycosylated 
protein α-acid glycoprotein (α-AG) was added to concentrated CM to monitor 
PNGase activity. α-AG was deglysosylated in concentrated CM (as was transferrin), 
indicating that the enzyme remains active in concentrated CM.  
B 
A 
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 Treatment with PNGase F produced no change in the mass of secreted AGR2, but 
the enzyme was active in the concentrated CM as it was able to deglycosylate both α-acid 
glycoprotein and transferrin. Together, this presents strong evidence that AGR2 is not N-
glycosylated, but suggests instead that it is O-glycosylated upon its secretion from the cell. 
 
 
5.2.4.4 Glycosylated AGR2 appears to be produced from only healthy cells 
 
 To find out whether glycosylation of AGR2 also occurred in human cells that 
naturally overexpress AGR2, the CM was collected from the MCF7A breast cancer cell line. 
MCF7A cells are particularly susceptible to cell death and lysis upon serum-starvation 
(personal observation), so this presented an opportunity to test whether AGR2 was indeed 
secreted in a relatively active process, rather than being released as a result of cell lysis. CM 
from MCF7A cells in increasingly nutrient-poor media were collected and probed for AGR2 
(Fig. 5.9). 
 
 
 
 
 
 
 
 
 The extent of cell lysis was monitored by the appearance of LDHA in the CM. As 
expected, MCF7A cells appeared to be quite susceptible to cell death upon serum 
starvation, as demonstrated by the large amount of LDHA found in CM from DMEM-
incubated cells (+ and – non-essential amino acids (NEAA)) and also from Opti-MEM-
incubated cell without NEAA. There was, however, very little LDHA release from Opti-MEM 
Figure 5.9.  Glycosylated AGR2 is not released from lysed cells. MCF7A cells were 
incubated in the indicated serum-free media for 24 h. Conditioned medium (CM) was 
collected, precipitated and probed for the presence of AGR2 by Western blot. The 
levels of LDHA in these CM were used as a measure of the extent of cell lysis under 
each serum-free condition.  NEAA: non essential amino acids. 
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+ NEAA-incubated cells, indicating a much lower level of cell lysis in this medium and thus a 
higher proportion of live cells. This suggests that these cells are very dependent on both 
exogenous amino acids and growth factors for survival. 
 AGR2 was present in the CM from cells under all four test conditions. The amount 
of extracellular AGR2 was approximately equal under all conditions except for Opti-MEM + 
NEAA-incubated cells, where there was substantially less protein but importantly, the 
protein showed the characteristic upward shift in mass associated with glycosylation.   
Coupled with the very low amounts of LDHA released from these cells, the presence of 
glycosylated AGR2 here suggests that the protein is only glycosylated and secreted from 
live cells. Likewise, as MCF7A cells produce large amounts of AGR2 [309], the high levels of 
LDHA and lower mass AGR2 in CM from the DMEM- and Opti-MEM with no NEAA-
incubated cells suggests that at least some of this AGR2 has been released as a result of cell 
lysis.  
 
 
5.2.5 AGR2 is not a cell surface-resident protein 
 
 A number of ER chaperone proteins are known to localise to the cell surface under 
certain conditions, including GRP78 [447, 660] and calreticulin [661] during tumourigenesis, 
and PDI during platelet activation and coagulation [446, 662]. Therefore, having established 
that AGR2 can also be secreted, the binding of AGR2 to the cell surface was investigated. 
 Three staining methods were compared for their ability to stain specifically for 
surface proteins. Paraformaldehyde (PFA) fixation with Triton X-100 permeabilisation was 
used as a control for intracellular protein staining, while PFA fixation without 
permeabilising and ‘live cell IF’ [520] were used to assess surface staining. The cell surface 
protein CD44 was used as a positive control for surface staining, as the antibody used 
recognised an extracellular epitope of the protein. Likewise, the cytoplasmic protein, MEK1, 
was used as a monitor of cell permeabilisation, as non-permeabilised cells should not stain 
for MEK1.  
 Permeabilised cells stained for AGR2, MEK1 and CD44 as expected (Fig. 5.10A and 
B). In non-permeabilised cells, the staining pattern of AGR2 was more punctuate and less 
uniform than in permeabilised cells, but these non-permeabilised cells also stained for 
MEK1 to the same extent as permeabilised cells. This suggests that the membrane integrity 
of these cells has been compromised and that they are in fact permeabilised, and so the 
AGR2 staining seen with these cells could be intracellular protein. However, cells stained 
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using the live-cell IF technique stained positively for the cell surface marker CD44 but were 
negative for both MEK1 and AGR2. This indicates that the cells remained impermeable to 
antibody and that the staining observed is in fact cell surface protein. Furthermore, the 
data indicate that AGR2 is not detectably resident on the cell surface and so any 
interactions with cell surface molecules are likely to be at least only transient events. 
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5.3 Discussion 
 
5.3.1 AGR2-induced changes to the cell proteome 
 
 It has been shown here that AGR2 does not appear to have a strong effect on the 
abundance of cellular proteins, at least in a pooled population of cells. This is perhaps not 
unexpected, given the ER-localisation of AGR2 and the largely extracellular (or at least post-
ER) nature of its substrates reported to date, including mucins and AREG [301, 408, 412, 
418, 427, 506], and the lysosomal proteases cathepsins B and D [437]. Of course, there may 
be influences on signalling pathways through PTMs induced by AGR2, as previously shown 
with the AGR2-dependent de-phosphorylation of the Hippo pathway co-activator YAP-1 
[506], but this is a question for a separate study. 
 The changes to the intracellular proteome therefore most likely reflect indirect 
changes induced by AGR2, rather than direct regulation of particular substrate molecules. 
As mentioned above, the downregulation of CRABP1 and glypican-4 in WT AGR2 pool cells 
have been reported to promote cell dedifferentiation and migration, through influences on 
retinoic acid and the Wnt pathway, respectively [626, 629]. The change in level also 
observed in the extracellular signalling protein WISP2 (Wnt-inducible secreted protein 2), a 
Wnt activator [663], in AGR2-expressing cells (Table 5.3) may point to a link between  AGR2 
and Wnt signalling, at least in Rama 37 cells. 
 The effects of AGR2 on secreted proteins were much more substantial, particularly 
in the context of clonal cells. It is possible that many of the downregulated proteins in WT 
AGR2 clonal cells relative to EV clonal cells simply relates to differences in levels of cell lysis 
between these cell types. This may account, in part, for the differences in the sets of 
proteins that are differentially expressed between WT AGR2 clonal and pooled cells. 
Additionally, the differences in cell morphologies between clonal cells also likely have 
fundamental effects on the cell secretome, given that EMT-like transformations encompass 
a strong element of altered transcription (reviewed in [210]) and thus would be expected to 
have more a more fundamental effect on the proteome than the presumably post-
translational chaperone activity of AGR2.  There were, however, some similarities in the 
classes of proteins differentially regulated in WT AGR2 clonal and pooled cells, e.g. laminins 
were downregulated in both cell types, whereas ADAMTS proteins were generally 
upregulated. Both MEGF10 (multiple epidermal growth factor-like domains protein 10), 
which appears to be a pro-adhesive protein [664, 665], and glypican-4 were downregulated 
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in both clonal and pooled cells lines, but as membrane proteins, it is not clear whether 
differences in abundances of these proteins in the secretome reflect differences in 
membrane levels or differences in soluble fragments. As a result, the multiple changes to 
the secretome might reflect a global chaperone function for AGR2, similar to BiP [310], 
where specific client proteins might be determined simply by the proteins that are 
produced by a given cell (e.g. as a result of transcriptional changes in EMT). With this is 
mind however, AGR2 most likely has some specific substrates as well, as overexpression of 
AGR2 alone is able to induce metastasis [309]. However, these substrates still remain 
elusive. 
 In the absence of truly common proteins between clonal and pooled cells, it is 
important to note that the vast majority of differentially regulated proteins contain at least 
one disulphide bond, which is perhaps not unexpected given the prevalence of this PTM in 
secreted proteins [312]. However, given the recorded thiol-dependent interactions 
between AGR2 and at least one substrate proteins [422], this does provide a means 
whereby AGR2 might directly interact with these proteins to affect the extracellular 
abundance. The fact that downregulated proteins also contain disulphides might suggest 
that AGR2 interaction with these proteins results in their degradation, possibly through 
ERAD (ER-associated degradation). PDI has been shown to promote ER retention of 
procollagen I and its subsequent proteasomal degradation, an activity that was lost upon 
deletion of the PDI ER-retention sequence and thus exit from the ER, suggesting that it is 
indeed the retention in the ER that promotes the degradation [666]. Similarly, ERp44, which 
contains a single-cysteine active-site motif like AGR2 [315], mediates retention of 
incompletely folded proteins in the ER [320, 573], although whether this also results in the 
activation of ERAD has not been determined. Thus while AGR2 clearly promotes the 
secretion of mucins [408, 412, 418, 422, 427], it might also downregulate the secretion of 
other proteins, although how this process might be regulated is unclear. 
 
 
5.3.2 Relating proteomic changes to cell adhesion 
 
 Using IPA analysis, differentially regulated protein in clonal WT AGR2 and EV cells 
related to cell adhesion were investigated, in order to relate possible proteomic changes to 
the reduced attachment behaviour of AGR2 positive cells in monolayer culture observed in 
Chapter 4. Proteins potentially related to ‘decreased adhesion of tumour cells’ are shown in 
Table 5.4. 
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Uniprot 
Accession 
Description 
Fold 
Change 
Literature reports 
(number of 
publications) 
Q9ERB4 Versican core protein (VCAN) 30.68 Decreases (3) 
P17491 Inhibin beta B (INHBB) 6.85 Decreases (8) 
    
P08699 Galectin-3 (LGALS3) -3.23 Increases (4) 
F1LST1 Fibronectin (FN1) -3.26 Increases (22) 
F1M6X1 Vascular endothelial growth factor A (VEGFA) -3.84 Increases (7) 
P08721 Osteopontin (SPP1) -16.38 Increases (5) 
F1LRH4 Laminin subunit gamma-2 (LAMC2) -16.39 Increases (6) 
G3V6C1 Serpin B5 -24.28 Increases (2) 
 
Table 5.4. Differentially expressed secretome proteins associated with the term 
‘decreased adhesion of tumour cells’ by IPA. Both up- and down-regulated proteins 
in the secretome of WT AGR2 versus EV clonal cells were analysed by IPA in relation 
to possible functions in cell adhesion. Max fold change is expressed relative to EV 
clone 2 cells. Literature reports refers to the reported effect of the relevant protein 
on adhesion in the literature, and the number of publications identified by IPA that 
support this role.  
 
 
 In this way, it appears that both up- and down-regulation of secreted protein in WT 
AGR2 clonal cells can affect their adhesion. In particular, the downregulation of fibronectin 
and LAMC2 might explain why monolayer cells were much less adherent than EV clone 
cells, producing lower amount of matrix for cells to adhere to. In a similar vein, versican has 
been shown to be an anti-adhesive protein [667, 668], which prevented the adhesion of 
prostate cancer cells to fibronectin but not laminin [669], suggesting that reduced cell 
adhesion in WT AGR2 clonal cells might be the result of weakened or inhibited cell-matrix 
interactions. 
 IPA was also used to identify changes in proteins that might account for the higher 
attachment rate of WT AGR2 clonal cells relative to EV clone cells (Chapter 4). Whereas 
most proteins involved in adhesion identified by IPA related to decreased adhesion (as 
above), a small group of proteins associated with ‘increased adhesion of connective tissue’ 
was also identified (Table 5.5). 
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Uniprot 
Accession 
Description 
Fold 
Change 
Literature reports 
(number of 
publications) 
P02454 Collagen alpha-1 (I) chain (COL1A1) 24.88 Increases (1) 
D3ZE04 Collagen alpha-1 (VII) chain (COL7A1) 13.63 Increases (3) 
G3V7F3 
WNT1 inducible signaling pathway protein 2 
(WISP2) 
12.66 Increases (1) 
P43145 Adrenomedullin (ADM) 5.66 Increases (5) 
 
Table 5.5. Differentially expressed proteins associated with the term ‘increased 
adhesion of connective tissue’ by IPA. Both up- and down-regulated proteins in the 
secretome of WT AGR2 clonal cells were analysed by IPA in relation to possible 
functions in cell adhesion. Max fold change is expressed relative to EV clone 2 cells. 
Literature reports refers to the reported effect of the relevant protein on adhesion in 
the literature, and the number of publications identified by IPA that support this role.  
 
 
 Whilst changes to collagen molecules are probably related to longer term adhesion 
effects, adrenomedullin has been shown to stimulate an enhanced rate of adhesion in 
prostate cancer cell lines [670], and thus might play a role in cell attachment in Rama 37 
cells.  It is also interesting that these molecules were identified as promoting adhesion of 
connective tissue (and thus presumably mesenchymal-type cells), which would be 
consistent with the change in morphology observed in WT AGR2 clonal cells. It will be 
interesting to determine if these proteins directly affect the adhesion behaviour of WT 
AGR2 clonal cells and thus may warrant further investigation as possible substrates of 
AGR2. 
 
 
5.3.3 AGR2-influenced regulatory and interaction networks 
 
 In order to identify potential regulatory pathways that might explain some of the 
changes observed in AGR2-expressing cells, the secretome data were analysed by IPA. 
Upstream analysis revealed that two proteins upregulated in WT AGR2 clone cells, IGF2 
(insulin-like growth factor 2) and WISP2, were themselves upstream regulators of several 
proteins differentially expressed between AGR2-positive and -negative cells: IGFBP2, 
IGFBP7, LAMB3, LAMC2, CTGF, Serpine 1, VEGFA and fibronectin (Fig. 5.11). WISP2 is a 
regulator of the majority of these proteins and may provide clues to a possible mechanism 
whereby AGR2 induces pro-metastatic effects. Aside from the favourable downregulation 
of laminin proteins observed here (in the context of promoting metastasis), secreted WISP2 
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has been shown to activate the canonical Wnt pathway, causing partial dedifferentiation of 
adipocytes and promoting the assumption of a myofibroblast phenotype, associated with 
increased migration [663, 671]. WISP2 overexpression has been reported in both pre-
neoplastic and neoplastic breast lesions [672] but equally, studies have shown that it is a 
protective factor against EMT [673, 674]. These differences in WISP2 function might reflect 
the influence of the tissue microenvironment on Wnt signalling (which can be a source for 
Wnt ligands) [675, 676], relative to one Wnt ligand in isolation. Accordingly, it is important 
to note that connective tissue growth factor (CTGF), which was downregulated in CM from 
WT AGR2 clone cells and is also regulated by WISP2 (Fig. 5.11), modulates Wnt pathway 
signalling [677] and thus could play a role in determining the outcome of WISP2 signalling.  
 Given its role in EMT, differentiation and migration [41, 678], influences on the Wnt 
pathway through AGR2 provide an attractive mechanism whereby AGR2 might promote the 
acquisition of a migratory and invasive phenotype. AGR2 has been associated with the Wnt 
pathway through its repression of the Sox9 transcription factor in gastric mucous cells, 
which itself represses several Wnt ligands [408], although no direct action of AGR2 on the 
Wnt pathway was explored. It will be interesting therefore to investigate changes in 
intracellular Wnt pathway proteins in WT AGR2 clonal cells, to determine whether Wnt 
signalling might account for the differential regulation of other proteins in these cells, as 
well as phenotypic alterations, thus potentially placing an AGR2-Wnt axis at the heart of 
AGR2-induced metastasis. It is also interesting that Wnt ligands tend to be cysteine-rich 
proteins, where correct disulphide bond formation is crucial for function, at least in the 
case of Wnt3a [679]. This indirectly suggests a role for PDI proteins in the regulation of the 
Wnt pathway through the generation of active Wnt ligands. However, given the 
morphological change in WT AGR2 clonal cells, it remains to be determined whether WISP2 
expression is directly governed by AGR2, or whether it changes as a result of (or indeed a 
cause of) the change in morphology.  
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 The contribution of IGF2 to the regulation of proteins differentially expressed in WT 
AGR2 clonal cells may be less significant given the few proteins it appears to regulate in 
these cells (Fig. 5.11) but again, as only secreted proteins are represented here, it is unclear 
what effects IGF2 might have intracellularly. Nevertheless, overexpression of IGF2 is 
associated with poorer disease prognosis and is seen in many cancers (reviewed in [680]), 
and the increased abundance of IGF2 and the IGF-binding proteins (IGFBP-2, and -5, Table 
5.3) could promote tumour progression through anti-apoptotic and anti-adhesive effects 
[681, 682]. Overall, it might be interesting to investigate the roles of Wnt and IGF signalling 
pathways as regulators of AGR2-mediated tumourigenesis.
Figure 5.11. Top regulatory network of AGR2-influenced proteins in clonal cells. 
IGF2 and WISP2 were differentially expressed in AGR2-positive and negative clonal 
cells lines, and amongst these differentially expressed proteins, both were identified 
by Ingenuity Pathway Analysis as the top regulatory proteins. Red shading indicates 
upregulation in AGR2 clonal cells and green shading a downregulation. The intensity 
of shading reflects the intensity of change. 
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Figure 5.12. Top interaction network of AGR2-influenced proteins in clonal cells. Ingenuity 
Pathway Analysis was used to highlight the network with the most interactions involving 
differentially regulated proteins from AGR2-positive and negative clonal cells. Red shading 
indicates upregulation in AGR2 clonal cells and green shading a downregulation. The intensity of 
shading reflects the intensity of change. Solid lines represent direct protein-protein interactions. 
Solid arrows represent direct effects on expression or function, and dashed arrows indirect 
effects.  
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 WISP2 and IGF2 interactions are seen in the context of a broader landscape in the 
top interaction network (based on published literature) for secreted proteins from the 
clonal cells tested shown in Fig. 5.12. This figure displays both protein-protein interactions 
and influences on protein expression/function. This network seems to highlight the 
multitude of factors in the CM of WT AGR2 clonal cells that converge on modulating the 
expression of fibronectin. As discussed above, downregulation of fibronectin might partly 
explain why these cells were so easily detachable in monolayers (Chapter 4), as there is a 
relatively lower amount of fibronectin matrix for these cells to adhere to relative to EV 
clone cells. In a wider context, downregulation of fibronectin has been observed in some 
cancers, where downregulation seems to correlate with a more metastatic phenotype [683-
685]. Thus AGR2-associated downregulation of fibronectin could contribute to cell adhesion 
and metastasis. 
 The network in Fig. 5.12 also highlights the effects of WISP2, as well as a number of 
other proteins, on two major components of the plasmin system, resulting in upregulation 
of  serpine 1 (also known as plasminogen activator inhibitor-1 (PAI-1)),and downregulation 
of urokinase-type plasminogen activator (uPA/PLAU). This points to an overall 
downregulation of the plasmin system, which is somewhat unexpected given the 
association of increased plasmin activity with matrix degradation and cancer dissemination 
(reviewed in [686]). However, in the context of cell adhesion, increased levels of PAI-1 have 
been shown to promote integrin internalisation in a uPA and uPA receptor (uPAR)-
dependent manner, which leads to increased cell detachment [687, 688]. This was found to 
occur on a variety of matrix proteins, including fibronectin, and thus the combined 
decrease in secreted fibronectin and anti-adhesive effects of increased PAI-1 in WT AGR2 
clonal cells probably contribute to reduced cell adhesion. Again in a wider context, 
increased PAI-1 might increase tumour cell dissemination by promoting tumour 
angiogenesis [689, 690], and also through promoting fibrin formation and release of pro-
coagulation factors from the endothelium [691, 692], leading to thrombus formation that 
promotes arrest of circulating tumour cells in the vasculature and aids in their extravasation 
[693, 694].   
 Thus several regulatory and effector proteins have been identified in the secretome 
of WT AGR2 clonal cells that might contribute to both the observed adhesion behaviour of 
these cells, and might also contribute to the pro-metastatic activity associated with AGR2.  
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5.3.4 Glycosylation of AGR2 
 
 It has been demonstrated here for the first time that AGR2 becomes glycosylated 
upon secretion as mutant protein from Rama 37 rat cells and as wild type protein secreted 
from human MCF7A cells, and that the glycosylation is not N-linked, but probably O-linked. 
Whilst it is possible that the KTEL deletion could be wholly or partially responsible for this 
glycosylation in Rama 37 cells, this seems unlikely given the observation of a similar shift in 
mass of secreted WT AGR2 from MCF7A cells. Furthermore, the predicted glycosylation 
site(s) are situated at the N-terminus of the protein (Appendix 26), away from the C-
terminal KTEL sequence (Fig. 3.1). Thus the KTEL mutant probably highlights that 
glycosylation is a post-ER event, rather than causing an ectopic glycosylation event. 
 WT AGR2 is localised to the ER (Chapter 3) and several other ER resident chaperone 
proteins have been reported to be secreted or cell surface-bound [446, 447, 660-662, 695-
697], and at least two of these (GRP78 and ERp44) are believed to be also O-glycosylated 
[447, 695-697]. However, while this indicates that glycosylation and secretion of ER 
proteins is not unique to AGR2, the consequences of these events in the context of AGR2 
are largely unknown.  
 As O-glycosylation occurs within the Golgi [359], it is possible that secretion and 
glycosylation of ER proteins occurs due to lack of retrieval back to the ER through the C-
terminal ER-retention sequence. This implies some sort of ‘escape’ from the ER. Ni and 
colleagues [698] suggest that, at least in the case of GRP78, this may occur through an 
overwhelming of the KDEL receptor system by overexpression of GRP78 protein, such that 
the retrieval system is simply not able to recover all molecules due to the their sheer 
number, and this is possibly the case in the AGR2-overproducing MCF7A cells. Alternatively, 
AGR2 may be secreted through interaction with a transport protein, in a manner akin to 
GRP78 where the proteins MTJ-1 and Par-4 appear to be required for its transportation to 
the cell membrane [699, 700]. A recent report showing AGR2 secretion into the 
gastrointestinal mucus also noted that C81S AGR2 was secreted from transfected CHO cells 
whereas WT AGR2 was not, possibly suggesting that Cys81 plays a role in ER retention and 
that masking it, either through mutation or substrate binding, could lead to AGR2 secretion 
[426]. The exact mechanism involved in AGR2 secretion will require further investigation.   
 It is also difficult to predict the role of secreted AGR2 when the role of intracellular 
AGR2 is still unclear, although data from Chapter 4 suggests that secreted AGR2 may still 
play a role in cell adhesion. Similarly, the effects of the possible O-glycosylation of AGR2 are 
not clear. The predicted glycosylation sites all lie within the flexible N-terminal region of 
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AGR2, between Thr23 and Ser45 (Appendix 26) and O-glycosylation is indeed preferentially 
found in unstructured protein regions [701]. The addition of glycan chains appears to 
enhance thermodynamic stability of proteins, by favouring a more folded protein state 
through steric hindrance of the glycan chain [702]. Reports and simulations have indeed 
suggested that glycosylation causes a loss of structural flexibility [703, 704] (again probably 
through steric hindrance), and one study has shown that N-glycosylation of a flexible loop 
region of porcine peptidase increases its structural stability [705]. Therefore, glycosylation 
of secreted AGR2 may serve to stabilise this flexible region of AGR2, effectively making it 
less flexible, but with unknown consequences for the activity of AGR2. It is interesting 
however that loss of flexibility in an unstructured region of the RNA chaperone α-crystallin 
resulted in reduction of its chaperone activity [337], possibly suggesting that glycosylated 
AGR2 may have compromised or altered substrate binding specificity. 
 Despite several reports that have noted that AGR2 is associated with the cell 
membrane [302, 443-445] and that it is also present on the cell surface [437], the present 
study could not find any evidence of membrane-bound AGR2. It is important to note 
however that most of the previously mentioned studies used immunohistochemical 
methods and did not necessarily observe extracellular AGR2 directly, possibly indicating 
that it was resident on the cytoplasmic side of the membrane. However, the study by 
Dumartin and colleagues [437] noted cell surface AGR2 expression based on data from both 
flow cytometry and immunofluorescence (IF) imaging. It is important to note that their 
reports of cell surface AGR2 using IF were based on cells fixed in PFA and then stained for 
AGR2, which has been demonstrated here to still stain for intracellular proteins. This ‘cell 
surface’ AGR2 may therefore be intracellular AGR2. The observation of cell surface AGR2 
from flow cytometry is harder to explain, but due to the necessity of trypsinising adherent 
cells for flow cytometry analysis, it is possible that AGR2 antibody may have penetrated the 
cell during sample preparation and given a false positive reading of cell surface AGR2, as 
several reports have shown that trypsinisation affects membrane integrity and cell 
permeability [706, 707]. Several studies have employed the staining method used in the 
present study to demonstrate cell surface expression of proteins [708-710] and so the lack 
of membrane staining with AGR2 seen with three different AGR2 antibodies (personal 
observation) strongly suggests that secreted AGR2 does not have prolonged interaction 
with the cell surface, at least of MCF7A cells. Whether extracellular AGR2 behaves 
differently in different cell types (as in [437]) remains a possibility. 
 Overall, exploring the role of this secreted form of AGR2 presents an exciting new 
direction in the biology of AGR2, and it will be particularly interesting to examine the 
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biophysical characteristics of secreted AGR2, along with any potential interactions with cell 
surface proteins such as dystroglycan and C4.4a that have been previously reported in the 
yeast two hybrid system [389]. 
 
 
5.4 Conclusions 
 
 In this chapter, it has been demonstrated that AGR2 expression results in a number 
of changes to both the intracellular and extracellular proteome of Rama 37 cells, and these 
changes are more numerous between AGR2-positive and –negative clonal cells. The 
secretion of a glycosylated form of AGR2 (probably O-glycosylated) has also been 
described, although the consequences of this glycosylation remain presently unclear.  
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Chapter 6 
 
 
 
General Discussion 
 
 
 
 The work presented here examined the role of the endoplasmic reticulum (ER) 
protein AGR2 in cell adhesion. AGR2 is overexpressed in a number of cancer types, and 
determining the role of AGR2 in cancer progression could be fruitful in identifying new drug 
targets in AGR2-positive cancers, given the association of AGR2 expression with reduced 
patient survival [309, 443, 457-462, 467]. 
 AGR2 was demonstrated to be associated with an elongated cell morphology in 
clonal cell Rama 37 rat mammary cells, which in turn led to decreased adhesion of the cells 
in confluent monolayers. On the other hand, AGR2 expression was associated with an 
increase in the rate of attachment of single or clumps of cells. It was also demonstrated 
that both intracellular and extracellular AGR2 appear to affect cell adhesion. 
 Through NMR structural studies and mutagenesis, the dimerisation interface of 
AGR2 was identified, along with the key residues that mediate this dimerisation. Although 
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all the forces governing this association are not entirely clear, these experiments have 
permitted the generation of a monomeric form of AGR2, enabling the study of the role of 
dimerisation in AGR2 activity, as well as several other potentially important domains. 
Through these experiments, the underlying features defining the adhesion phenotype of 
Rama 37 cells appears to be cell morphology, but the AGR2 active site Cys residue, as well 
as AGR2 dimerisation, appear to be the most important features that promote AGR2-
associated morphology changes. Additionally, through the use of a highly secreted mutant 
form of AGR2 (∆KTEL AGR2), it has been demonstrated here that AGR2 becomes 
glycosylated upon its secretion from Rama 37 cells, and WT AGR2 from human MCF7A 
breast cancer cells shows a similar change in mass upon secretion. While this glycosylation 
is probably O-linked in nature, the significance of its attachment to secreted AGR2 remains 
unclear. 
 Finally, a proteomics approach was utilised to identify changes to the proteome of 
AGR2-expressing cells that might account for the role of AGR2 in adhesion and metastasis. 
These experiments revealed that AGR2-expressing clonal cells secrete decreased levels of 
ECM proteins relative to non-AGR2-expressing cells, which might explain why these cells 
are generally less adherent when grown as a monolayer. The reason for the increased rate 
of attachment of clonal AGR2 cells is not as evident, although at least one protein 
(adrenomedullin) was identified that might promote this increased attachment. Overall, an 
association between AGR2, cell elongation and changes to cell adhesion have been 
identified, along with changes in the secretome of AGR2-expressing cells that might 
contribute to these characteristics.  Although proteome changes were identified in relation 
to the effects observed on cell adhesion, these observed changes might also offer an insight 
into how AGR2 induces metastasis. 
 
 
6.1 A role for AGR2 in metastasis 
 
 In addition to the downregulation of basement membrane proteins mentioned 
above, and the upregulation of matrix-degrading protease such as MMP19 and ADAMTS8 
(Table 5.3), which together would presumably promote metastasis by disrupting cell-matrix 
interactions, two classes of proteins that might contribute to AGR2-driven metastasis have 
emerged from the proteomics screen presented in Chapter 5. 
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6.1.1 Immunomodulatory proteins 
 
 AGR2-expressing cells showed elevated levels of the CXCL1 and CXCL2 chemokines, 
and AGR2-expressing clonal cells had decreased levels of the CXCL12 chemokine (Tables 5.2 
and 5.3). Both CXCL1 and CXCL2 are principally neutrophil chemoattractants [711-713] and 
CXCL12 can act as both a neutrophil chemoattractant [714], but also as an anti-
inflammatory factor [715]. This suggests that neutrophils might be recruited to AGR2-
expressing tumours. These tumour-associated neutrophils (TANs) can contribute to 
metastasis through the promotion of matrix degradation and angiogenesis. TANs secrete 
several proteases (collagenase-IV, heparanase and neutrophil elastase) that can degrade 
the basement membrane and surrounding extracellular matrix, facilitating the 
dissemination of tumour cells, whilst at the same time releasing pro-angiogenic factors, 
including VEGF, CXCL1 and CXCL6 (reviewed in [184]). Thus TANs can act to couple ECM 
degradation with neovascularisation, promoting metastasis. 
 Aside from the release of chemotactic cytokines, there was also a strong reduction 
in levels of the histocompatibility antigen RT1-AW2 in clonal WT AGR2-expressing cells 
(Table 5.3). This may point to an AGR2-mediated programme of evasion of immune-
surveillance mechanisms, a mechanism that is known to be exploited by neoplastic cells 
[716-718]. This is further supported by the downregulation of CXCL12 seen here in AGR2-
expressing cells, as this molecule has been shown to act as an anti-inflammatory cytokine 
and is associated with increased metastasis of breast cancer cells, possibly through relieving 
an autocrine loop of CXCL12 that allows chemotaxis of breast cancer cells towards CXCL12-
secreting sites such as the bone marrow [715, 719, 720]. Overall, this association of 
immunomodulatory protein release from AGR2-expressing cells might provide a novel 
pathway for AGR2-mediated tumour progression, promoting neovascularisation and 
tumour cell dissemination, whilst at the same time preventing tumour cell recognition by 
the host immune system. 
 
 
6.1.2 Collagens 
 
 There was a marked increase in the abundance of several collagens in AGR2-
expressing cells clonal cells (Table 5.3), where there was increased abundance of all three 
chains of collagen VI (COL6A1, COL6A2 and COL6A3), as well as two collagen I chains 
(COL1A and COL2A), COL3A1, COL7A1 and COL12A1. There was also a strong upregulation 
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of procollagen C-endopeptidase enhancer 1 (PCOLCE), a secreted protein required for the 
processing and maturation of newly-secreted collagen molecules [721] and ADAMTS2, 
which is involved in the maturation of procollagens I, II and III [722]. This might be 
important given that a signature pattern of expression of COL1A1, COL1A2, COL3A1, 
COL6A3 is associated with EMT [723].  
  In particular, the upregulation of all three subunits of collagen VI in clonal AGR2 
cells in the present study suggests that it may play a particularly important role in AGR2-
mediated tumour progression. Collagen VI induces EMT in breast cancer and has been 
shown to promote tumour angiogenesis both in vitro and in vivo [724, 725]. Collagen VI 
expression within tumours is often associated with the vasculature or invasive front 
(reviewed in [726]), and Col6a1-/- mice show defects in vasculature formation as a result of 
lost survival and sprouting of endothelial cells, with a resultant slowing of tumour growth 
[725]. This suggests that collagen VI plays an important role in tumour angiogenesis. It is 
also important to highlight the overlapping and complementary actions of possible TAN 
recruitment and collagen VI secretion by AGR2-expressing cells, as the new vessels 
stimulated by TANs should be stabilised by the release of collagen VI, thus establishing 
vasculature that can support tumour cell dissemination and metastasis.  
 
 
6.1.3 A model for AGR2-driven metastasis 
 
 With the above proteomic changes to AGR2-expressing cells in mind, coupled with 
changes in adhesion and morphology (Chapter 4), a possible mechanism of AGR2-driven 
metastasis is emerging (Fig. 6.1). Through overexpression of AGR2, a subset of epithelial 
cells undergoes an EMT-type transformation. This is evidenced not only from the 
correlation between AGR2 expression and elongated cell morphology (Chapter 4), but also 
that clonal AGR2-expressing cells upregulated the expression of several proteins related to 
EMT, including TGFβ, neural cell adhesion molecule (NCAM) and vimentin (Table 5.3), 
although further experimentation will be required to confirm that EMT is indeed induced in 
these cells. These cells are, as a result, less adherent to the cell matrix and are more 
migratory (Chapter 4). At the same time, the decreased output of basement membrane 
proteins from AGR2-expressing cells, as well as increased secretion of matrix degrading 
enzymes (Chapter 5), causes fundamental changes to the surrounding matrix, which 
presumably allow these cells to break away from the main tumour mass. Release of 
chemokines could at the same time promote the recruitment of neutrophils, resulting in 
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further matrix breakdown and the stimulation of angiogenesis. The release of collagens 
from AGR2-expressing cells can then serve to stabilise the newly formed vasculature, in this 
way presenting a possible pathway for the more migratory AGR2 cells to disseminate to 
secondary sites. These cells have been shown in the present study to be resistant to anoikis 
and also exhibit a faster rate of attachment as single cell suspensions or clumps of cells in 
suspension, characteristics which should be favourable to promote survival of these cells in 
the bloodstream and promote their adhesion to the endothelium as secondary sites.  
 It is also interesting to note that normal breast tissue undergoes profound 
architectural changes during puberty, pregnancy and lactation, where ECM must be 
remodelled and cells must migrate through this remodelled ECM to form new breast alveoli 
(reviewed in [505]). It is also noteworthy that this process is coupled to new blood vessel 
formation in these tissues [727] and hematopoietic cells play an important role in branching 
and elongation of these new ducts [728]. Furthermore, AGR2 has been shown to facilitate 
lobuloalveolar development in a mouse model [456] and its expression is observed in 
normal breast tissue [390, 497]. Thus it might be that AGR2 plays a physiological role in 
breast tissue remodelling, but over activation of this pathway through overexpression of 
AGR2 leads to tumourigenesis and metastasis. 
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Figure 6.1 (continued overleaf). Possible mechanism of AGR2-induced metastasis in 
breast tissue. (A) In the existing breast duct, epithelial cells surround the ductal 
lumen, and themselves are surrounded by myoepithelial cells and extracellular 
matrix. (B) Overexpression of AGR2 promotes an EMT-type transformation of some 
epithelial cells, at the same time leading to production of matrix-degrading enzymes 
such as MMP19. The transformed cells also downregulate the production of 
basement membrane proteins, leading to further matrix remodelling. (C) These cells 
become less adherent to the surrounding matrix and more migratory, also releasing 
cytokines to recruit neutrophils that aid in matrix remodelling and angiogenesis. 
These new blood vessels are stabilised by the release of collagen IV from AGR2-
expressing cells, leading to eventual intravasation of these cells and travel to 
secondary sites. 
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Figure 6.1 (cont.). Possible mechanism of AGR2-induced metastasis in breast tissue. 
(A) In the existing breast duct, epithelial cells surround the ductal lumen, and 
themselves are surrounded by myoepithelial cells and extracellular matrix. (B) 
Overexpression of AGR2 promotes an EMT-type transformation of some epithelial 
cells, at the same time leading to production of matrix-degrading enzymes such as 
MMP19. The transformed cells also downregulate the production of basement 
membrane proteins, leading to further matrix remodelling. (C) These cells become 
less adherent to the surrounding matrix and more migratory, also releasing cytokines 
to recruit neutrophils that aid in matrix remodelling and angiogenesis. These new 
blood vessels are stabilised by the release of collagen IV from AGR2-expressing cells, 
leading to eventual intravasation of these cells and travel to secondary sites. 
 
 
6.2 Future work 
 
 A number of unanswered question still remain surrounding the role of AGR2 in 
adhesion and metastasis presented in the present study. It is still unclear whether AGR2 is 
responsible for the EMT-type transformation observed in the highest expressing WT AGR2 
Rama 37 cells. Despite several attempts, AGR2 could not be knocked down by shRNA to 
investigate whether cells reverted or at least partially reverted to a more epithelial 
C 
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morphology upon loss of AGR2. MET is thought to promote the colonisation of secondary 
tumours (reviewed in [264]) and so it is not unreasonable to assume that loss of AGR2 
expression could allow cells to revert back to an epithelial phenotype. Indeed, knockdown 
of AGR2 in the PC3 prostate cancer cell line promoted these cells to revert from a 
fibroblast-type morphology to a more epithelial morphology [515], suggesting that AGR2-
induced changes to cell morphology are at least partially reversible.  
 In relation to morphology changes in AGR2-expressing cells, it is also not entirely 
clear which proteins differentially expressed in clonal WT AGR2-expressing cells are 
mediated directly by AGR2, and which are downstream effects of the change in 
morphology. Determining the substrates for AGR2 will therefore also be important for the 
future development of any therapeutic agents. For these reasons, achieving knockdown of 
AGR2 will therefore be a priority of future work. 
 One other area of important future work will be to determine the extent to which 
the metastatic ability of cell lines expressing mutant AGR2 is affected by each mutation, if 
at all. Mutations resulting in loss of AGR2 dimerisation or the Cys81 thiol appeared to 
completely ablate the change to an elongated morphology associated with WT AGR2 
expression, potentially suggesting that these are the most important features driving AGR2 
activity. Through the use of a previously employed rat model of breast cancer progression 
[309], it should be possible to shed light on functionally important regions of AGR2 in 
promoting metastasis, which might lead to the identification of a novel therapeutic target 
within AGR2. 
 Several new avenues of investigation have also been opened up by the present 
report.  The discovery of a secreted and glycosylated form of AGR2 should also be an 
interesting line of future investigation. Although it is not the only report of a secreted and 
glycosylated ER chaperone [446-449, 695-697], it is the first to demonstrate this facet in 
AGR2 biology. The main focus of future studies should revolve around the nature of this 
glycosylation, its consequences on AGR2 structure and the consequence of this form of 
AGR2 on cellular activity. 
 Several differentially expressed proteins in AGR2-expressing cells were associated 
with immunomodulatory functions and angiogenesis. A handful of previous studies have 
reported the association of AGR2 with angiogenesis [301, 414], but, as far as the present 
author is aware, none so far on the possible immunomodulatory effects of AGR2 (aside 
from using AGR2 in targeted immune therapy [729, 730]). Thus exploring the role of AGR2 
in these processes in the context of tumour progression could yield important information 
in the hunt for anti-AGR2 therapies. 
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6.3 Conclusion 
 
 Although the exact function of AGR2 still remains elusive, the data presented in this 
thesis reveal several possible ways that it may be involved in both normal development and 
also in the generation of metastases. A framework has been established for identifying 
AGR2-induced changes to the cell proteome (in particular the secretome) which may be 
productive in better pinpointing the actions of AGR2, due to the importance of secreted 
factors in the metastatic process and the identification of a number of differentially-
expressed secreted proteins in AGR2-expressing cells. Important insights have been gained 
into the biophysical properties of AGR2, which may serve to better understand its 
regulation of cellular processes. Overall, a clearer picture of the role of AGR2 in metastasis 
is emerging, which might eventually lead to the generation of anti-AGR2 therapeutic agents 
to treat AGR2-positive cancers. 
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Abstract 
 
Anterior gradient 2 (AGR2) is a normal endoplasmic reticulum protein that has two important abnormal 
functions, amphibian limb regeneration and human cancer metastasis promotion. These normal 
intracellular and abnormal extracellular roles can be attributed to the multidomain structure of AGR2. The 
NMR structure shows that AGR2 consists of an unstructured N-terminal region followed by a thioredoxin 
fold. The protein exists in monomer–dimer equilibrium with a Kd of 8.83 μM, and intermolecular salt 
bridges involving E60 and K64 within the folded domain serve to stabilize the dimer. The unstructured 
region is primarily responsible for the ability of AGR2 to promote cell adhesion, while dimerization is less 
important for this activity. The structural data of AGR2 show a separation between potential catalytic redox 
activity and adhesion function within the context of metastasis and development.  
© 2012 Published by Elsevier Ltd. Open access under CC BY license. 
 
 
 
Introduction 
 
Anterior gradient 2 (AGR2) is a major develop-
ment-regulating protein that specifies the formation of 
embryonic ectoderm of  tadpoles
1
 and induces the 
remarkable effect of limb regeneration in  
salamanders.
2
 In mammals, AGR2 is produced in a 
restricted number of normal tissues, most notably in 
the secretory goblet cells of the  intestine,
3
 where it is 
associated with normal processes of secretion of  
mucin,
4
 a large cysteine-rich glycoprotein that pro-
tects the inner lining of the intestine.  
AGR2's rise to prominence among proteins that 
control development, however, has been its role in 
abnormal progression of disseminated disease, in 
particular, cancer. In oncogenesis, AGR2 is upregu-lated 
in the primary tumors of  breast,
5,6
 lung, 
7
  ovarian,
8
  
oesophageal,
9
  pancreatic
10
 and prostate  cancers.
11
 Its 
elevated level in breast and prostate cancer is asso-
ciated with markedly reduced survival of  patients.
11–14
 
 
 
 
AGR2 has been found in circulating tumor cells 
from breast, colon and prostate cancer patients,
15
 
in the circulating blood of patients with ovarian  
cancer
16
 and in ectopic lesions of the non-
malignant condition of  endometriosis,
17
 hence 
suggesting a potential role for AGR2 in cancer 
dissemination. Overexpression of AGR2 in a 
benign mammary cell system induced a metastatic 
dissemination to other organs, particularly the 
lungs, when transplanted into the mammary 
glands of syngeneic  rats.
6
 In this metastatic 
model, a change in cell activity induced by AGR2 
was an enhanced rate of cell  adhesion.
6
  
AGR2 is distantly related to the large protein 
disulfide isomerase (PDI) family. Its primary se-
quence contains a signal sequence between resi-
dues 1 and 20, which is required for import into the 
endoplasmic reticulum but is not found in the mature 
protein. AGR2 also contains an atypical C-terminal 
endoplasmic reticulum retention sequence,  KTEL.
18
 
 
0022-2836 © 2012 Published by Elsevier Ltd. Open access under CC BY license.  J. Mol. Biol. (2013) 425 , 929–943 
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AGR2 has a single CXXS motif that is likely to be 
responsible for its normal role by forming mixed 
disulfides with the intestinal mucin  MUC2
4
, mucins  
MUC1
19
 and  MUC5AC.
20
 A closely related protein,  
AGR3,
21
 of unknown function also contains a 21-
amino-acid signal sequence for endoplasmic retic-
ulum entry and is about 72% identical with amino 
acids 41–175 of AGR2. However, at the N-terminus, 
outside the signal peptide region, AGR3 has a 
shorter segment corresponding to AGR2 amino 
acids 21-40 ( Fig. 1).  
We describe here the first structure of AGR2 
(without the 20-amino-acid signal peptide) and show 
that the N-terminal amino acid region 21–40 is 
unfolded and that the C-terminal domain adopts the 
thioredoxin fold. The N-terminal region is primarily 
responsible for the cell adhesion properties of 
AGR2, whereas the folded domain forms a dimer 
through specific intermolecular salt bridges. AGR2, 
therefore, appears to have a bifunctional role in 
promoting cell adhesion and in PDI-like reactions. 
 
Results 
 
Biophysical characterization of AGR2 
 
AGR221–175 and the truncated AGR241–175 (Fig. 
1) have a molecular mass of 30.6±0.1 kDa and 26.0 
±0.1 kDa, respectively, rather than the 
corresponding 
 
 
theoretical molecular mass of 17.8 kDa and 16.1 
kDa, suggesting that both proteins exist in 
equilibrium between monomers and dimers ( Fig. 
2a). The determined molecular mass suggests that 
the region 21–40 makes only minimal, if any, 
contribu-tion to the dimerization.  
The heterogeneous nature of AGR2 is not unique; 
the closely related protein AGR3, which shares 65% 
amino acid sequence identity with AGR2, is a mixture 
of species with a molecular mass ranging from 31.5 
kDa to 26.3 kDa ( Fig. 2a). Mutation of the only 
cysteine residue in AGR241–175, C81 to serine, had a 
minimal effect on its dimeric state ( Fig. 2b) and 
treatment with DTNB [5,5′-dithiobis-(2-nitrobenzoic 
acid)] showed that this cysteine residue exists in the 
reduced state, thereby eliminating an intersubunit 
disulfide bridge. The monomer–dimer equilibrium of 
AGR241 –175 was investigated using equilibrium 
analytical ultracentrifugation ( Fig. 2d). The results fit 
well to a monomer–dimer distribution model, with a 
random distribution of residuals. The association 
constant (log10 Ka) was 5.054, indicating that the 
concentration for dissociation is approximately 8.83 
μM. Therefore, at the 0.5- to 1-mM concentra-tions 
used for the structural studies, the protein is 
predominantly a dimer.  
The 
1
H–
15
N heteronuclear single quantum co-
herence (HSQC) spectrum of AGR221–175 contains a 
mixture of well-dispersed and intense poorly dispersed 
resonances, whereas the AGR241–175 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Sequence of AGR2 and AGR3. Sequence alignment of AGR221–175, AGR324–166, Erp18 and thioredoxin A. 
The sequences are shown without their N-terminal signal peptides. Conserved residues are shaded in red. The 
asterisks (*) indicate the residues that were mutated during these studies. Secondary structure elements of AGR2 
determined in this paper are shown above the sequence. 
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Fig. 2. MALLS and analytical ultracentrifugation characterization of AGR2 and AGR3. (a) MALLS analysis of wild-type  
AGR2 21–175, AGR241–175 and AGR324–166. The major isolated peak for AGR241–175 has a mean molecular mass of 
26.0± 0.1 kDa, 31.1±0.6 kDa for AGR221–175 and 30.6±0.1 kDa for AGR324–166, rather than the expected molecular mass 
of, respectively, 16.1 kDa, 17.8 kDa and 16.9 kDa (for monomers) or 32.2 kDa, 35.6 kDa and 33.8 kDa (for dimers),  
confirming monomer–dimer equilibrium. (b) MALLS analyses of AGR241–175 and its mutants E60A, C81S, Y63A and 
K64A confirm that mutation of the E60 residue abolishes dimerization whereas mutation Y63 or K64A disrupts, rather 
than abolishes, dimerization. The minimal effects of the C81S mutation indicate that dimerization is not due to 
intersubunit disulfide linkages. (c) MALLS analysis of AGR221–175 and E60A AGR221–175 confirms that residue E60 
plays an important part in AGR2 dimerization. (d) Fitting of AGR241–175 equilibrium analytical ultracentrifuge data to a 
monomer–dimer equilibrium at 62 μM, 31 μM and 6 μM. The sample was in 20 mM sodium phosphate (pH 6.5) with 
150 mM NaCl at 20 °C. The results fit well to a monomer–dimer distribution model with a random distribution of 
residuals to give a dissociation constant of 8.83 μM under these conditions. 
 
 
 
 
spectrum consists of predominantly well-dispersed 
cross-peaks. This suggests that the first 20 amino 
acids of AGR221– 175 are largely unstructured. The 
absence of peak doubling in the 
1
H–
15
N HSQC 
spectrum of AGR241–175 indicates that the dimer is 
symmetrical ( Fig. 3a). The monomer–dimer equilib-
rium significantly reduced the NMR spectral quality 
through chemical exchange line-broadening and 
made the resonance assignments and structure 
determination more challenging. However, since there 
were no suitable proteins against which modeling 
could be undertaken to identify the residues 
responsible for dimerization, it was not possible to 
convert the dimeric state to a monomer through 
mutagenesis until after the structure of the dimer was 
determined. Besides, there were also no previous 
data that identified the specific roles, if any, of the 
structured and unstructured domains of AGR2. 
Hence, NMR studies were pursued with 
 
 
 
 
conditions under which the protein was predomi-
nantly dimeric. 
 
NMR studies of AGR241–175 homodimer 
 
To obtain good quality data, a combination of high-
level deuterium labeling of the protein, selective 
13
C-
methyl labeling and transverse relaxation optimized 
spectroscopy-based NMR experiments was required 
to yield complete backbone resonances (
15
N, 
1
H, 
13
C
α
, 
13
C
β
 and 
13C′) and the important nuclear 
Overhauser enhancement (NOE) data re-quired for 
structure determination. Leucines, iso-leucines and 
valines account for nearly 24% of the AGR241– 175 
polypeptide sequence, and these side-chain 
resonances were readily assigned using the three-
dimensional (3D) (H)CCH3–TOCSY experi-ments ( 
Fig. 3b)  
22
 on {[U- 
15
 N, 
13
 C, 
2
 H], Ile 
δ1 
[
13
CH3],Leu,Val[
13
CH3]}AGR241–175. The residue- 
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Fig. 3. Spectra of AGR241–175. 
(a) 
15
N–
1
H  HSQC  spectrum  of  
{[U-
15
N,
13
C, 
2
H]}AGR241–175. (b) 
Strips from the 3D (H)CCH3–
TOCSY experiments using {[U-
15
N,
13
C,
2
H], Ile
δ1
[
13
CH3],Leu, 
Val[
13
CH3]}AGR241–175 showing the 
side-chain assignments of Val110, 
Val125 and Ile128.              (c) The  
assigned methyl region  of the 
1
 H – 
1 3
 C HSQC spectrum of 
{[U-
15
N,
13
C,
2
H], Ile
δ1
[
13
CH3],Leu, 
Val[
13
CH3]}AGR2 41–175. Asterisks 
(*) represent peaks with multiple or 
ambiguous assignments. 
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specific assignments ( Fig. 3c) enabled the NOE 
spectroscopy (NOESY) spectrum to be assigned 
and the generation of the key distance restraints.  
The monomer subunit structure was calculated 
using 595 inter-proton distance restraints obtained 
from methyl-methyl, methyl-HN and HN-HN NOE's; 
95 residual dipolar coupling (RDC) restraints mea-
sured in two different alignment media [Pf1 bacteri-
ophage and 5% (v/v) pentaethylene glycol 
monododecyl ether:hexanol in a 0.96:1 ratio]; 179 
TALOS-derived backbone torsion angles and 37 
hydrogen bonds. The 10 calculated structures with 
the lowest total free energy and the least number 
of violations have a backbone RMSD of 0.42 Å for 
the structured regions ( Table 1 and  Fig. 4a). It is 
interesting to note that, despite the low number of 
NOE restraints, it is possible to obtain a high-
resolution structure. This is due to the fact that the 
distance restraints that are important to “fold” the 
protein are available, since they often involve 
amino acid residues with methyl groups. 
 
Dimerization of AGR241–175 occurs via the 
antiparallel arrangement of the α1 helix 
 
Although it was possible to produce heterodimers 
composed of unlabeled and 
13
C/
15
N AGR241–175 
(Fig. S1), no intermolecular NOEs were detected  
using the inherently insensitive 
13
C/
15
N-filtered NOE 
experiments. We, therefore, used an RDC-assisted 
 
Table 1. Structure statistics for AGR241–175  and E60A 
AGR241–175 
 
 AGR241–175 E60A AGR241–175  
NMR distance and dihedral constraints  
 
Distance constraints   
 
Total NOE 595 2364 
 
Ambiguous 22 253 
 
Intra-residue 73 993 
 
Inter-residue 500 1118 
 
Sequential (|i −j|=1) 218 572 
 
Medium range (|i −j| b 4) 142 314 
 
Long range (|i −j| N 5) 141 232 
 
Hydrogen bonds 37 40 
 
Total dihedral angle restraints 
90 82 
 
φ 
 
ψ 89 80 
 
Total RDCs 95 57 
 
NH phage 43 57 
 
NH  PEG
a 52  —b 
 
RDC Q-factor 0.018 0.101 
 
Average pairwise RMSD** (Å)   
 
 Heavy
b 1.31 1.55 
 
 Backbone
c 0.42 0.59 
  
a
 NH PEG RDCs were not collected. 
  
b RMSD calculated with CNS.   
c
 Ten structures were superimposed using the backbone atoms of 
residues in secondary structure elements of AGR241–175 (58– 67, 72–
77, 82–93, 95–103, 105–108, 127–132, 135–138 and 157–168). The 
corresponding secondary structures are α1, β1, α2, α3, β2, β3, β4 and 
α4. 
 
 
 
modeling method, which was reported to be suitable 
for the determination of the solution structures of 
symmetrical  dimers,
23
 to determine the structure of 
the AGR241–175 dimer. In this approach, RDCs are 
first used to obtain the orientation of the symmetry 
axis relative to the monomer structure. As the 
symmetry axis adopts the same orientation relative to 
the monomers, irrespective of alignment media, two 
non-degenerate alignment tensors should share a 
common axis, enabling the orientation of the 
symmetry axis to be identified. AGR241–175 dimer 
was aligned in Pf1 bacteriophage and 5% (v/v) 
pentaethylene glycol monododecyl ether:hexanol in a 
0.96:1 ratio; the RDCs were measured and the 
orientation of the symmetry axis was determined as 
described in the experimental procedure ( Fig. 4c and 
d). Homodimer models in agreement with these 
symmetry restraints were then constructed using the 
grid-search algorithm, and these models were 
evaluated based on the quality of the interface 
between the subunits and the agreement with the 
experimental data.  
The correlation between the measured and back-
calculated dimer RDCs shows a good fit between the 
two values, with a Q value of 0.018 for data acquired in 
both phage and polyethylene glycol (PEG). The 
AGR241–175 dimer model structure obtained ( Fig. 5a) 
shows that the interface is made up of the α1 helix, with 
a buried area of approximately 812 Å
2
. Across the 
representative models of the ensemble, the ionic 
interaction between E60 of one subunit and K64 of the 
other (labeled as K64*) is absolutely conserved with 
intact electrostatic interactions between the two side-
chain carboxylate oxygens of E60 and the side-chain 
ammonium hydrogen of K64 ( Fig. 5b). Both these 
residues are located in the α1 helix, and hence the E60–
K64* electrostatic interaction can only be achieved 
through an antiparallel arrangement of the α1 helix ( Fig. 
5b and c). Y63–Y63* hydrophobic interactions are also 
possible from the model. Further evidence that the α1 
helix forms the dimer interface was obtained from amide 
solvent protec-tion data obtained using paramagnetic 
relaxation agents ( Fig. 5a and Fig. S2). 
 
Mutagenesis of residues 
responsible for dimerization 
 
The importance of E60, Y63 and K64 in forming the 
intermolecular interactions was tested by mutat-ing 
each to an alanine followed by characterization using 
multi-angle laser light scattering (MALLS) ( Fig. 2b). 
E60A AGR241 – 175 is a monomer (molec-ular mass, 
16.4 kDa). The K64A (molecular mass, 18.7 kDa) 
mutant exhibits disrupted dimerization, thus 
confirming the importance of the E60–K64 interaction 
in maintaining the dimer structure. The molecular 
mass of Y63A AGR241– 175 (molecular mass, 18.9 
kDa) is similar to that of the K64A 
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mutant. The MALLS analysis of AGR221–175 and 
E60A AGR221–175 further shows that AGR2 
dimer-ization occurs independently of residues 
21–40 ( Fig. 2c), since both proteins dimerize 
irrespective of whether or not these N-terminal 
residues are present. The intersubunit E60–K64* 
salt bridge is confirmed by the effects of salt 
concentration on the stability of the dimer. A 
comparison of the chemical shifts between the 
monomeric E60A AGR241–175 and the wild-type 
AGR241–175 protein shows that the residues 
whose chemical shifts are most affected are from 
the α1 helix (Fig. S3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Overall structure of AGR2 
monomer subunit and directions of 
alignment axis for of AGR241–175. 
(a) Superposition of the 10 lowest-
energy conformers of monomer subunit of 
AGR241–175. (b) Ribbon representation of 
the subunit struc- 
ture of AGR241–175 with the sec-
ondary structures marked. (c) Sauson-
Flamsteed plot showing orientations of 
the principle align-ment tensor solutions 
calculated from RDCs of AGR241–175 in 
Pf1 bacteriophage and 5% pentaethy-
lene glycol monododecyl ether:hex-anol in 
a 0.96:1 ratio. The overlap of the PEG Sxx 
and bacteriophage Syy alignment tensor 
axes indi-cates the C2 symmetry axis of 
AGR241–175. (d) The order tensor 
directions plotted onto the molecu-lar 
frame of AGR241–175 to show the 
symmetry axis obtained from the two 
alignment media. 
 
Structure determination of the E60A 
AGR241-175 monomer 
 
E60A AGR241–175 is monomeric in solution. The 
structure of E60A AGR241–175, determined using 
standard methods, yielded 10 low-energy and least 
restraint violation structures ( Table 1 and  Fig. 6a and 
b). The all-atom RMSD between the mutant and one 
subunit of the wild-type dimer is 2.82 Å ( Fig. 6c), 
confirming the structure of the latter, which was 
obtained using a significantly reduced number of 
structural restraints. E60A AGR241–175 had a 
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Fig. 5. Structural analysis of 
AGR241–175 homodimer. (a) Homo-
dimeric model of AGR241–175 
show-ing the antiparallel 
arrangement of the α1 helix. (b) 
Dimeric interface, with the residues 
comprising the α1 helix represented 
as sticks. The intersubunit salt 
bridge between the carboxylate 
group of Glu60 and the ammonium 
group of Lys64 forms the major 
interaction between the subunits, 
with the Y63–Y63 hydrophobic 
interaction having some influence on 
dimer stability.  
(c) Complementary charged sur-faces 
at the dimer interface with surface 
representation for one and ribbons for 
the other subunit. (d) Ribbon 
representation of AGR241–175 mapped 
according to paramagnetic relaxation 
effect induced by the presence of 
Gd(III)-DTPA. Re-gions of high solvent 
protection are colored blue and regions 
of low solvent protection or no data 
avail-able are colored green. Regions 
are  
considered to have high solvent protection if the peak intensity ratio, calculated from 
15
N HSQC spectra of AGR241–
175 collected in the presence and absence of 2 mM Gd(III)-DTPA, is above 0.65 and are considered to have low 
solvent protection if the peak intensity ratio is below 0.65. 
 
tendency to aggregate over time, degrading the 
overall quality of the NMR data, especially those 
involving residues that form the dimer interface in 
the wild-type protein. This explains why the 
structure of the monomer is of lower quality than 
that of the dimer. The solution-state characteristics 
of the monomeric protein suggest that AGR2 
requires a binding partner (either another protein or 
itself) to achieve structural stability. 
 
Overall structure of AGR2 
 
Each AGR241–175 monomer subunit consists of a 
four-stranded β-sheet core surrounded by four α-
helices: α1 (residues 58–67), β1 (residues 72–77), α2 
(residues 82–93), α3 (residues 95–103), β2 (residues 
105–108), β3 (residues 127–132), β4 (residues 135–
138) and α4 (residues 157–168) ( Fig. 4b). This α-β-
α-α-β-β-β-α arrangement is similar to a thioredoxin 
fold. The active-site CPHS motif is located at the N-
terminal end of the α3 helix, consistent with other 
known structures of thioredoxin  domains.
24
 The α3 
and α4 helices are bent with respect to each other at 
an angle near to 90°. A short 310 helix is present in 
the region between the β2 and β3 strands, which is 
otherwise intrinsically disor-dered. Another 19-residue 
region of intrinsic disorder occurs between the β4 and 
α4 structural elements; within this region is an 
insertion consisting of residues 150–156, which is 
unique to AGR2, 
 
AGR3 [Protein Data Bank (PDB) accession 
number 3PH9] and  Erp18,
25
 when compared to 
other PDI family functional domains.  
The structure of AGR2 possesses features typi-
cally observed in members of the PDI family. The 
conserved proline (P126 in AGR2) at the start of β3, 
like other PDI family members, is in the cis 
conformation ( Fig. 6d). This conserved cis proline is 
located close to the potential catalytic active site and 
has been shown to be important for preserving the 
structural integrity of the active site for both substrate 
binding and catalysis in other PDI mem-bers. Another 
feature of thioredoxin domains, also found in the 
AGR241–175 structure, is the broken helix 
immediately following the CXXC(S) motif. However, 
rather than a proline being present in this kink, as 
found in many PDI domains, the corresponding 
residues in AGR2 are Asn94 and Lys95. In the case 
of the closely related AGR3 (GI: 66774045), the 
equivalent residues are Asn84/Glu85.  
Similar to human PDI, Erp44 and Erp18, a 
hydrophobic patch formed by residues including A86, 
V90, I92, Y124, V125, I128, Y150, A151, Y152 and 
L161 can be found surrounding the CPHS motif ( Fig. 
6e) of AGR2. As has been shown or postulated for 
other PDI proteins, this large hydrophobic patch could 
be involved in binding target proteins.  
We have detected neither isomerase nor glutar-
edoxin activity using biochemical enzymatic assays 
and standard substrates, although mixed disulfide 
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Fig. 6. Structure of E60A AGR241–175. (a) Superposition of the 10 lowest-energy conformers of monomer subunit of 
E60A AGR241–175. Structures were calculated with a total of 2257 NOE-derived distance restraints, 162 dihedral 
angles, 40 hydrogen bonds and 57 RDC restraints. (b) Ribbon representation of the structure of E60A AGR241–175 with 
the secondary structures indicated. (c) Superposition of lowest-energy conformers of AGR241–175 and E60A AGR2 with 
an all-atom RMSD of 2.82 Å between the two structures. (d) Catalytic active-site conformation in PDIs. This is well 
formed around the CXXC motif of Erp18 (PDB ID: 1SEN) (left) in comparison with the poorer conformation of CPHS in 
AGR2 (right). The cis proline is a structural requirement for correct function in PDI members. (e) Hydrophobic patch 
(brown) around the CPHS motif (green) shows its location is distant from the dimerization helix α1 (red). The 
orientations of the two structures differ by 180°. 
 
 
formation between AGR2 and MUC2 has been 
reported.
4
 In PDIs, there has been considerable 
attention paid to the buried glutamate and lysine salt 
bridge within the proximity of the cysteines in the 
CXXC motif; in human PDI (GI: 110815912), these 
are formed between Glu49 and Lys83. In AGR2, the 
corresponding residues, I75 and N108, do not form 
salt bridges, similar to the structure of Erp44 where 
the equivalent residues are Asn23 and  Arg60.
26
 In 
addition, the highly conserved Arg120 in human PDI 
has been shown, through mutation analysis, to have 
a direct effect on catalytic activity. This residue 
occurs in an unstructured region of the protein, with 
its side chain able to adopt a continuum of 
conformations ranging from totally solvent exposed 
to buried conformations, in which it is able to form 
other hydrogen bonding networks. The movement of 
the Arg side chain, in and out of the active site, 
affects the pKas of both active-site cysteines, and 
this modulation is important in the thiol-disulfide 
catalytic cycle. In AGR2, this conserved arginine 
(Arg128) also adopts a range of  conformations
27
 
and is likewise expected to play a role in modulating 
the pKa of the active-site cysteine during this cycle. 
 
 
Amino acids 21–40, not dimerization, determine 
the effect of AGR2 on the rate of cell adhesion 
 
AGR221–175, when coated on plastic substrata, 
significantly enhances the rate of adhesion of rat 
mammary tumor  cells
6
 by 2.4-fold over uncoated 
substrata (adhesion efficiencies, 45.0 ±1.4% and 18.6 
±1.3%, respectively; P b 0.001, Student's t test) ( Fig. 
7). In contrast, AGR241–175, which lacks the 21– 40 
region, not only failed to enhance the rate of cell 
adhesion but also, like the negative control protein 
bovine serum albumin, exhibited a significantly reduced 
rate relative to uncoated wells (adhesion efficiencies: 
AGR241– 175, 10.4±0.2%; bovine serum albumin, 
3.6±1.5%; P =0.001 and P b 0.001, respec-tively, 
compared to uncoated plates, Student's t test) ( Fig. 7). 
The importance of amino acids 21–40 of AGR2 in 
enhancing the rate of cell adhesion was further 
demonstrated by the closely related protein  
AGR324–166, in which segment 21–40 of AGR2 is 
replaced by 9 amino acids in AGR3, of which 7 are  
identical with or similar to those found in AGR2. 
However, unlike AGR221–175, AGR324–166 exhibited 
similar adhesion ability (adhesion efficiency, 12.9 ± 
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Fig. 7. AGR2 residues 21–40 are necessary for 
promoting cell adhesion. 24-well tissue culture plates with 
the indicated proteins or with coating buffer only (uncoated). 
Following a 60-min incubation with Rama 37 cells, adhering 
cells were counted and adhesion efficien-cies were 
calculated as the percentage of starting cells that adhered 
to the plate. Each condition was carried out in duplicate and 
the data represent the mean±standard error of the 
duplicates from six independent experiments for uncoated 
and AGR221 –175 or three independent experi-ments for 
other conditions. The adhesion efficiencies of dimer 
AGR221–175 and monomer E60 AGR221–175 are similar, 
showing that dimerization is not important for the 
adhesion properties of AGR2. The effect of removal of 
the N-terminal region, 21–40, shows the importance of 
this region for adhesion. 
 
 
 
2.4%; P =0.43, Student's t test) to the truncated 
AGR241–175 ( Fig. 7). This suggests that the role in 
cell adhesion is specific for the N-terminal 
sequence 21–40 of AGR2. However, further 
investigation showed that a synthetic peptide 
consisting of this polybasic amino acid sequence 
21–40 of AGR2 alone was unable to promote an 
enhanced rate of adhesion of the cells to the 
substratum (Fig. S4). It would appear that the 
folded domain must also be present and covalently 
linked to the 21–40 peptides to increase the rate of 
cell adhesion. However, an SXXS mutant of 
AGR221–175, which might be expected to abolish 
any potential PDI or disulfide-forming activity by 
AGR2, exhibited the same enhancement of 
adhesion as the non-mutant protein (Fig. S5), 
suggesting that these activities are not associated 
with the adhesion-enhancing activity of AGR2.  
The monomeric mutant proteins E60A AGR221–175 
and E60A AGR241–175 exhibited rates of cell adhe-sion 
(48.3±4.3% and 11.5±0.3%, respectively) that were 
not significantly different from the corresponding 
native dimeric proteins, AGR221–175 and AGR241–175 (P 
=0.58 and P =0.74, respectively, Student's t test) ( 
Fig. 7). This shows that monomeric and dimeric forms 
have similar cell adhesion properties. 
 
Discussion 
 
NMR structure of AGR2 
 
The AGR2 dimer and monomer structures 
described here are examples, which clearly 
demonstrate that the quality rather than the 
number of NOEs is important for obtaining a high-
resolution structure, provided that NOEs are 
supplemented with RDC restraints.  
The experiments to confirm the dimer structure— 
mutagenesis and solvent protection—are neces-sary, 
since the method used to obtain this structure is a 
modeling approach, assisted by experimental  
restraints.
23
 One of the main problems with this 
method is reproducibility, although other factors are 
also important. The method relies on two assump-
tions. The first one is that the multimer in question 
possesses C2 symmetry around the symmetry axis; 
for the vast majority of biological homodimers, this is 
a safe assumption. The second assumption is that 
the calculated starting subunit structure is good 
enough to produce an accurate representation of the 
oligomeric complex. The initial AGR2 subunit struc-
ture was calculated with limited NOEs due to the 
isotope labeling schemes adopted, which were 
necessary to overcome the line-broadening effects 
and allow good data for resonance assignments and 
to provide the crucial NOEs to determine the protein 
fold. An added advantage of the labeling scheme 
used is that there is little possibility of misinterpreting 
intersubunit NOEs as intrasubunit NOEs, or vice 
versa. Furthermore, intersubunit NOEs are unlikely to 
be observed in the NOESY spectra because of the 
nature of the labels introduced. In theory, these 
sparse NOEs could have led to very poor structures; 
in the event, however, when supplemented with high-
quality RDCs, good structures of the monomer 
subunits are obtained, giving confidence to the final 
dimer structure. 
 
Dimerization of AGR2 
 
The RDCs are also crucial for calculating the dimer 
structure. The rigid-body docking method is followed 
by minimization at the interface, back-calculation of 
the RDCs of the homodimer and then analysis of the 
quality of the interface. It is, however, not difficult to 
imagine situations where flexible or other regions in a 
structure could interfere with the docking of the 
subunits, resulting in these dimer structures being 
rejected as plausible structures. One other condition 
that is required for this method to work is that, in 
cases where there might be a mixture of species in 
equilibrium, the oligomer being calculated is the 
dominant contributor to the RDC data being  
collected.
23
 In the case of AGR2, which has been 
shown to have a dissociation constant of 8.8 μM, the 
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vast majority of the protein in solution is in a 
homodimer form; thus, this condition is satisfied.  
Only a limited number of PDIs exist as dimers; 
yeast PDI, which contains multiple active and 
inactive thioredoxin domains, forms dimers by in-
teractions involving the inactive thioredoxin b′ 
domain.
28
 However, this domain is not present in 
AGR2. Erp29, which contains a single thioredoxin 
fold with a single CLPC active site, forms a tight 
dimer with an extensive dimer interface consisting 
of multiple electrostatic and hydrophobic 
interactions involving residues toward its N-
terminal region.
29
 Erp16/18 also resembles 
AGR2 and AGR3 in possessing only one 
thioredoxin fold; although originally thought to be 
a  dimer,
30
 this was not confirmed in the NMR 
structure, which showed Erp16/18 to be a  
monomer.
25
 That Erp16/18 is a monomer is not 
surprising from our structure of AGR2; both lysine 
and tyrosine residues corre-sponding to positions 
64 and 63, respectively, in AGR2, that are 
identified in the present paper to have a role in 
AGR2 dimerization are absent in Erp16/18.  
A comparison of the amino acid sequences of 
AGR2 from 21 species (Fig. S6) shows that amino 
acid 63 is conserved as Y in amphibians, marsupials 
and mammals and as a highly conservative substi-
tution to F63 in fish and birds. E60 is conserved in 
all 21 species from zebrafish to humans, and K64 is 
conserved in amphibians, marsupials and mam-
mals, but as R in mouse. However, in fish, K64 is 
hydrophobic W (or L in one case), suggesting that 
fish AGR2 either does not form dimers or does not 
form dimers through the same salt bridge, relying 
perhaps on the hydrophobic interactions involving F 
or Y at position 63. A comparison of the amino acid 
sequence of AGR3 from 15 species (Fig. S7) shows 
that the glutamic acid, which corresponds to position 
60 in AGR2, is conserved in 14 out of 15 species, 
including fish, except as D in Northern Pike; 
however, the position in AGR3 corresponding to 
position K64 of AGR2 is not conserved at all, even 
in human AGR3. This result is consistent with the 
MALLS experiments on human AGR3, which 
showed self-association of AGR3 but, in contrast to 
human AGR2, behaved heterogeneously, with mo-
lecular mass varying from 23 kDa to 37 kDa. Thus, 
AGR3 behaves differently from AGR2 with regard to 
oligomer formation. 
A role of AGR2 dimerization has yet to be defined, 
in common with some better-characterized mem-
bers of the PDI family.  
25,28,29
 The calculated  
dissociation constant of dimerization in the present 
paper suggests that AGR2 is dimeric in its normal 
location of the endoplasmic reticulum, where high 
concentrations will be maintained. Since one normal 
client protein of AGR2, the cysteine-rich  MUC2,
4
 is 
multimeric, this dimerization may enable AGR2 to 
present multiple sites for MUC2 binding. It is notable 
 
 
that the dimerization interface of AGR2 is located at the 
region far from the hydrophobic patch around the 
catalytic CPHS motif ( Fig. 6e), suggesting that this 
patch is free to interact with other client proteins. 
Hydrophobic interactions have been reported to be 
important for the interaction between PDI and a large 
substrate, creatine kinase. Further-more, at higher 
concentrations of PDI, the formation of PDI oligomers 
was associated with a chaperonin activity, rather than 
with protein folding  activity.
31
 A similar change in 
function from folding to chaperone has been reported 
to be associated with the concentration-dependent 
oligomerization of the Arabidopsis thioredoxin-like 
protein, AtTDX. 
32
 Thus, the dimerization of AGR2 may 
also play a role in its normal function. 
 
Normal and abnormal roles of AGR2 
 
The results here are consistent with AGR2 
exhibiting normal intracellular and abnormal extra-
cellular roles. In normal cells, intracellular AGR2  
forms mixed disulfides with mucins, MUC1, MUC2 
and  MUC5AC,
4,19,20
 and thereby contributes to  
their secretion. In tumor cells, however, AGR221–175 
can stimulate cell adhesion  activity.
6
 The results here 
are also consistent with reports that AGR2 is not only 
located on the cell surface in cancer cells using 
immunofluorescence  techniques
33
 and se-creted from 
pancreatic cancer  cells,
10
 but also found in the blood 
and possibly urine of, respec-tively,  ovarian
16
 and 
prostate 
34,35
 cancer patients. AGR2, however, is not 
unique among PDI-related proteins by acting 
extracellularly at the cell mem-brane. Other proteins 
that contain thioredoxin folds have been found to play 
important roles on the cell surface because many cell 
surface proteins contain disulfide  linkages.
36,37
 PDI 
and related endoplas-mic reticulum proteins can 
influence, through their catalytic activity on the cell 
surface, the behavior of diverse  receptors,
38
  
proteases
39
 and particularly cell adhesion molecules 
such as integrins.
37
 PDI itself catalyses disulfide 
exchange on integrins to enhance platelet  adhesion
40
; 
blocking cell surface PDI with function-blocking PDI-
specific antibodies specifically reduces fibrinogen-
mediated platelet aggregation.
41
 The unstructured 
region, amino acids 21–40, of AGR2 is required for the 
cell-adhesion-promoting activity of AGR2. Thus, it is 
likely that the unstructured region serves to attach the 
AGR2 protein to the substratum, allowing the 
structured part of the protein to mediate cell adhesion, 
either by interacting, in a dimerization-independent 
manner, with one of its proposed cell surface targets, 
for example, dystroglycan or  C4.4a,
5
 or alternatively, 
through a specific thior-edoxin activity, to interact with 
the cell surface. The observation that the SXXS 
mutation does not reduce the adhesion-promoting 
effect of AGR2 
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suggests that the adhesion-promoting effect of 
AGR2 may be mediated by binding to one of its 
partner proteins, further highlighting an abnormal 
extracellular role for AGR2.  
However, how AGR2 functions at the tumor cell 
surface to induce cell adhesion in cancer develop-
ment and metastasis 
6
 and to affect patient  
survival
12–14
 is largely unknown. The elucidation of 
the 3D structure of AGR2 has revealed a 
separation between potential catalytic redox 
activity and adhesion function within the context of 
metastasis and development. 
 
Materials and Methods 
 
Plasmids for expression of proteins 
 
Wild-type cDNA encoding human AGR221–175 (residues 
21–175) (GI: 68012759) was cloned into the pTWIN1 vector 
(NEB), and the AGR241 –175 construct was gener-ated by 
subcloning the relevant part of AGR221–175 cDNA into 
pET151-D vector (Invitrogen). The E60A AGR221–175, 
E60A AGR241–175, C81S AGR241–175, K64A AGR241–
175 and Y63A AGR241–175 mutations were generated 
using a  
QuikChange site-directed mutagenesis kit (Stratagene), 
in accordance with the manufacturer's instructions. 
Details of the primers are given in Supplementary Data. 
 
Protein expression and purification 
 
Unlabeled AGR221–175  and AGR241–175, including all 
mutants, were expressed in LB medium. [U-
15
N], [U-
15
N, 
13
C]AGR241–175 and E60 AGR241–175, [U-
15
N,
13
C,
2
H] 
AGR241–175 and {[U-
15
N,
12
C,
2
H], Ile 
δ1
[
13
CH3],Leu,Val 
[
13
CH3]}AGR241–175 were prepared for these studies. For  
[U-
15
N] and [U-
15
N,
13
C]proteins, expressions were carried out 
in M9 medium containing 1 g/L 
15
NH4Cl with either 4 g/L 
12
C-
glucose or 
13
C-glucose. For the production of [U-
15
N,  
13
C,
2
H]AGR241–175, Silantes OD2 medium was used 
(Silantes GmbH). The bacteria were grown to an OD600 of 
0.5–0.6 at 37 °C, and protein expression was induced with 
1 mM IPTG overnight at 18 °C. 
Wild-type {[U-
15
N,
13
C,
2
H], Ile
δ1
[
13
CH3],Leu,Val[
13
CH3]}  
AGR241–175 was prepared using a modified protocol to that 
described by Tugarinov et al .
42
 A 5-mL culture of LB 
medium was inoculated with a freshly transformed colony 
of BL21 Star (DE3) cells and grown at 37 °C to an OD600 of 
0.7. The cells were centrifuged at 1200g at room 
temperature, resuspended in 20 mL of unlabeled M9/ 
H2O medium to a starting OD600 of 0.1 and incubated to 
OD600 of 0.6. The cells were again centrifuged at 1200g, 
resuspended in 100 mL M9/D2O medium, prepared with  
[
2
H, 
13
C]glucose and 
15
NH4Cl to a starting OD600 of 0.1 
and grown to an OD600 of 0.5. The culture was diluted to 
200 mL with M9/D2O medium and grown to an OD600 of 
0.5. The culture was diluted to 1 L using the same M9/D2O  
medium and grown to an OD600 of 0.25, after which 2-keto-3-
d2-1,2,3,4-
13
C-butyrate and 2-keto-3-methyl-
13
C-d1-  
4-
13
C-butyrate were added to final concentrations of 70 
mg/L and 120 mg/L, respectively. The culture was 
incubated further for 1 h, and protein expression was 
 
induced with 1 mM IPTG for 7–8 h at 30 °C. The 
process of cell growth took 30 h from start to completion. 
Cells were harvested and sonicated in 20 mM Tris–HCl 
(pH 7.5), 500 mM NaCl and 20 mM imidazole; the soluble 
fraction was obtained by centrifugation at 27,000g for 45 
min. The supernatant was applied to a charged HisTrap FF 
5-mL affinity column (GE Healthcare); washed with 20 mM 
Tris–HCl (pH 7.5), 500 mM NaCl, 20 mM imidaz-ole and 
eluted in 20 mM Tris (pH 7.5), 500 mM NaCl with a linear 
imidazole gradient from 20 mM to 500 mM. The eluted 
protein was cleaved with recombinant tobacco etch virus 
protease overnight at 4 °C and further purified by gel 
filtration on a Superdex-75 column (GE Healthcare). Protein 
concentrations were determined from the absor-bance at 
280 nm.  
All wild-type AGR241–175 samples for NMR were 
prepared in 20 mM 4-morpholineethanesulfonic acid  
(pH 6.5), 100 mM NaCl, 2 mM DTT, 0.02% (w/v) NaN3 and 
10% (v/v) D2O or 99.9% D2O, at a final protein 
concentration of 1 mM. E60A AGR241–175 samples were 
prepared in 20 mM phosphate buffer (pH 6.0), 150 mM 
NaCl, 3 mM DTT, 0.02% (w/v) NaN3 and 10% (v/v) D2O or 
99.9% D2O, at a final protein concentration of 0.3–1.2 mM.  
Mixed-labeled samples of AGR241–175 were made by 
mixing equal concentrations of labeled and unlabeled 
wild-type AGR241–175 at room temperature for between 
1 h and 120 h and with gentle heating up to 40 °C for 
between 2 min and 15 min. Mild denaturing conditions 
were also used in which hexahistidine-tagged 
13
C/
15
N-
labeled AGR241–175 and untagged unlabeled AGR241–
175 were incubated in 2 M urea overnight. The mixture 
was then thoroughly dialyzed into non-denaturing buffer 
over a period of 48 h. Nickel-affinity chromatography 
was then used to isolate hexahistidine-tagged protein 
and eluted with an imidazole gradient. Two peaks from 
the elution gradient were observed, one corresponding 
to mixed-labeled AGR241–175 and one corresponding to 
purely labeled wild-type AGR241–175. 
 
Sedimentation equilibrium 
 
Purified AGR241–175 was buffer exchanged into 20 
mM sodium phosphate (pH 6.5) with 150 mM NaCl, on a 
Superdex-75 10/300 (GE Healthcare) column. The 
eluted fractions were pooled and used for the dilution 
series. The final concentrations were 62 μM, 31 μM and 
6 μM, which were loaded into 6-well Epon-filled 
centerpieces with quartz windows. The samples were 
centrifuged at 15,000 rpm, 22,000 rpm and 30,000 rpm 
for 15 h at 20 °C performing scans at 290 nm, 280 nm 
and 232 nm for the three concentrations and analyzed 
using the Sedfit/ Sedphat suite of  programs.
43
 
 
Size-exclusion chromatography MALLS 
 
Proteins were chromatographed on Superdex-75 300 
mm×10 mm gel-filtration columns (GE Healthcare 
Life Sciences) equilibrated in 50 mM phosphate and 
50 mM  NaCl (pH 6.8)  at  0.71 mL/min.  Elution  was 
monitored by a Wyatt EOS 18-angle laser photometer 
(Wyatt Technology, Santa Barbara, CA), an Optilab rEX 
refractive index detector and a Jasco UV-2077 Plus UV/ 
Vis spectrophotometer (Jasco, Easton, MD); these were 
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coupled to a quasi elastic light-scattering detector for 
simultaneous measurement of hydrodynamic radius. 
Molar mass measurements were performed using both 
Astra 5.3.2.16 software (Wyatt Technology) and the “three 
detector method”. Values of mass and hydrodynamic 
radius are expressed as mean±standard error. 
 
NMR spectroscopy 
 
All spectra were acquired at 298 K on Bruker Avance  
III 600- and 800-MHz spectrometers. For AGR241–175, 
sequence-specific backbone resonance assignment 
was  
obtained using transverse relaxation optimized 
spectros-copy-based multidimensional heteronuclear 
NMR exper-iments [HNCA, HN(CO)CA, HNCACB, 
CBCA(CO)NH, HNCO, HN(CA)CO]. Leucine, 
isoleucine and valine side-chain methyl group 
assignments were obtained from a 3D (H)CCH3–
TOCSY experiment with 22.8 ms mixing  time.
22
 For 
E60A AGR241–175, sequence-specific back-bone 
resonance assignment was obtained using stan-dard 
NMR experiments [HNCA, HN(CO)CA, HNCACB, 
CBCA(CO)NH, HNCO, HN(CA)CO, HBHANH, HBHA 
(CO)NH]. Side-chain assignment was obtained using a 
3D HCCH–TOCSY experiment. NOEs were derived 
from 3D 
15
N- and 
13
C-edited NOESY–HSQC and 3D 
HMQC-NOESY-HMQC experiments with 200 ms 
mixing times. Paramagnetic surface mapping studies 
were carried out in 0.5–12 mM gadolinium complexed 
with diethylenetria-mine pentaacetic acid (Gd-DTPA) 
and 5–30 mM TEMPO, as paramagnetic relaxation 
agents. One-bond 
1
H–
15
N RDCs were obtained from 
[
1
H,
15
N] in-phase/ antiphase HSQC spectra. Values of 
the axial and rhombic components of the molecular 
alignment tensor for RDCs were obtained using the 
program  PALES.
44
 
 
RDC measurements 
 
For dimeric AGR241–175, RDCs were collected in two 
separate media: Pf1 bacteriophage (21 mg/mL) (Asla 
Biotech) and 5% (v/v) pentaethylene glycol 
monododecyl ether:hexanol in a 0.96:1 ratio. Protein 
concentrations in the range 0.3–0.6 mM were used in 
these experiments. The final values of the axial and 
rhombic components in the refinement stage were, 
respectively, −18.95 Hz and 0.40 Hz. For E60A 
AGR241–175, RDCs were collected in Pf1 
bacteriophage medium and the final values of the axial 
and rhombic components in the refinement stage were, 
respectively, 14.05 Hz and 0.46 Hz. 
 
NMR assignments and structure calculations 
 
All NMR spectra were processed with TopSpin 
(Bruker) and analyzed using the CCPN Analysis 
Package. AGR241–175 and E60A AGR241–175 
structure calculations were carried out using the  
CNS.
45
 The structures of AGR241–175 monomer 
subunit and E60A AGR241– 175 monomer were carried 
out using the CNS program with the IUPAC 
PARALLHDGv5.3 and TOPALLHDGv5.3 parameter 
sets. Backbone torsion angles were derived from 
analysis of C
α
, C
β
 and C′ chemical shifts using the 
TALOS+  program.
46
 The final set of calculated  
 
 
structures was obtained from water-refinement 
calculations in XPLOR-NIH. 
 
Dimer modeling 
 
An RDC-assisted modeling method, suitable for the 
structure determination of symmetrical  dimers,
23
 was 
used to orientate the monomeric subunits to obtain the 
dimeric structure. The method relies on the fact that an 
aligned protein has one of the principle axes of the 
alignment tensor orientated in parallel with the symmetry 
axis of the multimer. Hence, when the alignment tensors 
of a protein in two or more different alignment media are 
measured, the common alignment tensor is indica-tive of 
the symmetry axis. We measured the RDCs of AGR241–
175 in two media, Pf1 bacteriophage (21 mg/ mL) (Asla 
Biotech) and 5% (v/v) pentaethylene glycol monododecyl 
ether:hexanol. The  REDCAT
47
 program and the 
monomeric structure of AGR241–175 were used to 
determine the alignment tensors in each medium. 
Directions of the axes were plotted on a Sauson-
Flamsteed plot; the overlap of the PEG Sxx and 
bacteriophage Syy alignment tensor axes indicated the C2 
symmetry axis of AGR241– 175. Homodimer models in 
agreement with this symmetry restraint were then 
constructed using a grid-search algorithm, and these 
models were evaluated based on the quality of the 
interface between the subunits and the agreement with 
the experimental data.  
The VMD software  package
48
 was used to generate 
models of the homodimer. The lowest-energy structure of 
the ensemble of calculated monomeric subunit AGR241 –
175 structure was selected and rotated 180° about the 
derived symmetry axis to generate the orientation of the 
second subunit of the AGR241–175 homodimer. The grid 
search was performed using 230 steps in the x- and z-
axes (1 step equivalent to 1 Å), generating a total of 3002 
dimeric models with different x and z grid points. 
Generated models were rejected if intermolecular 
backbone atoms were b 4 Å or if the closest 
intermolecular atomic distance was N 2 Å, in accordance 
with Ref.  23. Relaxation of the side chains at the interface 
was performed with 500 ps molecular dynamics simulation 
and 100 steps of energy minimi-zation using the NAMD  
program
49
 and the CHARMM22 force field software. The 
calculated models were then evaluated according to the 
correlation between mea-sured and simulated RDC 
values using PALES and a residue-pairing score for each 
model. 
50
 Rigid-body minimization was performed on the 
20 best dimer structures selected from the residue-pairing 
and RDC correlation scores; 75.4% of the non-proline and 
non-glycine residues are in the most favored regions of 
the Ramachandran plot, 22.2% are in the additionally 
allowed regions, 0.8% are in the generously allowed 
regions and 1.6% are in the disallowed regions. 
 
Biochemical analyses 
 
Assay of free sulfhydryl groups was carried out using 
the Ellman's assay, which is a colorimetric assay based 
on the reaction between free thiol groups and  DTNB.
51
 
AGR2 (3.5 μM) and DTNB (4 mg/mL) in 0.1 M phosphate 
buffer (pH 8.0) (total volume of 2.2 mL) were incubated for 
5 min, and the absorbance was measured at 412 nm. 
Bovine RNase A and C81S AGR241–175 were used as 
negative controls in these assays. 
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Cell adhesion assays 
 
Cell adhesion assays were performed as described by 
Liu et al .
6
 24-well tissue culture plates with 1 nmol, or a 
specified concentration of AGR2 protein, by air drying at 
37 °C. Before use, coated wells were washed once with 
phosphate-buffered saline and left to air dry at room 
temperature. Cells were grown to 60–70% confluence, 
trypsinized and counted using a Coulter counter (Beck-
man Coulter). The cells were then resuspended to 2×10
5
 
cells/mL, recounted and 1 mL of cell suspension added 
to each well. Following a 60-min incubation at 37 °C, 
cells were washed three times with phosphate-buffered 
saline, 5×10
−
 
4
% (w/v) trypsin was added and the 
number of released cells was determined. Adhesion 
efficiency was calculated as the percentage of the total 
number of cells added to the well that had adhered 
during 60 min. Error bars represent the standard errors 
of the means from three independent experiments 
carried out with duplicate wells. 
 
Accession numbers 
 
Accession codes are as follows: wild-type AGR241–175,  
PDB ID: 2LNS; E60A AGR241–175, PDB ID: 2LNT; wild-
type AGR241–175 and E60A AGR241–175 chemical shifts, 
BioMagResBank codes 18178 and 18179, respectively. 
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Appendix 2. PiggyBac transposon vector maps. (A) Transposase expression vector. 
(B) Gene of interest expression vector. Note that the vector used in these studies 
contained the neomycin resistance marker (PB533A-2). Reproduced from Systems 
Biosciences [739]. 
 
  
 
 
 
 
A 
B 
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NoLS predictions for AGR2 
(these predictions are based on sequence and Jpred predictions) 
 
 
This protein has no predicted NoLS.  
 
 
 
 
 
Appendix 3. Prediction of AGR2 nucleolar localisation sequences (NoLS) by NoD 
server [731]. Full length AGR2 primary protein sequence was submitted to 
http://www.compbio.dundee.ac.uk/www-nod/ for NoLS prediction. A score above 
0.8 represent a candidate NoLS. 
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cNLS Mapper Result 
 
Predicted NLSs in query sequence 
MEKIPVSAFLLLVALSYTLARDTTVKPGAKKDTKDSRPKLPQTLSRGWGD 50  
QLIWTQTYEEALYKSKTSNKPLMIIHHLDECPHSQALKKVFAENKEIQKL 100  
AEQFVLLNLVYETTDKHLSPDGQYVPRIMFVDPSLTVRADITGRYSNRLY 150  
AYEPADTALLLDNMKKALKLLKTEL                          175 
 
Predicted monopartite NLS 
Pos. Sequence Score 
 
Predicted bipartite NLS 
Pos. Sequence Score 
138 
144 
RADITGRYSNRLYAYEPADTALLLDNMKKALKL 
RYSNRLYAYEPADTALLLDNMKKALKLLKTE 
5.7 
5.1 
 
 
Appendix 4. Prediction of AGR2 nuclear localisation sequences (NLS) by cNLS 
Mapper server [575]. Full length AGR2 primary protein sequence was submitted to 
http://nls-mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi for NLS prediction. 
The predicted NLS is highlighted in red. Green fluorescent protein tagged with an NLS 
with a score above 8 localises exclusively to the nucleus, with a score of 3-5 to the 
nucleus and cytoplasm and with a score of 1-2 to the cytoplasm. 
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Pdb file name: 2LNS.pdb 
 
 Protein-Protein  hydrophobic  Interaction 
 ----------------------------------------- 
POS     RES     CHA     POS     RES     CHA 
53      ILE     A       53      ILE     B 
63      TYR     A       63      TYR     B 
 
 NO PROTEIN-PROTEIN DISULPHIDE BRIDGES ARE FOUND 
 
 NO PROTEIN-PROTEIN HYDROGEN BONDS ARE FOUND 
 
 NO PROTEIN-PROTEIN MAIN CHAIN-SIDE CHAIN HYDROGEN BONDS ARE FOUND 
 
 Protein-protein Side chain-Side chain hydrogen bonds 
 ---------------------------------------------------- 
POS     CHAIN   RES     ATOM    POS     CHAIN   RES     ATOM    MO      Dd-a    Dh-a    A(d-H-N) A(a-O=C) 
54      A       TRP     NE1     50      B       ASP     OD2     -       2.94    2.32    125.15   999.99 
64      A       LYS     NZ      60      B       GLU     OE1     -       2.24    9.99    999.99   999.99 
64      A       LYS     NZ      60      B       GLU     OE2     -       2.23    9.99    999.99   999.99 
54      B       TRP     NE1     50      A       ASP     OD2     -       2.78    2.03    139.32   999.99 
64      B       LYS     NZ      60      A       GLU     OE1     -       2.39    9.99    999.99   999.99 
Appendix 5 (continued overleaf). Measurement of protein 
interactions by Protein Interaction Calculator (PIC) server 
[732]. The AGR2 41-175 structure file (2LNS.pdb) was 
submitted to http://pic.mbu.iisc.ernet.in/. POS: position. 
RES: residue. CHA: chain. DIST: distance. ANGL: angle. Dd-a: 
distance between donor and acceptor (Å). Dh-a: distance 
between donor hydrogen and acceptor (Å). A (d-H-N): angle 
between donor and acceptor amine group (degrees). A value 
of 1 (999.99) indicates the angle is not defined. A (d-O=C): 
angle between donor and acceptor carbonyl group 
(degrees). A value of 999.99 indicates that the angle is not 
defined. 
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64      B       LYS     NZ      60      A       GLU     OE2     -       2.33    9.99    999.99   999.99 
 Protein-Protein Ionic Interaction 
 --------------------------------- 
POS     RES     CHA     POS     RES     CHA 
60      GLU     A       64      LYS     B 
64      LYS     A       60      GLU     B 
 
 Protein-Protein  aromatic-aromatic Interaction 
 ---------------------------------------------- 
POS     RES     CHA     POS     RES     CHA     DIST    ANGL 
63      TYR     A       63      TYR     B       6.54    72.55 
 
 NO PROTEIN-PROTEIN AROMATIC-SULPHUR INTERACTIONS ARE FOUND 
 
 Protein-Protein Cation-pi Interaction 
 ------------------------------------- 
POS     RES     CHA     POS     RES     CHA     DIST    ANGL 
 
54      TRP     A       46      ARG     B       5.36    68.02 
54      TRP     B       46      ARG     A       5.06    65.58 
 
Appendix 5 (cont.). Measurement of protein interactions by 
Protein Interaction Calculator (PIC) server [732] (cont.). The 
AGR2 41-175 structure file (2LNS.pdb) was submitted to 
http://pic.mbu.iisc.ernet.in/. POS: position. RES: residue. 
CHA: chain. DIST: distance. ANGL: angle. Dd-a: distance 
between donor and acceptor (Angstrom (Å)). Dh-a: distance 
between donor hydrogen and acceptor (Å). A (d-H-N): angle 
between donor and acceptor amine group (degrees). A value 
of 1 (999.99) indicates the angle is not defined. A (d-O=C): 
angle between donor and acceptor carbonyl group 
(degrees). A value of 999.99 indicates that the angle is not 
defined. 
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Welcome to the CaPTURE program.  Copyright 1999 Justin P. Gallivan. 
*****************  Report for the protein pdb2lns.ent  ***************** 
 
This protein has 280 amino acids of which: 
 24 (8.6%) are Lysine 
 10 (3.6%) are Arginine 
 8 (2.9%) are Phenylalanine 
 14 (5.0%) are Tyrosine 
 4 (1.4%) are Tryptophan 
This protein has 2 chains.  They are: 
 Chain A with 140 residues. 
 Chain B with 140 residues. 
 
The protein has an apparent molecular  
weight of 32427 D 
 
***********************  Cation-Pi Summary  *********************** 
Number of ARG/PHE interacting pairs: 0 
Number of energetically significant ARG/PHE cation-pi interactions: 0 
Number of ARG/TYR interacting pairs: 6 
Number of energetically significant ARG/TYR cation-pi interactions: 0 
Number of ARG/TRP interacting pairs: 2 
Number of energetically significant ARG/TRP cation-pi interactions: 0 
Number of LYS/PHE interacting pairs: 2 
Number of energetically significant LYS/PHE cation-pi interactions: 0 
Number of LYS/TYR interacting pairs: 2 
Number of energetically significant LYS/TYR cation-pi interactions: 0 
Number of LYS/TRP interacting pairs: 2 
Number of energetically significant LYS/TRP cation-pi interactions: 0 
 
* There is a total of 0 energetically significant cation-pi interactions. 
 
* There are 0 cation-pi interactions with E(es) <= -2.0 kcal/mol 
 
* There are 0 cation-pi interactions with E(es) between -2.0 and -1.0 
  kcal/mol and with E(vdw) <= -1.0 kcal/mol 
 
 
Appendix 6. Measurement of cation-π interaction in AGR2 structure by CaPTURE server 
[565]. The AGR2 41-175 structure file (2LNS.pdb) was submitted to 
http://capture.caltech.edu/. 
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HBPLUS Hydrogen Bond Calculator v 3.2             
(c) I McDonald, D Naylor, D Jones and J Thornton 1993 All Rights Reserved. 
Citing HBPLUS in publications that use these results is condition of use. 
2LNS <- Brookhaven Code "2LNS.pdb" <- PDB file 
 
<---DONOR---> <-ACCEPTOR-->    atom                        ^                
c    i                          cat <-CA-CA->   ^        H-A-AA   ^      H-  
h    n   atom  resd res      DA  || num        DHA   H-A  angle D-A-AA Bond 
n    s   type  num  typ     dist DA aas  dist angle  dist       angle   num 
A0046-ARG N   A0043-THR O   2.56 MM   3  4.69 133.3  1.79 109.7 125.5     1 
A0046-ARG NH2 A0050-ASP OD2 2.43 SS   4  7.62 129.3  1.67 146.5 129.9     2 
A0052-LEU N   A0049-GLY O   2.83 MM   3  4.58 111.0  2.33  98.6 117.3     3 
A0051-GLN NE2 A0050-ASP OD2 2.62 SS   1  3.74 152.0  1.72 104.0 101.4     4 
B0054-TRP NE1 A0050-ASP OD2 2.78 SS  -1  7.48 147.2  1.90  92.4  98.2     5 
A0055-THR N   A0053-ILE O   3.10 MM   2  5.83 130.7  2.37 106.2  92.4     6 
A0057-THR N   A0056-GLN OE1 2.68 MS   1  3.74 159.0  1.74 114.2 106.7     7 
A0056-GLN NE2 A0108-ASN O   2.86 SM  52  6.00 145.5  2.00 160.6 159.2     8 
A0061-ALA N   A0058-TYR O   2.46 MM   3  5.00 115.3  1.88 128.4 147.4     9 
A0062-LEU N   A0058-TYR O   3.10 MM   4  6.40 152.8  2.19 138.6 146.6    10 
A0059-GLU N   A0059-GLU OE2 2.48 MS   0 -1.00 131.2  1.72  97.8  91.4    11 
A0062-LEU N   A0059-GLU O   2.52 MM   3  4.90 110.2  2.00 112.9 132.9    12 
A0063-TYR N   A0059-GLU O   2.69 MM   4  5.92 162.4  1.74 153.8 159.4    13 
A0064-LYS N   A0060-GLU O   2.88 MM   4  6.16 168.1  1.91 171.1 167.7    14 
B0064-LYS NZ  A0060-GLU OE2 2.33 SS  -1  9.06 115.9  1.68 115.4  92.5    15 
A0065-SER N   A0061-ALA O   3.10 MM   4  6.16 160.2  2.15 145.2 151.4    16 
A0066-LYS N   A0062-LEU O   2.69 MM   4  5.74 166.6  1.72 157.1 161.9    17 
A0067-THR N   A0063-TYR O   3.04 MM   4  6.32 156.0  2.11 158.7 165.2    18 
A0067-THR OG1 A0064-LYS O   2.49 SM   3  5.29 136.0  1.70 141.1 138.4    19 
A0064-LYS NZ  A0067-THR OG1 2.89 SS   3  5.29 111.4  2.34  95.2 103.2    20 
A0068-SER N   A0065-SER O   2.86 MM   3  5.57 153.1  1.94 122.3 130.7    21 
A0069-ASN N   A0066-LYS O   2.59 MM   3  4.36 141.2  1.75 101.4 114.9    22 
A0066-LYS NZ  A0069-ASN OD1 2.44 SS   3  4.36 121.1  1.74 111.1 130.7    23 
A0066-LYS NZ  A0133-PRO O   2.63 SM  67  7.21 134.2  1.80 148.5 160.1    24 
A0069-ASN ND2 A0069-ASN O   2.55 SM   0 -1.00 116.1  1.96 127.1 113.7    25 
A0072-LEU N   A0131-VAL O   2.74 MM  59  4.47 162.6  1.78 141.8 145.7    26 
A0131-VAL N   A0072-LEU O   2.60 MM  59  4.47 138.5  1.79 138.2 145.4    27 
A0074-ILE N   A0129-MET O   2.82 MM  55  5.20 173.7  1.84 159.1 157.5    28 
A0129-MET N   A0074-ILE O   3.01 MM  55  5.20 143.5  2.16 142.7 135.1    29 
A0076-HIS N   A0127-ARG O   2.90 MM  51  5.00 140.0  2.08 145.4 135.5    30 
A0127-ARG N   A0076-HIS O   3.34 MM  51  5.00 155.1  2.42 158.2 153.9    31 
A0076-HIS ND1 A0125-VAL O   3.43 SM  49  7.14 159.4  2.49 148.6 142.8    32 
A0076-HIS NE2 A0109-LEU O   3.02 SM  33  6.40 123.8  2.36 137.9 141.3    33 
A0077-HIS NE2 A0108-ASN OD1 2.48 SS  31  5.66 126.1  1.77 158.1 156.2    34 
A0084-SER N   A0081-CYS O   3.02 MM   3  6.24 130.9  2.29 153.1 153.9    35 
A0086-ALA N   A0083-HIS O   2.70 MM   3  5.29 146.7  1.82 115.7 127.0    36 
A0087-LEU N   A0084-SER O   2.90 MM   3  5.39 105.2  2.48 117.3 133.0    37 
A0088-LYS N   A0084-SER O   2.93 MM   4  6.08 179.3  1.94 163.9 164.1    38 
A0089-LYS NZ  A0085-GLN O   2.65 SM   4  6.24 145.3  1.73 109.0  97.7    39 
A0089-LYS N   A0086-ALA O   2.86 MM   3  5.29 146.4  1.99 109.3 120.2    40 
A0091-PHE N   A0087-LEU O   2.81 MM   4  5.66 146.7  1.94 160.8 169.2    41 
Appendix 7 (continued overleaf). Measurement of hydrogen bonding in the AGR2 
structure by HBPLUS software [733]. The AGR2 41-175 structure file (2LNS.pdb) was used 
for hydrogen bond measurements. chn: chain. ins: insert. red/res: residue. D: donor. A: 
acceptor. AA: acceptor antecedent (next residue in chain after acceptor). cat: category. 
M: main chain. S: side-chain. CA: alpha carbon. num aas: distance (in amino 
acids)between donor and acceptor groups (-1 indicates this does not apply). dist: 
distance. DHA angle: angle formed at the hydrogen of donor and acceptor. H-A-AA: 
smaller angle at the acceptor formed by the hydrogen and an acceptor antecedent. D-A-
AA: smaller angle at the acceptor formed by the donor and an acceptor antecedent. H: 
hydrogen. num: number. All distances are in Angstroms (Å) and all angles in degrees. 
Inter-chain hydrogen bonds are highlighted in red. 
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A0092-ALA N   A0089-LYS O   3.18 MM   3  6.08 153.2  2.27 124.2 128.0    42 
A0093-GLU N   A0090-VAL O   2.75 MM   3  5.20 129.7  2.02 112.9 127.6    43 
A0094-ASN N   A0090-VAL O   2.69 MM   4  5.74 166.6  1.73 167.8 169.6    44 
A0094-ASN ND2 A0090-VAL O   2.79 SM   4  5.74 161.2  1.85 110.1 105.5    45 
A0095-LYS N   A0093-GLU O   2.55 MM   2  5.48 136.5  1.75 116.6 101.8    46 
A0097-ILE N   A0094-ASN O   2.68 MM   3  5.57 126.0  1.99 133.7 145.6    47 
A0157-THR OG1 A0094-ASN OD1 2.72 SS  63  7.48 144.3  1.87 150.4 144.2    48 
A0099-LYS N   A0095-LYS O   2.92 MM   4  6.00 164.7  1.96 163.0 162.7    49 
A0100-LEU N   A0096-GLU O   3.30 MM   4  6.56 141.0  2.47 144.7 154.3    50 
A0100-LEU N   A0097-ILE O   2.85 MM   3  5.29 133.7  2.08 111.5 124.9    51 
A0101-ALA N   A0097-ILE O   2.75 MM   4  5.92 148.8  1.86 146.0 155.3    52 
A0101-ALA N   A0098-GLN O   2.43 MM   3  4.47 110.8  1.90 108.8 130.9    53 
A0102-GLU N   A0098-GLN O   2.68 MM   4  5.57 158.0  1.74 162.4 158.9    54 
A0103-GLN NE2 A0099-LYS O   2.61 SM   4  6.24 149.0  1.72 129.6 129.7    55 
A0113-THR OG1 A0111-TYR O   2.77 SM   2  6.00 165.7  1.82 158.9 160.8    56 
A0115-ASP N   A0113-THR O   2.66 MM   2  5.66 121.1  2.02 120.0 104.3    57 
A0118-LEU N   A0115-ASP O   2.73 MM   3  5.48 161.1  1.78 132.9 138.5    58 
A0127-ARG N   A0125-VAL O   2.43 MM   2  5.57 105.4  1.97 124.5 112.1    59 
A0152-TYR OH  A0126-PRO O   2.70 SM  26  7.28 135.3  1.93 165.8 166.0    60 
A0129-MET N   A0127-ARG O   2.99 MM   2  5.66 114.6  2.44 111.7  95.4    61 
A0127-ARG NH2 A0152-TYR OH  2.31 SS  25  9.85 108.2  1.79 164.2 171.1    62 
A0132-ASP N   A0136-THR O   2.84 MM   4  5.00 142.8  2.00 145.9 137.3    63 
A0135-LEU N   A0132-ASP O   2.56 MM   3  5.29 142.6  1.72 140.2 144.0    64 
A0136-THR OG1 A0132-ASP OD1 3.01 SS   4  5.00 148.4  2.14 109.2  99.6    65 
A0138-ARG NH1 A0132-ASP OD2 3.28 SS   6  6.32 163.3  2.30 133.2 135.8    66 
A0138-ARG N   A0136-THR O   2.62 MM   2  5.66 122.7  1.96 119.8 104.5    67 
A0139-ALA N   A0137-VAL O   2.73 MM   2  5.48 140.9  1.89 109.0  95.9    68 
A0141-ILE N   A0138-ARG O   3.02 MM   3  5.74 133.6  2.26 126.8 130.2    69 
A0163-ASN ND2 A0141-ILE O   2.95 SM  22  7.75 152.6  2.04 150.2 142.8    70 
A0166-LYS NZ  A0142-THR O   3.05 SM  24  8.83 147.0  2.12 178.0 168.3    71 
A0148-ARG N   A0145-TYR O   2.74 MM   3  5.48 170.4  1.77 137.1 139.3    72 
A0151-ALA N   A0148-ARG O   2.90 MM   3  5.83 150.3  2.01 139.9 145.2    73 
A0148-ARG NE  A0156-ASP OD1 2.30 SS   8  7.68 127.4  1.55 147.2 164.9    74 
A0153-GLU N   A0151-ALA O   2.38 MM   2  5.57 105.6  1.92 124.0 114.2    75 
A0156-ASP N   A0153-GLU O   2.87 MM   3  4.69 172.6  1.89 114.0 114.9    76 
A0159-LEU N   A0156-ASP O   2.66 MM   3  5.74 125.0  1.97 147.4 157.3    77 
A0160-LEU N   A0156-ASP O   3.25 MM   4  6.32 160.4  2.31 139.6 142.8    78 
A0161-LEU N   A0157-THR O   2.65 MM   4  5.48 161.7  1.70 146.7 152.2    79 
A0162-ASP N   A0158-ALA O   2.94 MM   4  6.08 167.4  1.97 147.1 151.0    80 
A0163-ASN N   A0159-LEU O   2.68 MM   4  5.66 170.5  1.71 161.1 164.5    81 
A0164-MET N   A0160-LEU O   3.09 MM   4  6.24 169.4  2.12 150.6 150.8    82 
A0165-LYS N   A0161-LEU O   2.67 MM   4  5.66 163.0  1.72 164.1 167.7    83 
A0166-LYS N   A0162-ASP O   2.55 MM   4  5.57 122.8  1.88 139.8 157.9    84 
A0166-LYS N   A0163-ASN O   2.66 MM   3  4.69 123.4  1.99  98.4 116.3    85 
A0167-ALA N   A0163-ASN O   2.48 MM   4  5.74 136.1  1.68 152.4 167.8    86 
A0167-ALA N   A0164-MET O   2.88 MM   3  4.69 121.2  2.25  94.2 110.6    87 
A0168-LEU N   A0164-MET O   3.05 MM   4  6.24 163.6  2.10 165.0 166.0    88 
A0169-LYS NZ  A0165-LYS O   2.24 SM   4  6.63 102.6  1.76 137.3 126.3    89 
A0169-LYS N   A0166-LYS O   3.13 MM   3  5.00 149.6  2.24 102.9 106.9    90 
B0040-THR OG1 B0039-PHE O   2.65 SM   1  3.74 141.9  1.83 105.6  93.9    91 
B0040-THR OG1 B0040-THR O   2.60 SM   0 -1.00 122.1  1.96  97.0  90.8    92 
B0046-ARG N   B0043-THR O   2.74 MM   3  4.69 138.9  1.93 105.6 117.9    93 
B0047-GLY N   B0045-SER O   2.58 MM   2  5.48 139.1  1.76 115.4 101.1    94 
B0046-ARG NH1 B0050-ASP OD1 2.42 SS   4  7.00 125.5  1.69 110.5 112.3    95 
B0046-ARG NH2 B0050-ASP OD2 2.54 SS   4  7.00 148.4  1.63 110.7 101.3    96 
B0050-ASP N   B0047-GLY O   2.70 MM   3  4.36 147.4  1.82 117.1 116.4    97 
B0051-GLN NE2 B0050-ASP O   2.50 SM   1  3.74 132.6  1.73  95.3  91.2    98 
B0051-GLN NE2 B0050-ASP OD2 2.57 SS   1  3.74 142.4  1.72 124.9 117.2    99 
B0055-THR N   B0053-ILE O   3.07 MM   2  5.74 132.0  2.32 106.4  92.6   100 
B0108-ASN ND2 B0055-THR O   3.30 SM  53  7.35 140.8  2.48 172.6 162.3   101 
B0057-THR N   B0056-GLN OE1 2.66 MS   1  3.74 152.7  1.76 117.8 108.5   102 
B0056-GLN NE2 B0108-ASN O   2.66 SM  52  6.00 150.9  1.76 160.0 157.9   103 
B0061-ALA N   B0057-THR O   3.36 MM   4  6.56 166.0  2.40 149.1 153.2   104 
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B0061-ALA N   B0058-TYR O   2.53 MM   3  5.00 110.0  2.02 123.4 142.6   105 
B0062-LEU N   B0058-TYR O   2.96 MM   4  6.24 154.1  2.04 142.8 150.1   106 
B0062-LEU N   B0059-GLU O   2.54 MM   3  4.80 110.4  2.03 106.9 127.3   107 
B0063-TYR N   B0059-GLU O   2.77 MM   4  6.08 157.8  1.83 158.3 165.5   108 
B0064-LYS N   B0060-GLU O   2.88 MM   4  6.16 174.3  1.89 172.7 170.8   109 
B0065-SER N   B0061-ALA O   3.29 MM   4  6.40 158.8  2.36 144.1 149.8   110 
B0066-LYS N   B0062-LEU O   2.70 MM   4  5.83 155.6  1.78 147.0 155.4   111 
B0067-THR N   B0063-TYR O   2.85 MM   4  6.08 166.4  1.88 175.0 172.3   112 
B0068-SER N   B0065-SER O   2.67 MM   3  5.20 145.4  1.81 115.8 127.8   113 
B0069-ASN N   B0065-SER O   3.00 MM   4  6.24 116.4  2.44 138.6 153.0   114 
B0065-SER OG  B0070-LYS O   3.00 SM   5  6.16 143.8  2.17 161.9 167.1   115 
B0069-ASN N   B0066-LYS O   2.65 MM   3  4.69 146.7  1.78 108.2 119.9   116 
B0069-ASN ND2 B0069-ASN O   2.62 SM   0 -1.00 135.8  1.83 122.1 107.8   117 
B0072-LEU N   B0131-VAL O   2.81 MM  59  4.58 168.2  1.84 141.7 144.3   118 
B0131-VAL N   B0072-LEU O   2.58 MM  59  4.58 138.5  1.77 141.0 147.8   119 
B0074-ILE N   B0129-MET O   2.82 MM  55  5.29 169.5  1.84 164.0 160.8   120 
B0129-MET N   B0074-ILE O   3.05 MM  55  5.29 137.4  2.25 144.2 135.8   121 
B0076-HIS N   B0127-ARG O   2.94 MM  51  5.00 139.2  2.12 143.8 133.4   122 
B0127-ARG N   B0076-HIS O   3.34 MM  51  5.00 150.2  2.46 154.2 152.7   123 
B0077-HIS NE2 B0108-ASN OD1 2.47 SS  31  5.66 124.3  1.78 154.9 154.7   124 
B0084-SER OG  B0078-LEU O   2.83 SM   6  6.48 104.0  2.44 145.8 163.9   125 
B0084-SER OG  B0079-ASP OD1 3.19 SS   5  5.74 168.8  2.23 163.8 160.5   126 
B0084-SER N   B0081-CYS O   2.85 MM   3  6.08 135.1  2.07 156.1 156.6   127 
B0086-ALA N   B0083-HIS O   2.71 MM   3  5.20 143.7  1.86 112.2 124.5   128 
B0087-LEU N   B0084-SER O   2.92 MM   3  5.48 106.0  2.49 120.8 135.9   129 
B0088-LYS N   B0084-SER O   2.97 MM   4  6.16 178.3  1.99 162.7 162.5   130 
B0089-LYS NZ  B0085-GLN O   2.60 SM   4  6.24 144.3  1.68 109.6  97.9   131 
B0089-LYS N   B0086-ALA O   2.88 MM   3  5.29 147.4  2.00 109.5 120.0   132 
B0091-PHE N   B0087-LEU O   2.83 MM   4  5.66 147.4  1.96 161.5 169.3   133 
B0092-ALA N   B0089-LYS O   3.16 MM   3  6.08 153.3  2.25 125.3 129.0   134 
B0093-GLU N   B0090-VAL O   2.76 MM   3  5.20 129.5  2.03 113.0 127.7   135 
B0094-ASN N   B0090-VAL O   2.69 MM   4  5.74 166.7  1.73 167.8 169.5   136 
B0094-ASN ND2 B0090-VAL O   2.79 SM   4  5.74 161.1  1.85 110.2 105.5   137 
B0095-LYS N   B0093-GLU O   2.55 MM   2  5.48 136.5  1.75 116.7 101.9   138 
B0097-ILE N   B0094-ASN O   2.68 MM   3  5.57 126.1  1.99 133.7 145.6   139 
B0157-THR OG1 B0094-ASN OD1 2.72 SS  63  7.48 143.6  1.88 150.6 144.2   140 
B0099-LYS N   B0095-LYS O   2.91 MM   4  6.00 165.0  1.96 163.1 162.8   141 
B0100-LEU N   B0096-GLU O   3.30 MM   4  6.56 140.7  2.48 144.5 154.3   142 
B0100-LEU N   B0097-ILE O   2.85 MM   3  5.29 133.8  2.08 111.4 124.8   143 
B0101-ALA N   B0097-ILE O   2.75 MM   4  5.92 148.7  1.87 146.0 155.3   144 
B0101-ALA N   B0098-GLN O   2.44 MM   3  4.47 111.0  1.91 108.8 130.9   145 
B0102-GLU N   B0098-GLN O   2.68 MM   4  5.57 157.8  1.74 162.6 159.0   146 
B0103-GLN NE2 B0099-LYS O   2.60 SM   4  6.24 147.7  1.72 130.5 130.2   147 
B0113-THR OG1 B0111-TYR O   2.78 SM   2  6.00 165.8  1.83 159.4 160.4   148 
B0115-ASP N   B0113-THR O   2.69 MM   2  5.66 122.8  2.03 118.7 103.0   149 
B0118-LEU N   B0115-ASP O   2.73 MM   3  5.48 161.9  1.78 133.4 138.9   150 
B0116-LYS N   B0115-ASP OD1 2.76 MS   1  3.74 108.6  2.29 115.2 110.6   151 
B0127-ARG N   B0125-VAL O   2.52 MM   2  5.66  98.4  2.18 123.3 112.3   152 
B0129-MET N   B0127-ARG O   2.87 MM   2  5.57 118.3  2.27 113.0  96.5   153 
B0127-ARG NH2 B0152-TYR OH  2.31 SS  25  9.85  91.9  2.05 127.7 140.9   154 
B0132-ASP N   B0136-THR O   2.84 MM   4  5.10 136.1  2.05 153.2 140.1   155 
B0135-LEU N   B0132-ASP O   2.55 MM   3  5.39 134.0  1.77 140.1 148.2   156 
B0138-ARG NH1 B0132-ASP OD2 3.29 SS   6  6.16 148.5  2.39 101.9 110.6   157 
B0138-ARG N   B0136-THR O   2.64 MM   2  5.66 117.9  2.03 120.5 106.0   158 
B0139-ALA N   B0137-VAL O   2.80 MM   2  5.48 143.9  1.94 104.5  93.1   159 
B0141-ILE N   B0138-ARG O   2.97 MM   3  5.74 135.6  2.19 128.7 132.9   160 
B0163-ASN ND2 B0141-ILE O   3.00 SM  22  7.81 154.3  2.08 145.9 139.2   161 
B0166-LYS NZ  B0142-THR O   3.02 SM  24  8.77 145.5  2.10 177.8 169.3   162 
B0142-THR OG1 B0146-SER OG  2.64 SS   4  5.57 150.7  1.76  95.1  90.5   163 
B0148-ARG N   B0145-TYR O   2.71 MM   3  5.39 166.8  1.75 132.1 136.1   164 
B0151-ALA N   B0148-ARG O   3.06 MM   3  5.92 141.7  2.23 133.3 140.0   165 
B0148-ARG NE  B0156-ASP OD1 2.35 SS   8  7.68 133.0  1.55 150.6 166.5   166 
B0153-GLU N   B0151-ALA O   2.39 MM   2  5.57 110.1  1.87 124.1 112.9   167 
 
 
 
 
 
Appendix 7. Measurement of hydrogen bonding in the AGR2 structure by HBPLUS 
software (cont.).   
Appendices 
233 
 
B0156-ASP N   B0153-GLU O   2.90 MM   3  4.80 172.9  1.93 113.5 114.6   168 
B0159-LEU N   B0156-ASP O   2.67 MM   3  5.74 123.7  2.00 146.7 157.1   169 
B0160-LEU N   B0156-ASP O   3.24 MM   4  6.24 161.0  2.29 140.2 143.2   170 
B0161-LEU N   B0157-THR O   2.64 MM   4  5.48 161.4  1.70 146.1 151.7   171 
B0162-ASP N   B0158-ALA O   2.94 MM   4  6.08 168.4  1.97 148.7 152.1   172 
B0163-ASN N   B0159-LEU O   2.68 MM   4  5.66 169.6  1.71 160.1 163.8   173 
B0164-MET N   B0160-LEU O   3.09 MM   4  6.24 169.7  2.12 150.9 151.1   174 
B0165-LYS N   B0161-LEU O   2.67 MM   4  5.66 163.4  1.72 164.2 167.7   175 
B0166-LYS N   B0162-ASP O   2.54 MM   4  5.57 122.7  1.87 139.9 158.0   176 
B0166-LYS N   B0163-ASN O   2.66 MM   3  4.69 123.6  1.99  98.4 116.3   177 
B0167-ALA N   B0163-ASN O   2.49 MM   4  5.74 137.2  1.68 152.6 167.6   178 
B0167-ALA N   B0164-MET O   2.89 MM   3  4.80 120.4  2.27  93.9 110.4   179 
B0168-LEU N   B0164-MET O   3.05 MM   4  6.24 163.1  2.10 164.3 165.7   180 
B0169-LYS NZ  B0165-LYS O   2.24 SM   4  6.63 102.7  1.76 137.3 126.3   181 
B0169-LYS N   B0166-LYS O   3.10 MM   3  5.00 149.1  2.22 104.3 107.9   182 
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Appendix 8. SDS-resistant dimers in recombinant AGR2 purification. Proteins were 
purified as described in Materials and Methods and the unpurified and purified 
fractions runs on SDS-PAGE gels. AGR221-175 has an expected molecular weight of 17.8 
kDA for a monomer and 35.6 kDa for a dimer. AGR241-175 has an expected molecular 
weight of 16.1 kDa for a monomer and 32.2 kDa for a dimer. The band seen at ~45 
kDa in AGR221-175 is spill over from the unpurified lane, whilst the band at ~10 kDa is a 
low molecular weight contaminant. Notice the slight increase in dimer band size in 
AGR241-175 compared to AGR221-175 and the lack of dimer band in E60A AGR221-175.  
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Appendix 9. Peptide coating does not affect rate of cell adhesion. Wells were coated 
overnight with buffer containing equimolar concentrations of either AGR221-175, a 
peptide corresponding to residues 21-40 of AGR2 (sequence 
RDTTVKPGAKKDTKDSRPKL) or an unrelated peptide with a similar number of 
positively charged residues (sequence TADAMNREVSSLKNKLRRGD). Rama 37 cells 
were then allowed to adhere to the coated wells for 60 min and the number of 
bound cells was counted using an automated cell counter. The number of adhering 
cells is expressed as a percentage of the number added to each well. The means from 
duplicate wells from 3 independent experiments are shown, ±SE. 
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Appendix 10. Calibration of AGR2 21-40 peptide coating. Wells were coated 
overnight with the indicated concentrations of AGR221-175 or 21-40 peptide and then 
subjected to an ELISA assay to measure the relative amounts of protein/peptide 
bound. (A) ELISA of coating in PBS buffer (pH 7.4). (B) ELISA of coating in carbonate 
buffer (pH 10.6). The bottom x-axis (blue) indicates the amount of AGR2 21-175 coated 
and the top x-axis (red) indicates the amount of peptide coated. (C) Representative 
calibration curve of AGR221-175 binding used to determine the amount of peptide 
required to achieve equal binding. 
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Appendix 11. Optimisation of trypsin detachment assay. (A) Wild type (WT) AGR2-
expressing and empty vector (EV) control cells were allowed to adhere for 30 min to 
cell culture plates. Attached cells were then treated with the indicated 
concentrations of trypsin for 5 min and the remaining attached cells were counted 
with an automated cell counter. The percentage of trypsin-resistant cells represents 
the proportion of applied cells attaching in 30 min that remained adherent after 
treatment with the indicated trypsin concentrations. The means from duplicate wells 
from a single experiment are shown, ±SD. (B) Cells were grown overnight to 70-80 % 
confluence and then trypsinised in the indicated trypsin solutions for 5 min. The 
remaining adhering cells were counted with an automated cell counter. The number 
of trypsin-resistant cells is expressed as a percentage of the total number of cells in 
each well. The means from duplicate wells from a single experiment are shown, ±SD. 
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Appendix 12. Clonal AGR2-expressing cell attach more strongly than control cells. 
Cells in suspension were added to wells and briefly centrifuged at 10 x g to ensure all 
cells were in contact with the plate surface. After a subsequent 10 min incubation, 
plates were sealed and centrifuged upside down for 10 min at 300 x g. Remaining 
adhering cells were quantified using crystal violet staining as described in Materials 
and Methods. The mean staining relative to WT AGR2 clone 2 from 3 independent 
experiments carried out using duplicate wells is shown, ±SE. 
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Appendix 13. R37E cells are elongated but do not express AGR2. Cells were grown to 
70-80 % confluence, harvested and probed for AGR2 by Western blot. The R37E lane 
is from a different part of the same blot. 
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Appendix 14. Quantification of steady-state protein levels of mutant AGR2 cell 
lines. Mean steady-state protein levels from three sets of whole cell lysates were 
measured by Western blot, and AGR2 abundance was measured relative to the levels 
in WT AGR2 pool 2 cells. Data are shown ±SE.  
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Appendix 15. Monolayer attachment properties of mutant-AGR2- expressing clonal 
cell lines. The indicated cells were grown overnight to 70-80 % confluence and then 
trypsinised in a weak trypsin solution for 5 min. The remaining adhering cells were 
counted with an automated cell counter. The number of trypsin-resistant cells is 
expressed as a percentage of the total number of cells in each well. The proportion of 
trypsin-resistant cells is expressed relative to the number of trypsin-resistant WT 
clone 2 cells in individual experiments. The means from duplicate wells from 3 
independent experiments are shown, ±SE. 
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Cell SR 
EV clone 1 1.82 
EV clone 2 1.78 
EV clone 3 1.94 
WT AGR2 clone 2 2.48 
WT AGR2 clone 5 2.53 
WT AGR2 clone 13 2.09 
E60A AGR2 clone 1 1.78 
E60A AGR2 clone 18 1.78 
E60A AGR2 clone 19 1.81 
C81S AGR2 clone 7 1.74 
C81S AGR2 clone 10 1.58 
C81S AGR2 clone 15 1.70 
Δ1-20 AGR2 clone 6 1.68 
Δ1-20 AGR2 clone 8 1.93 
Δ1-20 AGR2 clone 11 1.84 
Δ21-40 AGR2 clone 3 2.13 
Δ21-40 AGR2 clone 4 1.99 
Δ21-40 AGR2 clone 8 1.72 
ΔKTEL AGR2 clone 5 2.06 
ΔKTEL AGR2 clone 8 1.85 
ΔKTEL AGR2 clone 20 1.70 
 
Appendix 16. Mean shape ratio (SR) values for clonal cell lines. The SR values for at 
least 150 cells for each cell line were measured as described in Materials and 
Methods, and the mean values are presented here. 
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Appendix 17. Morphology and SR values of comparable AGR2-expressing cell lines. 
Representative images and mean SR values for AGR2-expressing clonal cell lines 
expressing similar steady-state proteins levels of AGR2. The SR values for at least 200 
cells for each cell line were measured as described in Materials and Methods, and the 
mean values are presented here. (A) WT AGR2 clone 13, (B) E60A AGR2 clone 18, (C) 
C81S AGR2 clone 10, (D) ∆1-20 AGR2 clone 6, (E) ∆21-40 AGR2 clone 4 and (F) ∆KTEL 
AGR2 clone 8. SR: shape ratio. 
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Appendix 18. Knockdown of AGR2 in WT AGR2 clone 2 cells. (A) WT AGR2 clone 2 
cells were grown for 2 weeks in selection-free medium and then transfected with the 
indicated amount of PiggyBac transposase vector or with PiggyBac excision-only 
transposase vector, as described by the manufacturer (Systems Biosciences). Cells 
were passaged 3 times, harvested and AGR2 protein was measured by Western blot. 
(B) WT AGR2 clone 2 cells were transfected with 2 µg of the indicated short hairpin 
RNA (shRNA) or scrambled RNA (scRNA, see Appendix 19 for more details). After 
selection in hygromycin medium for approximately 14 days, cells were harvested and 
AGR2 protein was measured by Western blot. Although there appears to be some 
AGR2 knockdown with shRNA 4, the equivalent knockdown in scRNA-transfected 
cells indicates that this potential effect is not AGR2 shRNA-specific. 
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shRNA1: GAGCCGATATCACTGGAAGAT 
shRNA2: GCAGTTTGTCCTCCTCAATCT 
shRNA3: AAGCAACAAACCCTTGATGAT 
shRNA4: AGACATATGAAGAAGCTCTAT 
scRNA : GGAATCTCATTCGATGCATAC 
 
 
 
ATGGAGAAAATTCCAGTGTCAGCATTCTTGCTCCTTGTGGCCCTCTCCTACACTCTGGCCAGAGATACCACAGT
CAAACCTGGAGCCAAAAAGGACACAAAGGACTCTCGACCCAAACTGCCCCAGACCCTCTCCAGAGGTTGGGG
TGACCAACTCATCTGGACTCAGACATATGAAGAAGCTCTATATAAATCCAAGACAAGCAACAAACCCTTGATG
ATTATTCATCACTTGGATGAGTGCCCACACAGTCAAGCTTTAAAGAAAGTGTTTGCTGAAAATAAAGAAATCCA
GAAATTGGCAGAGCAGTTTGTCCTCCTCAATCTGGTTTATGAAACAACTGACAAACACCTTTCTCCTGATGGCC
AGTATGTCCCCAGGATTATGTTTGTTGACCCATCTCTGACAGTTAGAGCCGATATCACTGGAAGATATTCAAAT
CGTCTCTATGCTTACGAACCTGCAGATACAGCTCTGTTGCTTGACAACATGAAGAAAGCTCTCAAGTTGCTGAA
GACTGAATTGTAA 
 
Appendix 19. shRNA constructs used for AGR2 knockdown. (A) Vector map of shRNA 
plasmid. (B) shRNA sequences generated by Qiagen for AGR2 knockdown. (C) 
Position of targeted sequences of shRNAs (underlined) within the AGR2 coding 
sequence. 
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Appendix 20. WT AGR2 clonal cells display fewer focal adhesions than EV clonal 
cells. Cells were seeded onto fibronectin-coated CultureSlides and grown overnight. 
Cells were then fixed and permeabilised, and focal adhesions were visualised through 
paxillin staining. There was a much greater concentration of punctate paxillin staining 
in EV clone cells (A), whereas in WT AGR2 clone 2 cells (B), staining was more limited 
to the edges of the cells (white arrows). The focal adhesions in WT AGR2 clone 2 cells 
were also more elongated than those in EV clone 2 cells, indicative of higher traction 
forces travelling through these focal adhesions [108, 110] and thus suggesting that 
these cells are more motile than EV clone 2 cells. Images kindly provided by Richard 
Smith, Institute of Integrative Biology, University of Liverpool. Scalebar: 25 µm. 
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Appendix 21. Normalisation of conditioned medium to cell number. CM was 
collected from 4 replicate plates of WT AGR2 pool and EV pool cells in serum-free 
medium. After CM collection, the number of cells in these plates was counted using 
an automated cell counter. Protein was captured onto Strataclean beads (see 
Materials and Methods) from 1 mL of CM from the replicate with the lowest cell 
count (out of the 8 total replicates). For other replicates, protein was captured from 
proportionally less than 1 mL CM, based on cell count, e.g. for a sample with a cell 
count 1.25 times greater than the lowest cell count, protein was captured from 1.25 
times less CM (i.e. 800 µL in this case). The captured proteins were then run on an 
SDS-PAGE gel and stained with Coomassie brilliant blue. Note that even between 
replicates from the same cells, the levels of secreted proteins were not equal as 
denoted by the different protein staining intensities in the relevant lanes. This 
suggests that normalising CM samples to cell number is poorly reproducible. 
Numbers 1-4 denote the biological replicates. Gel image provided by Dr Deborah 
Simpson, Centre for Proteome Research, Institute of Integrative Biology, University of 
Liverpool. 
 
 
 
 
 
Appendices 
248 
 
Phosphorylation sites predicted: Ser: 5 Thr: 5 Tyr: 2 
 
Serine predictions 
 
Name           Pos   Context    Score  Pred 
_________________________v_________________ 
Sequence         7   KIPVSAFLL  0.016    . 
Sequence        16   LVALSYTLA  0.120    . 
Sequence        36   DTKDSRPKL  0.870  *S* 
Sequence        45   PQTLSRGWG  0.190    . 
Sequence        65   ALYKSKTSN  0.748  *S* 
Sequence        68   KSKTSNKPL  0.971  *S* 
Sequence        84   ECPHSQALK  0.194    . 
Sequence       119   DKHLSPDGQ  0.990  *S* 
Sequence       134   FVDPSLTVR  0.019    . 
Sequence       146   TGRYSNRLY  0.913  *S* 
_________________________^_________________ 
 
Threonine predictions 
 
Name           Pos   Context    Score  Pred 
_________________________v_________________ 
Sequence        18   ALSYTLARD  0.012    . 
Sequence        23   LARDTTVKP  0.963  *T* 
Sequence        24   ARDTTVKPG  0.976  *T* 
Sequence        33   AKKDTKDSR  0.366    . 
Sequence        43   KLPQTLSRG  0.179    . 
Sequence        55   QLIWTQTYE  0.013    . 
Sequence        57   IWTQTYEEA  0.961  *T* 
Sequence        67   YKSKTSNKP  0.211    . 
Sequence       113   LVYETTDKH  0.088    . 
Sequence       114   VYETTDKHL  0.842  *T* 
Sequence       136   DPSLTVRAD  0.919  *T* 
Sequence       142   RADITGRYS  0.428    . 
Sequence       157   EPADTALLL  0.248    . 
Sequence       173   KLLKTEL--  0.009    . 
_________________________^_________________ 
 
Tyrosine predictions 
 
Name           Pos   Context    Score  Pred 
_________________________v_________________ 
Sequence        17   VALSYTLAR  0.040    . 
Sequence        58   WTQTYEEAL  0.395    . 
Sequence        63   EEALYKSKT  0.970  *Y* 
Sequence       111   LNLVYETTD  0.277    . 
Sequence       124   PDGQYVPRI  0.405    . 
Sequence       145   ITGRYSNRL  0.099    . 
Sequence       150   SNRLYAYEP  0.738  *Y* 
Sequence       152   RLYAYEPAD  0.054    . 
_________________________^_________________ 
 
Appendix 22. Prediction of AGR2 phosphorylation sites by the NetPhos2.0 server [734]. 
The full length AGR2 sequence was submitted to 
http://www.cbs.dtu.dk/services/NetPhos/ for phosphorylation prediction. Residues 
flanked with asterisks (*x*) are predicted to be phosphorylated. 
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Residue Number Residue Score O-glycosylation Prediction 
7 Ser 0.078 - 
16 Ser 0.173 - 
18 Thr 0.327 - 
23 Thr 0.639 Positive 
24 Thr 0.775 Positive 
33 Thr 0.863 Positive 
36 Ser 0.943 Positive 
43 Thr 0.860 Positive 
45 Ser 0.782 Positive 
55 Thr 0.281 - 
57 Thr 0.163 - 
65 Ser 0.142 - 
67 Thr 0.046 - 
68 Ser 0.051 - 
84 Ser 0.084 - 
113 Thr 0.080 - 
114 Thr 0.045 - 
119 Ser 0.211 - 
134 Ser 0.136 - 
136 Thr 0.134 - 
142 Thr 0.168 - 
146 Ser 0.347 - 
157 Thr 0.110 - 
173 Thr 0.010 - 
 
Appendix 23. Prediction of AGR2 O-glycosylation sites by the NetOGlyc 4.0 server 
[735]. The full length AGR2 sequence was submitted to 
http://www.cbs.dtu.dk/services/NetOGlyc/ for O-glycosylation prediction. 
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Appendix 24. Control reactions for enzyme deglycosylation kit. To ensure that the 
deglycosylation enzymes were not inhibited by elements of cell lysis buffer or 
concentrated conditioned medium, the extent of fetuin deglycosylationin the 
supplied buffer was compared to that in lysis buffer and concentrated culture 
medium, using the procedure described in Materials and Methods. Fetuin is both N- 
and O-glycosylated, and was equally well deglycosylated under all three reaction 
conditions. 
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